Macromolecular compounds having controlled stoichiometry

ABSTRACT

The following invention is directed to macromolecules having controlled stoichiometry and topology, processes for their production, and applications for their use. The macromolecules have a controlled functional moiety stoichiometry and include at least one dendritic motif having a surface layer formed from at least one surface building unit and at least one subsurface layer formed from at least one building unit, the surface building unit and building units having a hydrocarbon backbone bearing a carbonyl group and at least one amine group; and at least two different functional moieties on the building unit and/or surface building unit; where functional moiety stoichiometry refers to the number and type of functional moieties.

FIELD OF THE INVENTION

The present invention relates to macromolecules whose surfacearchitecture may be controlled to produce an enriched proportion of atopological isomer. In particular the macromolecules may be synthesisedfrom lysine or lysine analogue dendritic motifs having two or moresurface groups.

BACKGROUND OF THE INVENTION

In recent years, dendritic macromolecules have been found to haveincreasing applications in biotechnology and pharmaceutical applicationson the basis of their unique properties and structure, and subsequently,function. Dendritic macromolecules are a special class of polymers withdensely branched structures that are characterized by higherconcentrations of functional groups per unit of molecular volume thanordinary polymers. There are three subclasses of dendriticmacromolecules (Frechet and Tomalia “Dendrimers and other DendriticPolymers”): random hyperbranched polymers; dendrigraft polymers anddendrimers (which include dendrons), classified on the basis of therelative degree of structural control present in each of the dendriticarchitectures. Generally, a dendritic macromolecule includes at leasttwo layers or generations of building units and all contain one or morebranches originating from a core molecule.

In particular, peptide-based dendritic molecules, such as those based onpolylysine FIG. 1, have been developed as promising vaccine, antiviraland antibacterial candidates. A specific architecture of lysine andlysine analogue dendrimers has been described by Denkewalter in U.S.Pat. No. 4,289,872. This patent describes branched compounds essentiallyof identical lysine-like trifunctional units.

Denkewalter's methodology has the advantage that a plurality of amidelinkages are provided to connect the trifunctional units so that thefinal dendrimeric moiety tends to be biocompatible and locallyprotein-like. However the dendrimeric moiety thus provided comprisesmultiple substantially equivalent outer terminal reactable groups (forexample amine groups) as the point of attachment for functional moietiesand the following adverse consequences arise:

-   -   If a further reagent (e.g. a biological effector molecule) is        used to react with the outer terminal reactable groups of the        dendrimer moiety in such a way that some of the outer terminal        reactable groups remain unreacted, there is a statistical spread        of reaction products (i.e. monodispersity in the dendrimer is        lost in the dendrimer reaction product).    -   If a combination of reagents is used to react with the outer        terminal reactable groups of the dendrimer moiety there is a        statistical spread of reaction products and monodispersity is        lost. This situation is described by Newkome et al.        (Combinational Chemistry) Vol 61, No 4 1998/99 “Dendrimer        Construction and Macromolecular Property Modification Via        Combinational Methods” (p 244) in the following terms: “There is        an uncontrolled radial monomer juxtaposition while generational        functional group control is retained”.

Thus whilst the generational character in the dendrimer is maintained,and whilst the amide linkages are advantageous in the provision ofbiocompatibility, the inability to provide radial (i.e. surfacedecoration) monodispersity is a significant disadvantage.

In U.S. Pat. No. 5,229,490 and WO 9011778, Tam teaches that dendriticcore molecules of 2 or 3 generations of lysine may be constructed usingsolid phase peptide synthesis and making use of orthogonally protectedlysine at the final step of the process, to provide a composition thathas a surface topology of (PG₁PG₂)₄. In particular, Tam describes adendritic polymer bearing multiple B- and T-epitopes, wherein the B- andT-epitopes are arranged as couplets (B-epitope T-epitope) on the surfacebuilding unit. The process of solid phase peptide synthesis provides noopportunity for purification until after the final iteration of thesynthesis. Materials provided by such a method are often mixtureswherein the target component is contaminated by the components which areof amino acid deletion products.

The preparation of dendritic macromolecules with a homogenous surfacecomprised of only a single type of functional moiety is now consideredto be routine. Furthermore, Tam and others provide teaching for theconstruction of dendritic macromolecules in which a core ormacromolecule has a homogenous surface stoichiometry that is 1:1 for twofunctional moieties A and B. Furthermore the topology of the twofunctional moieties is specified as homogenous at the level of (AB)couplets; that is each of the surface building units has two functionalmoieties A and B attached to the same surface building unit (as for FIG.3.5).

One key determinant of a dendritic macromolecule's efficacy in any givenapplication is the nature of the macromolecule surface. This applicationdescribes macromolecule topological isomers using a hierarchy ofdescriptive terms which serve to elucidate the way functional moieties,surface building units and building units are interconnected.

It is, accordingly, an object of the present invention to overcome or atleast alleviate one or more of the difficulties and deficiencies relatedto the prior art.

It will be understood that the present invention disclosed and definedin this specification extends to all alternative combinations of two ormore of the individual features mentioned or evident from the text ordrawings. All of these different combinations constitute variousalternative aspects of the present invention.

Reference to any prior art in the specification is not, and should notbe taken as, an acknowledgment or any form of suggestion that this priorart forms part of the common general knowledge in Australia or any otherjurisdiction or that this prior art could reasonably be expected to beascertained, understood and regarded as relevant by a person skilled inthe art.

SUMMARY OF THE INVENTION

In a first aspect of the present invention there is provided amacromolecule having a controlled functional moiety stoichiometryincluding at least one dendritic motif having a surface layer formedfrom at least one surface building unit and at least one subsurfacelayer formed from at least one building unit, the surface building unitand building units having a hydrocarbon backbone bearing a carbonylgroup and at least one amine group; and at least two differentfunctional moieties on the building unit and/or surface building unit;where functional moiety stoichiometry refers to the number and type offunctional moieties.

Preferably, the building units of the dendritic motif are selected fromlysine or lysine analogues, and the surface building units are selectedfrom lysine or lysine analogues, glutamate and aspartate.

The macromolecules of the present invention may be selected from apreparation of macromolecules, wherein the preparation is enriched in aselected functional moiety stoichiometry.

In a preferred embodiment, the macromolecule is selected from apreparation of macromolecules that exhibit at least 10%, preferably 20%,and more preferably 40% enrichment in the selected functional moietystoichiometry compared to random techniques.

Most preferably, the preparations of macromolecules is enriched to thepoint where at least 80%, preferably 90%, more preferably 95% and mostpreferably 99% of the macromolecules exhibit the same functional moietystoichiometry.

In a further preferred embodiment, the macromolecule is a selectedtopological isomer, where topology describes the relationship betweenone functional moiety and another in terms of its connection to thesubsurface structure.

Preferably the macromolecule that is a selected topological isomer isselected from a preparation of macromolecules exhibiting enrichment inthe selected topological isomer. Preferably the macromolecules exhibit a10%, preferably 20%, more preferably 40% enrichment in the selectedtopological isomer.

In a further embodiment, there is provided a macromolecule having acontrolled functional moiety stoichiometry including at least onedendritic motif having a surface layer formed from at least one surfacebuilding unit and at least one subsurface layer formed from at least onebuilding unit, the surface building unit and building units having ahydrocarbon backbone bearing a carbonyl group and at least one aminegroup; and at wherein the macromolecule is a selected topologicalisomer; where functional moiety stoichiometry refers to the number andtype of functional moieties, and topology describes the relationshipbetween each functional moiety in terms of its connection to the surfaceand subsurface layers.

The macromolecules according to this aspect of the present invention maybe utilised in various applications, as discussed below, where theability to control both the surface properties and the overall structureof the macromolecule is advantageous. This is particularly importantwhere more than one functional moiety is included.

For example, the macromolecule may advantageously be utilised to deliverto a desired site a pharmaceutically active compound on its surface,together with a secondary surface compound that may function to modify aspecified characteristic, e.g. solubility, pharmacokinetics, targeting,bioavailability, potency, reactivity, plasma life and the like.

Moreover, the capacity to enrich a dendritic macromolecule preparationin molecules of the same topology, where topology describes therelationship between one functional moiety and another in terms of theirconnection to the subsurface structure, is desirable in the same waythat it has been shown to be desirable to enrich organic materials inparticular stereoisomers or regioisomers, particularly for biologicalapplications. Thus it will be understood that topological isomerism inthe macromolecule represents a subset of the complete set of regio andstereochemical isomers for the macromolecule. That is, the set thatspecifically pertains to positioning of the surface groups relative toone another, and it will be further understood that as such it may bethat one topological isomer may be more effective in a given applicationthan another topological isomer. Even without knowing which topologicalisomer is the best for a given application, the capacity to preparemacromolecule topological isomers in relatively pure form is very usefulin screening for structure-activity relationships.

In a preferred embodiment of this aspect of the present invention, thedendritic motifs of the macromolecule include a lysine or lysineanalogue building unit having a carboxylate group or residue thereof atthe apex thereof, attached to two amine groups, at least one amine groupbeing attached to a carboxylate group or residue thereof of a secondbuilding unit, which is in turn attached directly or indirectly to afirst and second functional moiety, at least one of the functionalmoieties being attached to a surface amine on the second building unit.Preferably, the surface building unit is a lysine or lysine analogue,glutamate or aspartate. When the second building unit is a surfacebuilding unit that is a lysine or lysine analogue, the second functionalmoiety may be attached to a second surface amine on the second buildingunit.

In addition to the functional moieties attached to the second, surfacebuilding unit, a third functional moiety may be attached to the secondamine group of the lysine or lysine analogue building unit, resulting ina dendritic motif with functionalisation at the surface and subsurfacelevel.

In another embodiment, the macromolecule may include one or moresubsurface layers intermediate the apex carboxylate group or residuethereof and the at least one surface amine groups. Optionally, themacromolecule may include two or more subsurface layers. Preferably, atleast one of the subsurface layers includes an apex carboxylate group orresidue thereof and two reactable amine groups, at least one amine groupin turn being attached to a further carboxylate group or residuethereof.

In a further embodiment, each surface amine may bear a functional moietyA or B, with a pair of adjacent functional moieties on the same surfacebuilding unit forming a couplet selected from (AA), (BB) and (AB), orany combination thereof. Optionally, the surface amines may bear afurther functional moiety D, with a pair or adjacent functional moietieson the same building unit forming a couplet selected from (AA), (AB),(AD), (BB), (BD), (DD) or any combination thereof.

The macromolecules bearing functional moieties A and B, or A, B and D,may be selected from a preparation of macromolecules exhibiting anenrichment in a selected topological isomer. The enrichment may be atthe couplet level; at the quartet level, where a pair of adjacentcouplets form a quartet, each quartet having a line of connection to anapex carboxylate group of a surface-but-one building unit; at the octetlevel where adjacent quartets form an octet, each octet having a line ofconnection to an apex carboxylate group of a surface-but-two buildingunit; or at the 16-tet level, where adjacent octets form a 16-tet, each16-tet having a line of connection to an apex carboxylate group of asurface-but-three building unit.

The surface topology of a macromolecule or dendritic motif bearingfunctional moieties may also be described in terms of quartets, octetsand 16-tets. For example a quartet of the form ((AA)(BD))⁴ is used torepresent four functional moieties A,A,B,D which have a line ofconnection to the same building unit, in particular to a surface-but-onebuilding unit. An octet of the form (((AA)(AB))⁴((AB)(AA))⁴)⁸ is used torepresent six functional moieties of type A and two functional moietiesof type B which have a line of connection to the same building unit, inparticular to a surface-but-two building unit. A 16-tet of the form((((AA)(AA))⁴((AA)(AA))⁴)⁸(((AA)(AA))⁴((AA)(AA))⁴)⁸)¹⁶ is used torepresent sixteen functional moieties of type A which have a line ofconnection to the same generation building unit, in particular to asurface-but-three generation-building unit.

In an alternative embodiment, when the macromolecule of the presentinvention has only two types or functional moiety A and B on the samebuilding unit or surface building unit, the functional moietystoichiometry is other than 1:1.

The macromolecules or dendritic motifs of the present invention may beattached to cores. In the absence of a core, the dendritic motif mayitself be the macromolecule. In a preferred aspect there is provided amacromolecule having a core and at least one dendritic motif of theformula:Core[[Building Unit]_(m)[Surface Building Unit]_(n)[Functionalmoieties]_(p)]_(q)wherein:

a [Building Unit]_(m)[Surface Building Unit]_(n)[Functionalmoieties]_(p) defines a dendritic motif;

the core may be any compound, particle or substrate to which thedendritic motif may be attached;

the Building Unit is selected from a lysine or lysine analogue;

the Surface Building Unit is selected from lysine or lysine analogues,glutamate or aspartate;

the Functional moieties include two or more different functionalmoieties selected from protecting groups; biological effect moietyligands for extracellular receptors; property modifiers; biologicaltargeting groups; signalling groups; antigenic materials; geneticmaterials; pharmaceutically active agents; groups adapted to mediatebinding to a second entity, and linkers.

m represents the sum of the building units of the subsurface layers ofthe dendritic motif and is an integer of value: 1≦integer≦64;

n represents the number of surface building units of the dendritic motifand is an integer of value: 2≦integer<128;

p represents the total number of functional moieties on the surface ofthe macromolecule and is an integer of value: 4<integer<256; and

q represents the total number of dendritic motifs on the core of themacromolecule and is an integer of value: 1<integer≦10⁶.

In one embodiment, more than one dendritic motif may be attached to acore to enable the construction of larger, more complex macromolecules.For example, two dendritic motifs, each having 3 subsurface layers and 1surface layer and bearing 16 functional moieties, may be attached to adivalent core, producing a macromolecule having two dendritic motifs andbearing 32 functional moieties.

There are a number of ways of synthesising or “building” a macromoleculeof the present invention. Preferably the macromolecule is a dendrimer.One process for synthesising macromolecules of the present inventioninvolves the sequential reaction of a growing macromolecule core moietyand one or more layers of building compounds. Such a process includes:

i) providing

-   -   a growing macromolecule including at least one reactable group;    -   a first building compound having a hydrocarbon backbone, and        bearing an apex carbonyl group and at least one amine group        bearing a functional moiety being a protecting group;        iii) activating the apex carbonyl group of the first building        compound; and        iii) reacting the deprotected growing macromolecule with the        apex carbonyl group of the first building compound.

The steps of the process will then be reiterated until a macromoleculeof the desired subsurface and surface layers is achieved.

In an alternative process, the macromolecule may be prepared by thefollowing steps:

i) providing

-   -   a growing macromolecule including a first reactable group;    -   a compound including at least one dendritic motif bearing at        least two functional moieties, the motif having a surface layer        and at least one subsurface layer, and having a hydrocarbon        backbone and bearing an apex carbonyl group;        ii) activating the apex carbonyl group of the dendritic motif;        and        iii) reacting the deprotected growing macromolecule with the        carbonyl group of the dendritic motif.

The process may further include the preliminary steps of preparing thecompound including at least one dendritic motif, the process including:

iv) providing

-   -   a first building compound including an apex carbonyl group,        attached directly or indirectly to at least one amine group        bearing at least one functional moiety being a protecting group;    -   a second building compound including an apex carbonyl group,        attached to at least one amine group bearing a first and second        functional moiety;        v) activating the amine group on the first building compound by        removing the protecting group;        vi) activating the apex carbonyl of the second building        compound; and        vii) reacting the deprotected first building compound with the        apex carbonyl group of the second building compound.

Depending on the macromolecule and the functional moieties on thebuilding unit or surface building unit, the macromolecules may have adiverse number of prophylactic and/or therapeutic uses, particularlywhen formulated as a pharmaceutical composition. Accordingly, there isprovided a pharmaceutical composition including a macromolecule having acontrolled functional moiety stoichiometry according to the invention.

DETAILED DESCRIPTION

As used herein in this specification and claims, the singular forms “a”,“an” and “the” include plural referents unless the context clearlydictates otherwise. Thus, for example, reference to a “a macromolecule”includes one or more such macromolecules.

The term “comprises” (or its grammatical variants), as used herein inthe specification and claims, is equivalent to the term “includes” andshould not be taken as excluding the presence of other elements orfeatures.

By the term “building unit” as used herein in the specification andclaims, we mean a unit used in the construction of a dendritic motif.For example, the building unit may be lysine or lysine analogues havinga carboxylate at the apex thereof (apex carboxylate). Layers of buildingunits bear at least one amine or other reactable group that may befurther reacted with the apex carboxylate group of a further buildingunit.

By the term “surface building unit” as used herein in the specificationand claims we mean a building unit within the outermost layer ofbuilding units of the macromolecule. i.e. there are no further buildingunits attached to the surface reactable groups of any of the buildingunits within the layer. A surface building unit has an apex carbonylmoiety and a hydrocarbon framework by which functional moieties may beattached to the macromolecule or dendritic motif.

By the term “dendritic motif”, as used herein in the specification andclaims, we mean a discrete unit of the macromolecule. When themacromolecule is cut at a bond which connects one of the reactableamines of the building unit or core to the apex carboxylate group of theattached building unit, the dendritic motif will “fall out”. The valencyof the apex carboxylate group of the dendritic motif is incomplete, asit represents the point at which the dendritic motif would be attachedto a growing macromolecule core during the process of synthesising amacromolecule of the invention.

By the term “surface amine” as used herein in the specification andclaims we mean any of the outer-most reactable nitrogens of themacromolecule or dendritic motif which derive from the constituent core,building units or linkers. These surface amines represent the points ofattachment for additional building units, linkers or functionalmoieties.

By the term “reactable nitrogen” as used herein in the specification andclaims we mean the nitrogen is able to react with a carboxylic acid oractivated residue thereof to form a covalent bond.

By the term “functional moiety” as used herein in the specification andclaims we mean any group including protecting groups, with the exceptionof a building unit or a linker, which may be attached at a surface aminewith the purpose of serving a particular function.

By the term “end stopping functional moiety” as used herein in thespecification and claims we mean a functional moiety that may beattached to a surface amine and which will maintain its functionalitythrough subsequent transformations used to complete the building of themacromolecule or dendritic motif. An end stopping functional moiety maybe transformed into a functional moiety once assembly of themacromolecule or dendritic motif is complete in order for it to performits required function.

By the term “functional moiety stoichiometry”, as used herein in thespecification and claims, we mean the composition, or number and type,of the functional moieties on the surface of the macromolecule.

By the term “functional moiety topology”, as used herein in thespecification and claims, we mean the relationship between onefunctional moiety and another in terms of their connection to thesurface and subsurface structure.

By the term “enrichment”, as used herein in the specification andclaims, we mean the macromolecule composition having macromoleculesbearing a specified plurality of functional groups as provided by aprocess of this invention, that have a greater uniformity of molecularidentity, both in terms of functional moiety stoichiometry andfunctional moiety topology, than a macromolecule composition havingmacromolecules with an equivalent specified functional groupstoichiometry that has been prepared using a random surfacefunctionalisation. There are statistical methods which can be applied tomodel the theoretical outcome of a random surface functionalisationusing two or more functional moieties; and the output of such models canprovide a point of reference for the determination of the relativeenrichment for the compositions of this invention.

By the term “topological isomer”, as used herein in the specificationand claims, we mean a macromolecule having a particular topology,wherein topology describes the relationship between one functionalmoiety and another in terms of its connection to the subsurfacestructure.

By the term “subsurface”, as used herein in the specification andclaims, we mean the layer of building units bearing amines reactablewith the apex carboxylate group of a further building unit or carbonylgroup of a surface building unit. The layers may in turn be described asthe surface-but-one layer, meaning the first subsurface immediatelyadjacent the surface layer; the surface-but-two layer is the secondlayer below the surface layer; the surface-but-three layer is the thirdlayer below the surface layer; and so on.

By the term “amine-protecting groups”, as used herein in thespecification and claims, we mean a chemical group attached to an aminemoiety of a macromolecule or dendritic motif for the purpose ofpreventing the amine moiety from forming an amide bond when in thepresence of an activated carbonyl group, but which can be removed fromthe same amine moiety without detriment to amide bond integrityelsewhere in the macromolecule or dendritic motif and, groups for whichan order of removal exists such that those groups that are not meant forcleavage removal are inert to the removal cleavage conditions. Whenprotecting groups are defined as “resolvable”, this means that theconditions for removal of one group may affect the integrity of thesecond group whereas conditions exist by which the second group may beremoved without affecting the integrity of the first group. Whenprotecting groups are further defined as “orthogonal”, this means thateach group is inert to the cleavage removal conditions required toremove each of the other groups of the orthogonal set. It is importantto note that protecting groups are resolvable or orthogonal only whenthe appropriate reaction conditions are used.

By the term “linker”, as used herein in the specification and claims, wemean a moiety comprising two reactive groups which are connected by oneor more carbons or heteroatoms.

Wide-ranging uses have been claimed for dendritic moieties, for exampleas therapeutic agents per se or as therapeutic agents whenmacromolecules are combined with bioactive materials. However, theinability to provide monodisperse surface decoration is particularlyacute for human pharmaceutical applications, where regulators are movingto insist that macromolecular therapeutic moieties must be as tightlydefined (monodisperse) as small-molecule therapeutic moieties.

Furthermore, in macromolecules which carry two or more differentfunctional moieties, and are prepared as different topological isomers,it has been demonstrated that the way in which each topological isomerinteracts with a complex system may be different, which indicates thatthere is a specific benefit to be gained from the ability to control thesurface distribution of different functional moieties. For example, thepharmaceutical industry's need to identify drug-like molecules thattarget clinically relevant pathways by being presented in a controlledfashion to ensure activity. While the development of high-throughputscreening methodologies allows large numbers of compounds to bescreened, the most conceptually straightforward approach of advancingcompounds generally requires highly specific or energetically favourableneighbouring contacts to succeed (Erlanson et al 2004).

Erlanson and co-workers (2004) describe numerous examples whereby knowncompounds are linked to fragments of newly identified compounds toimprove the overall properties of the compound by binding to additionalcontact points. But while techniques exist for selecting combinations ofcompounds that can bind concurrently, productively linking themnoncompetitively remains a significant technical challenge.

One key determinant of a dendritic macromolecule's-efficacy in any givenapplication is the nature of the macromolecule surface. This applicationdescribes macromolecule topological isomers using a hierarchy ofdescriptive terms which serve to elucidate the way the functionalmoieties are interconnected by the subsurface structure.

In a first aspect of the present invention there is provided amacromolecule having a controlled functional moiety stoichiometryincluding at least one dendritic motif having a surface layer formedfrom at least one surface building unit and at least one subsurfacelayer formed from at least one building unit, the surface building unitand building units having a hydrocarbon backbone bearing a carbonylgroup and at least one amine group; and at least two differentfunctional moieties on the building unit and/or surface building unit;where functional moiety stoichiometry refers to the number and type offunctional moieties.

In one embodiment the dendritic motif according to the present inventionincludes at least one building unit, the building unit being selectedfrom lysine and lysine analogues having moiety # to indicate a bondwhich connects the building unit to a reactable amine, selected from thegroup consisting of:

Lysine 1: having the structure:

Glycyl-Lysine 2 having the structure:

Analogue 3, having the structure below, where a is an integer of 1 or 2;b and c are the same or different and are integers of 1 to 4.

Analogue 4, having the structure below, where a is an integer of 0 to 2;b and c are the same or different and are integers of 2 to 6

Analogue* 5, having the structure below, where a is an integer of 0 to5; b and c are the same or different and are integers of 1 to 5

Analogue 6, having the structure below, where a is an integer of 0 to 5;b and c are the same or different and are integers of 0 to 5

Analogue 7, having the structure below, where a is an integer of 0 to 5;b and c are the same or different and are integers of 1 to 5

Analogue 8, having the structure below, where a is an integer of 0 to 5;b, c and d are the same or different and are integers of 1 to 5

Analogue 9, having the structure below, where a is an integer of 0 to 5;b and c are the same or different and are integers of 1 to 5

and furthermore, the alkyl chain moieties of the building units may beunderstood to include either alkoxy fragments as C—O—C or C—C—O—C—C butnot O—C—X where X is O or N.

In a preferred aspect of the invention, the building units are selectedfrom Lysine 1, Glycyl-Lysine 2 or Lysine analogue 5:

where a is an integer of 0 to 2 or the alkyl link is C—O—C; b and c arethe same or different and are integers of 1 to 2.

In one embodiment, the surface building unit may be selected from theset of building units 1-9 described above. In an alternative embodiment,the surface building unit may be a compound wherein the reactablenitrogen may be replaced by another reactable moiety.

Chemical reactable groups which provide a useful means of attachingfunctional moieties to a surface building unit are: amine, carboxylate,hydroxyl, thiol, alkyl halide, allyl halide, heteroaryl halide, arylhalide, vinyl halide, epoxide, aziridine azide, alkyne. Where thechemical functional groups of the surface building unit are the same, asin hydroxyl, thiol, carboxylate, they may be orthogonally protected toachieve attachment of two or more different functional moieties.

Where the chemical reactable groups of the surface building unit maypotentially interact with one another under the reaction conditions usedto attach the functional moieties, then one or more of the differentchemical functional groups may be protected whilst the other chemicalfunctional group is reacted with a functional moiety.

Examples of chemical functional groups that may potentially interact andwhich may be included in a surface building unit are: carboxylate withany of amine, thiol or hydroxyl; heteroaryl halide with any of amine,thiol or hydroxyl; alkyl halide and any of amine, thiol or hydroxyl;epoxide and any of amine, thiol or hydroxyl; aziridine and any of amine,thiol or hydroxyl.

In yet another embodiment, the surface building unit may be selectedfrom the group consisting of:

Analogue 10, having the structure below, where a is an integer of 0 to2; b and c are the same or different and are integers of 1 to 4. A₁ andA₂ are the same or different and selected from NH₂, CO₂H, OH, SH, X asF, Cl, Br or I, Allyl-X as F, Cl, Br or I, epoxide, aziridine, N₃ oralkyne.

Analogue 11, having the structure below, where a is an integer of 0 to2; b and c are the same or different and are integers of 2 to 6. A₁ andA₂ are the same or different and selected from NH₂, CO₂H, OH, SH,epoxide, N₃ or alkyne.

Analogue 12, having the structure below, where a is an integer of 0 to5; b and c are the same or different and are integers of 1 to 5. A₁ andA₂ are the same or different and selected from NH₂, CO₂H, OH, SH, X asF, Cl, Br or I, Allyl-X as F, Cl, Br or I, epoxide, aziridine, N₃ oralkyne

Analogue 13, having the structure below, where a is an integer of 0 to5; b and c are the same or different and are integers of 0 to 5. A₁ andA₂ are the same or different and selected from NH₂, CO₂H, OH, SH, X asF, Cl, Br or I, Allyl-X as F, Cl, Br or I, epoxide, aziridine, N₃ oralkyne

Analogue 14, having the structure below, where a is an integer of 0 to5; b and c are the same or different and are integers of 1 to 5. A₁ andA₂ are the same or different and selected from NH₂, CO₂H, OH, SH, X asF, Cl, Br or I, Allyl-X as F, Cl, Br or I, epoxide, aziridine, N₃ oralkyne

Analogue 15, having the structure below, where a is an integer of 0 to5; b, c and d are the same or different and are integers of 1 to 5. A₁and A₂ are the same or different and selected from NH₂, CO₂H, OH, SH, Xas F, Cl, Br or I, Allyl-X as F, Cl, Br or I, epoxide, aziridine, N₃ oralkyne

Analogue 16 having the structure below, where a is an integer of 0 to 5;b and c are the same or different and are integers of 1 to 5. A₁ and A₂are the same or different and selected from NH₂, CO₂H, OH, SH, X as F,Cl, Br or I, Allyl-X as F, Cl, Br or I, epoxide, aziridine, N₃ or alkyne

and furthermore, the alkyl chain moieties of the building units may beunderstood to include either alkoxy fragments as C—O—C or C—C—O—C—C butnot O—C—X where X is O or N. Groups A₁ and A₂ may be further protectedwhere required.

Preferred surface building units include glutamate and aspartate.

The type of building units and surface building units allows attachmentof different functional moieties to the surface and subsurface by anumber of ways. In one embodiment, where the dendritic motifs of themacromolecule include a lysine or lysine analogue building unit having acarboxylate group or residue thereof at the apex thereof, attached totwo amine groups, at least one amine group may in turn be attached to acarboxylate group or residue thereof of a second building unit. When thesecond building unit is a surface building unit that is glutamate oraspartate for example, and bears two functional moieties, one of thosefunctional moieties may be attached via a surface amine. When the secondbuilding unit is a surface building unit that is a lysine or lysineanalogue having two amine groups, two functional moieties may beattached to the amines.

In addition to the functional moieties attached to the second, surfacebuilding unit, a third functional moiety may be attached to the secondamine group of the lysine or lysine analogue building unit, resulting ina dendritic motif with functionalisation at the surface and subsurfacelevel.

The present invention is directed to macromolecules having controlledfunctional moiety stoichiometry and topology and will now be describedin more detail.

In a preferred embodiment, the surface amines or other reactable groupsof the building units and/or surface building units bear a functionalmoiety A or B, with a pair of adjacent functional moieties on the samesurface building unit or building unit forming a couplet selected from(AA), (BB) and (AB), or any combination thereof. When there are only twotypes of functional moiety A and B on the same building unit or surfacebuilding unit, the functional moiety stoichiometry is other than 1:1.

When a macromolecule having two or more different functional moieties issynthesised using random surface functionalisation methods, twoapproaches may be considered, e.g. an equal mixture of two functionalmoieties is required.

In a first prior art approach using lysine or lysine analogues as anexample of a surface building unit, a substoichiometric amount of thefirst activated functional moiety is used in an attempt to cap only halfthe reactive surface amine groups on the surface of the macromolecule.The remaining reactive surface amines may then be reacted, and in thissecond reaction, an excess of the second activated functional moiety maybe used to force the reaction to completion. In this approach, there isa statistical distribution of products which vary in the number ofattached first functional moieties arising from the first stage of thereaction, and furthermore there is little or no control over thetopology of the two different functional moieties.

In a second prior art approach, both activated functional moieties maybe simultaneously reacted with the reactive surface amine groups. Insuch an approach, it may be possible to adjust the stoichiometries ofeach surface derivatising agent to account for their differingreactivities, but molecule to molecule variability will still arisebecause more than one type of functional moiety is available to reactwith the reactive surface amine groups and so the likely outcome of eachreaction may only be described by a statistical distribution, and again,there is no control over the topological outcome of the reaction.

In contrast to the random prior art approaches, the present invention isconcerned with controlled surface and subsurface functionalisationmethods. This difference is more clearly illustrated in the sets below.

Set 1 represents a preparation of macromolecules in which fourmacromolecules, each with 16 reactable terminal groups, has been allowedto react with a mixture of 32 dark and 32 light functional moieties.Whilst the outcome is only illustrative, it can be seen that whilst the“average” property of each molecule of the preparation is a 1:1stoichiometry of light and dark; the actual likelihood of any individualmolecule of the preparation having a 1:1 stoichiometry is determined bystatistics.

For comparison, Set 2 represents a preparation of macromolecules with acontrolled stoichiometry and topology of light and dark functionalmoieties, as is the subject of the present invention. It can be seenthat for this preparation, each macromolecule is identical.

Set 1: Random Stoichiometry and Topology

Set 2: Control Over Stoichiometry and Topology

A macromolecule composition is considered “enriched” if the fractionalabundance of macromolecules with precisely specified composition offunctional moieties is greater than the fractional abundance in arandomly surface functionalised material by a factor of at least 2(2-fold enriched monodispersity) and preferably 4 (4-fold enrichedmonodispersity). This enrichment may be specified by comparing theprecisely specified composition with a randomly functionalisedmacromolecule composition. Suppose that this random method provides aparticular functional moiety stoichiometry in 5% of the macromolecules.Then enrichment would constitute an increase in the macromolecule with aparticular functional moiety stoichiometry over this 5% level. Forexample a two-fold enrichment would mean that 10% of the macromoleculesexhibited the particular functional moiety stoichiometry.

At an extreme level of stoichiometric enrichment each macromolecule willhave the same number and type of functional moieties. A more moderatelevel of enrichment, such as enrichment at 20%, is taken to mean that20% of the macromolecules will have the same number and type offunctional moieties. Accordingly, in one embodiment of the presentinvention there is provided a preparation of macromolecules having atleast 10% enrichment in a selected functional moiety stoichiometry. Inturn, in a preferred embodiment, there is provided a preparation whereinat least 80% of the macromolecules have the same functional moietystoichiometry.

The concept of enrichment, which has been illustrated for functionalmoieties, may also be applied to “topological enrichment”, being thenumber and type of couplets, quartets and octets etc, which aredescribed in detail below. Even if the general make up of the surface ofthe macromolecule is maintained, at 100% enrichment, for example with50% functional moiety A and 50% functional moiety B, it does not followthat there is 100% topological enrichment. This is because thefunctional moieties A and B may be grouped into couplets, quartets,octets and 16-tets in a multitude of ways. Accordingly, in anotherembodiment, there is provided a preparation of macromolecules, whereinthe macromolecules further exhibit enrichment in a selected topologicalisomer, wherein topology describes the relationship between functionalmoiety and another in terms of its connection to the surface andsubsurface layers.

There are many stereochemical and regiochemical consequences that mayarise when the carbonyl-to-amine bond sequence is asymmetric within abuilding unit, as it is for native lysine 1. For the purposes of thepresent invention, such consequences will not be analysed. The presentinvention will identify the relative configuration of the differenttopological elements. The order of functional moieties within a coupletis then, for the present analysis, redundant. That is (AB) is equivalentto (BA), and this also holds true for couplets within quartets, quartetswithin octets and octets within 16-tets.

The simplest type of topological enrichment is enrichment at the levelof couplets i.e., two functional moieties attached to the same surfacebuilding unit or building unit. A macromolecule composition may be fullyenriched at the level of functional moieties, but not fully enriched atthe level of couplets. This is because the same functional moieties maybe grouped into couplets in a number of ways. For example in FIGS. 3.1to 3.5, where A and B represent different functional moieties, themacromolecules contain 16 A groups and 16 B groups. However in FIGS.3.1, 3.2, 3.3 and 3.4 there are eight (AA) couplets and eight (BB)couplets while in FIG. 3.5 there are sixteen (AB) couplets.

Topological enrichment at 20% is taken to mean that 20% of themacromolecules will have the same composition (number and type) ofcouplets.

Alternatively as described above in relation to stoichiometricenrichment this enrichment may be specified by comparing the enrichedcomposition with a randomly functionalised macromolecule composition,from which has been selected all macromolecules with the specifiedcouplet stoichiometry. Assuming this selection provides a particularcomposition of couplets at a level of 5% of the total number ofmacromolecules, then, a two-fold enrichment at the level of coupletswould mean that 10% of the macromolecules had the required coupletcomposition. Accordingly, in one embodiment, there is provided amacromolecule composition having at least 10% enrichment in a selectedfunctional moiety topology.

A higher order of topological enrichment is enrichment at the level ofquartets.

A macromolecule composition with at least two layers of building unitsmay be fully enriched at the level of functional moieties and couplets,but not fully enriched at the level of quartets. This is because thesame couplets may be grouped into quartets in a multitude of ways. Forexample in FIGS. 3.1 to 3.5 the macromolecules contain 16 A groups and16 B groups, however in FIGS. 3.1, 3.2 and 3.3 there are four((AA)(AA))⁴ quartets and four ((BB)(BB))⁴ quartets while in FIG. 3.4there are eight ((AA)(BB))⁴ quartets and in FIG. 3.5 there are eight((AB)(AB))⁴ quartets.

A higher order specification of topological enrichment would thusrequire a specification of enrichment at the level of quartets. Thisenrichment may be specified in two ways, as described previously, i.e.either enrichment at 20% means that 20% of the macromolecules will havethe same quartet composition (number and type) or two fold enrichment atthe level of quartets means that there are twice as many macromoleculeswith specified quartet composition than is achievable from a randomfunctionalisation experiment.

Thus the topological enrichment is specified in terms of a hierarchy ofenrichment values that will correspond to couplet enrichment, quartetenrichment, octet enrichment, 16-tet enrichment etc. In a preferredembodiment, there is provided a macromolecule according to claim 17wherein the macromolecule exhibits topological enrichment at:

the couplet level;

at the quartet level, where a pair of adjacent couplets form a quartet,each quartet having a line of connection to an apex carboxylate group ofa surface-but-one building unit;

at the octet level where adjacent quartets form an octet, each octethaving a line of connection to an apex carboxylate group of asurface-but-two building unit; or

at the 16-tet level, where adjacent octets form a 16-tet, each 16-tethaving a line of connection to an apex carboxylate group of asurface-but-three building unit. The hierarchy of enrichment values isdetermined by the number of layers in the macromolecule. The order atwhich a macromolecule is specified, i.e. at the couplet, quartet, octetlevel, or 16-tet provides a level of information about the structure forvarious dendrimer motifs. A couplet represents a minimal dendriticmotif, whilst a 16-tet represents a much larger dendritic motif.

The macromolecules of the invention may bear two or more differentfunctional moieties on the building unit and/or surface building unit.Each functional moiety may be independently chosen from protectinggroups including Boc, CBz, 4-nitrobenzyloxycarbamate (4-NO₂-Nitro-CBz),Fmoc, Dde, CF₃CO₂, 2-halo-CBz, Aloc, Me₃SiEtSO₂, Troc, o-NO-₂PhSO₂ and,2,4-dinitrobenzene-sulfonyl and t-butyldimethylsilyl chloride, andpreferably from Boc, CBz, 4-NO₂-Nitro-CBz, Fmoc 2-halo-CBz, Alloc,Me₃SiEtSO₂, Troc, o-NO₂PhSO₂, 2,4-dinitrobenzene-sulfonyl.

The functional moieties may also be selected from the types listed inTable 1A.

TABLE 1A Functional moieties Ligands for extracellular Mono andoligosaccharides or analogues thereof receptors Peptide ligands orfragments or analogues: Chemokines or cytokines or binding motifs eg RGDpeptide Known small molecule agonists or antagonists, fragments thereofProperty modifiers Hydrophilic groups: PEG's or other hydrophilicpolymers, polyhydroxyl chains, oligosaccharides, aryl or heteroarylgroups, Hydrophobic groups: long chain alkyl groups, steroids, Chargedsurface groups: groups with negative charge at pH ≦ 1, ≦3, ≦5, ≦7, ≦9etc; groups with positive charge at pH ≦ 1, ≦3, ≦5, ≦7, ≦9 etc, groupsthat are zwitterionic at pH ≦ 1, ≦3, ≦5, ≦7, ≦9 etc. Pharmaceuticallyactive Cleavable linker: acid labile, photocleavable, reductivelylabile, agents (see Table 1B) enzymatically cleavable (protease,esterase); attached by cleavable linker Pharmaceutically active agentsconjugated for release to facilitate delivery via increased solubility,decreased toxicity Groups to effect targeting Ligands to extracellularreceptors; receptors to extracellular ligands eg lectins or antibodiesor functional fragments thereof; cell surface antigen recognisingantibodies or antibody fragments prepared either through cleavage ofwhole antibodies or through protein expression systems. Groups to effectsignalling Radioactive label, PET label, ligand-metal complex wheremetal is radioactive, PET active, MRI active; fluorescent label; labelsthat are quiescent but signal upon activation (cleavage, chemicalreaction, excitation via irradiation) Antigenic material Known peptideor glycopeptide or carbohydrate epitope, or protein comprising knownepitope. Genetic material Sequence of DNA or RNA Group to mediatebinding to Known partners in high affinity ligand-receptor interactions,such as second entity biotin-streptavidin, digoxin-antibody,nickel-histidine-binding motifs, complimentary single stranded DNA, RNAor PNA

When the functional moiety is a pharmaceutically active agent, aderivative thereof, or a precursor thereof, the pharmaceutically activeagent may be exemplified by, but not limited to one or more selectedfrom the groups in Table 1B:

TABLE 1B Pharmaceutically active agents Acetonemia preparations Anabolicagents Anaesthetics Analgesics Anti-acid agents Anti-arthritic agentsAntibodies Anti-convulsants Anti-fungals Anti-histamines Anti-infectivesAnti-inflammatories Anti-metabolites Anti-microbials Anti-mitoticsAnti-parasitic agents Anti-protozoals Anti-ulcer agents Antiviralpharmaceuticals Behaviour modification drugs Biologicals Blood and bloodsubstitutes Bronchodilators and expectorants Cancer therapy and relatedpharmaceuticals Cardiovascular pharmaceuticals Central nervous systempharmaceuticals Contrast agents Contraceptives Diuretics Diabetestherapies Growth hormones Fertility pharmaceuticals Hematinics Growthpromoters Hormone replacement therapies Hemostatics Immune suppressivesImmunostimulants Hormones and analogs Muscle relaxants Minerals Naturalproducts Nutraceuticals and nutritionals Obesity therapeutics Ophthalmicpharmaceuticals Osteoporosis drugs Pain therapeutics Peptides andpolypeptides Proteins Respiratory pharmaceuticals Sedatives andtranquilizers Transplantation products Urinary acidifiers Vaccines andadjuvants Vitamins

The present invention is particularly appropriate for pharmaceuticallyactive agents that are very, active even in extremely small quantitiesand whose sustained long-term administration is sought, particularly toovercome toxicity problems with standard doses.

In a preferred embodiment the functional moieties are independentlyselected from functional groups such as those listed in Table 1A and 1Band functional groups that are protecting groups. The stoichiometricratio between one type of functional moiety and all other functionalmoieties is approximately 1:1 or 1:2 or 1:3 or 1:4 or 1:5 or 1:6 or 1:7or 1:8 or 1:9 1:10 or 1:16, more preferably 1:1 or 1:3 or 1:7. In turn,the stoichiometric ratio between a selected couplet to all othercouplets, a selected quartet to all other quartets, and selected octetto all other octets, and a selected 16-tet to all other 16-tets isapproximately 1:1 or 1:2 or 1:3 or 1:4 or 1:5 or 1:6 or 1:7 or 1:8 or1:9 1:10 or 1:16, more preferably 1:1 or 1:3 or 1:7.

In many cases of practical interest, the relative configuration of thedifferent functional groups and their pattern of connectedness(topological isomeric character) is of principal interest. Thetopological isomeric character of a macromolecule or dendritic motif mayreadily be shown from planar representations of the motif when thebuilding units are all symmetric. By this we mean that the buildingunits are treated as if the bond path from apex to each reactable amineis identical, as exemplified in FIG. 4.

It is possible to rotate by 180° the chemical bond joining a non-surfaceamine to the apex carboxylate group of the attached building unit. Themacromolecule or dendritic motif, containing this rotated dendriticmotif component will also fit on the same plane of representation. Afterrotation, the macromolecule or dendritic motif may appear differentbecause the location of functional moieties at the surface of the motifare different relative to each other, as for F4.1, F4.2 and F4.3 in FIG.4. In order to check if two apparently different planar representationsof a macromolecule or dendritic motif actually represent the same thing,the planar representation of the first macromolecule or dendritic motifshould be taken as a reference and all permissible 180° degree rotationscarried out within the planar representation of the second macromoleculeor dendritic motif to form a rotation set. If the first planarrepresentation is contained in the rotation set of the second, the twodendritic motifs are the same.

In order to facilitate the description of the embodiments, analpha-numeric topological nomenclature of couplets, quartets, octets andbeyond has been introduced. In particular the nomenclature makes itpossible to identify the preferred quartets, octets and 16-tets whichare components of macromolecules and which are a preferred embodiment ofthis invention.

It should be understood that this alpha-numeric nomenclature is atranscription of one of many potential planar two-dimensionalrepresentations of a particular topological isomer. Before a planarrepresentation is transcribed into the topological nomenclature, itshould be positioned on a page such that an unhindered line can be drawnfrom outside the planar representation to meet the shortest bondsequence that joins two reactable amine groups of the core. This isdemonstrated by example in FIG. 1.1: reading clockwise from the verticalline the functional moieties are AAAABBBBAAAABBBB. If the core ismonovalent or macroscopic, or if a dendritic motif is being transcribed,then this line should meet the shortest bond sequence that joins the tworeactable amine groups of the first building unit i.e. that buildingunit with the apex carboxylate (F) is demonstrated by example in FIG.1.3: reading clockwise from the line the functional moieties areAAAABBBB. In those circumstances where a dendritic motif is describedthe apex carboxylate is represented as, it is often helpful to includethis feature in the alpha-numeric nomenclature, and this is done as aprefix F as in FIG. 1.3; where F represents the chemical functionalmoiety at the apex.

In the event that one or more of the building units is asymmetric, forexample in terms of the sequence of bonds from the apex of the buildingunit to the amines of the building unit capable of further reaction, orin terms of the presence of chirality, the description of the dendriticmotif as a topological isomer may be determined by representing eachbuilding unit as a symmetric unit on the diagram (even if it is not),and then checking to see if one representation is contained in therotation set of the other. An example of this approach is demonstratedin FIG. 4 for F4.4, symmetrised to F4.1 prior to bond rotation analysis.While there are many stereochemical and regiochemical consequences thatmay arise when the carboxylate-to-amine bond sequence is asymmetricwithin a building unit, as it is for native lysine 1. Such consequenceswill not be analysed for the purposes of the present invention. Thepresent invention will identify the relative configuration of thedifferent topological elements. The order of functional moieties withina couplet is then, for the present analysis, redundant. That is (AB) isequivalent to (BA), and this also holds true for couplets withinquartets, quartets within octets and octets within 16-tets.

The total number of functional moieties in a macromolecule or dendriticmotif can be represented by FM_(Total). The composition of functionalmoieties of a macromolecule or dendritic motif, wherein all the surfaceamines and/or surface building units groups are attached to functionalmoieties, can be provided in a formula of the form ΣFM_(i)=FM_(total)where the surface of the macromolecule or dendritic motif has anintegral quantity FM_(i) of functional moieties of type i. Consider FIG.3 which provides schematic diagrams of five different topologicalisomers of macromolecules which have the same FM_(Total) and furthermorehave the same equal number of two functional moieties A and B. For thesesystems, FM_(A)=FM_(B)=16 and ΣFM_(i)=(FM_(A)+FM_(B))=32. However it isimportant to note that each of these examples has a different surfacetopology and it is the purpose of the alpha-numeric topologicalnomenclature to identify and distinguish between these topologicalisomers even where the number and type of functional moieties of amacromolecule or dendritic motif is the same.

In one embodiment, two different functional moieties A and B areattached to the same surface building unit. In the alpha-numerictopological nomenclature of this invention the functional moietiesattached to a particular surface building unit are represented within asingle layer of parentheses, and can be described in terms of couplets.Preferred couplets are (AA), (BB) and (AB) and any combination thereof.For example, (AA) would represent that functional moiety A and a secondfunctional moiety A are attached to the same surface building unit. Thisconnectivity is demonstrated in FIG. 2.1. The macromolecules of FIG. 3are represented using couplets in the alpha-numeric topologicalnomenclature as follows:

TABLE 2 FIG. alpha-numeric topological nomenclature Composition 3.1(BB)(BB)(BB)(BB)(BB)(BB)(BB)(BB)(AA)(AA)(AA)(AA)(AA)(AA)(AA)(AA) 8 (AA)couplets and 8 (BB) couplets 3.2(AA)(AA)(AA)(AA)(BB)(BB)(BB)(BB)(BB)(BB)(BB)(BB)(AA)(AA)(AA)(AA) 8 (AA)couplets and 8 (BB) couplets 3.3(AA)(AA)(BB)(BB)(AA)(AA)(BB)(BB)(BB)(BB)(AA)(AA)(BB)(BB)(AA)(AA) 8 (AA)couplets and 8 (BB) couplets 3.4(AA)(BB)(AA)(BB)(AA)(BB)(AA)(BB)(BB)(AA)(BB)(AA)(BB)(AA)(BB)(AA) 8 (AA)couplets and 8 (BB) couplets 3.5(AB)(AB)(AB)(AB)(AB)(AB)(AB)(AB)(AB)(AB)(AB)(AB)(AB)(AB)(AB)(AB) 16 (AB)couplets

It is then possible to describe the macromolecules or dendritic motifsof this invention in terms of the composition (number and type) ofcouplets. This is demonstrated for clarity in the examples of FIG. 3 andsummarised in the “composition” column of Table 2.

The surface topology of a macromolecule or dendritic motif bearingfunctional moieties A and B may also be described in terms of coupletsand quartets. For example in the alpha-numeric topological nomenclaturea quartet of the form ((AA)(AA)⁴ is used to represent four functionalmoieties A,A,A,A which have a line of connection to the same buildingunit, in particular to a surface-but-one building unit. Thisconnectivity is demonstrated by FIG. F2.2. A description of the topologyof a macromolecule or dendritic motif in terms of quartets can providestructural information about the lines of connectivity between thefunctional moieties and the surface-but-one building units to which theyare attached.

The macromolecules of FIG. 3 are represented using quartets in thealpha-numeric topological nomenclature as follows:

TABLE 3A FIG. alpha-numeric topological nomenclature Composition 3.1((BB)(BB))⁴((BB)(BB))⁴((BB)(BB))⁴((BB)(BB))⁴ 4 quartets ((AA)(AA))⁴ and((AA)(AA))⁴((AA)(AA))⁴((AA)(AA))⁴((AA)(AA))⁴ 4 quartets ((BB)(BB))⁴ 3.2((AA)(AA))⁴((AA)(AA))⁴((BB)(BB))⁴((BB)(BB))⁴ 4 quartets ((AA)(AA))⁴ and((BB)(BB))⁴((BB)(BB))⁴((AA)(AA))⁴((AA)(AA))⁴ 4 quartets ((BB)(BB))⁴ 3.3((AA)(AA))⁴((BB)(BB))⁴((AA)(AA))⁴((BB)(BB))⁴ 4 quartets ((AA)(AA))⁴ and((BB)(BB))⁴((AA)(AA))⁴((BB)(BB))⁴((AA)(AA))⁴ 4 quartets ((BB)(BB))⁴ 3.4((AA)(BB))⁴((AA)(BB))⁴((AA)(BB))⁴((AA)(BB))⁴ 8 quartets ((AA)(BB))⁴((BB)(AA))⁴((BB)(AA))⁴((BB)(AA))⁴((BB)(AA))⁴ 3.5((AB)(AB))⁴((AB)(AB))⁴((AB)(AB))⁴((AB)(AB))⁴ 8 quartets ((AB)(AB))⁴((AB)(AB))⁴((AB)(AB))⁴((AB)(AB))⁴((AB)(AB))⁴

It is then possible to describe the macromolecules or dendritic motifsof this invention in terms of the composition (number and type) ofquartets. This is demonstrated for clarity in the examples of FIG. 3 andsummarised in the “composition” column of Table 3A.

When a quartet is to be assembled from two functional moieties,represented by A and B this may be done by making use of the preferredcouplets (AA), (AB) and (BB). The preferred composition of quartets canbe of the form:

TABLE 3B Ratio Type of quartet Equivalent quartet Homogenous ((AA)(AA))⁴((BB)(BB))⁴ 3:1 ((AA)(AB))⁴ ((AB)(BB))⁴ 1:1 ((AB)(AB))⁴; ((AA)(BB))⁴

In a preferred embodiment, the compositions of macromolecules ordendritic motifs include at least one quartet selected from Table 3B,including those quartets which can be considered equivalent by way oftheir topology and relative composition of two different functionalmoieties.

The surface topology of a macromolecule or dendritic motif bearingfunctional moieties A and B may also be described in terms of couplets,quartets and octets. For example in the alpha-numeric topologicalnomenclature an octet of the form: (((AA)(AA))⁴((AA)(AA))⁴)⁸ is used torepresent eight functional moieties A,A,A,A,A,A,A,A which have a line ofconnection to the same building unit, in fact to a surface-but-twobuilding unit. This connectivity is demonstrated by FIG. F2.3. Adescription of the topology of a macromolecule or dendritic motif interms of octets can provide structural information about the lines ofconnectivity between the functional moieties and the surface-but-twobuilding units to which they are attached.

The macromolecules of FIG. 3 are represented using octets in thealpha-numeric topological nomenclature as follows:

TABLE 4A FIG. alpha-numeric topological nomenclature Composition 3.1(((BB)(BB))⁴((BB)(BB))⁴)⁸(((BB)(BB))⁴((BB)(BB))⁴)⁸ 2 octets(((AA)(AA))⁴((AA)(AA))⁴)⁴ and(((AA)(AA))⁴((AA)(AA))⁴)⁸(((AA)(AA))⁴((AA)(AA))⁴)⁸ 2 octets(((BB)(BB))⁴((BB)(BB))⁴)⁸ 3.2(((AA)(AA))⁴((AA)(AA))⁴)⁸(((BB)(BB))⁴((BB)(BB))⁴)⁸ 2 octets(((AA)(AA))⁴((AA)(AA))⁴)⁴ and(((BB)(BB))⁴((BB)(BB))⁴)⁸(((AA)(AA))⁴((AA)(AA))⁴)⁸ 2 octets(((BB)(BB))⁴((BB)(BB))⁴)⁸ 3.3(((AA)(AA))⁴((BB)(BB))⁴)⁸(((AA)(AA))⁴((BB)(BB))⁴)⁸ 4 octets(((AA)(AA))⁴((BB)(BB))⁴)⁸(((BB)(BB))⁴((AA)(AA))⁴)⁸(((BB)(BB))⁴((AA)(AA))⁴)⁸ 3.4(((AA)(BB))⁴((AA)(BB))⁴)⁸(((AA)(BB))⁴((AA)(BB))⁴)⁸ 4 octets(((AA)(BB))⁴((AA)(BB))⁴)⁸(((BB)(AA))⁴((BB)(AA))⁴)⁸(((BB)(AA))⁴((BB)(AA))⁴)⁸ 3.5(((AB)(AB))⁴((AB)(AB))⁴)⁸(((AB)(AB))⁴((AB)(AB))⁴)⁸ 4 octets(((AB)(AB))⁴((AB)(AB))⁴)⁸(((AB)(AB))⁴((AB)(AB))⁴)⁸(((AB)(AB))⁴((AB)(AB))⁴)⁸

It is then possible to describe the macromolecules or dendritic motifsof this invention in terms of the composition (number and type) ofoctets. This is demonstrated for clarity in the examples of FIG. 3 andsummarised in the “composition” column of Table 4A.

When an octet is to be assembled from two functional moieties,represented by A and B this may be done by making use of the preferredquartets from Table 3B. The preferred composition of octets can be ofthe form:

TABLE 4B Ratio Type of octet Equivalent octet homogenous(((AA)(AA))⁴((AA)(AA))⁴)⁸ (((BB)(BB))⁴((BB)(BB))⁴)⁸ 7:1(((AA)(AA))⁴((AA)(AB))⁴)⁸ (((BB)(BB))⁴((BB)(AB))⁴)⁸ 6:2(((AA)(AA))⁴((AA)(BB))⁴)⁸, (((BB)(BB))⁴((BB)(AA))⁴)⁸(((AA)(AA))⁴((AB)(AB))⁴)⁸, (((BB)(BB))⁴((AB)(AB))⁴)⁸(((AA)(AB))⁴((AA)(AB))⁴)⁸. (((BB)(BA))⁴((BB)(AB))⁴)⁸ 5:3(((AA)(AA))⁴((AB)(BB))⁴)⁸, (((BB)(BB))⁴((AA)(AB))⁴)⁸(((AA)(AB))⁴((AA)(BB))⁴)⁸, (((BB)(AB))⁴((AB)(BB))⁴)⁸(((AA)(AB))⁴((AB)(AB))⁴)⁸. (((BB)(AB))⁴((AB)(AB))⁴)⁸ 4:4 (1:1)(((AA)(AA))⁴((BB)(BB))⁴)⁸, (((AA)(AB))⁴((AB)(BB))⁴)⁸,(((AA)(BB))⁴((AA)(BB))⁴)⁸, (((AA)(BB))⁴((AB)(AB))⁴)⁸,(((AB)(AB))⁴((AB)(AB))⁴)⁸.

In a preferred embodiment, the compositions of macromolecules ordendritic motifs include at least one octet selected from Table 4B,including those octets which can be considered equivalent by way oftheir topology and relative composition of two different functionalmoieties.

The surface topology of a macromolecule or dendritic motif bearingfunctional moieties A and B may also be described in terms of couplets,quartets, octets and 16-tets. For example in the alpha-numerictopological nomenclature a 16-tet of the form:((((AA)(AA))⁴((AA)(AA))⁴)⁸(((AA)(AA))⁴((AA)(AA))⁴)⁸)¹⁶ is used torepresent sixteen functional moieties of type A which have a line ofconnection to the same building unit, in fact to a surface-but-threebuilding unit. This connectivity is demonstrated by FIG. F2.4. Adescription of the topology of a macromolecule or dendritic motif interms of 16-tets can provide structural information about the lines ofconnectivity between the functional moieties and the surface-but-threebuilding units to which they are attached.

The macromolecules of FIG. 3 are represented using 16-tets in thealpha-numeric topological nomenclature as follows:

TABLE 5A FIG. alpha-numeric topological nomenclature 3.1((((BB)(BB))⁴((BB)(BB))⁴)⁸(((BB)(BB))⁴((BB)(BB))⁴)⁸)¹⁶((((AA)(AA))⁴((AA)(AA))⁴)⁸(((AA)(AA))⁴((AA)(AA))⁴)⁸)¹⁶ 3.2((((AA)(AA))⁴((AA)(AA))⁴)⁸(((BB)(BB))⁴((BB)(BB))⁴)⁸)¹⁶((((BB)(BB))⁴((BB)(BB))⁴)⁸(((AA)(AA))⁴((AA)(AA))⁴)⁸)¹⁶ 3.3((((AA)(AA))⁴((BB)(BB))⁴)⁸(((AA)(AA))⁴((BB)(BB))⁴)⁸)¹⁶((((BB)(BB))⁴((AA)(AA))⁴)⁸(((BB)(BB))⁴((AA)(AA))⁴)⁸)¹⁶ 3.4((((AA)(BB))⁴((AA)(BB))⁴)⁸(((AA)(BB))⁴((AA)(BB))⁴)⁸)¹⁶((((BB)(AA))⁴((BB)(AA))⁴)⁸(((BB)(AA))⁴((BB)(AA))⁴)⁸)¹⁶ 3.5((((AB)(AB))⁴((AB)(AB))⁴)⁸(((AB)(AB))⁴((AB)(AB))⁴)⁸)¹⁶((((AB)(AB))⁴((AB)(AB))⁴)⁸(((AB)(AB))⁴((AB)(AB))⁴)⁸)¹⁶

When a 16-tet is to be assembled from two functional moieties,represented by A and B this may be done by making use of the preferredcouplets, quartets and octets. The preferred composition of 16-tets canbe of the form:

((((AA)(AA))⁴((AA)(AB))⁴)⁸(((AA)(AA))⁴((AA)(AB))⁴)⁸)¹⁶

((((AA)(AA))⁴((AA)(AA))⁴)⁸(((AB)(AB))⁴((AB)(AB))⁴)⁸)¹⁶

((((AA)(AA))⁴((AB)(AB))⁴)⁸(((AB)(AB))⁴((AB)(AB))⁴)⁸)¹⁶

((((AA)(BB))⁴((AA)(BB))⁴)⁸(((AA)(BB))⁴((AA)(BB))⁴)⁸)¹⁶

In a preferred embodiment, the compositions of macromolecules ordendritic motifs include at least one 16-tet.

In another embodiment, the functional moieties attached to the surfacebuilding units of a macromolecule or dendritic motif are selected fromA, B and D. Consider FIG. 5 which provides schematic diagrams of fivedifferent topological isomers of macromolecules with the same ratio,2:1:1, of three functional moieties A, B and D. Furthermore thesemacromolecules have the same FM_(Total) and the same number of threefunctional moieties A, B and D, represented by FM_(A)=16, FM_(B)=8,FM_(D)=8, providing a description of the macromolecules in the form:ΣFM_(i)=(FM_(A)+FM_(B)+FM_(D))=16A+8B+8D=32. However it is important tonote that each of these examples has a different surface topology and itis the purpose of the alpha-numeric topological nomenclature to identifyand distinguish between these topological isomers where the number/typeof functional moieties of a macromolecule or dendritic motif is thesame.

When three different functional moieties A, B and D are attached to thesurface building units of a macromolecule or dendritic motif, preferredcouplets are selected from (AA), (BB), (DD), (AB), (AD) and (BD), andcombinations thereof.

The macromolecules of FIG. 5 are represented using couplets in thealpha-numeric topological nomenclature as follows:

TABLE 6 FIG. alpha-numeric topological nomenclature Composition 5.1(BB)(BB)(BB)(BB)(DD)(DD)(DD)(DD)(AA)(AA)(AA)(AA)(AA)(AA)(AA)(AA) 8 (AA),4 (BB) and 4 (DD) couplets 5.2(BB)(BB)(DD)(DD)(BB)(BB)(DD)(DD)(AA)(AA)(AA)(AA)(AA)(AA)(AA)(AA) 8 (AA),4 (BB) and 4 (DD) couplets 5.3(BB)(DD)(BB)(DD)(BB)(DD)(BB)(DD)(AA)(AA)(AA)(AA)(AA)(AA)(AA)(AA) 8 (AA),4 (BB) and 4 (DD) couplets 5.4(BD)(BD)(BD)(BD)(BD)(BD)(BD)(BD)(AA)(AA)(AA)(AA)(AA)(AA)(AA)(AA) 8 (AA)couplets and 4 (BD) couplets 5.5(AA)(AA)(AA)(AA)(BD)(BD)(BD)(BD)(BD)(BD)(BD)(BD)(AA)(AA)(AA)(AA) 8 (AA)couplets and 4 (BD) couplets

It is then possible to describe the macromolecules or dendritic motifsof this invention in terms of the composition (number and type) ofcouplets containing functional moieties selected from A, B and D. Thisis demonstrated for clarity in the examples of FIG. 5 and summarised inthe “composition” column of Table 6.

The surface topology of a macromolecule or dendritic motif bearingfunctional moieties A, B and D may also be described in terms ofcouplets and quartets. For example in the alpha-numeric topologicalnomenclature a quartet of the form ((AA)(BD))⁴ is used to represent fourfunctional moieties A,A,B,D which have a line of connection to the samebuilding unit, in particular to a surface-but-one building unit.

The macromolecules of FIG. 5 are represented using quartets in thealpha-numeric topological nomenclature as follows:

TABLE 7A FIG. alpha-numeric topological nomenclature Composition 5.1((BB)(BB))⁴((BB)(BB))⁴((DD)(DD))⁴((DD)(DD))⁴ 2 ((BB)(BB)) and 2((DD)(DD)) quartets; ((AA)(AA))⁴((AA)(AA))⁴((AA)(AA))⁴((AA)(AA))⁴ 4((AA)(AA)) quartets 5.2 ((BB)(BB))⁴((DD)(DD))⁴((BB)(BB))⁴((DD)(DD))⁴ 2((BB)(BB)) and 2 ((DD)(DD)) quartets;((AA)(AA))⁴((AA)(AA))⁴((AA)(AA))⁴((AA)(AA))⁴ 4 ((AA)(AA)) quartets 5.3((BB)(DD))⁴((BB)(DD))⁴((BB)(DD))⁴((BB)(DD))⁴ 4 ((BB)(DD)) quartets;((AA)(AA))⁴((AA)(AA))⁴((AA)(AA))⁴((AA)(AA))⁴ 4 ((AA)(AA)) quartets 5.4((BD)(BD))⁴((BD)(BD))⁴((BD)(BD))⁴((BD)(BD))⁴ 4 ((BD)(BD)) quartets((AA)(AA))⁴((AA)(AA))⁴((AA)(AA))⁴((AA)(AA))⁴ 4 ((AA)(AA)) quartets 5.5((AA)(AA))⁴((AA)(AA))⁴((BD)(BD))⁴((BD)(BD))⁴ 4 ((BD)(BD)) quartets((BD)(BD))⁴((BD)(BD))⁴((AA)(AA))⁴((AA)(AA))⁴ 4 ((AA)(AA)) quartets

It is also possible to describe the macromolecules or dendritic motifsof this invention in terms of the composition (number and type) ofquartets. This is demonstrated for clarity in the examples of FIG. 5 andsummarised in the “composition” column of Table 7.

When a quartet is to be assembled from three functional moieties,represented by A, B and D, this may be done by making use of preferredcouplets. The preferred composition of quartets additional to those inTable 3B can be of the form:

TABLE 7B Ratio Type of quartet Equivalent quartet 2:1:1 ((AA)(BD))⁴((BB)(AD))⁴ ((DD)(AB))⁴ 2:1:1 ((AB)(AD))⁴ ((BD)(AB))⁴ ((BD)(AD))⁴

In a preferred embodiment, the compositions of macromolecules ordendritic motifs include at least one quartet selected from Table 3B or7B, including those quartets which can be considered equivalent by wayof their topology and relative composition of two or three differentfunctional moieties.

The surface topology of a macromolecule or dendritic motif bearingfunctional moieties A, B and D may also be described in terms ofcouplets, quartets and octets. For example in the alpha-numerictopological nomenclature an octet of the form (((AA)(AA))⁴((BB)(DD))⁴)⁸is used to represent eight functional moieties A,A,A,A,B,B,D,D whichhave a line of connection to the same building unit, in particular to asurface-but-two unit.

The macromolecules of FIG. 5 are represented using octets in thealpha-numeric topological nomenclature as follows:

TABLE 8A FIG. alpha-numeric topological nomenclature Composition 5.1(((BB)(BB))⁴((BB)(BB))⁴)⁸(((DD)(DD))⁴((DD)(DD))⁴)⁸ 2(((AA)(AA))⁴((AA)(AA))⁴)⁸ octets(((AA)(AA))⁴((AA)(AA))⁴)⁸(((AA)(AA))⁴((AA)(AA))⁴)⁸ 1(((BB)(BB))⁴((BB)(BB))⁴)⁸ octet 1 (((DD)(DD))⁴((DD)(DD))⁴)⁸ octet 5.2(((BB)(BB))⁴((DD)(DD))⁴)⁸(((BB)(BB))⁴((DD)(DD))⁴)⁸ 2(((AA)(AA))⁴((AA)(AA))⁴)⁸ octets(((AA)(AA))⁴((AA)(AA))⁴)⁸(((AA)(AA))⁴((AA)(AA))⁴)⁸ 2(((BB)(BB))⁴((DD)(DD))⁴)⁸ octets 5.3(((BB)(DD))⁴((BB)(DD))⁴)⁸(((BB)(DD))⁴((BB)(DD))⁴)⁸ 2(((AA)(AA))⁴((AA)(AA))⁴)⁸ octets(((AA)(AA))⁴((AA)(AA))⁴)⁸(((AA)(AA))⁴((AA)(AA))⁴)⁸ 2(((BB)(DD))⁴((BB)(DD))⁴)⁸ octets 5.4(((BD)(BD))⁴((BD)(BD))⁴)⁸(((BD)(BD))⁴((BD)(BD))⁴)⁸ 2(((AA)(AA))⁴((AA)(AA))⁴)⁸ octets(((AA)(AA))⁴((AA)(AA))⁴)⁸(((AA)(AA))⁴((AA)(AA))⁴)⁸ 2(((BD)(BD))⁴((BD)(BD))⁴)⁸ octets 5.5(((AA)(AA))⁴((AA)(AA))⁴)⁸(((BD)(BD))⁴((BD)(BD))⁴)⁸ 2(((AA)(AA))⁴((AA)(AA))⁴)⁸ octets(((BD)(BD))⁴((BD)(BD))⁴)⁸(((AA)(AA))⁴((AA)(AA))⁴)⁸ 2(((BD)(BD))⁴((BD)(BD))⁴)⁸ octets

It is then possible to describe the macromolecules or dendritic motifsof this invention in terms of the composition (number and type) ofoctets. This is demonstrated for clarity in the examples of FIG. 5 andsummarised in the “composition” column of Table 8A.

When an octet is to be assembled from three functional moieties,represented by A, B and D, this may be done by making use of preferredquartets from Table 3B or 7B. The preferred composition of octetsadditional to those in Table 4B can be of the form:

TABLE 8B Ratio Type of Octet Examples of Equivalent Octets homog-(((DD)(DD))⁴((DD)(DD))⁴)⁸ enous 6:1:1 (((AA)(AA))⁴((AA)(BD))⁴)⁸(((BB)(BB))⁴((BB)(AD))⁴)⁸ (((AA)(AA))⁴((AB)(AD))⁴)⁸(((BB)(BB))⁴((AB)(BD))⁴)⁸ (((AA)(AB))⁴((AA)(AD))⁴)⁸(((BB)(AB))⁴((BB)(BD))⁴)⁸ 5:2:1 (((AA)(AA))⁴((AD)(BB))⁴)⁸(((BB)(BB))⁴((BD)(AA))⁴)⁸ (((AA)(AA))⁴((AB)(BD))⁴)⁸(((BB)(BB))⁴((AB)(AD))⁴)⁸ (((AA)(AB))⁴((AA)(BD))⁴)⁸(((BB)(AB))⁴((BB)(AD))⁴)⁸ (((AA)(AB))⁴((AB)(AD))⁴)⁸(((BB)(AB))⁴((AB)(BD))⁴)⁸ 4:3:1 (((AA)(AA))⁴((BB)(BD))⁴)⁸(((AA)(AB))⁴((DD)(DD))⁴)⁸ (((AA)(AD))⁴((BB)(BA))⁴)⁸(((AA)(AD))⁴((BD)(DD))⁴)⁸ (((AA)(AB))⁴((AB)(BD))⁴)⁸(((AA)(BD))⁴((AD)(DD))⁴)⁸ (((AA)(AB))⁴((BB)(AD))⁴)⁸(((AD)(BD))⁴((AD)(DD))⁴)⁸ (((AA)(BD))⁴((AA)(BB))⁴)⁸(((AA)(DD))⁴((AB)(DD))⁴)⁸ (((AA)(BD))⁴((AB)(BB))⁴)⁸(((AA)(DD))⁴((AD)(BD))⁴)⁸ (((AB)(AD))⁴((AA)(BB))⁴)⁸(((AD)(AD))⁴((AB)(DD))⁴)⁸ (((AB)(AD))⁴((AB)(AB))⁴)⁸(((AD)(AD))⁴((AD)(BD))⁴)⁸ 4:2:2 (((AA)(AA))⁴((BB)(DD))⁴)⁸(((BB)(BB))⁴((AA)(DD))⁴)⁸ (((AA)(AA))⁴((BD)(BD))⁴)⁸(((BB)(BB))⁴((AD)(AD))⁴)⁸ (((AA)(AB))⁴((AB)(DD))⁴)⁸(((BB)(AB))⁴((AB)(DD))⁴)⁸ (((AA)(AB))⁴((AD)(BD))⁴)⁸(((BB)(AB))⁴((AD)(BD))⁴)⁸ (((AA)(BB))⁴((AA)(DD))⁴)⁸(((AA)(BB))⁴((BB)(DD))⁴)⁸ (((AA)(BB))⁴((AD)(AD))⁴)⁸(((AA)(BB))⁴((BD)(BD))⁴)⁸ (((AB)(AB))⁴((AA)(DD))⁴)⁸(((AB)(AB))⁴((BB)(DD))⁴)⁸ (((AB)(AB))⁴((AD)(AD))⁴)⁸(((AB)(AB))⁴((AD)(AD))⁴)⁸ 3:3:2 (((AA)(AB))⁴((BB)(DD))⁴)⁸(((BB)(AB))⁴((AA)(DD))⁴)⁸ (((AA)(AB))⁴((BD)(BD))⁴)⁸(((BB)(AB))⁴((AD)(AD))⁴)⁸ (((AA)(BB))⁴((AB)(DD))⁴)⁸(((AA)(DD))⁴((AD)(BB))⁴)⁸ (((AA)(BB))⁴((AD)(BD))⁴)⁸(((AA)(DD))⁴((AB)(BD))⁴)⁸ (((AB)(AB))⁴((AB)(DD))⁴)⁸(((AD)(AD))⁴((AD)(BB))⁴)⁸ (((AB)(AB))⁴((AD)(BD))⁴)⁸(((AD)(AD))⁴((AB)(BD))⁴)⁸

In a preferred embodiment, the compositions of macromolecules ordendritic motifs include at least one octet selected from Table 4B or8B, including those octets which can be considered equivalent by way oftheir topology and relative composition of two or three differentfunctional moieties.

The surface topology of a macromolecule or dendritic motif bearingfunctional moieties A, B and D may also be described in terms ofcouplets, quartets, octets and 16-tets. For example in the alpha-numerictopological nomenclature a 16-tet of the form((((AA)(AA))⁴((AA)(AA))⁴)⁸(((BB)(DD))⁴((BB)(DD))⁴)⁸)¹⁶ is used torepresent the sixteen functional moieties which have a line ofconnection to the same building unit, in fact to a surface-but-threebuilding unit.

The macromolecules of FIG. 5 are represented using 16-tets in thealpha-numeric topological nomenclature as follows:

TABLE 9A FIG. alpha-numeric topological nomenclature 5.1((((BB)(BB))⁴((BB)(BB))⁴)⁸(((DD)(DD))⁴((DD)(DD))⁴)⁸)¹⁶((((AA)(AA))⁴((AA)(AA))⁴)⁸(((AA)(AA))⁴((AA)(AA))⁴)⁸)¹⁶ 5.2((((BB)(BB))⁴((DD)(DD))⁴)⁸(((BB)(BB))⁴((DD)(DD))⁴)⁸)¹⁶((((AA)(AA))⁴((AA)(AA))⁴)⁸(((AA)(AA))⁴((AA)(AA))⁴)⁸)¹⁶ 5.3((((BB)(DD))⁴((BB)(DD))⁴)⁸(((BB)(DD))⁴((BB)(DD))⁴)⁸)¹⁶((((AA)(AA))⁴((AA)(AA))⁴)⁸(((AA)(AA))⁴((AA)(AA))⁴)⁸)¹⁶ 5.4((((BD)(BD))⁴((BD)(BD))⁴)⁸(((BD)(BD))⁴((BD)(BD))⁴)⁸)¹⁶((((AA)(AA))⁴((AA)(AA))⁴)⁸(((AA)(AA))⁴((AA)(AA))⁴)⁸)¹⁶ 5.5((((AA)(AA))⁴((AA)(AA))⁴)⁸(((BD)(BD))⁴((BD)(BD))⁴)⁸)¹⁶((((BD)(BD))⁴((BD)(BD))⁴)⁸(((AA)(AA))⁴((AA)(AA))⁴)⁸)¹⁶where:

-   -   there is one        ((((AA)(AA))⁴((AA)(AA))⁴)⁸(((AA)(AA))⁴((AA)(AA))⁴)⁸)¹⁶ and one        ((((BB)(BB))⁴((BB)(BB))⁴)⁸(((DD)(DD))⁴((DD)(DD))⁴)⁸)¹⁶ 16-tet in        FIG. 5.1;    -   there is one        ((((AA)(AA))⁴((AA)(AA))⁴)⁸(((AA)(AA))⁴((AA)(AA))⁴)⁸)¹⁶ and one        ((((BB)(BB))⁴((DD)(DD))⁴)⁸(((BB)(BB))⁴((DD)(DD))⁴)⁸)¹⁶ 16-tet in        FIG. 5.2;    -   there is one        ((((AA)(AA))⁴((AA)(AA))⁴)⁸(((AA)(AA))⁴((AA)(AA))⁴)⁸)¹⁶ and one        ((((BB)(DD))⁴((BB)(DD))⁴)⁸(((BB)(DD))⁴((BB)(DD))⁴)⁸)¹⁶ 16-tet in        FIG. 5.3;    -   there is one        ((((AA)(AA))⁴((AA)(AA))⁴)⁸(((AA)(AA))⁴((AA)(AA))⁴)⁸)¹⁶ and one        ((((BD)(BD))⁴((BD)(BD))⁴)⁸(((BD)(BD))⁴((BD)(BD))⁴)⁸)¹⁶ 16-tet in        FIG. 5.4; and    -   there are two        ((((AA)(AA))⁴((AA)(AA))⁴)⁸(((BD)(BD))⁴((BD)(BD))⁴)⁸)¹⁶ 16-tets        in FIG. 5.5.

It is then possible to describe the macromolecules or dendritic motifsof this invention in terms of the composition (number and type) of16-tets. This is demonstrated for clarity in the examples of FIG. 5 andsummarised in dot point form above.

When a 16-tet is to be assembled from three functional moieties,represented by A, B and D, this may be done by making use of thepreferred couplets, quartets and octets.

In a preferred embodiment, the compositions of macromolecules ordendritic motifs include at least one 16-tet.

Linkers

It may be desirable to alter the surface composition and/or topology ofa macromolecule or to provide an additional property to a functionalmoiety or macromolecule by way of the means through which the functionalmoiety is attached to the surface amine or surface building unit. Thismay be achieved by introducing linkers to the dendritic motif.Accordingly the macromolecules of the present invention as describedherein may include functional moieties optionally attached to thesurface or subsurface layers via linkers.

Linker moieties may be incorporated into the synthesis of a dendriticmotif by substitution for a building unit. A linker moiety comprises tworeactive groups, F and Y, which are connected by one or more carbons orheteroatoms, preferably by a hydrocarbon backbone. The functional groupF may be activated to react with reactive amine moieties such as thoseon a core or dendritic motif. Typically the functional group F is acarboxylate group or residue thereof. The other functional group, Y, maybe either an amine carrying a protecting group, or it is selected suchthat it has a specific reactivity that is complementary to a reactivegroup of a desired functional moiety that is to be attached to thesurface of a dendritic motif. Typical examples of Y include amine,carboxylate, amine, hydroxyl, thiol, alkyl halide, allyl halide,heteroaryl halide, aryl halide, vinyl halide, epoxide, aziridine azide,alkene or alkyne.

When linker moieties are incorporated in a dendritic motif, and thegroup Y is intended for further reaction with a building unit, then thegroup Y is a protected amine. Where linker moieties are used to connectfunctional moieties to the surface building units or building units ofdendritic motifs, the reaction between the linker and the functionalmoiety may be carried out either before, or after, the linker moiety isreacted with the surface building unit or building unit of the dendriticmotif.

Linkers by definition maintain but do not amplify the number of surfaceamine groups of a macromolecule or dendritic motif. The surfacecomposition and topology of a macromolecule which includes a completelayer of linkers, either attached to the surface amine groups or to theamine groups of a subsurface building unit, is equivalent to amacromolecule or dendritic motif which lacks this complete layer oflinkers.

The number of functional moieties on the surface of a macromolecule ordendritic motif is reduced when a building unit is replaced a linker.

For example:

Description of structure Resulting Surface Stoichiometry Linker replacesone surface building unit:

 1 functional moiety in affected couplet  3 functional moieties inaffected quartet  7 functional moieties in affected octet 15 functionalmoieties in affected 16-tet Linker replaces one surface-but-one buildingunit:

 2 functional moieties affected quartet  6 functional moieties inaffected octet 14 functional moieties in affected 16-tet Linker replacesone surface-but-two building unit:

 4 functional moieties in affected octet 12 functional moieties inaffected 16-tet

Incorporation of linkers is described in more detail below.

When linker moieties are incorporated in a macromolecule or dendriticmotif, and the group Y is intended for further reaction with a buildingunit, then the group Y is a protected amine. Once a linker has beenadded to a macromolecule or dendritic motif the reactable amine group ofthe linker serves the same purpose as a surface amine group and isdefined as such. Where linker moieties are used to connect functionalmoieties to the surface amine groups and/or surface building units ofmacromolecules or dendritic motifs, the reaction between the linker andthe functional moiety may be carried out either before, or after, thelinker moiety is reacted with the surface building units or buildingunits of the dendritic motif.

A reaction which is used to introduce one or more linker moieties to adendritic motif is conducted to ensure the complete reaction of alldeprotected surface amines of a macromolecule or dendritic motif withthe linker moieties. Typically this is done by using an excess of thechosen linker moiety.

The total number of functional moieties in a macromolecule or dendriticmotif in which linkers have been used can be represented by FM_(Total).The composition of functional moieties of a macromolecule or dendriticmotif, wherein all the surface amine groups and/or surface buildingunits are attached to functional moieties, can also be provided in termsof FM_(Total) in a formula of the form ΣFM_(i)=FM_(total) where thesurface of the macromolecule or dendritic motif has an integral quantityFM_(i) of functional moieties of type i: (FM_(i)=FM_(A), FM_(B) . . .FM_(Z)). Consider FIG. 7 which provides schematic diagrams of fivedifferent topological isomers of macromolecules wherein linkers havebeen used at various stages in the macromolecule synthesis. Each ofthese macromolecules can be described by a formulaΣFM_(i)=_(l)FM_(total), for example ΣFM_(i)=(8A+16B+4D)=28 for FIG. 7.1;ΣFM_(i)=(8A+16B)=24 for FIG. 7.2; ΣFM_(i)=(8A+8B+8D)=24 for FIG. 7.3;ΣFM_(i)=(12A+8B+4D)=24 for FIG. 7.4 and ΣFM_(i)=(8A+8B)=16 for FIG. 7.5.

The alpha-numeric topological nomenclature of couplets, quartets, octetsand beyond is able to provide a description of the functional moietycomposition in addition to the topology of macromolecules and dendriticmotifs in which linkers have been used by making use of the maximumfunctional moiety number FM_(MAX) in addition to utilising the nullsymbol Ø. The null groups can also be used in descriptions of “work inprogress” intermediates or growing macromolecules or dendritic motifs,which have an incomplete surface layer of building units due tosubsurface building units having not yet been reacted (as illustrated inthe examples). The use of null symbols maintains the integrity of theouter FM_(MAX).

The term FM_(MAX) is used to represent the number of functional moietiesthat would be present on a macromolecule or dendritic motif in ascenario wherein the layer of surface building units is complete and nobuilding units have been replaced by linkers in the preparation thereof,and can be calculated using the formula:FM _(Max) =N _(Core) ×N _(First Building Unit) × . . . ×FM_(Surface Building Unit)where:N_(core) is the number of reactable amines on the core to which buildingunits could be attached (this value is deleted when FM_(Max) iscalculated for dendritic motifs);N_(First building unit) is the number of reactable amines on thebuilding unit used in the first layer out from the core (when FM_(Max)is calculated for a dendritic motif, N_(First building unit) is thatbuilding unit with the apex carboxylate);FM_(Surface building unit) is the number of reactable amines on thesurface building unit used in the preparation of the macromolecule ordendritic motif;

In one example of a calculation of FM_(Max) for a dendritic motif,consider that lysine has two reactable amines and so from the apexcarboxylate a motif with two additional layers of lysine would have anFM_(MAX) of 2×2×2=8.

In a second example of a calculation of FM_(Max) for a macromolecule,consider FIG. 7.1 which is a macromolecule comprising 4 layers oflysine, each with two reactable amine groups from a core with tworeactable amine groups. The FM_(Max) for this macromolecule is thus2×2×2×2×2=32.

Identifiable differences between dendritic motifs which are enrichedwith respect to surface composition and in which linkers have been usedmay be described utilising the null symbol Ø in concert with knowledgeof the maximum functional moiety number FM_(Max). The null symbols andtheir inclusion in the alpha-numeric topological nomenclature make itpossible to describe the connectivity between the functional moietiesand the subsurface layers of building units when building units havebeen replaced by linkers. The use of the null symbol Ø in thealpha-numeric topological descriptions of macromolecules or dendriticmotifs that include linkers is demonstrated by example, making use ofthe schematic diagrams of FIGS. 6 and 7.

The examples of FIG. 7 are included to demonstrate how the alpha-numerictopological nomenclature can be used to provide a description ofmacromolecules that include linkers which have a defined surfacetopology in addition to a defined composition of functional moieties. Inparticular the nomenclature makes it possible to identify the preferredcouplets, quartets, octets and 16-tets which are components ofmacromolecules, and which are a preferred embodiment of this invention.

The use of the null symbols enables concepts such as doublets, quartets,octets and 16-tets to be retained in the alpha-numeric topologicalnomenclature when end stopping functional moieties (see below) orlinkers are used in the synthesis of a dendritic motif. The null symbolsand their inclusion in the topological nomenclature describe that partof a dendritic motif which has been lost as a result of replacingbuilding units with linkers or end stopping moieties in end stoppingreactions.

Consider FIG. 6.1 which represents a macromolecule comprising 4 layersof building units each with two reactable amine groups from a core withtwo reactable amine groups. The FM_(Max) for this macromolecule is thus2×2×2×2×2=32. In those circumstances where linkers are used only toattach functional moieties to the surface building units,FM_(Max)=FM_(Total). There is no requirement for the Ø null symbolunless a linker replaces a building unit or end stopping reaction hasbeen used on the surface amine group of a subsurface building unit.

A description of topology to the level of quartets is required todescribe the subsurface connectivity for macromolecules wherein surfacebuilding units have been replaced by linkers. It may be seen in FIG. 6.2that for each surface building unit that is replaced by a linker, avalue of 1 represented by Ø is lost from the final outer surfaceFM_(Total) so that FM_(Total)+ΣØ=FM_(Max). The use of the null symbolsrestores the integrity of the outer FM_(Total). In F6.2, the use of Ø isdemonstrated as the functional moieties and null symbols related to thesurface-but-one building units are gathered into their related coupletsand quartets. When one surface building unit is replaced by a linker,one of the couplets will contain a functional moiety and a null symbol,and the other couplet will contain two functional moieties, providingquartets of the form: ((AA)(AØ))⁴ and ((BB)(BØ))⁴. The quartet((AA)(AØ))⁴ indicates that there are three functional moieties A,A,A andall have a line of connection to the same building unit, in particularto the surface-but-one building unit and further indicates that couplet(AA) and functional moiety A are attached to the same building unit.Couplets that contain one or more null symbols Ø may be grouped togetherwith other couplets to provide quartet, octet and 16-tet descriptions ofsurface topology.

When three different functional moieties A, B and D are attached to thesurface building units of a macromolecule or dendritic motif, and atleast one building unit has been replaced by a linker, preferredcouplets are selected from (AA), (BB), (DD), (AB), (AD), (BD), (AØ),(BØ) and (DØ) and combinations thereof.

The macromolecules of FIG. 7 are described in terms of couplets makinguse of the alpha-numeric topological nomenclature as follows:

TABLE 10 FIG. alpha-numeric topological nomenclature Composition 7.1(DØ)(AA)(BB)(BB)(DØ)(AA)(BB)(BB) 4 (AA), 8 (BB) and 4 (DØ) couplets(DØ)(AA)(BB)(BB)(DØ)(AA)(BB)(BB) 7.2 (AA)(ØØ)(BB)(BB)(AA)(ØØ)(BB)(BB) 4(AA), 8 (BB) and 4 (ØØ) couplets (AA)(ØØ)(BB)(BB)(AA)(ØØ)(BB)(BB) 7.3(DD)(DD)(ØØ)(ØØ)(AA)(AA)(BB)(BB) 4 (AA), 4 (BB), 4 (DD) and 4 (ØØ)(DD)(DD)(ØØ)(ØØ)(AA)(AA)(BB)(BB) couplets 7.4(DD)(DD)(AA)(AA)(ØØ)(ØØ)(ØØ)(ØØ) 6 (AA), 4 (BB), 2 (DD) and 4 (ØØ)(AA)(AA)(BB)(BB)(AA)(AA)(BB)(BB) couplets 7.5(AA)(AA)(BB)(BB)(ØØ)(ØØ)(ØØ)(ØØ) 4 (AA), 4 (BB) and 8 (ØØ) couplets(AA)(AA)(ØØ)(ØØ)(BB)(BB)(ØØ)(ØØ)

It is possible to describe the macromolecules or dendritic motifs ofthis invention that contain linkers in terms of the composition (numberand type) of couplets containing functional moieties A, B and D andmaking use of the null symbol Ø. This is demonstrated for clarity in theexamples of FIG. 7 and summarised in the “composition” column of Table10.

The macromolecules of FIG. 7 are described in terms of quartets makinguse of the alpha-numeric topological nomenclature as follows:

TABLE 11A FIG. alpha-numeric topological nomenclature Composition 7.1((DØ)(AA))⁴((BB)(BB))⁴((DØ)(AA))⁴((BB)(BB))⁴ 4 ((BB)(BB))⁴ and 4((DØ)(AA))⁴ quartets ((DØ)(AA))⁴((BB)(BB))⁴((DØ)(AA))⁴((BB)(BB))⁴ 7.2((AA)(ØØ))⁴((BB)(BB))⁴((AA)(ØØ))⁴((BB)(BB))⁴ 4 ((AA)(ØØ))⁴ and 4((BB)(BB))⁴ quartets ((AA)(ØØ))⁴((BB)(BB))⁴((AA)(ØØ))⁴((BB)(BB))⁴ 7.3((DD)(DD))⁴((ØØ)(ØØ))⁴((AA)(AA))⁴((BB)(BB))⁴ 2 ((AA)(AA))⁴, 2((BB)(BB))⁴, 2 ((DD)(DD))⁴((ØØ)(ØØ))⁴((AA)(AA))⁴((BB)(BB))⁴ ((DD)(DD))⁴and 2 ((ØØ)(ØØ))⁴ quartets 7.4((DD)(DD))⁴((AA)(AA))⁴((ØØ)(ØØ))⁴((ØØ)(ØØ))⁴ 3 ((AA)(AA))⁴, 2((BB)(BB))⁴, 1 ((AA)(AA))⁴((BB)(BB))⁴((AA)(AA))⁴((BB)(BB))⁴ ((DD)(DD))⁴and 2 ((ØØ)(ØØ))⁴ quartets 7.5((AA)(AA))⁴((BB)(BB))⁴((ØØ)(ØØ))⁴((ØØ)(ØØ))⁴ 2 ((AA)(AA))⁴, 2((BB)(BB))⁴, and 4 ((AA)(AA))⁴((ØØ)(ØØ))⁴((BB)(BB))⁴((ØØ)(ØØ))⁴((ØØ)(ØØ))⁴ quartets

It is possible to describe the macromolecules or dendritic motifs ofthis invention that contain linkers in terms of the composition (numberand type) of quartets. This is demonstrated for clarity in the examplesof FIG. 7 and summarised in the “composition” column of Table 11A.

When a quartet is to be assembled from three functional moietiesrepresented by A, B and D; and at least one building unit has beenreplaced by a linker, this may be done by making use of the preferredcouplets, in addition to using the null couplet (ØØ).

In a preferred embodiment, the composition of macromolecules ordendritic motifs includes at least one quartet selected from the set:

TABLE 11B Ratio Type of quartet Examples of equivalent quartetshomogenous ((AA)(AØ))⁴ ((BB)(BØ))⁴ ((DD)(DØ))⁴ homogenous ((AA)(ØØ))⁴((BB)(ØØ))⁴ homogenous ((AØ)(AØ))⁴ ((BØ)(BØ))⁴ homogenous ((AØ)(ØØ))⁴((DØ)(ØØ))⁴ 2:1 ((AA)(BØ))⁴ ((AA)(DØ))⁴ ((BB)(AØ))⁴ ((BB)(DØ))⁴ 2:1((AB)(AØ))⁴ ((AD)(AØ))⁴ ((AB)(BØ))⁴ ((BD)(BØ))⁴ 1:1 ((AB)(ØØ))⁴((BD)(ØØ))⁴ 1:1 ((AØ)(BØ))⁴ ((BØ)(DØ))⁴ 1:1:1 ((AB)(DØ))⁴ ((AD)(BØ))⁴((BD)(AØ))⁴

In a preferred embodiment, the compositions of macromolecules ordendritic motifs include at least one quartet selected from Table 3B or7B or 11B, including those quartets which can be considered equivalentby way of their topology and relative composition of two or threedifferent functional moieties.

A description of topology to the level of octets is required to describethe subsurface connectivity for macromolecules wherein surface-but-onebuilding units have been replaced by linkers. It may be seen in FIG. 6.3that for each surface-but-one building units that is replaced by alinker, a value of 2 represented by ØØ is lost from the final outersurface FM_(Total) so that FM_(Total)+ΣØ=FM_(Max). The use of the nullsymbols restores the integrity of the outer FM_(Total).

In F6.3, the use of ØØ is demonstrated as the functional moieties andnull symbols related to the surface-but-two building units are gatheredinto their related couplets, quartets and octets. When onesurface-but-one building unit is replaced by a linker, one of thequartets of the octet will contain a null couplet (ØØ), and the othercouplet will contain two functional moieties. The second quartet will becomplete, providing octets of the form: (((AA)(AA))⁴((AA)(ØØ))⁴)⁸ and(((BB)(BB))⁴((BB)(ØØ))⁴)⁸. The octet (((AA)(AA))⁴((AA)(ØØ))⁴)⁸ indicatesthat there are six functional moieties A,A,A,A,A,A all having a line ofconnection to the same building unit, in particular to thesurface-but-two building unit and further indicates that quartet((AA)(AA))⁴ and couplet (AA) are attached to the same building unit.Quartets that contain one or more null symbols Ø may be grouped togetherwith other quartets to provide octet and 16-tet descriptions of surfacetopology.

The macromolecules of FIG. 7 are described in terms of octets making useof the alpha-numeric topological nomenclature as follows:

TABLE 12A FIG. alpha-numeric topological nomenclature Composition 7.1(((DØ)(AA))⁴((BB)(BB))⁴)⁸(((DØ)(AA))⁴((BB)(BB))⁴)⁸ 4(((DØ)(AA))⁴((BB)(BB))⁴)⁸ octets(((DØ)(AA))⁴((BB)(BB))⁴)⁸(((DØ)(AA))⁴((BB)(BB))⁴)⁸ 7.2(((AA)(ØØ))⁴((BB)(BB))⁴)⁸(((AA)(ØØ))⁴((BB)(BB))⁴)⁸ 4(((AA)(ØØ))⁴((BB)(BB))⁴)⁸ octets(((AA)(ØØ))⁴((BB)(BB))⁴)⁸(((AA)(ØØ))⁴((BB)(BB))⁴)⁸ 7.3(((DD)(DD))⁴((ØØ)(ØØ))⁴)⁸(((AA)(AA))⁴((BB)(BB))⁴)⁸ 2(((DD)(DD))⁴((ØØ)(ØØ))⁴)⁸ and(((DD)(DD))⁴((ØØ)(ØØ))⁴)⁸(((AA)(AA))⁴((BB)(BB))⁴)⁸ 2(((AA)(AA))⁴((BB)(BB))⁴)⁸ octets 7.4(((DD)(DD))⁴((AA)(AA))⁴)⁸(((ØØ)(ØØ))⁴((ØØ)(ØØ))⁴)⁸ 2(((AA)(AA))⁴((BB)(BB))⁴)⁸ octets,(((AA)(AA))⁴((BB)(BB))⁴)⁸(((AA)(AA))⁴((BB)(BB))⁴)⁸ 1(((DD)(DD))⁴((AA)(AA))⁴)⁸ and 1 (((ØØ)(ØØ))⁴((ØØ)(ØØ))⁴)⁸ octet 7.5(((AA)(AA))⁴((BB)(BB))⁴)⁸(((ØØ)(ØØ))⁴((ØØ)(ØØ))⁴)⁸ 1(((AA)(AA))⁴((BB)(BB))⁴)⁸,(((AA)(AA))⁴((ØØ)(ØØ))⁴)⁸(((BB)(BB))⁴((ØØ)(ØØ))⁴)⁸ 1(((AA)(AA))⁴((ØØ)(ØØ))⁴)⁸ , 1 (((BB)(BB))⁴((ØØ)(ØØ))⁴)⁸, and 1(((ØØ)(ØØ))⁴((ØØ)(ØØ))⁴)⁸ octet

It is possible to describe the macromolecules or dendritic motifs ofthis invention that contain linkers in terms of the composition (numberand type) of octets. This is demonstrated for clarity in the examples ofFIG. 7 and summarised in the “composition” column of Table 12A.

When an octet is to be assembled from three functional moietiesrepresented by A, B and D; and at least one building unit has beenreplaced by a linker, this may be done by making use of the preferredquartets from Table 3B, 7B and 11B, in addition to using the nullquartet ((ØØ)(ØØ))⁴ in the manner which has been demonstrated forcombining quartets to provide octets above.

In a preferred embodiment, the composition of macromolecules ordendritic motifs includes at least one octet selected from the set:(((AA)(AA))⁴((AB)(AØ))⁴)⁸, (((AA)(AB))⁴((AA)(DØ))⁴)⁸,(((AA)(AB))⁴((AD)(BØ))⁴)⁸, (((AB)(AD))⁴((AB)(DØ))⁴)⁸,((AA)(AØ))⁴((AB)(AØ))⁴)⁸, (((AB)(AD))⁴((AØ)(AØ))⁴) 8 or(((AB)(AD))⁴((AØ)(BØ))⁴)⁸.

A description of topology to the level of 16-tets is required todescribe the subsurface connectivity for macromolecules whereinsurface-but-two building units have been replaced by linkers. It may beseen in FIG. 6.4 that for each surface-but-two building unit that isreplaced by a linker, a value of 4 represented by ØØØØ is lost from thefinal outer surface FM_(Total) so that FM_(Total)+ΣØ=FM_(MAX). The useof the null symbols restores the integrity of the outer FM_(Total).

In F6.4, the use of ØØØØ is demonstrated as the functional moieties andnull symbols related to the surface-but-three building units aregathered into their related couplets, quartets, octets and 16-tets. Whenone surface-but-two building unit is replaced by a linker, one of theoctets will contain a null quartet ((ØØ)(ØØ))⁴, and the other quartetwill contain four functional moieties. The second octet will becomplete, providing 16-tets of the form:((((AA)(AA))⁴((AA)(AA))⁴)⁸(((AA)(AA))⁴((ØØ)(ØØ))⁴)⁸)¹⁶ and((((BB)(BB))⁴((BB)(BB))⁴)⁸(((BB)(BB))⁴((ØØ)(ØØ))⁴)⁸)¹⁶. The 16-tet(AA)(AA))⁴((AA)(AA))⁴)⁸(((AA)(AA))⁴((ØØ)(ØØ))⁴)⁸)¹⁶ indicates that thereare 12 functional moieties of type A all having a line of connection tothe same building unit, in particular to the surface-but-three buildingunit and further indicates that octet (((AA)(AA))⁴((AA)(AA))⁴)⁸ andquartet ((AA)(AA))⁴ are attached to the same building unit. Octets thatcontain one or more null symbols Ø may be grouped together with otheroctets to provide 16-tet descriptions of surface topology.

The macromolecules of FIG. 7 are described in terms of 16-tets makinguse of the alpha-numeric topological nomenclature as follows:

TABLE 13 FIG. alpha-numeric topological nomenclature 7.1((((DØ)(AA))⁴((BB)(BB))⁴)⁸(((DØ)(AA))⁴((BB)(BB))⁴)⁸)¹⁶((((DØ)(AA))⁴((BB)(BB))⁴)⁸(((DØ)(AA))⁴((BB)(BB))⁴)⁸)¹⁶ 7.2((((AA)(ØØ))⁴((BB)(BB))⁴)⁸(((AA)(ØØ))⁴((BB)(BB))⁴)⁸)¹⁶((((AA)(ØØ))⁴((BB)(BB))⁴)⁸(((AA)(ØØ))⁴((BB)(BB))⁴)⁸)¹⁶ 7.3((((DD)(DD))⁴((ØØ)(ØØ))⁴)⁸(((AA)(AA))⁴((BB)(BB))⁴)⁸)¹⁶((((DD)(DD))⁴((ØØ)(ØØ))⁴)⁸(((AA)(AA))⁴((BB)(BB))⁴)⁸)¹⁶ 7.4((((DD)(DD))⁴((AA)(AA))⁴)⁸(((ØØ)(ØØ))⁴((ØØ)(ØØ))⁴)⁸)¹⁶((((AA)(AA))⁴((BB)(BB))⁴)⁸(((AA)(AA))⁴((BB)(BB))⁴)⁸)¹⁶ 7.5((((AA)(AA))⁴((BB)(BB))⁴)⁸(((ØØ)(ØØ))⁴((ØØ)(ØØ))⁴)⁸)¹⁶((((AA)(AA))⁴((ØØ)(ØØ))⁴)⁸(((BB)(BB))⁴((ØØ)(ØØ))⁴)⁸)¹⁶where:

-   -   there are two        ((((DØ)(AA))⁴((BB)(BB))⁴)⁸(((DØ)(AA))⁴((BB)(BB))⁴)⁸)¹⁶ 16-tets        in FIG. 7.1;    -   a there are two        ((((AA)(ØØ))⁴((BB)(BB))⁴)⁸(((AA)(ØØ))⁴((BB)(BB))⁴)⁸)¹⁶ 16-tets        in FIG. 7.2;    -   there are two        ((((DD)(DD))⁴((ØØ)(ØØ))⁴)⁸(((AA)(AA))⁴((BB)(BB))⁴)⁸)¹⁶ 16-tets        in FIG. 7.3;    -   there is one        ((((DD)(DD))⁴((AA)(AA))⁴)⁸(((ØØ)(ØØ))⁴((ØØ)(ØØ))⁴)⁸)¹⁶ and one        ((((AA)(AA))⁴((BB)(BB))⁴)⁸(((AA)(AA))⁴((BB)(BB))⁴)⁸)¹⁶ 16-tet in        FIG. 7.4; and    -   there is one        ((((AA)(AA))⁴((BB)(BB))⁴)⁸(((ØØ)(ØØ))⁴((ØØ)(ØØ)⁴)⁸)¹⁶ one        ((((AA)(AA))⁴((ØØ)(ØØ))⁴)⁸(((BB)(BB))⁴((ØØ)(ØØ))⁴)⁸)¹⁶ 16-tet in        FIG. 7.5.

It is possible to describe the macromolecules or dendritic motifs ofthis invention that contain linkers in terms of the composition (numberand type) of 16-tets. This is demonstrated for clarity in the examplesof FIG. 7 and summarised in dot point form above.

When an 16-tet is to be assembled from three functional moietiesrepresented by A, B and D; and at least one building unit has beenreplaced by a linker, this may be done by making use of the preferredoctets including homogenous octets, in addition to using the null octet(((ØØ)(ØØ))⁴((ØØ)(ØØ))⁴)⁸ in the manner which has been demonstrated forcombining quartets to provide octets above.

Summary of Various Cleavable Linkers

Cleavable linkers may be designed to be enzymatically cleaved, and mayfor example, be used in dendrimers targeted to tissues expressing thoseenzymes. Alternatively, an acid labile linker may be preferred such thatthe compound attached to it is released under acid conditions, such asin hypoxic tissue. In a further alternative, photocleavable linkers maybe used.

The linker moiety may be selected from one or more of the following:

Linker type Linker Stable Amide; PEG-peptide Acid Labile Hydrazone,Oxime, Imine; Ester and Orthoester; Aconitic amide; Acetal/Ketal. ThiolLabile Disulfide Enzyme Labile Esters (Esterases and proteases); PeptidesequencesStable LinkersAmide Linkers:

The nature of an amide bond is important in determining whether thefunctional moiety will be released from a conjugate. The release of freedrug from protein carriers bound via a direct amide linker will only beachievable in rare circumstances where the drug is itself a peptide-likemolecule and the bond between drug and carrier is enzymaticallycleavable.

PEG-Peptide:

PEG-peptides are used in a similar way to conventional peptides, exceptthe PEG moiety provides additional in vivo stability and mass for thecarrier. It has the advantage of increasing the distance between acarrier and a drug for example while exposing the site of enzymaticcleavage, decrease immunogenicity of the conjugate, increase bloodcirculation times and increasing the solubility of the complex.

Acid Labile

Hydrazone, Oxime and Imine linkers:

Hydrazone, oxime and imine bonds do not require the presence of enzymesto allow cleavage of the drug from the carrier. They are able to becleaved hydrolytically at the C═N bond in low pH environments such as inthe tumour extravascular space or within lysosomes.

Ester Linkers:

Both acid labile and metabolisable ester linkers can be made.Orthoesters have been used to conjugate PEG to lipids which bind anionicmembrane carriers. The stability of the conjugate in acidic conditions(pH 4-6) depends on the structure of the ester or orthoester linker. Interms of simple ester conjugation to small molecules, diesterfunctionalities provide more sites for metabolic cleavage compared withmonoesters which are more stable than disulfides but less stable thanamide bonds.

Acetals and Ketals:

This kind of linker is particularly useful when the pharmaceuticallyactive agent includes a hydroxyl moiety. In general ketals are more acidlabile than acetal linkages.

Thiol Labile

Disulfide Linkers:

Disulfide linkers are the most unstable linkers currently used andundergo rapid reductive cleavage in vitro. Their in vivo stability isgenerally higher, however, than their in vitro stability. They may beformed via disulfide linkages between sulphur containing amino acids orat non peptide based disulfide bonds. They also show greater reactivitywith other nucleophilic thiols in the body and hence show rapid plasmaclearance.

Enzyme Labile

Peptide Linkers:

Peptide linkers are by far the most versatile of all cleavable linkersin that many different combinations of amino acids can be used tocontrol the rate of cleavage and the cleavage enzyme. While there are anumber of problems associated with their use as conjugates for drug andcarrier, it may be controlled by choosing an appropriate peptide bounddirectly to the drug molecule, e.g. proline. Generally, cathepsin Bcleavable linkers have been designed to be cleaved by cathepsin (locatedin lysosomes and not free in the cytosol) following endocytosis of thecomplex. Non-specific proteases (i.e. proteases that are not specificfor a particular peptide sequence) may cleave a drug from a PEGylateddendrimer after it has undergone sufficient extravasation andaccumulation in tumour tissue.

Summary of Non-Cleavable Linkers

Non-cleavable linkers may be selected from the group consisting ofpolypeptides (i.e. amino acid residues, oligomeric polyamines andpolyamine amides), peptide nucleic acids (PNAs), synthetic polymers(PEG, PEOX, N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers,poly(vinyl-pyrrolidone) (PVP), poly(ethyleneimine) (PEI), linearpolyamidoamines and DIVEMA); natural polymers (dextran (alpha-1,6polyglucose), dextrin (alpha-1,4 polyglucose), hyaluronic acid,chitosans); and pseudosynthetic polymers, such as the man-madepoly(amino acids) poly(L-lysine), poly(glutamic acid) (PGA), poly(malicacid), poly(aspartamides), poly(lactides), poly(glycolides) andpoly(lactides co glycolides).

In a preferred embodiment, the linker may include a hydrocarbon, PEG orPEOX backbone, or a combination thereof.

Another preferred embodiment of the linker is described in formula 1{A-[V]_(a)-(X¹)_(b)-[Y¹]_(c)-(X²)_(d)-[Y²]_(e)-(X³)_(p)}_(f)-Z  (Formula1)

a a = 0 or 1 (see V below) provides optional CH or CH₂ linker, tofacilitate hydrazone, oxime or ether type linkages. b b = 0 then linkersection Y¹ or Y² to connect directly to ligand A b = 1 allows use of X¹:preferred. c c = 0 eliminates first linker section, and would mostlikely require b = 0 as well c = 1 allows use of Y¹: preferred. d d = 0then linker section Y² connects directly to linker section Y¹ etc. d = 1allows use of X²: preferred. e e = 0 eliminates second linker section,and d = 0 as well preferred e = 1 allows use of Y²: preferred. p p = 0then dendrimer Z connects directly to linker section Y² (or Y¹ or V orA) and allows for f = 2. p = 1 allows use of X³: preferred. f f = 1 whenX³ is used: preferred. f = 2 when X³ is not used, allows for two linkersper dendrimer Z. X³ C(W³), OC(W³), NRC(W³), SC(W³); preferably C(W³)where W = O In the preferred embodiment, the join X³ is an amideconnection between the dendrimer Z and the second linker section Y².X^(n) (X¹ and O, S, NR, NRO, ONR X²) C(W^(n)), OC(W^(n)), C(W^(n))O,NRC(W^(n)), C(W^(n))NR, OC(W^(n))O, OC(W^(n))NR, NRC(W^(n))O,NRC(W^(n))NR Preferably C(W^(n))NR where W = O and R = H. There are twojoins, X¹ and X². X² “joins” the two linker sections (Y¹ to Y²), andpreferably an amide, carboxyl from Y¹. X¹ “joins” the ligand to thefirst linker section (Y¹) and preferably an amide, carboxyl from A; oran ether where a = 0 or 1. R hydrogen or small group, each R is same ordifferent, small group defined as: an alkyl chain of 1 to 10 atoms whichmay incorporate within the chain an aryl moiety of 5 to 10 atoms, wherethe alkyl chain and/or aryl moiety may include one or more O, N or Satoms exchanged for one or more C atoms; preferably R = H. W O or S;preferably O Y^(n) (Y¹ and The linker section may be made up from acombination of one or more fragment types. Y²) Y¹ is the first linkersection and functions to connect ligand to longer linker section,sensitive to needs of receptor; possibly more hydrophobic, withpotential H bond donor/acceptor. Y² is the second linker fragment andprovides water solubility, length and possibly rigidity. fragment 1:(CH₂)_(g) where g = 1-12 fragment 2: [O—(CH₂)_(h)]_(i) where h = 2-6 andi = 1-30 fragment 3: [(O)_(j)—(CH₂)_(k)-Aryl-(CH₂)_(l)—(O)_(m)]_(o)where j = 0-1, k = 0-3, l = 0-3, m = 0-1, o = 1-10 fragment 4:oligopeptides of up to 30 amino acids preferably including Glycine,Serine, Glutamate, Aspartate or β-alanine fragment 5: linearoligosaccharides of up to 10 hexose units, preferably including Glucose,N-acetylglucosamine, mannose, galactose; interconnected by glycosidicbonds selected from 1-2, 1-4 or 1-6. V CH(R)_(r) where r = 1 if bond toX^(n) or Y^(n) is saturated; r = 0 if bond to X^(n) or Y^(n) isunsaturated. A A is a functional moiety: optionally modified to includeV; or optionally modified to provide a new functional group forattachment to X^(n) or Y^(n); or optionally modified to convert anexisting functional group into a functional group for attachment toX^(n) or Y^(n) Z Z is a lysine dendrimer terminal nitrogen group (whichmay form one or two bonds, so f = 1 or 2);

The length of the linker will vary depending on the functional moietybeing used.

The use of the null symbols enables concepts such as doublets, quartets,octets and 16-tets to be retained in the alpha-numeric topologicalnomenclature when end stopping reactions (see below) or linkers havebeen used in the synthesis of a dendritic motif. The null symbols andtheir inclusion in the topological nomenclature describe that part of adendritic motif which has been lost as a result of replacing buildingunits with linkers or end stopping reactions.

End-Stopping Reactions

It may be desirable to alter the surface topology of a macromolecule orto provide a particular encapsulated site therein. This may be achievedby utilising functional moieties that function as end stopping moieties(or groups) to introduce modifications to the macromolecule or dendriticmotif.

An end stopping reaction is defined as the complete reaction of alldeprotected surface amine groups of a macromolecule or dendritic motifwith an end stopping functional moiety R where the moiety R is theninert to subsequent chemical transformations that are carried out on themacromolecule or dendritic motif for the purposes of the addition offurther building units, linker groups or end stopping reactions. The endstopping functional moiety may be transformed into a functional moietyby a chemical or other stimulus at a chosen stage in the process ofpreparing the macromolecule or dendritic motif.

A reaction which is used to introduce one or more end stopping moietiesto a dendritic motif is conducted to ensure the complete reaction of alldeprotected surface amine groups of a macromolecule or dendritic motifwith the reactive end stopping functional moieties. Typically this isdone by using an excess of the end stopping functional moiety. Thereaction is described in more detail in Example 72.

The total number of functional moieties in a macromolecule or dendriticmotif in which end stopping has occurred can be represented byFM_(Total). The composition of functional moieties of a macromolecule ordendritic motif, wherein all the surface amine groups and/or surfacebuilding units are attached to functional moieties, can also be providedin terms of FM_(Total) in a formula of the form ΣFM_(i)=FM_(total) wherethe surface of the macromolecule or dendritic motif has an integralquantity FM_(i) of functional moieties of type i: (FM_(i)=FM_(A), FM_(B). . . FM_(Z)) and where FM_(i) may comprise one or more functionalmoieties R of type i: (R_(i)=R₁, R₂ . . . R_(n)). Consider FIG. 9 whichprovides schematic diagrams of five different topological isomers ofmacromolecules wherein end stopping reactions have been used at variousstages in the macromolecule synthesis. Each of these macromolecules canbe described by a formula ΣFM_(i)=FM_(total), for exampleΣFM_(i)=(16R₁+16R₂)=32 for FIG. 9.1; ΣFM_(i)=(8A+16B+4R₁)=28 for FIG.9.2; ΣFM_(i)=(16B+4R₁)=20 for FIG. 9.3; ΣFM_(i)=(8A+8B+2R₁)=18 for FIG.9.4 and ΣFM_(i)=(8A+4R₁+4R₂)=16 for FIG. 9.5.

The alpha-numeric topological nomenclature of couplets, quartets, octetsand beyond is able to provide a description of the functional moietycomposition in addition to the topology of macromolecules and dendriticmotifs in which end stopping reactions have been used by making use ofthe maximum functional moiety number FM_(MAX) in addition to utilisingthe null symbol Ø.

The term FM_(MAX) is used to represent the number of functional moietiesthat would be present on a macromolecule or dendritic motif in ascenario where no end stopping functional moieties or linkers areattached at or below a surface-but-one building unit in the preparationthereof.

Identifiable differences between dendritic motifs which are enrichedwith respect to surface stoichiometry and in which end stoppingreactions have been used may be described utilising the null symbol Ø inconcert with knowledge of the maximum functional moiety number FM_(MAX).

The null symbols and their inclusion in the alpha-numeric topologicalnomenclature make it possible to describe the connectivity between thefunctional moieties and the subsurface layers of building units when endstopping has been used. The use of the null symbol Ø in thealpha-numeric topological descriptions of macromolecules or dendriticmotifs that contain end stopping moieties is demonstrated by example,making use of the schematic diagrams of FIGS. 8 and 9.

The examples of FIG. 9 are included to demonstrate how the alpha-numerictopological nomenclature can be used to provide a description ofmacromolecules that include end stopping functional moieties and whichhave a defined surface topology in addition to a defined surfacecomposition of functional moieties. In particular the nomenclature makesit possible to identify the preferred couplets, quartets, octets and16-tets which are components of macromolecules, and which are apreferred embodiment of this invention.

The use of the null symbols enables concepts such as couplets, quartets,octets and 16-tets to be retained in the alpha-numeric topologicalnomenclature when end stopping reactions or linkers have been used inthe synthesis of a dendritic motif. The null symbols and their inclusionin the topological nomenclature describe that part of a dendritic motifwhich has been lost as a result of end stopping reactions or byreplacing building units with linkers.

Consider FIG. 8.1 which represents a macromolecule comprising 4 layersof building units each with two reactable amine groups from a core withtwo reactable amine groups. The FM_(MAX) for this macromolecule motif isthus 2×2×2×2×2=32. In those circumstances where linkers and end stoppingfunctional moieties are attached only on the surface building units,FM_(Max)=FM_(Total) and there is no requirement for the Ø null symbol.

A description of topology to the level of quartets is required todescribe the subsurface connectivity for macromolecules wherein endstopping functional moieties have been attached at the surface-but-onelayer building units. It may be seen in FIG. 8.2 that for each endstopping functional moiety Ri that is attached to a surface amine groupof a surface-but-one building unit, a value of 1 represented by Ø islost from the final outer surface FM_(Total) so thatFM_(Total)+ΣØ=FM_(MAX). The use of the null symbols restores theintegrity of the outer FM_(Total). In F8.2, the use of Ø is demonstratedas the functional moieties and null symbols related to thesurface-but-one building units are gathered into their related coupletsand quartets. When one end stopping functional moiety is attached to thesurface-but-one building unit, one of the couplets will contain a endstopping functional moiety and a null symbol (R_(i)Ø), and the othercouplet will contain two functional moieties, providing quartets of theform: ((AA)(R₁Ø))⁴ and ((BB)(R₂Ø))⁴. The quartet ((AA)(R₁Ø))⁴ indicatesthat there are three functional moieties A,A,R₁ and all have a line ofconnection to the same building unit, in particular to thesurface-but-one building unit and further indicates that couplet (AA)and end stopping functional moiety R₁ are attached to the same buildingunit. Couplets that contain one or more null symbols Ø may be groupedtogether with other couplets to provide quartet, octet and 16-tetdescriptions of surface topology.

The macromolecules of FIG. 9 are described in terms of couplets makinguse of the alpha-numeric topological nomenclature as follows:

TABLE 14 FIG. alpha-numeric topological nomenclature Composition 9.1(R₁R₁)(R₁R₁)(R₂R₂)(R₂R₂)(R₁R₁)(R₁R₁)(R₂R₂)(R₂R₂) 8 (R₁R₁) and 8 (R₂R₂)(R₁R₁)(R₁R₁)(R₂R₂)(R₂R₂)(R₁R₁)(R₁R₁)(R₂R₂)(R₂R₂) couplets 9.2(AA)(R₁Ø)(BB)(BB)(AA)(R₁Ø)(BB)(BB) 4 (AA), 8 (BB) and 4 (R₁Ø) couplets(AA)(R₁Ø)(BB)(BB)(AA)(R₁Ø)(BB)(BB) 9.3(R₁Ø)(ØØ)(BB)(BB)(R₁Ø)(ØØ)(BB)(BB) 8 (BB), 4 (R₁Ø) and 4 (ØØ)(R₁Ø)(ØØ)(BB)(BB)(R₁Ø)(ØØ)(BB)(BB) couplets 9.4(AA)(AA)(BB)(BB)(R₁Ø)(ØØ)(ØØ)(ØØ) 4 (AA), four (BB), 2 (R₁Ø)(AA)(AA)(BB)(BB)(R₁Ø)(ØØ)(ØØ)(ØØ) and 6 (ØØ) couplets 9.5(R₁Ø)(AA)(R₂Ø)(ØØ)(R₁Ø)(AA)R₂Ø)(ØØ) 4 (AA), 4 (R₁Ø), 4 (R₂Ø)(R₁Ø)(AA)(R₂Ø)(ØØ)(R₁Ø)(AA)(R₂Ø)(ØØ) and 4 (ØØ) couplets

It is possible to describe the macromolecules or dendritic motifs ofthis invention that contain end stopping moieties in terms of thecomposition (number and type) of couplets. This is demonstrated forclarity in the examples of FIG. 9 and summarised in the “composition”column of Table 14.

The macromolecules of FIG. 9 are described in terms of quartets makinguse of the alpha-numeric topological nomenclature as follows:

TABLE 15A FIG. alpha-numeric topological nomenclature Composition 9.1((R₁R₁)(R₁R₁))⁴((R₂R₂)(R₂R₂))⁴((R₁R₁)(R₁R₁))⁴((R₂R₂)(R₂R₂))⁴ 4((R₁R₁)(R₁R₁))⁴ and((R₁R₁)(R₁R₁))⁴((R₂R₂)(R₂R₂))⁴((R₁R₁)(R₁R₁))⁴((R₂R₂)(R₂R₂))⁴ 4((R₂R₂)(R₂R₂))⁴ quartets 9.2((AA)(R₁Ø))⁴((BB)(BB))⁴((AA)(R₁Ø))⁴((BB)(BB))⁴ 4 ((AA)(R₁Ø))⁴ and((AA)(R₁Ø))⁴((BB)(BB))⁴((AA)(R₁Ø))⁴((BB)(BB))⁴ 4 ((BB)(BB))⁴ quartets9.3 ((R₁Ø)(ØØ))⁴((BB)(BB))⁴((R₁Ø)(ØØ))⁴((BB)(BB))⁴ 4 ((R₁Ø)(ØØ))⁴ and((R₁Ø)(ØØ))⁴((BB)(BB))⁴((R₁Ø)(ØØ))⁴((BB)(BB))⁴ 4 ((BB)(BB))⁴ quartets9.4 ((AA)(AA))⁴((BB)(BB))⁴((R₁Ø)(ØØ))⁴((ØØ)(ØØ))⁴ 2 ((AA)(AA))⁴, 2((BB)(BB))⁴, ((AA)(AA))⁴((BB)(BB))⁴((R₁Ø)(ØØ))⁴((ØØ)(ØØ))⁴ 2((R₁Ø)(ØØ))⁴ and 2 ((ØØ)(ØØ))⁴ quartets 9.5((R₁Ø)(AA))⁴((R₂Ø)(ØØ))⁴((R₁Ø)(AA))⁴((R₂Ø)(ØØ))⁴ 4 ((R₁Ø)(AA))⁴ and((R₁Ø)(AA))⁴((R₂Ø)(ØØ))⁴((R₁Ø)(AA))⁴((R₂Ø)(ØØ))⁴ 4 ((R₂Ø)(ØØ))⁴ quartets

It is possible to describe the macromolecules or dendritic motifs ofthis invention that contain end stopping moieties in terms of thecomposition (number and type) of quartets. This is demonstrated forclarity in the examples of FIG. 9 and summarised in the “composition”column of Table 15A.

When a quartet is to be assembled from three functional moieties or endstopping functional moieties represented by A, B and D; and at least onebuilding unit has been replaced by a linker or end stopping reactionshave been used, this may be done by making use of the preferred coupletsin addition to using the null couplet (ØØ) in the manner which has beendemonstrated for combining couplets to provide quartets above.

In a preferred embodiment, the compositions of macromolecules ordendritic motifs include at least one quartet selected from Table 3B or7B or 11B, including those quartets which can be considered equivalentby way of their topology and relative composition of two or threedifferent functional moieties. In this preferred embodiment, the symbolsA, B and D are taken to represent different functional moieties or endstopping functional moieties.

A description of topology to the level of octets is required to describethe subsurface connectivity for macromolecules wherein end stoppingmoieties have been attached at the surface-but-two layer building units.It may be seen in FIG. 8.3 that for each end stopping functional moietyRi that is attached to a surface amine group of a surface-but-twobuilding unit, a value of 3 represented by ØØØ is lost from the finalouter surface FM_(Total) so that FM_(Total)+ΣØ=FM_(MAX). The use of thenull symbols restores the integrity of the outer FM_(Total). In F8.3,the use of ØØØ is demonstrated as the functional moieties and nullsymbols related to the surface-but-two building units gathered intotheir related couplets, quartets and octets. When an end stoppingfunctional moiety R is attached to a surface-but-two building unit, oneof the quartets will contain a null couplet (ØØ), and the other coupletwill contain R_(i) and a null symbol as (R₁Ø). The second quartet willbe complete, providing octets of the form: (((AA)(AA))⁴((R₁Ø)(ØØ))⁴)⁸and (((BB)(BB))⁴((R₂Ø)(ØØ))⁴)⁸. The octet (((AA)(AA))⁴((R₁Ø)(ØØ))⁴)⁸indicates that there are five functional moieties A,A,A,A,A,R₁ allhaving a line of connection to the same building unit, in particular tothe surface-but-two building unit. Quartets that contain one or morenull symbols Ø may be grouped together with other quartets to provideoctet and 16-tet descriptions of surface topology.

The macromolecules of FIG. 9 are described in terms of octets making useof the alpha-numeric topological nomenclature as follows:

TABLE 16A FIG. alpha-numeric topological nomenclature Composition 9.1(((R₁R₁)(R₁R₁))⁴((R₂R₂)(R₂R₂))⁴)⁸(((R₁R₁)(R₁R₁))⁴((R₂R₂)(R₂R₂))⁴)⁸ 4(((R₁R₁)(R₁R₁))⁴((R₂R₂)(R₂R₂))⁴)⁸(((R₁R₁)(R₁R₁))⁴((R₂R₂)(R₂R₂))⁴)⁸(((R₁R₁)(R₁R₁))⁴((R₂R₂)(R₂R₂))⁴)⁸octets 9.2 (((AA)(R₁Ø))⁴((BB)(BB))⁴)⁸(((AA)(R₁Ø))⁴((BB)(BB))⁴)⁸ 4(((AA)(R₁Ø))⁴((BB)(BB))⁴)⁸ octets(((AA)(R₁Ø))⁴((BB)(BB))⁴)⁸(((AA)(R₁Ø))⁴((BB)(BB))⁴)⁸ 9.3(((R₁Ø)(ØØ))⁴((BB)(BB))⁴)⁸(((R₁Ø)(ØØ))⁴((BB)(BB))⁴)⁸ 4(((R₁Ø)(ØØ))⁴((BB)(BB))⁴)⁸ octets(((R₁Ø)(ØØ))⁴((BB)(BB))⁴)⁸(((R₁Ø)(ØØ))⁴((BB)(BB))⁴)⁸ 9.4(((AA)(AA))⁴((BB)(BB))⁴)⁸(((R₁Ø)(ØØ))⁴((ØØ)(ØØ))⁴)⁸ 2(((AA)(AA))⁴((BB)(BB))⁴)⁸ and(((AA)(AA))⁴((BB)(BB))⁴)⁸(((R₁Ø)(ØØ))⁴((ØØ)(ØØ))⁴)⁸ 2(((R₁Ø)(ØØ))⁴((ØØ)(ØØ))⁴)⁸ octets 9.5(((R₁Ø)(AA))⁴((R₂Ø)(ØØ))⁴)⁸(((R₁Ø)(AA))⁴((R₂Ø)(ØØ))⁴)⁸ 4(((R₁Ø)(AA))⁴((R₂Ø)(ØØ))⁴)⁸ octets(((R₁Ø)(AA))⁴((R₂Ø)(ØØ))⁴)⁸(((R₁Ø)(AA))⁴((R₂Ø)(ØØ))⁴)⁸

It is possible to describe the macromolecules or dendritic motifs ofthis invention that contain end stopping moieties in terms of thecomposition (number and type) of octets. This is demonstrated forclarity in the examples of FIG. 9 and summarised in the “composition”column of Table 16A.

When an octet is to be assembled from three functional moieties or endstopping functional moieties represented by A, B and D; and at least onebuilding unit has been replaced by a linker or end stopping reactionshave been used, this may be done by making use of the preferred quartetsfrom Tables 3B, 7B and 11B, in addition to using the null quartet((ØØ)(ØØ))⁴ in the manner which has been demonstrated for combiningquartets to provide octets above.

A description of topology to the level of 16-tets is required todescribe the subsurface connectivity for macromolecules wherein endstopping functional moieties have been attached at the surface-but-threelayer building units. It may be seen in FIG. 8.4 that for each endstopping functional moiety Ri that is attached to a surface amine group,a value of 7 represented by ØØØØØØØ is lost from the final outer surfaceFM_(Total) so that FM_(Total)+ΣØ=FM_(MAX). When one end stoppingfunctional moiety is attached to a surface-but-three building unit, oneof the octets will contain a null quartet ((ØØ)(ØØ))⁴, and the otherquartet will contain only the R_(i) and null symbols as ((R₁Ø)(ØØ))⁴.The second octet will be complete, providing 16-tets of the form:((((AA)(AA))⁴((AA)(AA))⁴)⁸(((R₁Ø)(ØØ))⁴((ØØ)(ØØ))⁴)⁸)¹⁶ and((((BB)(BB))⁴((BB)(BB))⁴)⁸(((R₂Ø)(ØØ))⁴((ØØ)(ØØ))⁴)⁸)¹⁶. The 16-tet((((AA)(AA))⁴((AA)(AA))⁴)⁸(((R₁Ø)(ØØ))⁴((ØØ)(ØØ))⁴)⁸)¹⁶ indicates thatthere are 8 functional moieties of type A and an end stopping functionalmoiety R₁ all having a line of connection to the same building unit, inparticular to the surface-but-three building unit. Octets that containone or more null symbols Ø may be grouped together with other octets toprovide 16-tet descriptions of surface topology.

The macromolecules of FIG. 9 are described in terms of 16-tets makinguse of the alpha-numeric topological nomenclature as follows:

TABLE 17A FIG. alpha-numeric topological nomenclature 9.1((((R₁R₁)(R₁R₁))⁴((R₂ R₂)(R₂R₂))⁴)⁸(((R₁R₁)(R₁R₁))⁴((R₂R₂)(R₂R₂))⁴)⁸)¹⁶((((R₁R₁)(R₁R₁))⁴((R₂R₂) (R₂R₂))⁴)⁸(((R₁R₁)(R₁R₁))⁴((R₂R₂)(R₂R₂))⁴)⁸)¹⁶9.2 ((((AA)(R₁Ø))⁴((BB)(BB))⁴)⁸(((AA)(R₁Ø))⁴((BB)(BB))⁴)⁸)¹⁶((((AA)(R₁Ø))⁴((BB)(BB))⁴)⁸(((AA)(R₁Ø))⁴((BB)(BB))⁴)⁸)¹⁶ 9.3((((R₁Ø)(ØØ))⁴((BB)(BB))⁴)⁸(((R₁Ø)(ØØ))⁴((BB)(BB))⁴)⁸)¹⁶((((R₁Ø)(ØØ))⁴((BB)(BB))⁴)⁸(((R₁Ø)(ØØ))⁴((BB)(BB))⁴)⁸)¹⁶ 9.4((((AA)(AA))⁴((BB)(BB))⁴)⁸(((R₁Ø)(ØØ))⁴((ØØ)(ØØ))⁴)⁸)¹⁶((((AA)(AA))⁴((BB)(BB))⁴)⁸(((R₁Ø)(ØØ))⁴((ØØ)(ØØ))⁴)⁸)¹⁶ 9.5((((R₁Ø)(AA))⁴((R₂Ø)(ØØ))⁴)⁸(((R₁Ø)(AA))⁴((R₂Ø)(ØØ))⁴)⁸)¹⁶((((R₁Ø)(AA))⁴((R₂Ø)(ØØ))⁴)⁸(((R₁Ø)(AA))⁴((R₂Ø)(ØØ))⁴)⁸)¹⁶where:

-   -   there are two        ((((R₁R₁)(R₁R₁))⁴((R₂R₂)(R₂R₂))⁴)⁸(((R₁R₁)(R₁R₁))⁴((R₂R₂)(R₂R₂))⁴)⁸)¹⁶        16-tets in FIG. 9.1;    -   there are 2        ((((AA)(R₁Ø))⁴((BB)(BB))⁴)⁸(((AA)(R₁Ø))⁴((BB)(BB))⁴)⁸)¹⁶ 16-tets        in FIG. 9.2;    -   there are two        ((((R₁Ø)(ØØ))⁴((BB)(BB))⁴)⁸(((R₁Ø)(ØØ))⁴((BB)(BB))⁴)⁸)¹⁶ 16-tets        in FIG. 9.3;    -   a there are two        ((((AA)(AA))⁴((BB)(BB))⁴)⁸(((R₁Ø)(ØØ))⁴((ØØ)(ØØ))⁴)⁸)¹⁶ 16-tets        in FIG. 9.4; and    -   there are two        ((((R₁Ø)(AA))⁴((R₂Ø)(ØØ))⁴)⁸(((R₁Ø)(AA))⁴((R₂Ø)(ØØ))⁴)⁸)¹⁶        16-tets in FIG. 9.5.

It is then possible to describe the macromolecules or dendritic motifsof this invention that contain end stopping moieties in terms of thecomposition (number and type) of 16-tets. This is demonstrated forclarity in the examples of FIG. 9 and summarised in dot point formabove.

When an 16-tet is to be assembled from three functional moieties or endstopping functional moieties represented by A, B and D; and at least onebuilding unit has been replaced by a linker or end stopping reactionshave been used, this may be done by making use of the preferred octets,in addition to using the null octet (((ØØ)(ØØ))⁴((ØØ)(ØØ))⁴)⁸ in themanner which has been demonstrated for combining quartets to provideoctets above.

In a preferred embodiment, the compositions of macromolecules ordendritic motifs include at least one 16-tet assembled from preferredoctets including those octets which can be considered equivalent by wayof their topology and relative composition of two or three differentfunctional moieties. In this preferred embodiment, the symbols A, B andD are taken to represent different functional moieties or end stoppingfunctional moieties.

The macromolecules or dendritic motifs of the invention may be attachedto cores. In a preferred aspect of the present invention, there isprovided a macromolecule having a core and at least one dendritic motifof the formula:Core[[Building Unit]_(m)[Surface Building Unit]_(n)[Functionalmoieties]_(p)]_(q)wherein:a [Building Unit]_(m)[Surface Building Unit]_(n)[Functionalmoieties]_(p) defines a dendritic motif; the core may be any compound,particle or substrate to which the dendritic motif may be attached;Preferably the core contains one or more reactive nitrogens and isselected from the group consisting of lysine, a derivative thereof, adiamine compound, a triamine compound, or a tetramine compound;the Building Unit is selected from a lysine or lysine analogue;the Surface Building Unit, which may be the same as, or different tothat of the building unit, is selected from lysine or lysine analogue ora building unit selected from the sets herein described; the Functionalmoieties include two or more different functional moieties selected fromprotecting groups; biological effect moiety ligands for extracellularreceptors; property modifiers; biological targeting groups; signallinggroups; antigenic materials; genetic materials; pharmaceutically activeagents; groups adapted to mediate binding to a second entity, andlinkers.m represents the sum of the building units of the subsurface layers ofthe dendritic motif and is an integer of value: 1<integer≦64;n represents the number of surface building units of the dendritic motifand is an integer of value: 2≦integer≦128;p represents the total number of functional moieties on the surface ofthe macromolecule and is an integer of value: 4<integer≦256; andq represents the total number of dendritic motifs on the core of themacromolecule and is an integer of value: 1<integer<10⁶.

Depending on the type of core, the number of dendritic motifs that maybe attached to the core is quite variable. In one embodiment, more thanone dendritic motif may be attached to a core to enable the constructionof larger, more complex macromolecules. For example, two dendriticmotifs, each having 3 subsurface layers and 1 surface layer and bearing16 functional moieties, may be attached to a divalent core, producing amacromolecule having two dendritic motifs and bearing 32 functionalmoieties.

In yet another embodiment, wherein the core is the reactive amine groupsof a macroscopic surface, for example: the surface of a diagnosticdevice that is utilised for detection of one or more analytes, (seebelow for further options) a very large number of dendritic motifs maybe attached.

Preferably the core is a diamine compound selected from thebenzhydrylamide of lysine or other lysine amide or:

where a is an integer of 1 to 9, preferably 1 to 5;

where a, b and c, which may be the same or different, are integers of1-5, preferably 2 or 3 and d is an integer from 0-100, preferably 1-30;

where a and b, which may be the same or different, are integers of 0 to5;

where a and c, which may be the same or different, are integers of 1 to6 and where b is an integers from 0-6;

where a and d, which may be the same or different, are integers of 1 to6 and where b and c, which may be the same or different, are integersfrom 0-6.a triamine compound selected from:

where a, b and c, which may be the same or different, are integers of 1to 6;

where a, b and c, which may be the same or different, are integers of 0to 6;

where a, b and c, which may be the same or different, are integers of 0to 6;

where a, b and c, which may be the same or different, are integers of 0to 6; and d, e and f, which may be the same or different, are integersof 1 to 6.

where a, b and c, which may be the same or different, are integers of 1to 6.or a tetramine compound selected from

where a, b, c and d, which may be the same or different, are integers of0 to 6

where a, b, c and d, which may be the same or different, are integers of1 to 6

where a, b, c and d, which may be the same or different, are integers of0 to 6; and e, f, g and h, which may be the same or different, areintegers of 1 to 6.and furthermore, the alkyl chain moieties of the core may be understoodto include either alkoxy fragments as C—O—C or C—C—O—C—C but not O—C—Xwhere X is O or N.

More preferably the core is benzhydrylamido-lysine (BHALys), or acompound selected from the following:

where a is an integer of 1 to 5;

where a, b and c, which may be the same or different, are integers of 2or 3 and d is an integer from 1-30;

where a and d, which may be the same or different, are integers of 1 or2 and where b and c, which may be the same or different, are integersfrom 0-2.a triamine compound selected from:

where a, b and c, which may be the same or different, are integers of 1to 2;

where a, b and c, which may be the same or different, are integers of 0to 2; and d, e and f, which may be the same or different, are integersof 1 to 2.

where a, b and c, which may be the same or different, are integers of 1to 3.or a tetramine compound

where a, b, c and d, which may be the same or different, are integers of0 to 1

where a, b, c and d, which may be the same or different, are integers of1 to 2

where a, b, c and d, which may be the same or different, are integers of0 to 2; and e, f, g and h, which may be the same or different, areintegers of 1 to 2.

In an alternative embodiment, the core may itself be a non-lysinedendrimer. A poly(amidoamine) (PAMAM), poly(propyleneimine) POPAM orpolyethyleneimine (PEI) dendrimer, dendrigrafts, arborols or the likemay form the core. In a further embodiment, the core may be a linearpolymer, for example poly-lysine, poly-vinylamine orpoly-ω-aminoalkylmethacrylamides.

In yet another embodiment, the core may be a metallic or non-metallicparticle, for example a gold particle or colloid, latex, a metal oxide,a micelle, a vesicle, a liposome, a buckball, a carbon nanotube (singleand double wall), carbon fibre and silica. The cores may be reactablegroups, or the dendritic motif may be modified to be attachable to anysurface.

In a further embodiment, the core may be the reactive amine groups of amacroscopic surface, for example: the surface of a diagnostic devicethat is utilised for detection of one or more analytes; the surfaces ofmedical devices; the surfaces of components used in separationtechnologies such as chromatographic media or membranes; the surfaces ofsemiconductor components used in electronic devices. In anotherembodiment, the dendritic motif may be modified to allow attachment ofthe motif to the core, wherein the core does not have reactive aminegroups.

Synthesis of Macromolecules

There are a number of ways of synthesising or “building” a macromoleculeof the present invention. Preferably the macromolecule is a dendrimer.One process for synthesising macromolecules of the present inventioninvolves the sequential reaction of a growing macromolecule core moietyand one or more layers of building compounds.

Accordingly, in one aspect, there is provided a process for preparing amacromolecule, which process includes

i) providing

-   -   a growing macromolecule including at least one reactable group;    -   a first building compound having a hydrocarbon backbone, and        bearing an apex carbonyl group and at least one amine group        bearing a functional moiety being a protecting group;        ii) activating the apex carbonyl group of the first building        compound; and        iii) reacting the deprotected growing macromolecule with the        apex carbonyl group of the first building compound.

The steps of the process will then be reiterated until a macromoleculeof the desired subsurface and surface layers is achieved.

Preferably the building compounds are lysine or lysine analoguesselected from the compounds 1-9 described earlier; the surface buildingcompound is preferably a lysine or lysine analogue selected from thesame compounds as the building unit, or compounds 10-16 as alsodescribed earlier. Most preferably, it is glutamate or aspartate. Takinga lysine analogue as an example for use in the above process, the apexcarboxylate F of the lysine analogues will necessarily be activatedprior to reaction with an unprotected amine moiety, and each of thereactable amine groups of the lysine analogue is protected to preventself condensation. Reactable amines of the building compounds are alwaysprotected when the apex carboxylate of a building compound is reactedwith unprotected nitrogens of a growing macromolecule. Furthermore thereaction between unprotected amines and activated lysine analogues isalways carried out in such a way so as to ensure that the unprotectedamines are completely reacted with the chosen lysine analogue. This ismost simply done by using a stoichiometric excess of the activatedlysine analogue.

A growing macromolecule may be a core including reactable moieties ormodified to have reactable moieties bearing protecting groups, or a corehaving at least one layer of building compounds, to which further layersof building compounds may be reacted. The core may be selected fromcompounds 17 to 32 as described earlier. Alternatively the core may be anon-lysine dendrimer such as a poly(amidoamine) (PAMAM),poly(propyleneimine) POPAM or polyethyleneimine (PEI) dendrimer,dendrigrafts, arborols or the like may form the core, or a linearpolymer, such as poly-lysine, poly-vinylamine orpoly-ω-aminoalkylmethacrylamides.

In a further embodiment, the core may be a metallic or non-metallicparticle, for example a gold particle or colloid, latex, a metal oxide,a micelle, a vesicle, a liposome, a buckball, a carbon nanotube (singleand double wall), carbon fibre and silica.

In a further embodiment, the core may be the reactive amine groups of amacroscopic surface, for example: the surface of a diagnostic devicethat is utilised for detection of one or more analytes; the surfaces ofmedical devices; the surfaces of components used in separationtechnologies such as chromatographic media or membranes; the surfaces ofsemiconductor components used in electronic devices.

An alternative process for synthesising the macromolecule of the presentinvention includes the preliminary step of providing a dendritic motiffor attachment to the growing macromolecule.

Accordingly, in one aspect of the invention, there is provided a processfor preparing a macromolecule, which process includes

i) providing

-   -   a growing macromolecule including a first reactable group, at        least one of which bears a first functional moiety being a        protecting group;    -   a compound including at least one dendritic motif bearing at        least two functional moieties, the motif having a surface layer        and at least one subsurface layer, and having a hydrocarbon        backbone and bearing an apex carbonyl group;        ii) activating the first reactable group by removing the first        protecting group;        iii) activating the apex carbonyl group of the dendritic motif,        and        iv) reacting the deprotected growing macromolecule with the        carbonyl group of the dendritic motif.

In one embodiment, the two functional moieties may be the same ordifferent on each of the growing macromolecule and the compound havingat least one dendritic motif. In turn, depending on what the functionalmoieties are, the functional moiety stoichiometry can be controlled atthe surface and subsurface level. The functional moiety stoichiometrycan be controlled through the use of a dendritic motif in which thesurface amine protecting group stoichiometry and topology has beenestablished. It has been observed that such an approach can providemacromolecules of the present invention that are of high purity.

Preferably there is provided a preparation of macromolecules, wherein atleast 80% of the macromolecules exhibit the same functional moietystoichiometry prior to any end stage or final purification processes, asa result of the process for preparation.

The compound including at least one dendritic motif for use in theprocess of the present invention may be prepared in any suitable manner.In one embodiment, there is provided a process for preparing a compoundincluding at least one dendritic motif which process includes:

-   -   iv) providing    -   a first building compound including an apex carbonyl group,        attached directly or indirectly to at least one amine group        bearing at least one functional moiety;    -   a second building compound including an apex carbonyl group,        attached to at least one amine group, the building compound        bearing a first and second functional moiety one of which is        attached to the amine group;    -   v) activating the amine group on the first building compound by        removing the protecting group;    -   vi) activating the apex carbonyl of the second building        compound; and    -   vii) reacting the deprotected first building compound with the        apex carbonyl group of the second building compound.

The dendritic motif preferably has a surface layer and two or morelayers, and can be built by reiterating the steps above.

Alternatively, the first building compound may already include at leastlayers i.e. when the carbonyl group is indirectly attached to the atleast one functional moiety.

The order of removal of protecting groups may be an important factor indetermining the sequence of reactions that may be used to preparemacromolecules and the dendritic motifs thereof comprising differentamine protecting groups, particularly in those cases where the cleavageconditions for one amine protecting group can lead to the loss of aspectator amine protecting group. Accordingly, when the growingmacromolecule includes a second reactable group that bears a functionalmoiety being a protective group, and the second protecting group isdifferent to the first, the second protecting group is inert to theactivating conditions for removing the first protecting group. Theprotecting group table below provides the preferred set of resolvable,and orthogonal, amine protecting groups.

A set of resolvable amine protecting groups are defined as those forwhich an order of removal exists such that those groups that are notmeant for cleavage are inert to the cleavage conditions. When protectinggroups are defined as orthogonal, this means that each group is inert tothe cleavage conditions required to remove each of the other groups ofthe orthogonal set. Illustrative amine protecting groups may be sourcedin the following references: Protective groups in Organic Synthesis,3^(rd) Edition, John Wiley and Sons, New York 1999, Greene, T. W. andWuts, P. G. M., Protecting Groups 3^(rd) Edition, Thieme Stuttgart 2004,Kocienski, P. J. Preferred amine protecting groups may be selected fromTable 18.

TABLE 18 Preferred Amine Protecting Groups 2-halo- Protecting Group¹ BocCBz Fmoc CBz* Alloc SES Troc Ns DNP 4-Nitro-CBz Boc O O O O O O O O OCBz O R 3 O O R (Troc) R (Ns) R 3 (Fmoc) (DNP) Fmoc O R R R O O 3 3 R(Fmoc) (Fmoc) (Fmoc) (Fmoc) 2-halo-CBz² O 3 R O O R (Troc) R (Ns) R 3(Fmoc) (DNP) Alloc O O R R O O O O R (Alloc) (Fmoc) (Fmoc) Me₃SiEtSO₂ OO O O O O O O O (SES) Troc O R (Troc) O R (Troc) O O O O R (Troc)o-NO₂PhSO₂ (Ns) O R (Ns) 3 R (Ns) O O O 3 O 2,4- O R (DNP) 3 R (DNP) O OO 3 O dinitrobenzene- sulfonyl (DNP) 4-Nitro-CBz O 3 R 3 R (Alloc) O R(Troc) O O (Fmoc) Notes: ¹The combinations of the protecting groupslisted in the first column of the table with the protecting groupslisted across the top row of the table are defined as being either“resolvable” (R) or “orthogonal” (O). When a combination is deemed“resolvable”, the protecting group in parentheses denotes the groupwhich should be removed first. ²Refers to 2-chloro-CBz and 2-bromo-CBz.³Combination neither resolvable nor orthogonal.

The process for synthesis of the compound including a dendritic motifaccording to the present invention may include the removal of one ormore surface amine protecting groups to provide one or more reactiveamine groups. These reactive amine groups are then reacted with acarbonyl moiety. In an example using lysine or a lysine analogue, thecarboxylate moiety of the functional moiety precursor will either beactivated for amide bond formation either prior to the reaction or insitu.

Both the carboxylate group and the reactable amine groups may bederivatised to enhance or diminish the reactivity of these groups. Forexample the carboxylate group may be activated as in an acyl halidederivative or an activated ester derivative (The Peptides, Analysis,Synthesis and Biology Vol 1 Major Methods of Peptide Bond Formation;Academic Press New York 1979 eds Gross, E. and Meienhofer, J., Peptides:Chemistry and Biology. Wiley-VCH Weinheim 2002, Sewald, N. and Jakubke,H-D., The Chemical Synthesis of Peptides Clarendon Press, Oxford 1994,Jones, J.), and the reactable amine groups may be protected(deactivated) using amine-protecting groups such as Boc, CBz,4-nitrobenzyloxycarbamate (4-NO₂—CBz) Fmoc, Dde, CF₃CO₂, 2-halo-CBz,Alloc, Me₃SiEtSO₂, Troc, o-NO-₂PhSO₂ and2,4-dinitrobenzene-sulfonyl.groups.CBz.

In general, a free carboxylate group is not sufficiently reactive toreact with an amine to form the amide bond, so some means is preferablyprovided that facilitates the dehydration and so drives the reaction tocompletion. This may be achieved, for example, by utilising one of tworelated methods.

In the first activation method, the reagent which contains thecarboxylic acid is reacted with a second reagent containing a hydroxylmoiety in the presence of a dehydrating reagent and, where required,other activating agents, to provide a product in which the acidcontaining moiety and the hydroxyl containing moiety are joined by anester bond. This product is known as an “active ester”. The reagentcontaining the hydroxyl moiety is chosen such that the product esterwill readily react with primary amines to form amides with liberation ofthe aforementioned reagent containing the hydroxyl moiety. In somecases, the active ester is sufficiently stable to enable it to beisolated, purified and stored prior to use.

Preferred reagents containing the hydroxy moiety are: p-nitrophenol (andother nitro phenol derivatives); N-hydroxysuccinimide; pentafluorophenoland trifluorophenol. A more complete list is provided in Sewald page197. Preferred dehydrating agents are dicyclohexylcarbodiimide (DCC) andN-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide (EDC).

In a second activation method, the reagent which contains thecarboxylate group may be reacted “in situ” with an activating agent toform an acyl species which further reacts with primary amines alsopresent “in situ” or added after an appropriate prior activation time tolead to the formation of the required amide bond. Preferred activatingagents are (Benzotriazol-1-yloxy)tris(dimethylamino)phosphoniumhexafluorophosphate (BOP),(Benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate(PyBOP), O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (HATU),O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate(TBTU), O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (HBTU). Ancillary reagents like1-hydroxybenzotriazole (HOBt) may be required to facilitate thisreaction, for example through the formation of activated intermediateswhich are known to react further with amines to form amide bonds.

Any compound containing one or more reactive amines may be reacted withan activated apex carboxylate of either a building unit or a dendriticmotif to provide a macromolecule. The reactable amines of the buildingunit or dendritic motif need to be prevented from reacting with theactivated apex carboxylate either through appropriate use of amineprotecting groups, or through prior reaction with a functional moiety.The functional moiety needs to be inert to the reactive amine-activatedapex carboxylate reaction.

Any compound containing one or more reactive amines may be reacted withan activated dendritic motif to provide a macromolecule.

In one embodiment, the process for the preparation of the compoundincluding at least one dendritic motif may optionally include theprotection of a selected carboxylate group prior to removal ofprotecting groups on surface amines present on the lysine or lysineanalogue backbone. The protecting group used for the protectedcarboxylate group is preferably stable to the conditions required toremove the protecting groups present on the surface amines. Carboxylateprotecting groups such as methyl or more preferably ethyl esters aresuitable. Illustrative carboxylate protecting groups may be sourced inthe following references: Protective groups in Organic Synthesis, 3rdEdition, John Wiley and Sons, New York 1999, Greene, T. W. and Wuts, P.G. M., Protecting Groups 3rd Edition, Thieme Stuttgart 2004, Kocienski,P. J.

Where the synthesis of the compound including at least one dendriticmotif requires a further deprotection step subsequent to the addition ofa functional moiety that is not a protecting group, it is important totake the stability of this functional moiety toward subsequent reactionsinto consideration. In a preferred sequence of functional moietyadditions, the second functional moiety, which is selected, for example,to modify the pharmacokinetics of the pharmaceutically active agentand/or macromolecule, is added first to the lysine or lysine analoguebackbone. Accordingly, a non-protecting group functional moiety may beactivated and reacted with an amine group on the building compound thathas been deprotected. The building compound-functional moiety may thenbe reacted with a further building unit that is preferably alreadyattached to a growing macromolecule, i.e., non-protecting functionalmoiety reacted with building compound then reacted with buildingcompound on growing macromolecule. Furthermore, in those situationswhere the pharmaceutically active agent is to be attached to the lysineor lysine analogue backbone via a labile linker (see below), it may benecessary to activate the selected carboxylate of the building compoundprior to the reaction of the unprotected surface amine groups of thelysine or lysine analogue backbone, and furthermore where the selectedcarboxylate of the lysine or lysine analogue backbone is unprotected itwill be necessary for the carboxylate group of the pharmaceuticallyactive agent-linker moiety to be activated prior to the presence of theunprotected surface amine groups.

The process for synthesising a macromolecule of the present invention isthen continued by the reaction of unprotected amines of a growingmacromolecule with the compound including at least one dendritic motif,or individual building compounds. The carboxylate moieties will eitherbe activated for amide bond formation either prior to the reaction or insitu. In a preferred method, the carboxylate moiety is activated insitu. This method is preferred and it is possible, through the inclusionof water or other hydroxyl donors, to limit the adventitious formationof ester bonds to the macromolecule where unmasked hydroxyl moieties arepresent on either the growing macromolecule core or compound Includingat least one dendritic motif or individual building compounds.

In one embodiment, the compound including at least one dendritic motifor individual building compounds may be attached to the growingmacromolecule via a linker moiety.

A process for synthesising macromolecules of this invention may includethe reaction of unprotected amines of a growing macromolecule withlinker moieties. The carbonyl group of the linker is activated for amidebond formation either prior to the reaction or in situ. If the linkergroup includes a reactable amine then it is protected. Furthermore, thereaction between unprotected amines of the growing macromolecule and theactivated linkers is carried out in such a way as to ensure that theunprotected amines are completely reacted with the activated group,typically by using the activated group in excess.

An example of this approach may be seen in FIG. 16, whereinPNPO-Lys(Boc)₂, the reactive building compound, reactable nitrogens areprotected with the Boc group, and the carboxylate is activated as apara-nitrophenol ester.

Accordingly, in an alternative embodiment of the present invention thereis provided a process for preparing a macromolecule having controlledfunctional moiety stoichiometry including the steps of:

-   -   (i) providing        -   a growing macromolecule including a first reactable group,            at least one of which bears a first functional moiety being            a protecting group; and        -   a linker including a carbonyl group and a reactable group;    -   (ii) activating the carbonyl group on the linker;    -   (iii) activating the first reactable group on the growing        macromolecule; and    -   (iv) reacting the deprotected growing macromolecule with the        activated carbonyl group on the linker.

The process may then further include the steps of:

-   -   (v) providing a compound including at least one dendritic motif        bearing at least two functional moieties, the motif having a        surface layer and at least one sub-surface layer, and having a        hydrocarbon backbone and bearing an apex carbonyl group;    -   (vi) activating the carbonyl group of the dendritic motif;    -   (vii) activating the reactable group of the linker; and    -   (viii) reacting the activated carbonyl group and linker, either        before or after step (iv) of the process above.

In one embodiment the reactable group of the linker is a reactable aminethat is protected, and the activating step involves deprotecting thelinker using suitable conditions as have been discussed herein.

In yet another embodiment, the growing macromolecule may be reacted withan end-stopping functional moiety, optionally on a linker bearing theend-stopping functional moiety. The end-stopping functional moiety mayalso be activated for amide bond formation either prior to the reactionor in situ.

The macromolecule of the present invention may include a unique point ofattachment for either of the first or second functional moiety. In thisway, a macromolecule may be synthesised with a single first or secondfunctional moiety.

In an alternative embodiment the macromolecule of the present inventionmay include a selected single point of attachment for either the firstor second functional moiety.

There are general methods described in the art for the selectivemono-protection of polyamine molecules. Such methods are described inKrapcho and Kuell Synthetic Commun. 1990 20 2559. In a preferred methodmacromolecules with a unique point of attachment are prepared from a di-or tri-valent core wherein only one of the reactive amine groups isprotected, and with a protecting group that is inert, or orthogonal, tothe conditions that are used to remove other amine protecting groupsduring the process by which a macromolecule is constructed. It is thenpossible to conduct the iterative cycles of condensation and aminedeprotection, to build a macromolecule of 1 to 6 generations, morepreferably 3 to 5 generations, and in which there exists a singlesurface amine group that is distinguished from the other surface aminegroups by its unique amine protecting group. This unique surface aminegroup represents a site at which a single selected molecule, e.g. aprotein or peptide, a pharmaceutically active agent, a signallingmoiety, an anchoring moiety or a targeting molecule may be attached tothe macromolecule.

In a preferred form of this embodiment, there is provided amacromolecule having a controlled surface group composition, themacromolecule including a surface layer, at least one subsurface layerand at least two functional moieties including

-   -   a first functional moiety attached to a single selected point of        attachment on the macromolecule; and    -   a second functional moiety group;        wherein functional moiety composition refers to the number and        type of functional moieties.

In a preferred method, the protecting group of the unique surface aminegroup is removed, and the surface amine group is reacted with ahaloacetic acid derivative, or a maleimide derivative such as3-maleimidopropionic acid or 4-maleimidobutyric acid under conditionswhere the amide bond is formed. General methods for the coupling ofthiol containing peptides and proteins to such thiol active groups aredescribed in Hermanson, G. T. Bioconjugate Techniques (Academic Press1996) and the references cited therein, Blatter et al, Biochem., 24:1517 (1985) and Jue et al, Biochem., 17:5399 (1978).

Computer Modelling

In addition to the couplet, quartet, octet, and 16-tet notation used todescribe each different topological isomer, the macromolecules may berepresented graphically.

Computer simulation of the macromolecules may be used to illustrate thedistribution of functional moieties, and the three-dimensional structureadopted by the macromolecule. Such an illustration helps to demonstratethe differences that exist between different topological isomers ofmacromolecules which have the same surface group stoichiometry.

The molecular modelling of a set (see Table 19) of asymmetricmacromolecules which were constructed entirely from asymmetric lysinebuilding units is described in Example 65.

Each of asymmetric sets contained the following topological isomers:

TABLE 19 Topological Isomers used in Example 65 MacromoleculeTopological description Type 1: 16-tet cluster((((AA)(AA))⁴((AA)(AA))⁴)⁸(((AA)(AA))⁴((AA)(AA))⁴)⁸)¹⁶((((BB)(BB))⁴((BB)(BB))⁴)⁸(((BB)(BB))⁴((BB)(BB))⁴)⁸)¹⁶ Type 2: Octetcluster ((((AA)(AA))⁴((AA)(AA))⁴)⁸(((BB)(BB))⁴((BB)(BB))⁴)⁸)¹⁶((((AA)(AA))⁴((AA)(AA))⁴)⁸(((BB)(BB))⁴((BB)(BB))⁴)⁸)¹⁶ Type 3: Quartetcluster ((((AA)(AA))⁴((BB)(BB))⁴)⁸(((AA)(AA))⁴((BB)(BB))⁴)⁸)¹⁶((((AA)(AA))⁴((BB)(BB))⁴)⁸(((AA)(AA))⁴((BB)(BB))⁴)⁸)¹⁶ Type 4: Coupletcluster ((((AA)(BB))⁴((AA)(BB))⁴)⁸(((AA)(BB))⁴((AA)(BB))⁴)⁸)¹⁶((((AA)(BB))⁴((AA)(BB))⁴)⁸(((AA)(BB))⁴((AA)(BB))⁴)⁸)¹⁶ Type 5: Nocluster ((((AB)(AB))⁴((AB)(AB))⁴)⁸(((AB)(AB))⁴((AB)(AB))⁴)⁸)¹⁶((((AB)(AB))⁴((AB)(AB))⁴)⁸(((AB)(AB))⁴((AB)(AB))⁴)⁸)¹⁶

In general, simulation of the macromolecules of Example 65 exhibitedsignificantly different distributions of functional moieties A and Bdependent on the topological isomer.

TABLE 20 Means and standard deviations of A-B distances and theirvariation with Cluster Pattern. Mean A-B distance Standard Deviation ofA-B Cluster Pattern (Å) distance (Å) Type 1 23.16 7.57 Type 2 20.81 7.09Type 3 20.83 7.42 Type 4 20.62 7.38 Type 5 20.14 7.88

FIG. 18 shows the distribution of all functional-moiety-functionalmoiety distances. The most significant difference is between the Type 1clustering where the Functional Moieties are clustered in 16-tets; andType 5 where there is no clustering. These topological isomers aregraphically depicted in FIGS. 16 and 17.

In cases where the end groups possess different electrostatic charges, adivision of the dendrimer into distinct regions will result in apolarised dendrimer molecule. This may be measured by calculating thedistances between the centres of charge of the various functionalmoiety/functional moieties. The results of these calculations aredepicted in FIG. 19, it can be seen from this graph that Clustering atthe level of 16-tet and octet provides a significantly larger distancebetween the centre of mass of the different Functional Moieties thandoes smaller clustering topologies.

Applications of the Macromolecules

Depending on the macromolecule and the functional moieties on thebuilding unit or surface building unit, the macromolecules may have alarge number of prophylactic and/or therapeutic uses, particularly whenformulated as a pharmaceutical composition. Accordingly, there isprovided a pharmaceutical composition including a macromolecule having acontrolled functional moiety stoichiometry including

-   -   at least one dendritic motif having a surface layer formed from        at least one surface building unit and at least one subsurface        layer formed from at least one building unit, the surface        building unit and building units having a hydrocarbon backbone        bearing a carbonyl group and at least one amine group; and    -   at least two different functional moieties on the building unit        and/or surface building unit;        where functional moiety stoichiometry refers to the number and        type of functional moieties; and a pharmaceutically acceptable        carrier, or excipient.

In one embodiment of this aspect of the invention, the macromolecule hasa controlled topology, wherein topology refers to the relationshipbetween the functional moieties.

The pharmaceutically acceptable carriers or excipients may be selectedfrom any known carriers or excipients depending on the delivery routeselected for the active.

The pharmaceutical composition may be formulated for oral, injectable,rectal, parenteral, subcutaneous, intravenous, intramuscular or otherdelivery. The pharmaceutical composition may be formulated in tablet,capsule, caplet, injectable ampoule vial, or ready-to-use solution,lyophilised material, suppository, bolus or implant form.

The macromolecules and compositions of the present invention aresuitable for administration in any suitable manner, e.g. parenteral(including intravenously, intramuscularly, subcutaneous), orally,intraperitoneally, topically (skin), buccal, vaginally, rectally, to thesurface of the skin, transdermal (slow release preparation), into thejoint space, intranasally, by aerosol, by pulmonary administration, anddirectly to a body part.

It is especially advantageous to formulate the pharmaceuticalcomposition of the present invention in unit dosage form for ease ofadministration and uniformity of dosage. The specifications for thedosage unit forms of the present invention may be determined by a personskilled in the art depending on, for example (a) the uniquecharacteristics of the active ingredient and the particular therapeuticeffect to be achieved, and (b) the limitations inherent in the art ofcompounding such an active ingredient for the particular treatment.

Pharmaceutical formulations suitable for oral administration mayconveniently be presented as discrete units such as capsules, cachets ortablets each containing a predetermined amount of the active ingredient;as a powder or granules; as a solution, a suspension or as an emulsion.The active ingredient may also be presented as a bolus, electuary orpaste. Tablets and capsules for oral administration may containconventional excipients such as binding agents, fillers, lubricants,disintegrants, or wetting agents. The tablets may be coated according tomethods well known in the art. Oral liquid preparations may for examplebe in the form of aqueous or oily suspensions, solutions, emulsions,syrups or elixirs, or may be presented as a dry product for constitutionwith water or other suitable vehicle before use. Such liquidpreparations may contain conventional additives such as suspendingagents, emulsifying agents, non-aqueous vehicles, which may includeedible oils, or preservatives.

The macromolecule according to the present invention may also beformulated for parenteral administration by injection, for example bolusinjection, or continuous infusion, and may be presented in unit dosageform in ampoules, pre-filled syringes, small volume infusion or inmulti-dose containers with an added preservative. The compositions maytake such forms as suspensions, solutions, or emulsions in oily oraqueous vehicles, and may contain formulating agents such as suspending,stabilising and/or dispersing agents.

Alternatively, the active ingredient may be in powder form, obtained byaseptic isolation of sterile solid or by lyophilisation from solution,for constitution with a suitable vehicle, eg. sterile, pyrogen-freewater, before use.

For topical administration to the epidermis, the macromolecule accordingto the invention may be formulated as an ointment, cream or lotion, oras a transdermal patch.

Ointments and creams may, for example, be formulated with an aqueous oroily base with the addition of suitable thickening and/or gellingagents. Lotions may be formulated with an aqueous or oily base, and willin general also contain one or more emulsifying agents, stabilisingagents, dispersing agents, suspending agents, thickening agents, orcolouring agents.

Formulations suitable for topical administration in the mouth includelozenges comprising active ingredient in a flavoured base, usuallysucrose and gum acacia or gum tragacanth; pastilles comprising theactive ingredient in an inert base such as gelatin or sucrose and gumacacia; and mouthwashes comprising the active ingredient in a suitableliquid carrier.

Pharmaceutical formulations suitable for rectal administration whereinthe carrier is a solid are most preferably presented as unit dosagesuppositories. Suitable carriers include cocoa butter and othermaterials commonly used in the art, and the suppositories may beconveniently formed by admixture of the macromolecule with the softenedor melted carrier(s) followed by chilling and shaping moulds.

Formulations suitable for vaginal administration may be presented aspessaries, tampons, creams, gels, pastes, foams or sprays containing inaddition to the active ingredient such carriers as are known in the artto be appropriate.

For administration to the respiratory tract, including intranasaladministration, the macromolecule according to the present invention maybe administered by any of the methods and formulations employed in theart for administration to the respiratory tract.

Thus in general the macromolecule according to the present invention maybe administered in the form of a solution or a suspension or as a drypowder.

Solutions and suspensions will generally be aqueous, for exampleprepared from water alone (for example sterile or pyrogen-free water) orwater and a physiologically acceptable co-solvent (for example ethanol,propylene glycol or polyethylene glycols such as PEG 400).

Such solutions or suspensions may additionally contain other excipientsfor example preservatives (such as benzalkonium chloride), solubilisingagents/surfactants such as polysorbates (eg. Tween 80, Span 80,benzalkonium chloride), buffering agents, isotonicity-adjusting agents(for example sodium chloride), absorption enhancers and viscosityenhancers. Suspensions may additionally contain suspending agents (forexample microcrystalline cellulose, carboxymethyl cellulose sodium).

Solutions or suspensions are applied directly to the nasal cavity byconventional means, for example with a dropper, pipette or spray. Theformulations may be provided in single or multidose form. In the lattercase a means of dose metering is desirably provided. In the case of adropper or pipette this may be achieved by the patient administering anappropriate, predetermined volume of the solution or suspension. In thecase of a spray this may be achieved for example by means of a meteringatomising spray pump Administration to the respiratory tract may also beachieved by means of an aerosol formulation in which the macromoleculeaccording to the present invention is provided in a pressurised packwith a suitable propellant, such as a chlorofluorocarbon (CFC), forexample dichlorodifluoromethane, trichlorofluoromethane ordichlorotetrafluoroethane, carbon dioxide or other suitable gas. Morepreferably the propellant is an HCFC such as R134a or R125. The aerosolmay conveniently also contain a surfactant such as lecithin. The dose ofdrug may be controlled by provision of a metered valve.

Alternatively the macromolecule according to the present invention maybe provided in the form of a dry powder, for example a powder mix of themacromolecule according to the present invention in a suitable powderbase such as lactose, starch, starch derivatives such ashydroxypropylmethyl cellulose-14 and polyvinylpyrrolidine (PVP).Conveniently the powder carrier will form a gel in the nasal cavity. Thepowder composition may be presented in unit dosage form, for example incapsules or cartridges of eg. gelatin, or blister packs from which thepowder may be administered by means of an inhaler.

Compositions of the present invention may also be used in combinationwith existing and accepted therapeutic approaches as adjuvant therapy.For example, they may be used with antibacterial drugs, antiviral drugsor antifungal drugs. In rheumatoid arthritis and related conditions,Behcet's disease, inflammatory bowel disease and psoriasis, they may beused with steroids and disease modifying drugs such as methotrexate ordisease modifying therapeutic antibodies. In the treatment of organtransplant rejection, and in graft versus host disease, they may be usedwith steroids and/or cyclosporine and/or FK506 and/or azathioprineand/or tacrolimus and/or sirolimus and/or basiliximab and/or daclizumab.

Suitable pharmaceutically acceptable carriers, diluents and/orexcipients include conventional solvents, dispersion media, fillers,solid carriers, aqueous solutions, coatings, antibacterial andantifungal agents, isotonic, and absorption enhancing or delayingagents, and the like. The use of such media and agents forpharmaceutically active substances is well known in the art, and it isdescribed, by way of example, in Remington's Pharmaceutical Sciences,18th Edition, Mack Publishing Company, Pennsylvania, USA, the relevantdisclosure of which is incorporated herein by reference. Except insofaras any conventional media or agent is incompatible with the activeingredient, use thereof in the pharmaceutical composition of the presentinvention is contemplated. Supplementary active ingredients may also beincorporated into the composition.

The pharmaceutical composition may be prepared by any of the methodswell known in the art of pharmacy. Such methods include the step ofbringing the active component into association with a carrier, diluentor excipient, which may include one or more accessory excipients. Forexample, the composition may be prepared by uniformly and intimatelybringing the active component into association with a liquid carrier, afinely divided solid carrier, or both, and then, if necessary, shapingthe product.

The macromolecule of the present invention may be administered inprophylactically or therapeutically effective amounts. Aprophylactically or therapeutically effective amount means that amountnecessary to at least partly attain the desired effect, or to delay theonset of, inhibit the progression of, or halt altogether, the onset orprogression of the particular condition being treated. Such amounts willdepend, of course, on the particular condition being treated, theseverity of the condition and individual patient parameters includingage, physical condition, size, weight and concurrent treatment. Thesefactors are well known to those of ordinary skill in the art and may beaddressed with no more than routine experimentation. It is preferredgenerally that a maximum dose be used, that is, the highest safe doseaccording to sound medical judgement. It will be understood by those ofordinary skill in the art, however, that a lower dose or tolerable dosemay be administered for medical reasons, psychological reasons or forvirtually any other reasons.

Generally, daily doses of the macromolecule may be from about 0.01 mg/kgper day to 1000 mg/kg per day. Small doses (0.01-1 mg) may beadministered initially, followed by increasing doses up to about 1000mg/kg per day. In the event that the response in a subject isinsufficient at such doses, even higher doses (or effective higher dosesby a different, more localised delivery route) may be employed to theextent patient tolerance permits. Multiple doses per day arecontemplated to achieve appropriate systemic levels of compounds.

In a further preferred embodiment, pharmaceutically acceptable carriersor excipients may be selected from one or more of sterile aqueous saltsolutions, suspensions and emulsions, including saline and bufferedmedia, Ringer's dextrose, dextrose and sodium chloride, and lactatedRinger's solution. Intravenous vehicles include fluid and nutrientreplenishers, electrolyte replenishers, such as those based on Ringer'sdextrose, and the like. For administration by non-intravenous routes,the carrier can be in the form of clotted plasma, preferably thepatient's clotted plasma. Alternatively the carrier can be aplasma-free, physiologically compatible, biodegradable solid orsemi-solid, such as a gel, suspension or water soluble jelly. Acacia,methylcellulose and other cellulose derivatives, sodium alginate andtragacanth suspensions or gels are suitable for use as carriers in thepractice of this invention, for example, sodium carboxymethylcellulose2.5%, tragacanth 1.25% and guar gum 0.5%.

A number of non-limiting applications for the macromolecules accordingto the present invention may be illustrated as follows:

1. Anti-Sexually Transmitted Microbial Macromolecule

In a further aspect of the present invention, there is provided amacromolecule, having a controlled functional moiety stoichiometryincluding at least one dendritic motif having a surface layer formedfrom at least one surface building unit and at least one subsurfacelayer formed from at least one building unit, the surface building unitand building units having a hydrocarbon backbone bearing a carbonylgroup and at least one amine group and at least two different functionalmoieties on the building unit and/or surface building unit, at least oneof the functional moieties bearing an aromatic or heterocyclic sulphate,sulphonate, phosphate, phosphonate, carboxyl or carbonyl residue, orderivative thereof, and exhibiting an enrichment in a selectedfunctional moiety stoichiometry, where functional moiety stoichiometryrefers to the number and type of functional moieties.

International patent application no PCT/AU02/00407 (WO 02/079299), toapplicants, the entire contents of which are incorporated herein byreference, discloses a class of dendrimers (highly branchedmacromolecules with a defined envelope of polyanionic or cationicsurface groups) which have been shown to exhibit a range of antiviraland antimicrobial activity with minimal toxicity. These macromoleculesact to prevent infection of cells of the host organism by interferingwith the binding of the infectious microbe to the host.

Despite these advances in the art, difficulties remain in respect of thepotency of these macromolecules, in particular with regard to thedifferences in potency between in vitro test systems and in vivo testsystems. These macromolecules are primarily formulated as compositionswith a single functional moiety on the surface.

The presentation of a multiplicity of functional moieties on the surfaceof a macromolecule with control over topology and stoichiometry of thedifferent functional moieties is made possible through the applicationof this invention. In a preferred embodiment the first functional moietyis an aromatic or heteroaromatic moiety which includes at least one andpreferably two anionic residues per functional moiety. The role of thesecond functional moiety is to provide a second mechanism by which themacromolecule may bind to the targets through which the microbialinfection is mediated, and antimicrobial efficacy is achieved when thisbinding is enhanced. In a preferred embodiment of this invention thesecond functional moiety has lipophilic properties.

For example, the macromolecule according to this aspect of the presentinvention may be useful in the prophylactic and/or therapeutic treatmentof STI's including one or more of Human Immunodeficiency Viruses-I andII (HIV), Herpes Simplex viruses 1 and 2 (HSV), Cytomegalovirus (CMV),Varicella Zoster Virus (VZV), Epstein-Barr Virus (EBV), HepatitisViruses A, B, C & D, Human Papilloma Virus (HPV), Chlamydia trachomatis,Candida albicans, Trichomonas vaginalis, Neisseria gonorrhoeae,Treponema pallidum, Calymmato bacterium granulomatis, HaemophilusDucreyi, Sarcoptes scabiei, Phthirus pubis, Mycoplasma, Gardnerellavaginalis, and other microbial pathogens.

The macromolecule according to the present invention may exhibitsignificant in vivo efficacy, improved toxicity and pharmacokineticsrelative to the prior art.

In a preferred embodiment, there is provided a composition forprophylactic or therapeutic treatment of sexually transmitted infectionswhich includes a macromolecule having a controlled functional moietystoichiometry including

-   -   at least one dendritic motif having a surface layer formed from        at least one surface building unit and at least one subsurface        layer formed from at least one building unit, the surface        building unit and building units having a hydrocarbon backbone        bearing a carbonyl group and at least one amine group; and    -   at least two different functional moieties on the building unit        and/or surface building unit; where functional moiety        stoichiometry refers to the number and type of functional        moieties; and        optionally a pharmaceutically acceptable carrier or excipient.

An example of such a macromolecule isBHALys[Lys]₈[α-COCH₂O-3,6-Naph(SO₃Na)₂]₈[ε-Boc]₈ which is described inExample antimicrobial 9 and is illustrated in FIG. 11.

Desirably, the second functional moiety(s) may be selected from one ormore of the following: alkyl moieties of C1 to C20 either branched orstraight chain, cycloalkyl ring systems such as cyclohexyl, decalin, andthe various steroid scaffolds including cholic acids and deoxycholicacids, benzyl, naphthyl, thiophenes or other polycyclic aromaticmoieties; pyridines, quinolines and isoquinolines, pyrroles and indoles,imidazoles, oxazoles, pyrazoles, pyridazines, pyrimidines andquinazolines, pyrazines and quinoxalines; all optionally furthersubstituted with amine, hydroxyl alkyl or halo moieties where suchsubstitution does not lead to a chemically labile material.

A hydrophobic group, such as an alkyl C1 to C10, ring systems such ascyclohexyl, and the various steroid scaffolds including cholic acids anddeoxycholic acids, benzyl, pyridine or imidazole is preferred.

In a further preferred embodiment, the macromolecules are enriched in arelative stoichiometry of the anionic functional moiety to thehydrophobic functional moiety in the range from 63:1 through to 16:48,more preferably the relative stoichiometry is in the range of 60:4through to 1:1.

In a further preferred embodiment, the macromolecules may be selectedfrom a preparation of macromolecules enriched in topologies selectedfrom: anionic moieties clustered at the level of couplets or quartets oroctets or couplets of the form (AB) where A is an anionic functionalmoiety and B is a hydrophobic moiety.

The second functional moiety may be directly connected to themacromolecule or may be connected to the macromolecule by anon-cleavable linker.

In a preferred aspect of this embodiment of the present invention, thereis provided a macromolecule of the formula:Core[Building Unit]_(m)[Surface Building Unit]_(n)[Functionalmoiety]_(p)wherein:the Core is selected from the group consisting of lysine, or aderivative thereof, a diaminoalkane compound, or a trialkyltetraminecompound to which the first layer of building units (below) is added;the Building Unit is selected from lysine or lysine analogue;the Surface Building Unit, which may be the same as, or different tothat of the building unit is selected from lysine or lysine analogue;the Functional moieties include two or more different groups, a firstfunctional moiety having the structure of one or more of the following:

wherein W represents a functional group attached to a surface amine ofthe macromolecule and is selected from C(O) or S(O)₂and;a second functional moiety selected from one or more of the groupconsisting of property modifiers; alkyl moieties of C1 to C20 eitherbranched or straight chain, cycloalkyl ring systems such as cyclohexyl,decalin, and the various steroid scaffolds including cholic acids anddeoxycholic acids, benzyl, naphthyl, thiophenes or other polycyclicaromatic moieties; pyridines, quinolines and isoquinolines, pyrroles andindoles, imidazoles, oxazoles, pyrazoles, pyridazines, pyrimidines andquinazolines, pyrazines and quinoxalines; all optionally furthersubstituted with amine, hydroxyl alkyl or halo moieties where suchsubstitution does not lead to a chemically labile material;m represents the sum of building units of the subsurface layers of themacromolecule and is an integer between 1 to 64;n represents the number of surface building units with surface layer(s)of the macromolecule and is an integer between 2 and 128;p represents the number of functional moieties on the surface layer ofbuilding units and is an integer between 0 to 256.

The macromolecule, or precursor therefor may be selected from thefollowing

-   BHALys[Lys]₄[α-COCH₂O-3,6-Naph(SO₃Na)₂]₄[ε-COC₅H₁₁]₄-   BHALys[Lys]₄[α-COC₅H₁₁]₄[ε-COCH₂O-3,6-Naph(SO₃Na)₂]₄-   BHALys[Lys]₄[α-CO-4-PhSO₃Na]₄[ε-Hexyl]₄-   DAH [Lys]₈[α-COCH₂O-3,6-Naph(SO₃Na)₂]₈[ε-COC₅H₁₁]₈-   BHALys[Lys]₈[α-COCH₂O-3,6-Naph(SO₃Na)₂]₈[ε-CBz]₈-   BHALys[Lys]₈[α-CO-3,5-Ph(SO₃Na)₂]₈[ε-CBz]₈-   DAH [Lys]₈[α-CO-3,5-Ph(SO₃Na)₂]₈[ε-COC₅H₁₁]₈-   BHALys[Lys]₈[α-CO-4-Ph(SO₃Na)]₈[ε-CBz]₈-   BHALys[Lys]₁₆[α-COCH₂O-3,6-Naph(SO₃Na)₂]₁₆[ε-CBz]₁₆-   BHALys[Lys]₁₆[α-CO-3,5-Ph(SO₃Na)₂]₁₆[ε-CBz]₁₆-   BHALys[Lys]₁₆[α-CO-4-Ph(SO₃Na)]₁₆[ε-CBz]₁₆-   BHALys[GlyLys]₂[Lys]₄[α,α-Boc]₂[α,ε-Boc]₂[ε,α-COCH₂O-3,6-Naph(SO₃Na)₂]₂[ε,ε-COCH₂O-3,6-Naph(SO₃Na)₂]₂-   BHALys[GlyLys]₂[Lys]₄[α,α-COCH₂O-3,6-Naph(SO₃Na)₂]₂[α,ε-COCH₂O-3,6-Naph(SO₃Na)₂]₂[ε,α-COC₅H₁₂]₂[ε,ε-COC₅H₁₂]₂-   BHALys[Lys]₂[GlyLys]₄[Lys]₈[α,α-Boc]₄[α,ε-Boc]₄[ε,α-COCH₂O-3,6-Naph(SO₃Na)₂]₄[ε,ε-COCH₂O-3,6-Naph(SO₃Na)₂]₄-   BHALys[Lys]₂[GlyLys]₄[Lys]₈[α,α-COCH₂O-3,6-Naph(SO3Na)₂]₄[α,ε-COCH₂O-3,6-Naph(SO₃Na)₂]₄[ε,α-COC₅H₁₂]₄[ε,ε-COC₅H₁₂]₄-   BHALys[Lys]₂[α,ε-Lys][CBz]₂[Lys]₃[COCH₂O-3,6-Naph(SO3Na)₂]₆-   BHALys[Lys]₂[α,ε-Lys][COCH₂O-3,6-Naph(SO₃Na)₂]₂[Lys]₃[Boc]₆-   BHALys[GlyLys]₂[Lys]₄[COCH₂O-3,6-Naph(SO₃Na)₂]₆[ε,ε-CBz]₂-   BHALys[GlyLys]₂[Lys]₄[Boc]₆[ε,ε-COCH₂O-3,6-Naph(SO₃Na)₂]₂

The macromolecule may be utilised in a composition for use method forthe prophylactic or therapeutic treatment of sexually transmittedinfections including administering to a mammalian patient an effectiveamount of the composition as described above. The anti-sexuallytransmitted microbial macromolecule may also be used in a compositionfor the prophylactic or therapeutic treatment of a sexually transmittedinfection in a mammalian patient. Preferably the mammal is a human.

2. Drug Sustenance Macromolecule

A macromolecule according to the present invention may serve as animproved drug delivery platform with defined pharmacokinetics andrelease profiles.

Many drugs fail in clinical trials either because their physicalproperties (particularly solubility) make them difficult to formulate;or because of a poor therapeutic index that leads to toxic effectsduring the high drug concentrations that occur just after dosing.

There are many emerging technologies which seek to provide a drugdelivery vehicle which will act to overcome poor drug solubility bycapturing the drug in some kind of soluble matrix or particle; andreduce toxicity through controlled release or targeting drug to the siteof disease prior to release.

We have demonstrated that it is possible to control the pharmacokineticsof a macromolecule by manipulation of the surface PEG group size. In themacromolecule of FIG. 15 the drug of interest is covalently attached tothe macromolecule through a linker that cleaves in a manner consistentwith the disease treatment (i.e. either hydrolyses slowly in plasma oris cleaved specifically at the disease site).

In a preferred embodiment, the macromolecule according to the presentinvention includes one or more different pharmaceutically active agents,derivatives thereof, precursors therefore, or residues thereof, asfunctional moieties. The macromolecules according to this aspect of thepresent invention may have application in combination therapy.

The pharmaceutically active agent may be an anti-tumor agent selectedfrom one or more of the following:

rituximab, oxaliplatin, docetaxel, gemcitabine, trastuzumab, irinotecan,paclitaxel, bevacizumab, carboplatin, cetuximab, doxorubicin,pemetrexed, epirubicin, bortezomib, topotecan, azacitidine, vinorelbine,mitoxantrone, fludarabine, doxorubicin, alemtuzumab, carmustine,ifosfamide, idarubicin, mitomycin, fluorouracil, cisplatin,methotrexate, melphalan, arsenic, denileukin diftitox, cytarabine,calcium levofolinate, cyclophosphamide, etoposide, viscum album, mesna,gemtuzumab, ozogamicin, busulfan, pentostatin, cladribine, bleomycin,daunorubicin, bendamustine, dacarbazine, raltitrexed, vincristine,fotemustine, etoposide phosphate, porfimer sodium and vinblastine.

The pharmaceutically active agents may be a combination of any one ormore of the categories exemplified in Table 1A or B, and/or anti-tumoragents listed above.

Exemplary combinations include, but are not limited to, combinations of:chemotherapeutic pharmaceuticals; anti-inflammatory pharmaceuticals andanti-arthritic pharmaceuticals; obesity therapeutics and diabetestherapeutics; growth hormones and growth promoters; muscle relaxants andanti-inflammatories; respiratory pharmaceuticals and bronchodilators oranti-microbials; chemotherapeutics and vitamins and the like.

3. Anti-Inflammatory Macromolecule

An inflammatory response is produced in response to infection, immuneresponses and trauma. The various cellular processes involved in theinflammation response provide targets for potential anti-inflammatorytherapies. The most commonly used anti-inflammatory drugs are thenon-steroidal anti-inflammatory drugs (NSAIDs). Most NSAIDS act asnon-selective inhibitors of the enzyme cyclooxygenase (COX), meaningthat both COX-1 and COX-2 isoforms of the enzyme are targeted. However asubset of NSAIDs selectively target COX-2. Steroidal anti-inflammatorydrugs act by binding to cortisol receptors.

Protein binding to cell surface carbohydrates is a key trigger of theinflammatory response. Therefore, receptor-ligand interactions betweencarbohydrates and proteins are also a potential mechanism to be targetedin the modification of the inflammatory response.

Treatments to inhibit an inflammatory response are often limited by theinability to target the area of inflammation with a high enoughconcentration of an anti-inflammatory drug and/or the low watersolubility of the anti-inflammatory drug. Other short comings includepoor absorption, poor bioavailability, instability, systemic sideeffects due to an inability to target the drugs, and the inability tocontrol their biodistribution, metabolism and renal or hepatic clearanceonce administered. Furthermore the therapeutic profile of manyanti-inflammatory drugs already on the market could be improved byproviding formulations with better bioavailability, targeting etc.

It would be useful to be able to provide anti-inflammatory agentsdesirably in a form with reduced toxicity and/or improved targeting tothe site of action and/or improved bioavailability.

Accordingly, the macromolecule of the present invention may be used asdelivery vehicles for inflammatory response-modulating agents, such asanti-inflammatory drugs or carbohydrates. Such macromolecules have thepotential to provide multivalent delivery systems for agents that have apotential anti-inflammatory function, due to the ability of single ormultiple agents to participate in polyvalent interactions with, forexample, cell surface receptors. The macromolecule of the presentinvention also may be used to simultaneously target different aspects ofthe inflammatory response and related responses by combining two or moreactive agents in the same delivery vehicle to achieve a faster and moreeffective treatment.

An example of such a macromolecule is illustrated in FIG. 21; see alsoExample 66.

The macromolecules of the present invention may include functionalmoieties that are inflammatory response-modulating agent. These act toinhibit the production of proinflammatory chemokines and/or cytokines,or may inhibit the action of a second messenger involved in theinflammatory response, such as a prostaglandin. Suitable inhibitors ofprostaglandin include non-selective and selective cyclooxygenase (COX)inhibitors. The inflammatory response-modulating agent may alternativelyact by inhibiting phospholipid metabolism and suppressing the immuneresponse or by inhibiting the receptor-mediated synthesis ofproinflammatory cytokines and/or chemokines.

The inflammatory response-modulating agent may be a steroid; anon-steroidal anti-inflammatory drug; an agent that modulatescell-surface receptor-ligand interactions or other agent capable ofmodulating cellular activities responsible for the inflammatoryresponse. For example, the inflammatory response-modulating agent may bea saccharide or oligosaccharide containing carbohydrate moietiesselected from:

glucosamine, sialic acid, mannose, furanose, glucuronic acid, iduronicacid, galactose; or analogues or O- or N-sulfated derivatives thereof.

Further examples of inflammatory response-modulating agents that may beused in the present invention include, but are not limited to thefollowing:

diclofenac; diflunisal; etodolac; fenoprofen; floctafenine;flurbiprofen; ibuprofen; indomethacin; ketoprofen; meclofenamate;menamic acid; molicam; nabumentone; naproxen; oxaprozin; phenylbutazone;piroxicam; sulindac; tenoxicam; tiaprofenic acid; tolmetin; celecoxib;valdecoxib; rofecoxib; glucosamine; glucocorticoids; andcorticosteroids, such as beclomethasone, budesonide, dexamethasone,fluticasone, prednisone, methylprednisolone, mometasone furoate,triamcinolone and hydrocortisone.

The macromolecule may be modified to include a second functional moiety.The second moiety may be capable of modulating an inflammatory response.Alternatively, the second moiety may have a complementary therapeutic orprophylactic activity, or may modify the characteristics of themacromolecule by providing, for example, targeting of the macromolecule,increased plasma half life, or reduced toxicity.

Scar formation following injury or surgery results from a combination ofan inflammatory response and an angiogenesis response that promotesfibroblast proliferation. Using a combination of an anti-inflammatoryagent together with an anti-angiogenesis agent as terminus groups in themacromolecule according to the present invention may allow thesimultaneous targeting of both mechanisms responsible for scarformation. An examples of anti-angiogenic agents that may be included asa terminus group is glucosamine-6-sulphate (Shaunak et al., 2004). Afurther example of a functional moiety having anti-angiogenic functionis provided in AU2005905858 (the entire contents of which isincorporated herein by reference) and is represented as follows:

In a further embodiment, the macromolecule includes a second functionalgroup that targets the macromolecule to a specific cell and/or tissuetype. Examples of targeting groups include ligands for cell surfacemarkers specific to particular cell types, for example: Cellularadhesion molecules (CAMs) such as E-selectin, P-selectin, VCAM-1,ICAM-1, integrins, chemokine receptors such as CCR3, CXCR1, CXCR3;receptors for cytokine such as IL-1, TNF-alpha, TGF-beta, IL-6, IL-2;receptors for growth factors such as VEGF and FGF; Toll-like receptors;CD40 ligand (TNF superfamily); Heat shock protein 70 (HSP70); Fcreceptors such as FcRII; procoagulant molecules such as tissue factor(TF) and platelet glycoproteins such as collagen, fibronectin, vonWillebrands factor.

Some embodiments of the invention will now be described more fully withreference to the following non-limiting examples and figures:

In the figures:

FIG. 1 illustrates a lysine macromolecule according to a preferredembodiment of the invention with a lysine benzylhydrylamide divalentcore, and three layers of building units. Cleavage of the linkage Lshown provides dendritic motif F1.2, which is a 3 layer lysine dendriticmotif (note the eight bold N moieties represent the surface amines). Theapex carbonyl moiety is now at L. R can either be a functional moietythat is a protecting group or any other type of functional moiety.Another form of this dendritic motif is described in F1.3 wherein theapex carbonyl is in the form of a carboxylate moiety is described infull: such a motif may be prepared and used as part of the embodimentsof this invention.

FIG. 2 is a schematic representation of a selected topological isomer ofa lysine dendritic macromolecule according to a preferred embodiment ofthe invention having four layers of building units from theethylenediamine core, and bearing a total of 32 functional moieties Aand B in a ratio of 1:1. A, B represent two different functionalmoieties that may be protecting groups or other functional moieties.Bold bonds indicate the outermost building unit to which all theencircled functional moieties are connected, and the functional moietiesof the circled dendritic motif are underlined in the nomenclature.Further note in 2.1. the arrow to indicate the origin, and readingframe, that is used to generate the alpha-numeric topologicalnomenclature discussed in the text. 2.1 use of couplets; 2.2 use ofquartets; 2.3 use of octets; 2.4 use of 16-tets. building units (Lysineanalogues): F2.5 Core; F2.6 subsurface building unit; F2.7 surfacebuilding unit bearing functional moieties (AA); and F2.8 (BB).

FIG. 3 is a schematic representation of selected topological isomers oflysine dendritic macromolecules according to a preferred embodiment ofthe invention having four layers of building units from theethylenediamine core and bearing a total of 32 functional moieties A andB in a ratio of 1:1. A, B represent two different functional moietiesthat may be protecting groups or other functional moieties. Thetopological isomers are defined using nomenclature described in the textat the level of 16-tet building units (Lysine analogues): Topologicalequivalence of F3.6 and F3.7 asymmetric lysine surface units bearingfunctional moieties (AB) and symmetric lysine building unit F3.8.

FIG. 4 is a schematic representation of equivalent topological isomersaccording to a preferred embodiment of the invention of three layers oflysine or lysine analogue building units from the apex F having a 1:1surface stoichiometric ratio of A and B. A, B represent two differentfunctional moieties that may be protecting groups or other functionalmoieties and F represents the carbonyl moiety at the apex. Eachrepresentation differs by a 180° rotation of the indicatedinter-building unit bond. F4.4 is a representation of a dendritic motifwith asymmetric building units. Such a structure is simplified by“symmetrising” the building unit prior to undertaking the bond rotationanalysis.

FIG. 5 is a schematic representation of selected topological isomers oflysine dendritic macromolecules according to a preferred embodiment ofthe invention having four layers of building units from theethylenediamine core and bearing a total of 32 functional moieties A, Band D in a ratio of 2:1:1. The topological isomers are defined usingnomenclature described in the text at the level of 16-tet.

FIG. 6 is a schematic representation of selected topological isomersaccording to a preferred embodiment of the invention of lysinevariegated dendritic macromolecules of four layers from theethylenediamine core in which linkers have been used. A and B representtwo different functional moieties that may be protecting groups or otherfunctional moieties and Ø is the null symbol used to representfunctional moieties lost from an ideal FM_(MAX) due to linkers replacingbuilding units. F6.1 use of couplets and the dendritic macromolecule inwhich FM_(total)=FM_(MAX); F6.2 use of quartets with linkers replacingsurface building units; F6.3 use of octets and linkers replacingsurface-but-one building units; F6.4 use of 16-tets and linkersreplacing surface-but-two building units. Rectangles highlightfunctional moieties as Ø lost due to use of linkers. F6.5 internallinker.

FIG. 7 is a schematic representation of selected topological isomersaccording to a preferred embodiment of the invention of lysinevariegated dendritic macromolecules of four layers from theethylenediamine core in which linkers have been used. A, B and Drepresent three different functional moieties that may be protectinggroups or other functional moieties. The topological isomers are definedusing nomenclature described in the text at the level of 16-tet. F7.1shows a variegated dendritic macromolecule in which linkers replacesurface building units to provide a surface stoichiometry of 8A:16B:4D;F7.2 shows a dendritic macromolecule in which linkers replacesurface-but-one building units to provide a surface stoichiometry of8A:16B; F7.3 a dendritic macromolecule in which linkers replacesurface-but-two building units to provide a surface stoichiometry of8A:8B:8D; F7.4 shows a dendritic macromolecule in which a linkerreplaces a surface-but-three building unit to provide a surfacestoichiometry of 12A:8B:4D; F7.5 shows a dendritic macromolecule inwhich linkers replace both surface-but-two and surface-but-threebuilding units to provide a surface stoichiometry of 8B:8A.

FIG. 8 is a schematic representation of selected topological isomersaccording to a preferred embodiment of the invention of lysinevariegated dendritic macromolecules of four layers from theethylenediamine core in which end stopping functional moieties have beenused. A and B represent two different functional moieties that may beprotecting groups or other functional moieties and Ø is the null symbolused to represent functional moieties lost from an ideal FM_(MAX) due toan end stopping functional moiety at a subsurface building unit. F8.1use of couplets and the dendritic motifs in which FM_(total)=FM_(MAX);F8.2 use of quartets with end stopping functional moieties R1 and R2 atsurface-but-one building unit; F8.3 use of octets and end stoppingfunctional moieties R1 and R2 at surface-but-two building unit; F8.4 useof 16-tets and end stopping functional moieties at surface-but-threebuilding unit. Rectangles highlight functional moieties as Ø lost due toend stopping. F8.5 Building units bearing end stopping functionalmoieties.

FIG. 9 is a schematic representation of selected topological isomersaccording to a preferred embodiment of the invention of lysinevariegated dendritic macromolecules of four layers from theethylenediamine core in which linkers have been used. A and B representtwo different functional moieties and R1, R2 represent end stoppingfunctional moieties. The topological isomers are defined usingnomenclature described in the text at the level of 16-tet. F9.1 shows avariegated dendritic macromolecule in which end stopping reactions havebeen used at the surface layer of building units to provide a surfacestoichiometry of 16R1:16R2; F9.2 shows a dendritic macromolecule inwhich end stopping reactions have been used at the surface-but-one layerof building units to provide a surface stoichiometry of 4R1:16B:8A; F9.3shows a dendritic macromolecule in which end stopping reactions havebeen used at the surface-but-two layer of building units to provide asurface stoichiometry of 4R1:16B; F9.4 shows a dendritic macromoleculein which end stopping reactions have been used at the surface-but-threelayer of building units to provide a surface stoichiometry of 2R1:8B:8A;F9.5 shows a dendritic macromolecule in which end stopping reactionshave been used at both the surface-but-one and surface-but-two layers ofbuilding units to provide a surface stoichiometry of 4R1:4R2:8A.

FIG. 10 is DAH[Lys]₈[α-COCH₂O-3,6-Naph(SO₃Na)₂]₈[ε-COC₅H₁₂]₈ which isdescribed in Example 33. as an anti-sexually transmitted microbialmacromolecule according to a preferred embodiment of the invention, withpolyanionic surface molecules and lipophilic modifiers having activityagainst sexually transmitted infections such as HIV.

FIG. 11 is BHALys[Lys]₂[Su(NPN)₂]₄[MTX-OtBu]₄[PEG₂₄]₄ which is describedin Example 56, and which is a drug sustenance macromolecule according toa preferred embodiment of the invention, bearing surface PEG groups andto which a drug of interest is covalently attached.

FIG. 12 is a schematic illustration of the synthesis of Example 20(Scheme 1).

In Scheme 1: i. Reaction of BHALys[Boc]₂ with trifluoroacetic acid indichloromethane; ii. Reaction of BHALys[NH₂.TFA]₂ with excessPFP-Lys-α-Fmoc-ε-Boc and base in DMF; iii. Reaction ofBHALys[Lys]₂[α-Fmoc]₂[ε-Boc]₂ with trifluoroacetic acid indichloromethane; iv. Reaction of BHALys[Lys]₂[α-Fmoc]₂[ε-NH₂.TFA]₂ withexcess PNPO-Lys-(Boc)₂ and base in DMF; v. Reaction ofBHALys[Lys]₂[α-Fmoc]₂[ε-Lys]₂ [Boc]₄ with excess piperidine in DMF.

FIG. 13 is a schematic illustration of the synthesis of Example 18(Scheme 2). In Scheme 2: i. Reaction of EtOSu[NPN]₂[Boc][CBz] with amixture of TFA and Acetic acid; ii. Reaction ofEtOSu[NPN]₂[NH₂.TFA][CBz] with PNPOSu[NPN]₂[Boc]₂ in DMF and TEA; iii.Reaction of EtOSu[NPN]₂[CBz][Su[NPN]₂][Boc]₂ with ammonium formate andPd on C in DMF/Water; iv Reaction of EtOSu[NPN]₂[NH₂][Su[NPN]₂][Boc]₂with PNPOSu[NPN]₂[Boc][CBz] in DMF and TEA providedEtOSu[NPN]₂[Su[NPN]₂]₂[CBz][Boc]₃.

FIGS. 14A and 14B are schematic illustrations of the synthesis of amacromolecule (Example 15) that makes use of a dendritic motif preparedin Example 13.

In Scheme 3: 13.i. Reaction of methyl glycinate withPNPO-Lys-α-Boc-ε-CBz in DMF and TEA; 13.ii. Reaction ofMeO-GlyLys[α-Boc][ε-CBz] with TFA and Acetic acid; 13.iii. Reaction ofMeO-GlyLys[α-NH₂.TFA][ε-CBz] with PNPO-Lys(Boc)₂ in DMF and TEA; 13.iv.Reaction of MeO-GlyLys[ε-CBz][α-Lys][Boc]₂ with H₂ and Pd on Carbon inMethanol with TFA; 15.i. Reaction of GlyLys[ε-NH₂.TFA][α-Lys][Boc]₂ withPNPO-Lys-α-Boc-ε-CBz in DMF and TEA; 15.ii. Reaction ofMeOGlyLys[Lys]₂[Boc]₃[ε,ε-CBz] with NaOH in Methanol/Water to giveHO-GlyLys[Lys]₂[Boc]₃[ε,ε-CBz].

In Scheme 4: 15.ii. Reaction of BHALys[NH₂.TFA]₂ withHO-GlyLys[Lys]₂[Boc]₃[ε,ε-CBz], DCC and DMAP in DMF and TEA to giveBHALys[GlyLys]₂[Lys]₄[Boc]₆[ε,ε-CBz]₂.

FIG. 15A is a graph showing plasma concentration levels over time ofvarious macromolecules identified in Table 6, Example 64.

FIG. 15B is a series of graphs illustrating the correlation between PEGmacromolecule half-life and molecular weight, on a linear andlogarithmic scale and the correlation between PEG macromoleculemolecular weight and a % excreted in urea over time, on a linear andlogarithmic scale.

FIG. 16 shows the set of five topological isomers of the asymmetricmacromolecule structures in a 2D representation as described in Example65. The diagrams show the locations of the labelled functional moietiesA and B for the five different types of topological isomers that werecompared in Example 65.

FIG. 17 provides 3D graphical representations which derive from thecomputer modelling simulations conducted in Example 65 and demonstratethe distributions of the A and B functional moieties for five types oftopological isomers of the macromolecules according to the presentinvention.

FIG. 18. The distributions of all distances from functional moieties Ato functional moieties B, and the variation with clustering type fromExample 65: asymmetric building units (see text). Results are shown asthe fractional probability, that is, the chance of finding a functionalmoiety of the different type within 0.5 Å of the indicated distance.

FIG. 19 is a graph of the distances between the centre of mass of thefunctional moieties A and the centre of mass of the functional moietiesA for each of the cluster types from Example 65: asymmetric. The errorbars represent ±1 standard deviation.

FIG. 20 is a schematic diagram of the protocol used to obtain anequilibrated macromolecule structure in Example 65.

FIG. 21 is BHALys[Lys]₂[Glu]₄[α-COC2-α-S-GlcNAc]₄[γ-CO₂H]₄ which isdescribed in Example 66; this is an anti-inflammatory macromoleculeaccording to a preferred embodiment of the invention, bearing surfacecarbohydrate groups and carboxylate moieties in a 1:1 stoichiometry.

EXAMPLES

The following examples serve to illustrate the invention. The examplesare based on lysine building units, but are not limited to such.Examples 1 to 28 are structural examples which demonstrate the synthesisof the macromolecules and dendritic motifs of this invention. Includedin the Structural section is a demonstration (Example 28) of theChromatographic behaviour of different topological isomers which have acommon surface group stoichiometry. This example shows that thetopological isomers interact with the stationary phase differently,yielding different retention times which are recorded in Table 23.

In the Antimicrobial section, Examples 29 to 50 describe a number ofmacromolecules with two different functional moieties which haveanti-HIV activity. The anti-HIV data is collected in Table 24 of Example50. Again, a set of comparative data provides evidence that topologicalisomers with a common surface group stoichiometry can provide differentbiological activities. It is particularly important to note the potentanti-microbial activity achieved with Examples 46 and 48, which aresignificantly more active than SPL7013, a homogenous surface dendrimer.This demonstrates the usefulness of being able to provide amacromolecule with controlled stoichiometry/topology that includes twodifferent functional moieties.

In the ADME section, Examples 51 to 64 provide a series ofmacromolecules with surfaces comprised of both pharmaceutical activeagents and modifier compounds. The data provided by Example 64: seeTable 25 and FIGS. 15A and 15B, serves to demonstrate how thepharmacokinetic behaviour of macromolecules can be controlled throughthe appropriate tuning of the type and size of modifying functionalmoiety used on the surface in conjunction with the pharmaceuticallyactive moiety. An important feature of these macromolecules is thecontrolled stoichiometry and topology of the pharmaceutically activemoiety or residue thereof to surface modifier (PEG).

In the Anti-Inflammatory section, it has been demonstrated by the dataprovided in Example 73, Table 27 that macromolecules with a homogenoussurface of anionic functional moieties, 73.11 and 73.12 haveanti-inflammatory activity. It has also been observed that one of themacromolecules, 73.8 with a homogenous surface of the glucosaminemoiety: COC2CO-2-N-α-OMe-Glc functional moiety has anti-inflammatoryactivity. It is anticipated that macromolecules which combine anionicfunctional moieties with functional moieties that include theGlucosamine residue, such as Examples 66 through 71, with definedstoichiometries of 1:1, 1:2, 1:3, 1:4, 1:5, 1:6 and 1:7 of saccharide toanionic functional moiety, will have therapeutic anti-inflammatoryactivity on the basis that these molecules provide a controlledstoichiometry/topology of the two Functional Moieties which contributeto the anti-inflammatory activity of the homogenous surface compounds.

A system of nomenclature has been developed for the purposes ofidentifying the individual compounds described in this patent. Themacromolecule nomenclature makes use of the abbreviations in thefollowing table.

TABLE 21 Macromolecule Nomenclature Abbreviations and StructuresAbbreviation Function Name Structure¹ BHALys Core Benzhydrylamidolysine

DAH Core Diaminohexane

EDA Core Ethylenediamine

TETA Core Triethyltetraamine

NEOEOENLys Core

Su(NPN)₂ Building unit

Lys Building unit Lysine

GlyLys Building unit

NH₂•TFA Represents the surface amine groups of the building units, hereshown as the TFA salt, and is treated as a “functional moiety” for thepurposes of the nomenclature. Glu Surface building unit Glutamate

CO₂H Represents the surface carboxylate groups of the surface buildingunits and is treated as a “functional moiety” for the purposes of thenomenclature. Boc Functional moiety t-butyloxycarbonyl

Fmoc Functional moiety Fluorenylmethoxy- carbonyl

CBz Functional moiety Benzyloxycarbonyl

4-Nitro-CBz Functional moiety 4-Nitro-benzyloxycarbonyl

COCH₂O-3,6- Naph(SO₃Na)₂ Functional moiety 1-carboxy-3,6-naphthyldisulfonic acid di- sodium salt

CO-3,5- Ph(SO₃Na)₂ Functional moiety 1-carboxy-3,5- phenyldisulfonicacid di-sodium salt

CO-4-Ph(SO3Na) Functional moiety 1-carboxy-4- phenylsulfonic aciddi-sodium salt

CO₂(EtO)₃CH₃ Functional moiety

PEG₂₀₀ Functional moiety

COPEG₁₂ Functional moiety

PEG₁₁₀₀ Functional moiety

PEG_(2KD) Functional moiety

PEG₁₇₁₆ Functional moiety

PEG₂₈₄₅ Functional moiety

PEG₃₉₇₄ Functional moiety

α-tBu-MTX Functional moiety α-t-Butyl-N-[4-[[2,4- diamino-6-pteridinyl)methyl]methyl- amino]benzoyl]-L- glutamate

MTX Functional moiety N-[4-[[2,4-diamino-6- pteridinyl)methyl]methyl-amino]benzoyl]-L- glutamate

COCH₂CH₂CO- Taxol Functional moiety

COCH₃ Functional moiety Acetamide

COC2-α-S-GlcNAc Functional moiety

¹Asterisk indicates amine group bonded as amide to carboxyl group oflysine building unit, surface building unit or functional moiety. Hashindicates carboxyl group bonded as amide to amine of core or buildingunit

The dendrimer nomenclature in the following examples makes use of thefollowing formula:Core[Last Complete Layer;Building Unit]_(n)−[functionalmoiety]_(m)[Incomplete Outer Layer;Building Unit]_(p)[functionalmoiety]_(q)Where:

-   -   Core is the molecule to which the lysine building units are        attached and will include at least one amine moiety to which the        first layer of lysine building units is added; where a dendritic        motif is described, the building unit which includes the apex        carboxylate moiety is treated as the core,    -   n is the number of lysine building units on the outermost        complete layer of the macromolecule, p is the number of lysine        building units on the incomplete outer layer of the        macromolecule,    -   m is the number of functional moieties for example        pharmaceutical active moieties or protecting groups, on the        outermost complete layer of building units; q is the number of        functional moieties on the incomplete outer layer of building        units,

Optionally, a functional moiety, with or without building units may beappended to the core; these are then denoted as [functional moiety]_(r)[building unit]_(s) Core [Last Complete Layer; BuildingUnit]_(n)−[functional moiety]_(m) [Incomplete Outer Layer; BuildingUnit]_(p) [functional moiety]_(q).

Where:

-   -   r is the number of functional moieties appended, and    -   s is the number of lysine building units on the outer layer of        the motif appended to the core.

These Formulae are able to completely describe the size of amacromolecule through provision of the core and the outer layer(s) sincesufficient information is provided about the building units andfunctional moieties used in the construction of these macromoleculestructures and the valency of the core is known.

All lysine macromolecules prepared as the fully Boc protected forms weresynthesised and purified according to the procedures described in patentWO95/34595. Removal of the Boc protecting group was conducted accordingto the procedures described in same patent.

Further chemical abbreviations are listed in Table 22.

TABLE 22 Chemical Names and Abbreviations. Abbreviation Full Name PyBopBenzotriaxole-1-yl-oxy-tris-pyrrolidino-phosphonuim hexafluorophosphateDMF Dimethylformamide DCM Dichloromethane TFA Trifluoroacetic acid DIPEADiisopropyl amine TEA triethylamine Ether Diethyl ether EtOAc ethylacetate DMSO Dimethylsulfoxide can Acetonitrile Rt room temperature CaCirca Ppt Precipitate HPLC High Performance Liquid Chromatography MSMass Spectrometry CE Capillary Electrophoresis PFP-Lys-α-Fmoc-ε-BocPentafluorophenol active ester of α-Fmoc-ε-Boc-LysinePFP-Lys-α-Boc-ε-Fmoc Pentafluorophenol active ester ofα-Boc-ε-Fmoc-Lysine HO-Lys-α-Fmoc-ε-Boc α-Fmoc-ε-Boc-LysineHO-Lys-α-NH₂-ε-Boc α-NH₂-ε-Boc -Lysine PNPO-Lys-α,ε-(Boc)2 p-Nitrophenolactive ester of α,ε-(Boc)₂-Lysine PNPO-Lys(CBz)₂ p-Nitrophenol activeester of α,ε-(CBz)₂-Lysine PNPO-α-Boc-ε-CBz-Lys p-Nitrophenol activeester of α-Boc-ε-CBz-Lysine PNPO-α-CBz-ε-Boc-Lys p-Nitrophenol activeester of α-CBz-ε-Boc-Lysine Abbreviation Full Name Structure BHABenzhydrylamine

[NPN]₂[Boc][CBz]

HO-Su[NPN]₂[Boc] [CBz]

PNPO-Su[NPN]₂[Boc] [CBz]

[BOC][CBz][NPN]₂SuOEt

[BOC][NH₂][NPN]₂SuOEt

MeO-GlyLys[α-Boc][ε-CBz]

HO-GlyLysα-Boc][ε-CBz]

PNPO-CO₂PEG₃

HO-Lys-α-CO₂PEG₃-κ-Boc

EtO-Su(NPN)₂[Boc [COPEG] PEG₁₂ n = 10 PEG₂₄ n = 22

MTX-60 -OtBu

EtO-Su(NPN)₂[γ-CO- MTX-α-OtBu][COPEG] PEG₁₂ n = 10 PEG₂₄ n = 22

HO-Su(NPN)₂[γ-CO- MTX-α-OtBu][COPEG] PEG₁₂ n = 10 PEG₂₄ n = 22

NHS-COC2-(perAc)-α- S-GlcNAc (−) 2-Carboxyethyl 2- deoxy-2-acetamido-3,4,6-tetra-O-acetyl-1- thio-β-D- glucopyranoside.

HO-COC2-α-S-GlcNAc (−) 2-carboxyethyl 2- deoxy-2-acetamido-1- thio-α-D-glucopyranoside

HO-COC2CO-2-N-α- OMe-Glc Methyl 2-deoxy-2-[3- (methoxycarbonyl)prop-anamido]-α-D- glucopyranoside

PNPO-COC5-α-S- (perAc)-GlcNAc 5-{8 (4- nitrophenyl)oxy]carbon- yl}pentyl2-acetamido- 3,4,6-tri-O-acetyl-2- deoxy-1-thio-β-d- glucopyranoside

PNPO-Glu-α-Boc-δ-OBn p-Nitrophenol active ester of α-Boc-δ-Bn Glutamate

PNPO-Glu-α-Boc-δ-OMe p-Nitrophenol active ester of α-Boc-δ-Me GlutamatePNPO-Glu-α-Boc-δ-OFm p-Nitrophenol active ester of α-Boc-δ-Fluorenylmethyl- Glutamate HO-Lys-α-CBz-ε-Alloc Lysine-α-CBz-ε-Allyloxycarbonyl

NHS-COPEG₁₂ N-hydroxysuccinimide ester of MeO—(CH₂CH₂O)₁₁CH₂CH₂CO₂H

HO-COPEG₂₄

NHS-COPEG₂₄

NHSCOPEG₂₃₀₀

α-tBu-γ-MTX-OH α-t-Butyl-N-[4-[[2,4- diamino-6-pteridinyl)methyl]methyl- amino]benzoyl]-L glutamate

Centramate Details:Pall Filtron Centramate™ 3 gauge system (part # FS011K10) with 3KCentramate Cassette with Omega Membrane—Medium Screen (part #OS003C12).Operating with a back-pressure of 20-30 psi.NMR Equipment Details:Bruker 300 UltraShield™ 300 MHz NMR instrument.HPLC and MS Equipment DetailsHPLC—Waters 2795 with 2996 Diode Array Detector (DAD)MS—Waters ZQ4000 with ESI probe, inlet flow split to give around 50μL/min to the MS.

Mass Spectra data was acquired in negative electrospray ionisation mode.The raw data was deconvoluted using a Maximum Entropy algorithm (MaxEnt)as implemented in MassLynx software v4.0, supplied by WatersCorporation. The data reported in the experimental details correspondsto the observed value after deconvolution to a theoretical zero chargestate.

CE equipment

Beckman P/ACE MDQ with diode array detector

Capillary is underivatised fused silica, 75 μm i.d.×40 cm to detector

Preparation of:

Preparation of BHALys[Lys]₁₆[COCH₂O-3,6-Naph(SO₃Na)₂]₃₂ SPL7013 as perInternational patent application no PCT/AU02/00407 (WO 02/079299).

Structural Examples Example 1 BHALys[Lys]₂[α-Boc]₂[ε-NH₂]₂ i.BHALys[Lys]₂[α-Boc]₂[ε-CBz]₂

Surface Surface Topology Stoichiometry ((Boc CBz)(Boc CBz))⁴ 2 Boc 2 CBz

BHALys[NH₂.TFA] (200 mg, 0.371 mmol) was dissolved in DMF (2.0 ml) andtreated with TEA (258 μl, 1.85 mmol), stirring at ambient temperatureand resulting in a clear solution. PNPO-α-Boc-ε-CBz-Lys (446 mg, 0.890mmol) was added in one portion and the reaction mixture immediatelyturned bright yellow, and after five minutes all solid matter haddissolved. Stirring was continued for 24 h, then the reaction mixturewas poured onto iced water and stirred. This suspension was filtered andthe resulting solid pellet was rinsed repeatedly with water. The solidpellet was air-dried, resuspended in ACN, filtered and air-dried to giveBHALys[Lys]₂[α-Boc]₂[ε-CBz]₂ (343 mg, 89%) as an off-white solid.

LC/MS (Hydrophobic/TFA): ESI (+ve) m/z=1037.19 [M+H]+; calculated(C57H77N7O11) 1036.29 g/mol. Rf (min)=13.8.

ii. BHALys[Lys]₂[α-Boc]₂[ε-NH₂]₂

Surface Topology Surface Stoichiometry ((Boc NH₂)(Boc NH₂))⁴ 2 Boc 2 NH₂

BHALys[Lys]₂[α-Boc]₂[ε-CBz]₂ (170 mg, 0.164 mmol) was suspended in 9:1DMF/H₂O (5.0 ml) and ammonium formate (41 mg, 0.656 mmol) was added. Thesolution was stirred at ambient temperature for 10 min then Pd/C (10%w/w, 87 mg) was added and stirring was continued for 2 h. The reactionwas terminated by filtering off the catalyst and the filter was rinsedwith 9:1 DMF/H₂O (5.0 ml). The combined filtrates were pale yellow andclear, and concentrated in vacuo to give a pale yellow syrup. The syrupwas treated with water (15 ml) which was removed in vacuo, thenfreeze-dried in water (10 ml) to give BHALys[Lys]₂[α-Boc]₂[ε-NH₂]₂ as afine white lyophilate (120 mg, 96%).

LC/MS (Hydrophilic/TFA): ESI (+ve) m/z=882.12 [M+H+TFA]+, 769.08 [M+H]+,384.66 [M+2H]/2+; calculated (C41H65N7O7) 768.01 g/mol. Rf (min)=15.9.

Example 2 BHALys[Lys]₄[α-NH₂]₄[ε-Boc]₄ i. BHALys[Lys]₄[α-CBz]₄[ε-Boc]₄

Surface Topology Surface Stoichiometry (((Boc CBz)(Boc CBz))⁴((BocCBz)(Boc 4 Boc CBz))⁴)⁸ 4 CBz

A solution of BHALys[Lys]₂[NH₂.TFA]₄ (501 mg, 0.98 mmol), TEA (0.7 ml,5.02 mmol) and DMF (10 ml) was treated with PNPO-α-CBz-ε-Boc-Lys (1.18g, 2.35 mmol) following the method described in Example 1.i. The productBHALys[Lys]₄[α-CBz]₄[ε-Boc]₄ (830 mg, 84%) was obtained as a colourlesssolid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=1009.71 [M+2H]/2+; calculatedC107H153N15O23 2017.48 g/mol. Rf (min)=7.58.

ii. BHALys[Lys]₄[α-NH₂]₄[ε-Boc]₄

Surface Surface Topology Stoichiometry (((Boc NH₂)(Boc NH₂))⁴((BocNH₂)(Boc NH₂))⁴)⁸ 4 Boc 4 NH₂

To a magnetically stirred solution of BHALys[Lys]₄[α-CBz]₄[ε-Boc]₄ (400mg, 0.3 mmol) and 2,2,2-trifluoroethanol (8 ml) was added 10% Pd/C (203mg). The black suspension was hydrogenated under standard conditions(Rt, atmospheric pressure) for 19 h. After this time, the suspension wasfiltered through a 0.45 micron filter disk. The filtrate wasconcentrated under reduced pressure to give the productBHALys[Lys]₄[α-NH₂]₄[ε-Boc]₄ (285 mg, 96%) as a light fawn coloured oil.

LC/MS (Hydrophilic/TFA): ESI (+ve) m/z=1481.32 [M+H]+, 741.10 [M+2H]/2+;calculated C75H129N15O15 1480.94 g/mol. Rf (min)=8.40.

Example 3 BHALys[Lys]₄[α-Boc]₄[ε-NH₂]₄ i. BHALys[Lys]₄[α-Boc]₄[ε-CBz]₄

Surface Surface Topology Stoichiometry (((Boc CBz)(Boc CBz))⁴((BocCBz)(Boc CBz))⁴)⁸ 4 Boc 4 CBz

A solution of BHALys[Lys]₂[NH₂.TFA]₄ (503 mg, 0.49 mmol), TEA (0.7 ml,5.02 mmol) and DMF (10 ml) was treated with PNPO-α-Boc-ε-CBz-Lys (1.18g, 2.35 mmol). The reaction and product isolation were carried outaccording to the method described in Example 1.i. The productBHALys[Lys]₄[α-Boc]₄[ε-CBz]₄ (875 mg, 88%) was isolated as a colourlesssolid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=1009.71 [M+2H]/2+; calculatedC107H153N15O23 2017.48 g/mol. Rf (min)=7.40.

ii. BHALys[Lys]₄[α-Boc]₄[ε-NH₂]₄

Surface Surface Topology Stoichiometry (((Boc NH₂)(Boc NH₂))⁴((BocNH₂)(Boc NH₂))⁴)⁸ 4 Boc 4 NH₂

A solution of BHALys[Lys]₄[α-Boc]₄[ε-CBz]₄ (400 mg, 0.2 mmol) and2,2,2-trifluoroethanol (8 ml) was added 10% Pd/C (205 mg). The reactionand product isolation were carried out according to the method describedin Example 2.ii to give the product BHALys[Lys]₄[α-Boc]₄[ε-NH₂]₄ (288mg, 98%) as a glassy oil.

LC/MS (Phobic/TFA): ESI (+ve) m/z=741.1 [M+2H]/2+, 494.6 [M+3H]/3+;calculated C75H129N15O15 1480.94 g/mol. Data deconvoluted usingtransform calculation to give mw=1480.52. Rf (min)=1.04.

Example 4 BHALys[Lys]₈[α-Boc]₈[ε-NH2]₈ i. BHALys[Lys]₈[α-Boc]₈[ε-CBz]₈

Surface Surface Topology Stoichiometry ((((Boc CBz)(Boc CBz))⁴((BocCBz)(Boc CBz))⁴)⁸ 8 Boc (((Boc CBz)(Boc CBz))⁴((Boc CBz)(Boc CBz))⁴)⁸)¹⁶8 CBz

A solution of BHALys[Lys]₄[NH₂.TFA]₈ (1.59 mmol), TEA (4.50 ml, 32.30mmol) and DMF (30 ml) was treated with PNPO-α-Boc-ε-CBz-Lys (7.75 g,15.45 mmol) as a solid. The reaction and product isolation were carriedout according to the method described in Example 1.i to giveBHALys[Lys]₈[α-Boc]₈[ε-CBz]₈t (5.52 g, 87%) as a colourless solid.

LC/MS (Phobic/TFA): ESI (+ve) observed [M+H/3]+m/z=1328; calculated forC207H305N31O47 3979.9; Rf (min)=20.22 mins.

ii. BHALys[Lys]₈[α-Boc]₈[ε-NH₂]₈

Surface Surface Topology Stoichiometry ((((Boc NH₂)(Boc NH₂))⁴((BocNH₂)(Boc NH₂))⁴)⁸ 8 Boc (((Boc NH₂)(Boc NH₂))⁴((Boc NH₂)(Boc NH₂))⁴)⁸)¹⁶8 NH₂

BHALys[Lys]₈[α-Boc]₈[ε-CBz]₈ (500 mg, 0.126 mmol) was suspended in 9:1DMF/H₂O (12.5 ml) and ammonium formate (127 mg, 2.01 mmol) and Pd/C (10%w/w, 266 mg) were added. The reaction and product isolation were carriedout according to the method described in Example 1.ii to giveBHALys[Lys]₈[α-Boc]₈[ε-NH₂]₈ as a fine white lyophilate (155 mg, 42%).

LC/MS (Hydrophilic/TFA): ESI (+ve) m/z=969.83 [M+3H]/3+, 727.67[M+4H]/4+, 582.39 [M+5H]/5+; calculated (C143H257N31O31) 2906.8 g/mol.Data deconvoluted using transform calculation to give mw=2906.5. Rf(min)=14.7.

Example 5 BHALys[Lys]₈[α-NH₂.TFA]₈[ε-CBz]₈

Surface Surface Topology Stoichiometry ((((NH₂ CBz)(NH₂ CBz))⁴((NH₂CBz)(NH₂ CBz))⁴)⁸ 8 NH₂ (((NH₂ CBz)(NH₂ CBz))⁴((NH₂ CBz)(NH₂ CBz))⁴)⁸)¹⁶8 CBz

BHALys[Lys]₈[α-Boc]₈[ε-CBz]₈ (1000 mg, 0.251 mmol) was suspended inacetic acid (5.5 ml) and stirred at 0° C. while TFA (5.5 ml) was addeddrop wise. The reaction mixture was allowed to warm to Rt and left tostir for 17 h, at which point the reaction mixture was triturated inEther The resulting suspension was stirred for 10 min, and liquids wereremoved by centrifugation and decanting. The remaining precipitate waswashed by stirring for 10 min with Ether, which was again removed bycentrifugation and decanting, then the precipitate was dried in vacuo,dissolved in water and freeze-dried to giveBHALys[Lys]₈[α-NH₂.TFA]₈[ε-CBz]₈ as a white powder (840 mg, 105%).

LC/MS (Hydrophilic/TFA): ESI (+ve) m/z=1060.70 [M+3H]/3+, 795.51[M+4H]/4+, 636.30 [M+5H]/5+; calculated (C167H241N31O31) 3178.95 g/mol.Data deconvoluted using transform calculation to give mw=3178.0. Rf(min)-19.1.

Example 6 BHALys[Lys]₈[α-NH₂]₈[ε-Boc]₈ i. BHALys[Lys]₈[α-CBz]₈[ε-Boc]₈

Surface Surface Topology Stoichiometry ((((Boc CBz)(Boc CBz))⁴((BocCBz)(Boc CBz))⁴)⁸ 8 Boc (((Boc CBz)(Boc CBz))⁴((Boc CBz)(Boc CBz))⁴)⁸)¹⁶CBz

To a magnetically stirred solution of BHALys[Lys]₄[NH₂.TFA]B (1.59mmol), TEA (4.40 ml, 31.57 mmol) and DMF (32 ml) was addedPNPO-α-CBz-ε-Boc-Lys (7.69 g, 15.33 mmol) as a solid and in one portionat Rt. The reaction and product isolation were carried out according tothe method described in Example 1.i to give BHALys[Lys]₈[α-CBz]₈[ε-Boc]₈(5.41 g, 85%) as an off-white solid.

LC/MS (Phobic/TFA/Speedy Ramp): ESI (+ve) observed [M+H/3]+m/z=1328;calculated for C207H305N31O47 3979.9; Rf (min)=12.98 mins

ii. BHALys[Lys]₈[α-NH₂]₈[ε-Boc]₈

Surface Surface Topology Stoichiometry ((((Boc NH₂)(Boc NH₂))⁴((BocNH₂)(Boc NH₂))⁴)⁸ 8 Boc (((Boc NH₂)(Boc NH₂))⁴((Boc NH₂)(Boc NH₂))⁴)⁸)¹⁶8 NH₂

To a magnetically stirred solution of BHALys[Lys]₈[α-CBz]₈[ε-Boc]₈ (200mg, 0.05 mmol) and 2,2,2-trifluoroethanol (2 ml) was added 10% Pd/C (198mg). The reaction and product isolation were carried out according tothe method described in Example 2.ii to give the productBHALys[Lys]₈[α-NH₂]₈[ε-Boc]₈ (140 mg, 96%) as a near colourless oil.

LC/MS (Phobic/TFA): ESI (+ve) m/z=1454.45 [M+2H]/2+, 969.74 [M+3H]/3+,727.56 [M+4H]/4; calculated C143H257N31O31 2906.80 g/mol. Datadeconvoluted using transform calculation to give mw=2906.68. Rf(min)=1.25.

Example 7 BHALys[Lys]₈[α-CBz]₈[ε-NH₂.TFA]₈

Surface Surface Topology Stoichiometry ((((NH₂ CBz)(NH₂ CBz))⁴((NH₂CBz)(NH₂ CBz))⁴)⁸ 8 NH₂ (((NH₂ CBz)(NH₂ CBz))⁴((NH₂ CBz)(NH₂ CBz))⁴)⁸)¹⁶8 CBz

BHALys[Lys]₈[α-CBz]₈[ε-Boc]₈ (20.0 mg, 0.005 mmol) was suspended inacetic acid (109 μl) and stirred in water bath. TFA (109 μl) was addedcarefully. The reaction and product isolation were carried out accordingto the method described in Example 5.i to giveBHALys[Lys]₈[α-CBz]₈[ε-NH₂.TFA]₈ (12.1 mg, 76%) as a white solid.

LC/MS (Hydrophilic/TFA): ESI (+ve) m/z=1060.43 [M+3H]/3+, 795.63[M+4H]/4+, 636.79 [M+5H]/5+; calculated (C167H241N31O31) 3178.95 g/mol.Data deconvoluted using transform calculation to give mw=3179.25. Rf(min)=16.6.

Example 8 BHALys[Lys]₄[Su[NPN]₂]₈[NH₂.TFA]₈[CBz]₈ i.N-(Benzyloxycarbonyl)-3-bromopropylamine

TEA (6.91 g, 68.5 mmol) was added drop wise to an ice-cooled mixture of3-bromopropylamine.hydrobromide (10.0 g, 45.6 mmol) andN-(Benzyloxycarbonyloxy)-succinimide (11.22 g, 47.9 mmol) in DCM (200mL). The stirred mixture was allowed to warm to Rt overnight, thenwashed with water, brine, dried (MgSO₄), filtered and concentrated,providing 11.43 g (92%) of N-(Benzyloxycarbonyl)-3-bromopropylamine, asa pale yellow oil. 1H NMR (CDCl3): 7.35 (m, 5H), 5.10 (s, 2H), 4.89 (brs, 1H), 3.44 (t, J=6.6 Hz), 3.35 (dd, J=12.9, 6.3 Hz, 2H), m (2.06, 2H).LCMS (LC: Hydrophobic/TFA, RT=6.4 min; MS: 294, 296 ([M+NH4]+, 22%),272, 274 ([M+H]+, 100%).

ii. [NPN]₂[Boc][CBz]

TEA (17.1 mL, 123.5 mmol) was added drop wise to a stirred mixture ofN-(Benzyloxycarbonyl)-3-bromopropylamine (11.20 g, 41.2 mmol) and N-Bocdiaminopropane (7.16 g, 41.2 mmol) in DMF (150 mL) at Rt. The mixturewas heated to 70° C. for one hour, then ca. ⅔rds of the solvent wasremoved in vacuo. The concentrated DMF mixture was then diluted withwater and washed with ether. The DMF/aqueous mixture was then basified(1.0M NaOH), and extracted with ether. The combined ether extracts werethen washed with water, dried (MgSO₄), filtered and concentrated toprovide 7.13 g (47%) of [NPN]₂[Boc][CBz] as a clear colourless oil.

LCMS (LC: Hydrophobic/TFA, RT=14.0 min; MS: 366 ([M+H]+, 100%), 310([M−tBu]+, 94%), 266 ([M−Boc]+, 94%).

iii. HO-Su[NPN]₂[Boc][CBz]

Surface Surface Topology Stoichiometry HO—CO (Boc CBz) 1 CO₂H 1 Boc 1CBz

To a stirred mixture of [NPN]₂[Boc][CBz] (6.55 g, 17.9 mmol) in toluene(60 mL) at Rt was added succinic anhydride (1.79 g, 17.9 mmol). Themixture was heated to 70° C. for one hour, then concentrated. Theresidue was then dissolved in EtOAc/ether (5:1) and washed with NaOH.The base washes were then washed with ether, then acidified (HCl, 1.0 M,250 mL). The aqueous mixture was then washed with EtOAc (3×250 mL),dried (MgSO₄), filtered, and concentrated, providing 6.97 g (84%) ofHO-Su[NPN]₂[Boc][CBz] as a colourless viscous oil. 1H NMR (CDCl₃): δ7.36 (m, 5H), 5.65 (br s, 1H), 5.08, 5.10 (2s, 2H), 4.74 (br s, 1H),3.00-3.45 (m, 8H), 2.54-2.72 (m, 4H), 1.60-1.89 (m, 4H), 1.43, 1.45 (2s,9H). LCMS (LC: hydrophilic/TFA RT=15.0 min; MS: 466 ([M+H]+, 15%), 366([M−Boc]+, 100%).

iv. PNPO-Su[NPN]₂[Boc][CBz]

Surface Surface Topology Stoichiometry PNPO-CO (Boc CBz) 1 CO-OPNP 1 Boc1 CBz

To a stirred mixture of 4-nitrophenol (1.91 g, 13.7 mmol) andHO-Su[NPN]₂[Boc][CBz] (6.39 g, 13.7 mmol) in EtOAc (150 mL) at Rt wasadded DCC (2.97 g, 14.4 mmol), dissolved in EtOAc (50 mL). The mixturewas left to stir at Rt overnight, then filtered. The mixture was thenwashed with K₂CO₃ (1.0 M)/Brine 1:1, brine, dried (MgSO₄), filtered andconcentrated, providing 7.80 g of crude material. The crude was thenpurified by fcc (2% MeOH in DCM), providing 7.07 g (88%) ofPNPO-Su[NPN]₂[Boc][CBz]. 1H NMR (CDCl₃): δ 8.24 (d, J=9.0 Hz, 1H), 8.20(d, J=9.0 Hz, 1H), 7.13-7.39 (m, 8H), 5.63 (br s, 1H), 5.12 (br s, 1H),5.09, (s, 2H), 4.95 (br s, 1H), 4.62 (br s, 1H), 2.98-3.48 (m, 8H),2.86-2.94 (m, 2H), 2.66-2.74 (m, 2H), 1.58-1.89 (m, 4H), 1.43 (s, 9H).LCMS (LC: Hydrophilic/formate, RT=21.0 min; MS: 604 ([M+NH₄]+, 36%), 587([M+H]+, 100%), 531 ([M−tBu]+, 19%), 487 ([M−Boc]+, 12%).

v. BHALys[Lys]₄[Su[NPN]₂]₈[Boc]₈[CBz]₈

Surface Surface Topology Stoichiometry ((((Boc CBz)(Boc CBz))⁴((BocCBz)(Boc CBz))⁴)⁸ 8 CBz (((Boc CBz)(Boc CBz)⁴)((Boc CBz)(Boc CBz))⁴)⁸)¹⁶8 Boc

To a stirred mixture of PNPO-Su[NPN]₂[Boc][CBz] (564 mg, 0.96 mmol, 9.6eq.) and BHALys[Lys]₄[NH₂.TFA]₈ (200 mg, 0.10 mmol, 1.0 eq.) in DMF (17mL) was added TEA (0.28 mL, 2.0 mmol, 20.0 eq.). The mixture was stirredat Rt overnight, the solvent removed in vacuo, and the residue purifiedby flash chromatography (residue preadsorbed onto silica; impuritieseluted with 5% MeOH in DCM, product eluted in 10-15% MeOH) to provideBHALys[Lys]₄[Su[NPN]₂]₈[Boc]₈[CBz]₈ (455 mg, 95%) as a viscous yellowoil.

LCMS (LC: Hydrophilic/TFA, RT=17.05 min; MS: (transform) 4660 ([M+H]+,10%), 4561 ([M−Boc+H]+, 8%), 4460 ([M−2Boc+H]+, 7%), 4360 ([M−3Boc+H]+,10%), 4260 ([M−4Boc+H]+, 100%).

vi. BHALys[Lys]₄[Su[NPN]₂]₈[NH₂.TFA]₈[CBz]₈

Surface Surface Topology Stoichiometry ((((NH₂ CBz)(NH₂ CBz))⁴((NH₂CBz)(NH₂ CBz))⁴)⁸ 8 CBz (((NH₂ CBz)(NH₂ CBz)⁴)((NH₂ CBz)(NH₂ 8 NH₂CBz))⁴)⁸)¹⁶

BHALys[Lys]₄[Su[NPN]₂]₈[Boc]₈[CBz]₈ (93 mg, 19.9 μmol) was dissolved inacetic acid (2 mL) and cooled. To this stirred mixture was then addedTFA (2 mL), drop wise, then the mixture was allowed to warm to Rt. Afterstirring overnight, the mixture was poured into cold water, thenconcentrated. The residue was taken up in water and concentrated again(2×), then freeze-dried, providing 103 mg of white solid material (108%if calculate as TFA salt). LCMS (LC: Hydrophilic/formic acid, RT=12.57min; MS: (transform) 3858 ([M+H]+, 100%), 3724 ([M−CBz+H]+, 20%), 3589([M−2CBz+H]+, 7%).

Example 9 BHALys[Lys]₁₆ [α-Boc]₁₆ [ε-NH₂]₁₆ i. BHALys[Lys]₁₆ [α-Boc]₁₆[ε-CBz]₁₆

Surface Surface Topology Stoichiometry ((((Boc CBz)(Boc CBz))⁴((BocCBz)(Boc CBz))⁴)⁸ 16 Boc (((Boc CBz)(Boc CBz))⁴((Boc CBz)(BocCBz))⁴)⁸)¹⁶ 16 Boc 16 CBz

To a stirred solution of BHALys[Lys]₈[NH₂.TFA]₁₆ (0.81 mmol), TEA (4.50ml, 32.30 mmol) and DMF (30 ml) was added PNPO-α-Boc-ε-CBz-Lys (7.94 g,15.83 mmol) as a solid and in one portion at Rt. The reaction andproduct isolation were carried out according to the method described inExample 1.i to give BHALys[Lys]₁₆ [α-Boc]₁₆ [ε-CBz]₁₆ (5.79 g, 91%) as acolourless solid.

LC/MS (Phobic/TFA): ESI (+ve) observed [M+H/4]+m/z=1977;[M+H/5]+m/z=1582; calculated for C407H609N63O95 7904.9; Rf (min)=23.51mins.

ii. BHALys[Lys]₁₆ [α-Boc]₁₆ [ε-NH₂]₁₆

Surface Surface Topology Stoichiometry ((((Boc NH₂)(Boc NH₂))⁴((BocNH₂)(Boc NH₂))⁴)⁸ 16 Boc (((Boc NH₂)(Boc NH₂))⁴((Boc NH₂)(BocNH₂))⁴)⁸)¹⁶ ((((Boc NH₂)(Boc NH₂))⁴((Boc NH₂)(Boc NH₂))⁴)⁸ 16 NH₂ (((BocNH₂)(Boc NH₂))⁴((Boc NH₂)(Boc NH₂))⁴)⁸)¹⁶

A suspension of BHALys[Lys]₁₆ [α-Boc]₁₆ [ε-CBz]₁₆ (50 mg, 0.006 mmol),10% Pd/C (53 mg) and acetic acid (2 ml) was vigorously stirred underhydrogen at Rt for 16 h. The black suspension was filtered.Concentration of the filtrate in vacuo afforded the product (26 mg, 71%)a straw coloured oil.

LC/MS (Phobic/TFA): ESI (+ve) observed [M+H/5]+m/z=1152;[M+H/6]+m/z=961; [M+H/7]+m/z=824; [M+H/8]+m/z=721; [M+H/9]+m/z=641;calculated for C279H513N63O63 5758.53; Rf (min)=2.37 mins.

Example 10 BHALys[Lys]₁₆ [α-NH₂.TFA]₁₆ [ε-CBz]₁₆

Surface Surface Topology Stoichiometry ((((NH₂ CBz)(NH₂ CBz))⁴((NH₂CBz)(NH₂ CBz))⁴)⁸ 16 NH₂ (((NH₂ CBz)(NH₂ CBz))⁴((NH₂ CBz)(NH₂CBz))⁴)⁸)¹⁶ ((((NH₂ CBz)(NH₂ CBz))⁴((NH₂ CBz)(NH₂ CBz))⁴)⁸ 16 CBz (((NH₂CBz)(NH₂ CBz))⁴((NH₂ CBz)(NH₂ CBz))⁴)⁸)¹⁶

BHALys[Lys]₁₆ [α-Boc]₁₆ [ε-CBz]₁₆ (1000 mg, 0.127 mmol) was suspended inacetic acid (5.5 ml) and stirred at 0° C. while TFA (5.5 ml) was addeddrop wise. The reaction and product isolation were carried out accordingto the method described in Example 5.i to give BHALys[Lys]₁₆[α-NH₂.TFA]₁₆ [ε-CBz]₁₆ as a white powder (832 mg, 114%).

LC/MS (Hydrophilic/TFA): ESI (+ve) m/z=1576.85 [M+4H]/4+, 1261.34[M+5H]/5+, 1051.27 [M+6H]/6+, 901.15 [M+7H]/7+; calculated(C327H481N63O63) 6302.83 g/mol. Data deconvoluted using transformcalculation to give mw=6301.5. Rf (min)=19.0.

Example 11 BHALys[Lys]₁₆[α-NH₂]₁₆[ε-Boc]₁₆ i.BHALys[Lys]₁₆[α-4-Nitro-CBz]₁₆[ε-Boc]₁₆

Surface Topology Surface Stoichiometry ((((Boc 4-Nitro-CBz)(Boc4-Nitro-CBz))⁴ 16 Boc ((Boc 4-Nitro-CBz)(Boc 4-Nitro-CBz))⁴)⁸ (((Boc4-Nitro-CBz)(Boc 4-Nitro-CBz))⁴ ((Boc 4-Nitro-CBz)(Boc4-Nitro-CBz))⁴)⁸)¹⁶ ((((Boc 4-Nitro-CBz)(Boc 4-Nitro-CBz))⁴ 164-Nitro-CBz ((Boc 4-Nitro-CBz)(Boc 4-Nitro-CBz))⁴)⁸ (((Boc4-Nitro-CBz)(Boc 4-Nitro-CBz))⁴ ((Boc 4-Nitro-CBz)(Boc4-Nitro-CBz))⁴)⁸)¹⁶

To a magnetically stirred solution of BHALys[Lys]₈[NH₂.TFA]₁₆ (59 mg,0.015 mmol) and DMF (5 ml) was added pyBOP (248 mg, 0.48 mmol). To thissolution was added a mixture of HO-α-4-Nitro-CBz-ε-Boc-Lys (194 mg, 046mmol), DIPEA (0.35 ml, 2.00 mmol) and DMF (3 ml) at Rt. Stirring wascontinued for 24 hrs at Rt. After this time, the clear but now browncoloured solution was transferred to a conical flask containing ACN (500ml). A fine precipitate was observed to have formed which wassubsequently collected by filtration. This was allowed to air dry undersuction overnight thereby affording the product BHALys[Lys]₁₆[α-4-nitro-CBz]₁₆ [ε-Boc]₁₆ (98 mg, 76%) as an orange/brown colouredglass like solid.

ii. BHALys[Lys]₁₆ [α-NH₂]₁₆ [ε-Boc]₁₆

Surface Surface Topology Stoichiometry ((((Boc NH₂)(Boc NH₂))⁴((BocNH₂)(Boc NH₂))⁴)⁸ 16 Boc (((Boc NH₂)(Boc NH₂))⁴((Boc NH₂)(BocNH₂))⁴)⁸)¹⁶ ((((Boc NH₂)(Boc NH₂))⁴((Boc NH₂)(Boc NH₂))⁴)⁸ 16 NH₂ (((BocNH₂)(Boc NH₂))⁴((Boc NH₂)(Boc NH₂))⁴)⁸)¹⁶

To a magnetically stirred solution of BHALys[Lys]₁₆ [α-4-nitro-CBz]₁₆[ε-Boc]₁₆ (10 mg, 0.0012 mmol) and 2,2,2-trifluoroethanol (1 ml) wasadded 10% Pd/C (12 mg). The reaction and product isolation were carriedout according to the method described in Example 2.ii to give theproduct BHALys[Lys]₁₆ [α-NH₂]₁₆ [ε-Boc]₁₆ (5.4 mg, 81%) as a fawncoloured glassy solid.

LC/MS (Hydrophilic/TFA): ESI (+ve) m/z=1440.49 [M+4H]/4+, 1152.45[M+5H]/5+; calculated C279H513N63O63 5758.53 g/mol. Data deconvolutedusing transform calculation to give mw=5757.88. Rf (min)=8.22.

Example 12 BHALys[Lys]₁₆[α-Boc]₁₆[ε-NH₂]₁₆ i.BHALys[Lys]₁₆[α-Boc]₁₆[ε-4-nitro-CBz]₁₆

Surface Topology Surface Stoichiometry ((((Boc 4-Nitro-CBz)(Boc4-Nitro-CBz))⁴ 16 Boc ((Boc 4-Nitro-CBz)(Boc 4-Nitro-CBz))⁴)⁸ (((Boc4-Nitro-CBz)(Boc 4-Nitro-CBz))⁴ ((Boc 4-Nitro-CBz)(Boc4-Nitro-CBz))⁴)⁸)¹⁶ ((((Boc 4-Nitro-CBz)(Boc 4-Nitro-CBz))⁴ 164-Nitro-CBz ((Boc 4-Nitro-CBz)(Boc 4-Nitro-CBz))⁴)⁸ (((Boc4-Nitro-CBz)(Boc 4-Nitro-CBz))⁴ ((Boc 4-Nitro-CBz)(Boc4-Nitro-CBz))⁴)⁸)¹⁶

To a magnetically stirred solution of BHALys[Lys]₈[NH₂.TFA]₁₆ (0.25 g,0.13 mmol), TEA (0.35 ml, 2.51 mmol) and DMF (4 ml) was addedPNPO-α-Boc-ε-4-nitro-CBz-Lys (0.67 g, 1.23 mmol) as a solid and in oneportion at Rt. The reaction and product isolation were carried outaccording to the method described in Example 1.i and ultimately providedBHALys[Lys]₁₆[α-Boc]₁₆[ε-4-nitro-CBz]₁₆ (500 mg, 91%) as an off whitesolid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=1725.94 [M+5H]/5+; calculatedC407H593N79O127 8624.64 g/mol. Rf (min)=8.60.

ii. BHALys[Lys]₁₆[αBoc]₁₆ [ε-NH₂]₁₆

Surface Surface Topology Stoichiometry ((((Boc NH₂)(Boc NH₂))⁴((BocNH₂)(Boc NH₂))⁴)⁸ 16 Boc (((Boc NH₂)(Boc NH₂))⁴((Boc NH₂)(BocNH₂))⁴)⁸)¹⁶ ((((Boc NH₂)(Boc NH₂))⁴((Boc NH₂)(Boc NH₂))⁴)⁸ 16 NH₂ (((BocNH₂)(Boc NH₂))⁴((Boc NH₂)(Boc NH₂))⁴)⁸)¹⁶

To a magnetically stirred solution ofBHALys[Lys]₁₆[α-Boc]₁₆[ε-4-nitro-CBz]₁₆ (103 mg, 0.023 mmol) and2,2,2-trifluoroethanol (2 ml) was added 10% Pd/C (106 mg). The reactionand product isolation were carried out according to the method describedin Example 2.ii to give the product BHALys[Lys]₁₆[α-Boc]₁₆ [ε-NH₂]₁₆ (68mg, 98%) as a fawn coloured glassy solid.

LC/MS (Hydrophilic/TFA): ESI (+ve) m/z=1152.51 [M+5H]/5+, 960.59[M+6H]/6+, 823.70 [M+7H]/7+; calculated C279H513N63O63 5758.53 g/mol.Data deconvoluted using transform calculation to give mw=5757.94. Rf(min)=7.06.

Example 13 BHALys[GlyLys]₂[Lys]₄[α,α-Boc]₂[α,ε-Boc]₂[ε,α-NH₂]₂[ε,ε-NH₂]₂

Part of this example is described in FIG. 14A (Scheme 3).

i. MeO-GlyLys[α-Boc][ε-CBz]

Surface Surface Topology Stoichiometry MeO—CO (Boc CBz) 1 CO₂Me 1 Boc 1CBz

To a magnetically stirred suspension of MeOGly.HCl (12.56 g, 0.11 mol)and DMF (200 ml) was slowly added TEA (42 ml, 0.3 mol) at Rt. The activeester, PNPO-α-Boc-ε-CBz-Lys (50.15 g, 0.1 mol), was added to thesuspension in 2-3 g portions. The now bright yellow coloured reactionmixture was allowed to stir at Rt for 18 h. The volatiles were removedin vacuo and the resulting residue was partitioned between EtOAc (200ml), 10% aq. Na₂CO₃ solution (100 ml) and water (175 ml). The separatedorganic layer was washed sequentially with 5% aq. Na₂CO₃ (4×200 ml),0.25M aq. HCl (3×50 ml) and brine (1×50 ml) before being dried (MgSO₄),filtered and concentrated under reduced pressure to giveMeO-GlyLys[α-Boc][ε-CBz] (44.39 g, 98%) of a colourless oil.

LC/MS (Phobic/Formate): ESI (+ve) m/z=452.02 [M+H]+; calculatedC22H33N3O7 451.52 g/mol. Rf (min)=5.22.

ii. MeO-GlyLys[α-NH₂.TFA][ε-CBz]

Surface Surface Topology Stoichiometry MeO—CO (NH₂ CBz) 1 CO₂Me 1 NH₂ 1CBz

To a chilled (ice water bath) and magnetically stirred solution ofMeO-GlyLys[α-Boc][ε-CBz] (43.4 g, 96.03 mmol) in acetic acid (150 ml)was added neat TFA in 1 ml portions (total volume of acid added=150 ml).The cooling bath was removed and the reaction mixture was allowed tostir at Rt for 4 h. After this time, another 20 ml of TFA was added tothe reaction mixture and stirring was continued for a further 1 h at Rt.The volatiles were subsequently removed by rotary evaporation. The finaltraces of acid were removed from the crude product via azeoptroping withmethanol (5×200 ml). The product, MeO-GlyLys[α-NH₂.TFA][ε-CBz] (46.04 g,103%), was obtained as a pale yellow oil.

LC/MS (Hydrophilic/Formate): ESI (+ve) m/z=352 [M+H]+; calculatedC17H25N3O5 351.40 g/mol. Rf (min)=12.33.

iii. MeO-GlyLys[ε-CBz][α-Lys][Boc]₂

Surface Surface Topology Stoichiometry MeO—CO ((CBz Ø)(Boc Boc))⁴ 1CO₂Me 2 Boc 1 CBz

To a magnetically stirred solution of MeO-GlyLys[α-NH₂.TFA][ε-CBz] (96.0mmol) and DMF (200 ml) was added TEA (33.5 ml, 0.24 mol) followed byPNPO-Lys(Boc)₂ (49.37 g, 0.106 mol). The homogenous solution was allowedto stir at Rt for 17 h. A solution of glycine (3.98 g, 53 mmol) in water(50 ml) was added to the crude reaction mixture and stirring wascontinued for a further 18 h. Water (200 ml) was added to the reactionflask which induced precipitation of a yellow solid. This material wascollected by filtration and then re-suspended in 5% aq. Na₂CO₃ (200 ml).This suspension was left to stir for 1.5 h at Rt. The crude product wascollected by filtration and re-suspended in water a further 3 times(3×200 ml). The solids collected by filtration for the final time wereleft to air dry under suction for 17 h and final traces of moisture wereremoved under high vacuum (oil pump). The desired compound,MeO-GlyLys[ε-CBz][α-Lys][Boc]₂ (61.07 g, 94%), was ultimately obtainedas a pale, fine yellow coloured powder.

LC/MS (Phobic/Formate): ESI (+ve) m/z=680.15 [M+H]+; calculatedC33H53N5O10 679.82 g/mol. Rf (min)=7.90.

iv. MeO-GlyLys[ε-NH₂.TFA][α-Lys][Boc]₂

Surface Surface Topology Stoichiometry MeO—CO ((NH₂ Ø)(Boc Boc))⁴ 1CO₂Me 2 Boc 1 NH₂

To a magnetically stirred solution of MeO-GlyLys[ε-CBz][α-Lys][Boc]₂(2.00 g, 2.94 mmol), TFA (0.23 ml, 2.99 mmol) and methanol (60 ml) wascarefully added 10% Pd/C (322 mg). The black suspension was hydrogenatedunder standard conditions (Rt, atmospheric pressure) for 4 h. After thistime, the suspension was filtered through a 0.45 micron filter disk. Thefiltrate was concentrated under reduced pressure to give the productMeO-GlyLys[ε-NH₂.TFA][α-Lys][Boc]₂ (1.93 g, 99%) as a colourless foam.

LC/MS (Phobic/TFA): ESI (+ve) m/z=546.45 [M+H]+; calculated C25H47N5O8545.68 g/mol. Rf (min)=1.27.

v. MeO-GlyLys[Lys]₂[α,α-Boc][α,ε-Boc][ε,α-CBz][ε,ε-CBz]

Surface Surface Topology Stoichiometry MeO—CO ((CBz CBz)(Boc Boc))⁴ 1CO₂Me 2 Boc 2 CBz

To a magnetically stirred solution of MeO-GlyLys[ε-NH₂.TFA][α-Lys][Boc]₂(922 mg, 1.40 mmol), TEA (0.5 ml, 3.59 mmol) and DMF (25 ml) was addedPNPO-α-CBz-ε-Boc-Lys (822 mg, 1.65 mmol) as a solid. The reaction andproduct isolation were carried out according to the method described inExample 1.i and ultimately provided MeO-GlyLys[Lys]₂[α,α-Boc][α,ε-Boc][ε,α-CBz][ε,ε-CBz] (452 mg, 34%) as an off whitesolid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=942.53 [M+H]+; calculated C47H71N7O13942.13 g/mol. Rf (min)=5.28.

vi. HO-GlyLys[Lys]₂[α,α-Boc][α,ε-Boc][ε,α-CBz][ε,ε-CBz]

Surface Topology Surface Stoichiometry HO—CO ((CBz CBz)(Boc Boc))⁴ 1CO₂H 2 Boc 2 CBz

To a magnetically stirred solution ofMeO-GlyLys[Lys]₂[α,α-Boc][α,ε-Boc][ε,α-CBz][ε,ε-CBz] (452 mg, 0.48mmol), methanol (6 ml) and water (3 ml) was added 1M aq. NaOH solution(1 ml) at Rt. Stirring was continued at Rt for 3.5 h. The now clear butyellow coloured reaction mixture was concentrated to dryness underreduced pressure and the resulting gel like residue was treated withwater (20 ml) and Ether (20 ml). To the biphasic mixture was added 1Maq. KHSO₄ solution (3 ml) and immediately a white precipitate formed.The precipitate was collected by filtration and left to air dry undersuction for 48 h. The product,HO-GlyLys[Lys]₂[α,α-Boc][α,ε-Boc][ε,α-CBz][ε,ε-CBz] (343 mg, 77%), wasobtained as a colourless solid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=928.54 [M+H]+; calculated C46H69N7O13928.10 g/mol. Rf (min)=4.73.

vii. BHALys[GlyLys]₂[Lys]₄[α,α-Boc]₂[α,ε-Boc]₂[ε,α-CBz]₂[ε,ε-CBz]

Surface Surface Topology Stoichiometry (((CBz CBz)(Boc Boc))⁴((CBzCBz)(Boc Boc))⁴)⁸ 4 Boc 4 CBz

To a magnetically stirred solution of BHALys[NH₂.TFA]₂ (21 mg, 0.039mmol) and DMF (1.5 ml) was added pyBOP (82 mg, 0.16 mmol). To thissolution was added a mixture ofHO-GlyLys[Lys]₂[α,α-Boc][α,ε-Boc][ε,α-CBz][ε,ε-CBz] (138 mg, 0.15 mmol),DIPEA (0.1 ml, 0.60 mmol) and DMF (1 ml) at Rt. Stirring was continuedfor 48 h at Rt. After this time, the crude reaction mixture wastransferred to a beaker containing ACN (300 ml). The solution wasstirred at Rt for 2 h during which time a fine precipitate formed. Thismaterial was collected by filtration and air dried under suctionovernight. This process afforded the productBHALys[GlyLys]₂[Lys]₄[α,α-Boc]₂[α,ε-Boc]₂[ε,α-CBz]₂ [ε,ε-CBz]₂ (66 mg,83%) as an off white coloured solid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=1066.52 [M+2H]/2+; calculatedC111H159N17O25 2131.58 g/mol. Rf (min)=7.07.

viii. BHALys[GlyLys]₂[Lys]₄[α,α-Boc]₂[α,ε-Boc]₂[ε,α-NH₂]₂[ε,ε-NH₂]₂

Surface Surface Topology Stoichiometry (((NH₂ NH₂)(Boc Boc))⁴((NH₂NH₂)(Boc Boc))⁴)⁸ 4 Boc 4 NH₂

To a magnetically stirred solution of BHALys[GlyLys(Boc)₂(CBz)₂]₂ (60mg, 0.028 mmol) and 2,2,2-trifluoroethanol (3 ml) was added 10% Pd/C (59mg). The black suspension was hydrogenated under standard conditions(Rt, atmospheric pressure) for 17 h. After this time, the suspension wasfiltered through a 0.45 micron filter disk. The filtrate wasconcentrated under reduced pressure to give the product BHALys[GlyLys]₂[Lys]₄[α,α-Boc]₂[α,ε-Boc]₂[ε,α-NH₂]₂[ε,ε-NH₂]₂ (42 mg, 95%) as a fawncoloured glassy solid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=1595.71 [M+H]+, 798.20 [M+2H]/2+;calculated C79H135N17O17 1595.05 g/mol. Rf (min)=8.69.

Example 14BHALys[Lys]₂[GlyLys]₄[Lys]₈[α,α-Boc]₄[α,ε-Boc]₄[ε,α-NH₂]₄[ε,ε-NH₂]₄ i.BHALys[Lys]₂[GlyLys]₄[Lys]₈[α,α-Boc]₄[α,ε-Boc]₄[ε,α-CBz]₄[ε,ε-CBz]₄

Surface Surface Topology Stoichiometry ((((CBz CBz)(Boc Boc))⁴((CBzCBz)(Boc 8 Boc Boc))⁴)⁸(((CBz CBz)(Boc Boc))⁴((CBz 8 CBz CBz)(BocBoc))⁴)⁸)¹⁶

To a magnetically stirred solution of BHALys[Lys]₂[NH₂.TFA]₄ (21 mg,0.021 mmol) and DMF (1.5 ml) was added pyBOP (88 mg, 0.17 mmol). To thissolution was added a mixture ofHO-GlyLys[Lys]₂[α,α-Boc][α,ε-Boc][ε,α-CBz][ε,ε-CBz] (148 mg, 0.16 mmol),DIPEA (0.11 ml, 0.63 mmol) and DMF (1 ml) at Rt. The reaction andproduct isolation were carried out according to the method described inExample 11.i to provide the productBHALys[Lys]₂[GlyLys]₄[Lys]₈[α,α-Boc]₄[α,ε-Boc]₄[ε,α-CBz]₄[ε,ε-CBz]₄ (78mg, 70%) as an off white coloured solid.

LC/MS (Phobic/TFA): ESI (+ve) m/z 1403.39 [M+3H]/3+; calculatedC215H317N35O51 4208.09 g/mol. Rf (min)=8.10.

ii. BHALys[Lys]₂[GlyLys]₄[Lys]₈[α,α-Boc]₄[α,ε-Boc]₄[ε,α-NH₂]₄[ε,ε-NH₂]₄

Surface Surface Topology Stoichiometry ((((NH₂ NH₂)(Boc Boc))⁴((NH₂NH₂)(Boc 8 Boc Boc))⁴)⁸(((NH₂ NH₂)(Boc Boc))⁴((NH₂ NH₂)(Boc 8 NH₂Boc))⁴)⁸)¹⁶

To a magnetically stirred solution of BHALys[Lys]₂[GlyLys(Boc)₂(CBz)₂]₄(64 mg, 0.015 mmol) and 2,2,2-trifluoroethanol (3 ml) was added 10% Pd/C(65 mg). The black suspension was hydrogenated under standard conditions(Rt, atmospheric pressure) for 17 h. After this time, the suspension wasfiltered through a 0.45 micron filter disk. The filtrate wasconcentrated under reduced pressure to give the product BHALys[Lys]₂[GlyLys]₄[Lys]₈[α,α-Boc]₄[α,ε-Boc]₄[ε,α-NH₂]₄[ε,ε-NH₂]₄ (43 mg, 90%) asa fawn coloured glassy solid.

LC/MS (Philic/TFA): ESI (+ve) m/z=1568.12 [M+2H]/2+, 1045.70 [M+3H]/3+,784.54 [M+4H]/4+; calculated C151H269N35O35 3135.01 g/mol. Datadeconvoluted using transform calculation to give mw=3134.15. Rf(min)=8.75.

Example 15 HOGlyLys[Lys]₂[Boc]₃[ε,ε-CBz]

This synthesis is depicted in FIGS. 14A and 14B as Schemes 3 and 4.

i. MeO-GlyLys[Lys]₂[Boc]₃[ε,εCBz]

Surface Topology Surface Stoichiometry MeO—CO ((CBz Boc)(Boc Boc))⁴ 1CO₂Me 3 Boc 1 CBz

PNPO-Lys-α-Boc-ε-CBz (535 mg, 1.07 mmol) was added to a stirred solutionof MeO-GlyLys [ε-NH₂.TFA][α-Lys][Boc]₂ (640 mg, 0.97 mmol) indimethylformamide (10 ml). TEA (340 μl, 2.43 mmol) was added and thereaction and product isolation were carried out according to the methoddescribed in Example 1.i to give MeOGlyLys[Lys]₂[Boc]₃ [ε,ε-CBz] (818mg, 93%) as a brittle white foam.

¹H nmr (300 MHz, CD₃OD) δ (ppm): 1.2-2.0 (m, 45H); 3.03 (t, J 6.6 Hz,2H); 3.12 (t, J 6.6 Hz, 2H); 3.19 (m, 2H); 3.71 (s, 3H); 3.88 (d, J 17.4Hz, 1H); 3.93-4.06 (m, 2H); 4.00 (d, J 17.7 Hz, 1H); 4.38 (dd, J 5.4,8.4 Hz, 1H); 5.07 (s, 2H); 7.25-7.45 (m, 5H).

LC/MS (Hydrophobic/Formate): ESI (+ve) observed [M+H]⁺ m/z=908.4;calculated for C₄₄H₇₄N₇O₁₃ 908.5; observed [M+NH₄]⁺ m/z=925.4;calculated for C₄₄H₇₇N₈O₁₃ 925.5. Rf (min)=9.5.

ii. HO-GlyLys[Lys]₂[Boc]₃[ε,ε-CBz]

Surface Topology Surface Stoichiometry HO—CO ((CBz Boc)(Boc Boc))4 1CO2H 3 Boc 1 CBz

MeOGlyLys[Lys]₂[Boc]₃[ε,ε-CBz] (500 mg, 0.55 mmol) was dissolved in asolution of sodium hydroxide (44 mg, 1.10 mmol) in methanol (8 ml) andwater (4 ml). The reaction and product isolation were carried outaccording to the method described in Example 13.vi to giveHO-GlyLys[Lys]₂[Boc]₃[ε,ε-CBz] (481 mg, 96%) as an amorphous whitesolid.

¹H nmr (300 MHz, CD₃OD) δ (ppm): 1.2-2.0 (m, 45H); 3.03 (t, J 6.6 Hz,2H); 3.12 (t, J 6.6 Hz, 2H); 3.19 (m, 2H); 3.84 (d, J 18.0 Hz, 1H);3.95-4.07 (m, 2H); 3.97 (d, J 17.7 Hz, 1H); 4.39 (dd, J 5.4, 8.4 Hz,1H); 5.07 (s, 2H); 7.25-7.38 (m, 5H).

LC/MS (Hydrophobic/TFA): ESI (+ve) observed [M+H]⁺ m/z=894.3; calculatedfor C₄₃H₇₂N₇O₁₃ 894.5. Rf (min)=8.4.

iii. BHALys[GlyLys]₂[Lys]₄[Boc]₆[ε,ε-CBz]₂ (C₁₀₅H₁₆₃N₁₇O₂₅ MW 2063.5)

Surface Topology Surface Stoichiometry (((CBz Boc)(Boc Boc))⁴((CBzBoc)(Boc Boc))⁴)⁸ 6 Boc 2 CBz

N,N′-Dicyclohexylcarbodiimide (186 mg 0.90 mmol) was added to a solutionof HOGlyLys[Lys]₂[Boc]₃[ε,ε-CBz] (536 mg, 0.60 mmol), BHALys[NH₂.TFA]₂(135 mg, 0.250 mmol), 4,4-dimethylaminopyridine (7.3 mg, 60 μmol) andTEA (210 μl, 1.50 mmol) in dimethylformamide (10 ml). The solution wasstirred at Rt for 15 h and the volatile components were then removed invacuo. Silica gel chromatography (methanol/DCM gradient) gaveBHALys[GlyLys]₂[Lys]₄[Boc]₆[ε,ε-CBz]₂ (245 mg, 47%). A small sample (20mg) was treated with acetic acid/TFA in the usual way to provideanalytical data.

LC/MS (Philic/TFA): ESI (+ve) observed [M+H]⁺ m/z=1463.2; calculated forC₇₅H₁₁₆N₁₇O₁₃ 1462.9.

iv. BHALys[GlyLys]₂[Lys]₄[Boc]₆[ε,ε-NH₂]₂

Surface Topology Surface Stoichiometry (((NH₂ Boc)(Boc Boc))⁴((NH₂Boc)(Boc Boc))⁴)⁸ 2 NH₂ 6 Boc

To a magnetically stirred solution of BHALys[GlyLys(Boc)₃(CBz)]₂ (95 mg,0.046 mmol) and 2,2,2-trifluoroethanol (2 ml) was added 10% Pd/C (16.4mg). The black suspension was hydrogenated under standard conditions(Rt, atmospheric pressure) for 19 h. After this time, the suspension wasfiltered through a 0.45 micron filter disk. The filtrate wasconcentrated under reduced pressure to give the productBHALys[GlyLys]₂[Lys]₄ [Boc]₆[ε,ε-NH₂]₂ (83 mg, 93%) as a glass likesolid.

LC/MS (Phobic/Formate): ESI (+ve) m/z=898.50 [M+2H]/2+; calculatedC89H151N17O21 1795.23 g/mol. Rf (min)=4.34.

Example 16 BHALys[Lys]₁₆ [α,α-Boc]₈[α,ε-Boc]₈[ε,α-Boc]₈[ε,ε-CBz]₈ i.BHALys[Lys]₈[ε-CBz]₈[α-Lys]₈[Boc]₁₆

Surface Surface Topology Stoichiometry ((((CBz Ø)(Boc Boc))4((CBz Ø)(BocBoc))4)8(((CBz 16 Boc Ø)(Boc Boc))4((CBz Ø)(Boc Boc))4)8)16 ((((CBzØ)(Boc Boc))4((CBz Ø)(Boc Boc))4)8(((CBz 8 CBz Ø)(Boc Boc))4((CBz Ø)(BocBoc))4)8)16

PNPO-Lys(Boc)₂ (3.6 g, 7.2 mmol) and TEA (2.1 mL, 15 mmol) were added toa stirred solution of BHALys[Lys]₈[ε-CBz]₈[α-NH₂.TFA]₈ (3 g, 0.75 mmol)in DMF (30 mL). The reaction and product isolation were carried outaccording to the method described in Example 1.i to provideBHALys[Lys]₈[ε-CBz]₈[α-Lys]₈[Boc]₁₆ as a white powder (4.2 g, 98%).

LC/MS (Fast Hydrophobic/TFA): Rf (min)=13.70; ESI (+ve) m/z=1936([M+3]/3), 1452 ([M+4]/4), 1062 ([M+5−Boc]/5). Calc. C295H465N47O71.M+1. 5083.4

ii. BHALys[Lys]₈[ε-NH₂]₈[α-Lys]₈[Boc]₁₆

Surface Surface Topology Stoichiometry ((((NH₂ Ø)(Boc Boc))⁴((NH₂ Ø)(BocBoc))⁴)⁸(((NH₂ 16 Boc Ø)(Boc Boc))⁴((NH₂ Ø)(Boc Boc))⁴)⁸)¹⁶ ((((NH₂Ø)(Boc Boc))⁴((NH₂ Ø)(Boc Boc))⁴)⁸(((NH₂ 8 NH₂ Ø)(Boc Boc))⁴((NH₂ Ø)(BocBoc))⁴)⁸)¹⁶

To a stirred solution of BHALys[Lys]₈[ε-CBz]₈[α-Lys]₈[Boc]₁₆ (2.2 g,0.38 mmol) in acetic, acid (30 mL), was added 10% Pd/C (101 mg, 0.095mmol). The resulting homogeneous mixture was at Rt for 16 h underhydrogen. The solution was filtered and concentrated in vacuo. Theresulting sticky residue was redissolved in water and freeze dried toprovide BHALys[Lys]₈[ε-NH₂]₈[α-Lys]₈[Boc]₁₆ (1.97 g, 0.38 mmol) whichcontained some acetic acid residue.

LC/MS (Hydrophilic/TFA): Rf (min)=18.53; ESI (+ve) m/z=1184 ([M+4]/4),947 ([M+5]/5), 790 ([M+6]/6). Calc. C231H417N47O55. M+1. 4731.1

iii. BHALys[Lys]₁₆ [α,α-Boc]₈[α,ε-Boc]₈[ε,α-Boc]₈[ε,ε-CBz]₈

Surface Surface Topology Stoichiometry ((((CBz Boc)(Boc Boc))⁴((CBzBoc)(Boc Boc))⁴)⁸(((CBz 24 Boc Boc)(Boc Boc))⁴((CBz Boc)(Boc Boc))⁴)⁸)¹⁶((((CBz Boc)(Boc Boc))⁴((CBz Boc)(Boc Boc))⁴)⁸(((CBz 8 CBz Boc)(BocBoc))⁴((CBz Boc)(Boc Boc))⁴)⁸)¹⁶

PNPO-α-Boc-ε-CBz-Lys (90 mg, 0.18 mmol) and TEA (0.05 mL, 0.35 mmol)were added to a stirred solution of BHALys[Lys]₈[ε-NH₂]₈[α-Lys]₈[Boc]₁₆(90 mg, 0.019 mmol) in DMF (10 mL). The reaction and product isolationwere carried out according to the method described in Example 1.i toprovide BHALys[Lys]₁₆ [α,α-Boc]₈[α,ε-Boc]₈[ε,α-Boc]₈[ε,ε-CBz]₈ (51 mg,35%)

LC/MS (Phobic TFA Speedy Rp): Rf (min)=14.32; ESI (+ve) m/z=2544([M+3]/3), 1909 ([M+4]/4), 1527 ([M+5]/5). Calc. C383H625N63O95. M+1.7629

Example 17 BHALys[Lys]₁₆ [α,α-Boc]₈[α,ε-Boc]₈[ε,α-Boc]₈[ε,ε-Fmoc]₈

Surface Surface Topology Stoichiometry ((((Fmoc Boc)(Boc Boc))⁴((FmocBoc)(Boc 24 Boc Boc))⁴)⁸(((Fmoc Boc)(Boc Boc))⁴((Fmoc Boc)(BocBoc))⁴)⁸)¹⁶ ((((Fmoc Boc)(Boc Boc))⁴((Fmoc Boc)(Boc 8 FmocBoc))⁴)⁸(((Fmoc Boc)(Boc Boc))⁴((Fmoc Boc)(Boc Boc))⁴)⁸)¹⁶

PFP-Lys-α-Boc-ε-Fmoc (96 mg, 0.15 mmol) and TEA (0.04 mL, 0.27 mmol)were added to a stirred solution of BHALys[Lys]₈[ε-NH₂]₈[α-Lys]₈[Boc]₁₆(100 mg, 0.017 mmol) in DMF (10 mL). The solution was stirred at Rt for16 h. The reaction mixture was then added to ACN (100 ml) producing aclear gelatinous precipitate. This precipitate was collected byfiltration and washed with ACN. The precipitated was dried at Rt toprovide BHALys[Lys]₁₆ [α,α-Boc]₈[α,ε-Boc]₈[ε,α-Boc]₈[ε,ε-Fmoc]₈ (30 mg,21%)

LC/MS (Hydrophobic/TFA): Rf (min)=7.72; ESI (+ve) m/z=1667 ([M+5]/5),1389 ([M+6]/6), 1191 ([M+7]/7). Calc. C439H657N63O95. M+1 8332

Example 18 HO Su(NPN)₂[Su(NPN)₂]₂[CBz][Boc]₃

Part of this synthesis is schematically illustrated in FIG. 13 (Scheme2).

i. EtO-Su[NPN]₂[Boc][CBz]

Surface Topology Surface Stoichiometry EtO—CO (Boc CBz) 1 CO—OEt 1 Boc 1CBz

A stirred mixture of PNPO-Su[NPN]₂[Boc][CBz] (1.0 g, 1.7 mmol) and TEA(0.5 g, 4.95 mmol) in EtOH (80 mL) was heated at 70° C. for 16 h,concentrated, then purified by flash chromatography (PNPOH removed withhexane/EtOAc 1:1, ethyl ester with EtOAc only) to giveEtO-Su[NPN]₂[Boc][CBz] as an oil. LCMS (LC: Hydrophilic/formate, RT=17.8min; MS: 511 ([M+NH4]+, 10%), 494 ([M+H]+, 100%).

ii. EtO-Su[NPN]₂[NH₂.TFA][CBz]

Surface Topology Surface Stoichiometry EtO—CO (NH₂ CBz) 1 CO—OEt 1 NH₂ 1CBz

EtO-Su[NPN]₂[Boc][CBz] (720 mg, 1.46 mmol) was dissolved in acetic acid(10 mL) and cooled slightly. To this stirred mixture was then added TFA(10 mL), drop wise. After 30 min. the ice-bath was removed, and after 5hours the mixture was concentrated in vacuo. The residue was taken up inwater, then concentrated to remove excess acid. This was repeated (2×),then the sample was taken up in water and freeze-dried, providingEtO-Su[NPN]₂[NH₂.TFA][CBz] as a colourless oil, 715 mg (97% if calc. TFAsalt). LCMS (LC: Hydrophilic/TFA, RT=12.47 min; MS: 394 ([M+H]+, 100%).

iii. EtO-Su[NPN]₂[CBz][Su[NPN]₂][Boc]₂

Surface Surface Topology Stoichiometry EtO—CO ((CBz Ø)(Boc Boc))⁴ 1CO—OEt 2 Boc 1 CBz

To a stirred mixture of EtO-Su[NPN]₂[NH₂.TFA][CBz] (715 mg, 1.41 mmol)in DMF (20 mL) was added PNPOSu[NPN]₂[Boc]₂ (778 mg, 1.41 mmol) and TEA(0.49 mL, 3.52 mmol). The mixture was stirred at Rt overnight, thesolvent removed in vacuo, and the residue taken up in EtOAc (100 mL).This mixture was washed with a K₂CO₃ solution (5%), dried (MgSO₄),filtered and concentrated. The crude was purified by flashchromatography (10% MeOH in DCM), providing 0.95 g (84%) ofEtO-Su[NPN]₂[CBz][Su[NPN]₂][Boc]₂ as a viscous oil. LCMS (LC:Hydrophobic/formate, RT=6.91 min; MS: 807 ([M+H]+, 100%), 824 ([M+NH₄]+,32%).

iv. EtO-Su[NPN]₂[NH₂][Su[NPN]₂][Boc]

Surface Surface Topology Stoichiometry EtO—CO ((NH₂ Ø)(Boc Boc))⁴ 1CO—OEt 2 Boc 1 NH₂

To a stirred mixture of EtO-Su[NPN]₂[CBz][Su[NPN]₂][Boc]₂ (865 mg, 1.07mmol) in DMF/H₂O (9:1, 19 mL) was added ammonium formate (135 mg, 1.07mmol) and 10% Pd/C (288 mg, 0.25 equiv. Pd). The mixture was stirred for2 h. at Rt, filtered, and concentrated. The residue was taken up inwater, then concentrated to remove excess acid. This was repeated (2×),then the sample was taken up in water and freeze-dried, providing 672 mg(93%) of EtO-Su[NPN]₂[NH₂][Su[NPN]₂][Boc]₂ as a colourless oil. LCMS(LC: Hydrophilic/TFA, RT=13.9 min; MS: 673 ([M+H]+, 37%), 259 (100%).

v. EtO-Su[NPN]₂[Su[NPN]₂]₂[CBz][Boc]₃

Surface Surface Topology Stoichiometry EtO—CO ((CBz Boc)(Boc Boc))⁴ 1CO—OEt 3 Boc 1 CBz

To a stirred mixture of EtO-Su[NPN]₂[NH₂][Su[NPN]₂][Boc]₂ (739 mg, 1.1mmol) in DMF (20 mL) was added PNPOSu[NPN]₂[Boc][CBz] (644 mg, 1.1 mmol)and TEA (0.38 mL, 2.7 mmol). The mixture was stirred at Rt overnight,the solvent removed in vacuo, and the residue taken up in EtOAc (150mL). This mixture was washed with a K₂CO₃ solution (5%), dried (MgSO₄),filtered and concentrated, providing 1.30 g (106%) of crude material,EtO-Su[NPN]₂[Su[NPN]₂]₂[CBz][Boc]₃ as a pale yellow oil. LCMS (LC:Hydrophobic/formate, RT=3.3 min; MS: 1138 ([M+NH₄]+, 2%), 1121 ([M+H]+,3%), 561 ([M+2H/2]+, 100%).

vi. HO-Su[NPN]₂[Su[NPN]₂]₂[CBz][Boc]₃

Surface Surface Topology Stoichiometry HO—CO ((CBz Boc)(Boc Boc))⁴ 1CO₂H 3 Boc 1 CBz

To a stirred mixture of EtOSu[NPN]₂[Su[NPN]₂]₂[CBz][Boc]₃ (0.6 g, 0.6mmol) in THF (10 mL) was added NaOH solution (H₂O 4 mL, NaOH 127 mg, 3.0mmol). The mixture was stirred for 2 d at Rt, concentrated, the dilutedwith dilute HCl (50 mL). The aqueous phase was then washed with EtOAc,the organics combined, dried (MgSO₄), filtered and concentrated toprovide 0.8 g of white solid.

Example 19 BHALys[α-GlyLys][Lys]₂[Boc]₄[ε-GlyLys][Lys]₂[NH₂]₄ i.MeO-GlyLys[Lys]₂[Boc]₄

Surface Surface Topology Stoichiometry MeO—CO ((Boc Boc)(Boc Boc))⁴ 1CO₂Me 4 Boc

To a magnetically stirred solution of MeO-GlyLys[ε-NH₂.TFA][α-Lys][Boc]₂(968 mg, 1.47 mmol), TEA (0.51 ml, 3.66 mmol) and DMF (25 ml) was addedPNPO-α-Boc-ε-Boc-Lys (1.38 g, 2.95 mmol) as a solid and in one portionat Rt. The reaction and product isolation were carried out according tothe method described in Example 13.iii to give MeO-GlyLys[Lys]₂[Boc]₄(1.19 g, 93%) as a near colourless solid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=874.40 [M+H]+; calculated C41H75N7O13874.09 g/mol. Rf (min)=4.83.

ii. MeO-GlyLys[Lys]₂[NH₂.TFA]₄

Surface Surface Topology Stoichiometry MeO—CO (NH₂ NH₂)(NH₂ NH₂))⁴ 1CO₂Me 4 Boc

To a chilled (ice-water bath) and magnetically stirred suspension ofMeO-GlyLys[Lys]₂[Boc]₄ (1.19 g, 1.36 mmol) and DCM (60 ml) was addedneat TFA (4.2 ml, 54.5 mmol) in a drop wise manner. The reaction andproduct isolation were carried out according to the method described inExample 12. The product MeO-GlyLys[Lys]₂[NH₂.TFA]₄ (1.15 g, 91%) wasobtained as a glassy solid.

LC/MS (Philic/TFA): ESI (+ve) m/z 474.23 [M+H]+; calculated C21H43N7O5473.62 g/mol. Rf (min)=0.59.

iii. MeO-GlyLys[Lys]_(2[)4-Nitro-CBz]₄

Surface Surface Topology Stoichiometry MeO—CO ((4-Nitro-CBz4-Nitro-CBz)(4-Nitro-CBz 1 CO₂Me 4-Nitro-CBz))⁴ 4 4-Nitro-CBz

To a magnetically stirred mixture of MeO-GlyLys[Lys]₂[NH₂.TFA]₄ (606 mg,0.65 mmol), THF (12 ml) and DIPEA (1.4 ml, 8.03 mmol) was added, in oneportion and as a solid, 4-nitrobenzylchloroformate (853 mg, 3.96 mmol).The suspension was allowed to stir at Rt for a further 19 h. The crudereaction mixture was transferred to a beaker containing a 1:1 mixture ofACN and water (200 ml). The suspension was stirred for 2 h before beingfiltered and the solids collected left to dry overnight under suction.The desired product MeO-GlyLys[Lys]_(2[)4-Nitro-CBz]₄ (367 mg, 47%) wasobtained as a pale yellow coloured solid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=1190.35 [M+H]+; calculatedC53H63N11O21 1190.15 g/mol. Rf (min)=5.17.

iv. HO-GlyLys[Lys]_(2[)4-Nitro-CBz]₄

Surface Surface Topology Stoichiometry HO—CO ((4-Nitro-CBz4-Nitro-CBz)(4-Nitro-CBz 1 CO₂H 4-Nitro-CBz))⁴ 4 4-Nitro-CBz

To a magnetically stirred suspension ofMeO-GlyLys[Lys]_(2[)4-Nitro-CBz]₄ (297 mg, 0.25 mmol), methanol (3 ml),and water (1.5 ml) was added 1M aq. NaOH solution (1 ml). The suspensionwas stirred at 60° C. for ca. 5 h after which time, LCMS analysis of thecrude reaction mixture deemed the reaction complete. To the mixture wasadded 1M aq. KHSO4 solution (2 ml). After stirring at room temperaturefor approximately 10 mins, the suspension was filtered. The solidsretained were allowed to air dry under suction overnight. The product,HO-GlyLys[Lys]_(2[)4-Nitro-CBz]₄ (41 mg, 14%) was obtained as a lightgrey coloured solid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=1176.35 [M+H]+; calculatedC52H61N11O21 1176.13 g/mol. Rf (min)=4.85.

v. HO-GlyLys[Lys]₂[Boc]₄

Surface Surface Topology Stoichiometry HO—CO ((Boc Boc)(Boc Boc))⁴ 1CO₂H 4 Boc

To a magnetically stirred solution of MeO-GlyLys[Lys]₂[Boc]₄ (1.0 g,1.14 mmol), methanol (12 ml) and water (6 ml) was added 1M aq. NaOHsolution (2.2 ml) at Rt. The reaction mixture was stirred at Rt for 18h. The reaction and product isolation were carried out according to themethod described in Example 13.vi to afford HO-GlyLys [Lys]₂[Boc]₄ (1.05g, 107%) as a colourless solid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=860.62 [M+H]+; calculated C40H73N7O13860.07 g/mol. Rf (min)=4.41.

vi. PNPO-GlyLys[Lys]₂[Boc]₄

Surface Surface Topology Stoichiometry PNPO-CO ((Boc Boc)(Boc Boc))⁴ 1CO-OPNP 4 Boc

To a magnetically stirred solution of HOGlyLys[Lys]₂[Boc]₄ (983 mg, 1.14mmol) and EtOAc (20 ml) was added, in the following order, p-nitrophenol(175 mg, 1.26 mmol) and DCC (260 mg, 1.26 mmol). After stirring at Rtfor ca. 5 mins, the reaction mixture became a slurry due to theformation of a gel like precipitate. Stirring was continued at Rt for afurther 22 h. The crude reaction mixture was diluted upon the additionof EtOAc (10 ml) then filtered. The filtrate was concentrated underreduced pressure to give PNPO-GlyLys[Lys]₂[Boc]₄ as an orange/yellowcoloured solid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=981.71 [M+H]+; calculated C46H76N8O15981.16 g/mol. Rf (min)=5.65.

vii. BHALys[α-Boc][ε-Fmoc]

Surface Surface Topology Stoichiometry (Boc Fmoc) 1 Boc 1 Fmoc

HO-Lys-α-Boc-ε-Fmoc (10:34 g, 22.1 mmol) was dissolved in dry DMF (100mL) and chilled. DCC (4.74, 23.0 mmol) was added followed by HOBt (3.12g, 23.1 mmol). BHA (5 mL, 28.9 mol) was dissolved in dry DMF (25 mL) andadded drop wise to the reaction under argon. Reaction stirred at Rtovernight. DCU was filtered and the filtrate was partitioned betweenEtOAc and water. Organic layer was washed with 0.3M Na₂CO₃, then withbrine, followed by 0.1M KHSO₄ and then brine. EtOAc solution was driedover MgSO₄, filtered and concentrated under reduced pressure to giveBHALys[α-Boc][ε-Fmoc] as a pale yellow solid. Material was subjected tohigh vacuum overnight (14.36 g, 22.6 mmol, 103%) EtOAc, ¹H-nmr (300 MHz,D₆DMSO) λ 1-1.7 (15H); 2.9 (2H); 4.15-4.4 (3H) 6.1 (1H) 7.1-8 (18H) HPLC(Hydrophobic) Rt 12.92 min

ESI MS (+ve) 634.16 (M+H)⁺; Calc. MF C₃₉H₄₃N₃O₅ M+H. 633.79

viii. BHALys[ε-Fmoc][α-NH₂.TFA]

Surface Surface Topology Stoichiometry (Boc NH₂) 1 NH₂ 1 Fmoc

BHALys[α-Boc][ε-Fmoc] (14.26 g, 22.5 mmol) was suspended in DCM (40 mL)and chilled, forming a gel. TFA (30 mL, 43.2 mmol) was added slowly viaa dropping funnel which dissolved the gel and the homogeneous solutionwas stirred for 4 hours at Rt and then concentrated to giveBHALys[ε-Fmoc][α-NH₂.TFA] as a yellow oil. HPLC (Hydrophobic) Rt=8.59min; ESI MS (+ve) 534.19 (M+H)⁺; Calc MF: C₃₄H₃₅N₃O₃; M+H: 533.68 ¹H-nmr(MG-036-110-04) (300 MHz, D₆DMSO) λ (ppm) 1.0-1.8 (30H); 2.8-3.0 (4H);3.9 (1H); 4.2-4.5 (4H); 6.1 (1H); 7.2-7.9 (18H)

ix. BHALys[ε-Fmoc][α-GlyLys][Lys]₂[Boc]₄

Surface Surface Topology Stoichiometry (((4-Nitro-CBz Ø)(ØØ))⁴((BocBoc)(Boc Boc))⁴)⁸ 1 4-Nitro-CBz 4 Boc

To a magnetically stirred solution of BHALys[α-NH₂.TFA]₄[ε-Fmoc] (75 mg,0.12 mmol) and DMF (2 ml) was added PNPO-GlyLys[Lys]₂[Boc]₄ (230 mg,0.23 mmol), followed by triethylamine (22 μL, 0.16 mmol). The reactionand product isolation were carried out according to the method describedin Example 13.iii to afford BHALys[ε-Fmoc][α-GlyLys][Lys]₂[Boc]₄, incrude form, (314 mg) as a light yellow coloured gum like residue.

LC/MS (Phobic/TFA): ESI (+ve) m/z 1375.69 [M+H]+; calculatedC74H106N10O15 1375.73 g/mol. Rf (min)=7.14.

x. BHALys[ε-NH₂][α-GlyLys][Lys]₂[Boc]₄

Surface Surface Topology Stoichiometry (((NH₂Ø)(ØØ))⁴((Boc Boc)(BocBoc))⁴)⁸ 1 NH₂ 4 Boc

Piperidine (1 ml) was added to a magnetically stirred mixture ofBHALys[α-GlyLys(Boc)4][ε-Fmoc] (0.12 mmol) and DMF (4 ml). Stirring wascontinued at room temperature for 50 mins. The volatiles were removedunder reduced pressure and the residue treated with ethyl acetate (ca.100 ml). The precipitate which formed was collected and left to air dryunder suction for 2 h. The product, BHALys[ε-NH₂][α-GlyLys][Lys]₂[Boc]₄(33 mg, 24%) was obtained as a light yellow coloured solid.

LC/MS (Philic/TFA): ESI (+ve) m/z=1153.70 [M+H]+; calculatedC595H₉₆N10O13 1153.47 g/mol. Rf (min)=10.51.

xi. BHALys[α-GlyLys][Lys]₂[Boc]₄[ε-GlyLys][Lys][4-NitroCBz]₄

Surface Surface Topology Stoichiometry (((4-Nitro-CBz4-Nitro-CBz)(4-Nitro-CBz 4 4-Nitro-CBz 4-Nitro-CBz))⁴((Boc Boc)(BocBoc))⁴)⁸ 4 Boc

To a magnetically stirred solution BHALys[ε-NH₂][α-GlyLys][Lys]₂[Boc]₄(26 mg, 0.02 mmol) and DMF (1 ml) was added pyBOP (23 mg, 0.044 mmol).To this solution was added a mixture of HO-GlyLys[Lys]_(2[)4-Nitro-CBz]₄(40 mg, 0.034 mmol), DIPEA (25 μL, 0.14 mmol) and DMF (0.5 ml) at roomtemperature. The reaction and product isolation were carried outaccording to the method described in Example 11.i. The productBHALys[α-GlyLys][Lys]₂[Boc]₄[ε-GlyLys][Lys]_(2[)4-NitroCBz]₄ (7.8 mg,15%) was obtained as a grey coloured solid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=1156.63 [M+2H]/2+; calculatedC111H155N21O33 2311.59 g/mol. Rf (min)=7.02

xii. BHALys[α-GlyLys][Lys]₂[Boc]₄[ε-GlyLys][Lys]₂[NH₂]₄

Surface Topology Surface Stoichiometry (((4-Nitro-CBz4-Nitro-CBz)(4-Nitro-CBz 4 4-Nitro-CBz 4-Nitro-CBz))⁴((NH₂NH₂)(NH₂NH₂))⁴)⁸ 4 NH₂

A suspension ofBHALys[α-GlyLys][Lys]₂[Boc]₄[ε-GlyLys][Lys]_(2[)4-NitroCBz]₄,2,2,2-trifluoroethanol (3 ml) and 10% Pd/C was subjected to highpressure hydrogenation conditions (room temperature, 50 PSI) for 1.5 h.After this time, the black suspension was filtered and the filtratecollected was concentrated under reduced pressure. The productBHALys[α-GlyLys][Lys]₂[Boc]₄[ε-GlyLys][Lys]₂[NH₂]₄ (4.1 mg, 76%) wasobtained as a clear, colourless oily smear.

LC/MS (Phobic/TFA): ESI (+ve) m/z=798.08 [M+2H]/2+; calculatedC795H135N17O17 1595.06 g/mol. Rf (min)=3.33.

Example 20 BHALys[Lys]₂[α-NH₂]₂[ε-Lys]₂[Boc]₄

The synthesis is schematically illustrated in FIG. 12 (Scheme 1).

i. BHALys[NH₂.TFA]₂

Surface Topology Surface Stoichiometry (NH₂ NH₂) 2 NH₂

BHALys[Boc]₂ (10.014 g, 19.6 mmol) was suspended in DCM (30 mL) andchilled, forming a gel. TFA (30 mL, 43.2 mmol) was added slowly via adropping funnel which dissolved the gel and the homogeneous solution wasstirred overnight at Rt. Reaction mixture was slowly added to ice coldEther (300 mL) with stirring, to form of a fine white precipitate.Suspended solid was collected by filtration, washed with Ether (50 ml×2)dissolved in water and freeze dried to give BHALys[Lys]₂[NH₂.TFA]₂ (10.2g, 18.9 mmol, 97%).

HPLC (hydrophilic/formate) Rt=11.8 min; ESI MS (+ve) 311.83 (M+H)⁺. CalcMF: C₁₉H₂₅N₃O; M+H: 311.43

ii. BHALys[Lys]₂[α-Fmoc]₂[ε-Boc]₂

Surface Topology Surface Stoichiometry ((Fmoc Boc)(Fmoc Boc))⁴ 1 Fmoc 3Boc

DIPEA (6.8 mL, 39.0 mmol) and BHALys[NH₂.TFA]₂ (10.2 g, 18.9 mmol) weredissolved in dry DMF (30 mL) and were added drop wise under argon to asolution of PFP-Lys-α-Fmoc-ε-Boc (37.4 g, 38.9 mmol) in dry DMF (70 mL).The reaction and product isolation were carried out according to themethod described in Example 1.i to provide BHALys[Lys]₂[α-Fmoc]₂[ε-Boc]₂ as a white precipitate (18.9 g, 15.6 mmol,79.5%).

iii. BHALys[Lys]₂[α-Fmoc]₂[ε-NH₂.TFA]₂

Surface Topology Surface Stoichiometry ((NH₂ Boc)(Fmoc Boc))⁴ 1 NH₂ 3Boc

BHALys[Lys]₂[α-Fmoc]₂[ε-Boc]₂ (18.4 g, 15.2 mmol) was suspended in DCM(75 mL) and chilled, forming a gel. TFA (75 mL, 1.08 mol) was addedslowly. The reaction and product isolation were carried out according tothe method described in Example 19.ii to giveBHALys[Lys]₂[ε-Fmoc]₂[α-NH₂.TFA]₂ in quantitative yield. (19.2 g, 15.8mmol)—residual TFA present.

HPLC (Hydrophobic) Rt=10.4 min; ESI MS (+ve) 1012.15 (M+H)⁺. Calc MF:C₆₁H₆₉N₇O₇; M+H: 1013.27

iv. BHALys[Lys]₂[α-Fmoc]₂[ε-Lys]₂[Boc]₄

Surface Topology Surface Stoichiometry (((Fmoc Ø)(Boc Boc))⁴((FmocØ)(Boc Boc))⁴)⁸ 2 Fmoc 4 Boc

BHALys[Lys]₂[α-Fmoc]₂[ε-NH₂.TFA]₂ (19.2 g, 15.5 mmol) disolved in dryDMF (90 mL) was added drop wise under of argon to a solution ofPNPO-Lys(Boc)₂ (17.4 g, 37.2 mmol) and DIPEA (8.5 mL, 48.8 mmol) in dryDMF (250 mL) on ice. Once addition was complete the reaction was stirredovernight at Rt. Reaction mixture was slowly added to ACN (2 L) withvigorous stirring to form a white precipitate. Suspension was stirredfor 30 minutes after which the precipitate was collected. Filtered solidwas washed with ACN and dried giving a white solid (20.42 g), which wasinsoluble in a suitable HPLC solvent. 23 mg was deprotected for LCMSanalysis using the standard Boc deprotection method and the data showedincomplete reaction. PNPO-Lys(Boc)₂ (7.1 g, 15.2 mmol) was added to asolution of the partially reacted material (20.4 g) dissolved in DMF(315 mL), followed by DIPEA (2.6 mL, 15.2 mmol) and stirred overnight atRt. Reaction mixture was poured into ACN (2 L) and the precipitatecollected. Filtered solid was washed with ACN (250 mL×3) and driedovernight at 40° C. to give BHALys [Lys]₂[α-Fmoc]₂[Lys]₂[Boc]₄ as awhite solid (19.6 g, 11.7 mmol, 72%)

HPLC (Hydrophobic): rf 8.2 min. ESI MS (+ve) 1268.72 (M+H)⁺; 634.97((M+2H⁺)/2). Calc. MF C₉₃H₁₂₅N₁₁O₁₇; M+H⁺. 1669.1.

v. BHALys[Lys]₂[α-NH₂]₂[ε-Lys]₂[Boc]₄

Surface Topology Surface Stoichiometry (((NH2 Ø)(Boc Boc))4((NH2 Ø)(BocBoc))4)8 2 NH2 4 Boc

A solution of piperidine (11.6 mL, 145 mmol) in DMF (120 mL) was addedto BHALys [Lys]₂[α-Fmoc]₂[ε-Lys]₂[Boc]₄ (19.6 g) at Rt forming a yellowsolution. Reaction was stirred at Rt for 3 hours after which a slightcloudiness developed. The suspension was concentrated to approximately70 mL and added to a slurry of ice water with stirring. A fine, faintlyyellow precipitate was formed and this was collected. Methanol was addedto dissolve the solid. Filtrate was concentrated (10.2 g) and solidpurified by flash chromatography using 50:1:1Isopropanol:water:concentrated Ammonia giving BHALys[Lys]₂[α-NH₂]₂[ε-Lys]₂[Boc]₄ as a white solid (7.83 g, 6.4 mmol, 54%)

HPLC (Hydrophobic) Rt=8.75 min. ESI MS (+ve) 1224.81 (M+H)⁺. 612.85((M+2H⁺)/2) Calc MF: C₆₃H₁₀₅N₁₁O₁₃; M+H: 1224.61. ¹H-nmr (300 MHz, MeOD)λ (ppm) 1.2-1.8 (66H); 2.9-3.35 (5H); 3.85-4.0 (3H); 4.45 (1H); 6.2(1H); 7.2-7.4 (10H)

Example 21 Demonstration of Orthogonal Protecting Group RemovalBHALys[Lys]₈[ε-CBz]₈[αLys]₈[α-NH₂]₈[ε-Boc]₈ i.BHALys[Lys]₈[ε-CBz]₈[α-Lys]₈[α-Fmoc]₈[ε-Boc]₈

Surface Surface Topology Stoichiometry ((((CBz Ø)(Fmoc Boc))⁴((CBzØ)(Fmoc Boc))⁴)⁸(((CBz 8 CBz Ø)(Fmoc Boc))⁴((CBz Ø)(Fmoc Boc))⁴)⁸)¹⁶ 8Fmoc ((((CBz Ø)(Fmoc Boc))⁴((CBz Ø)(Fmoc Boc))⁴)⁸(((CBz 8 Boc Ø)(FmocBoc))⁴((CBz Ø)(Fmoc Boc))⁴)⁸)¹⁶

To a mixture of BHALys[Lys]₈[α-NH₂]₈[ε-CBz]₈ (0.025 mmol), TFA and DMFwas added N,N-diisopropylethylamine (0.105 ml, 0.60 mmol) andPFP-Lys-α-Fmoc-ε-Boc (154 mg, 0.24 mmol) at Rt. The clear, colourlessreaction mixture was stirred for a further 16 h at Rt. After this time,the reaction solution was transferred to a beaker containing ACN (ca.150 ml) and immediately, a colourless precipitate formed. Thisprecipitate, after being collected via filtration and washed with ACN,was air dried under suction overnight.BHALys[Lys]₈[ε-CBz]₈[α-Lys]₈[α-Fmoc]₈[ε-Boc]₈ (157 mg, 92%) was obtainedas a colourless solid.

The protecting groups may then be removed by one of the following threeprocesses:

ii. BHALys[Lys]₈[ε-CBz]₈[α-Lys]₈[α-NH₂]₈[ε-Boc]₈

Surface Surface Topology Stoichiometry ((((CBz Ø)(NH₂ Boc))⁴((CBz Ø)(NH₂Boc))⁴)⁸(((CBz Ø) 8 CBz (NH₂ Boc))⁴((CBz Ø)(NH₂ Boc))⁴)⁸)¹⁶ 8 NH₂((((CBz Ø)(NH₂ Boc))⁴((CBz Ø)(NH₂ Boc))⁴)⁸(((CBz Ø) 8 Boc (NH₂Boc))⁴((CBz Ø)(NH₂ Boc))⁴)⁸)¹⁶

A suspension of BHALys[Lys]₈[ε-CBz]₈[α-Lys]₈[α-Fmoc]₈[ε-Boc]₈ (20 mg,0.0029 mmol) and DMF was treated with piperidine at Rt. Stirring wascontinued at Rt for a further 18 h. After this time, the reactionmixture was diluted with DMF (ca. 2 ml), and concentrated under reducedpressure. The product was obtained as a colourless solid residue.

LC/MS (Phobic/TFA): ESI (+ve) observed [M+H/3]+m/z=1670;[M+H/4]+m/z=1252; [M+H/5]+m/z=1002; [M+H/6]+m/z=825; calculated forC255H401N47055 5005.27; Rf (min)=10.10 mins.

iii. BHALys[Lys]₈[ε-CBz]₈[α-Lys]₈[α-Fmoc]₈[ε-NH₂.TFA]₈

Surface Surface Topology Stoichiometry ((((CBz Ø)(Fmoc NH₂))⁴((CBzØ)(Fmoc NH₂))⁴)⁸(((CBz 8 CBz Ø)(Fmoc NH₂))⁴((CBz Ø)(Fmoc NH₂))⁴)⁸)¹⁶ 8Fmoc ((((CBz Ø)(Fmoc NH₂))⁴((CBz Ø)(Fmoc NH₂))⁴)⁸(((CBz 8 NH₂ Ø)(FmocNH₂))⁴((CBz Ø)(Fmoc NH₂))⁴)⁸)¹⁶

A suspension of BHALys[Lys]₈[ε-CBz]₈[α-Lys]₈[α-Fmoc]₈[ε-Boc]₈ (20 mg,0.0029 mmol) and AcOH was treated with neat TFA at Rt. Stirring wascontinued at Rt for a further 16 h. After this time, the reactionmixture was diluted with AcOH (ca. 2 ml), and concentrated under reducedpressure. BHALys[Lys]₈[ε-CBz]₈[α-Lys]₈[α-Fmoc]₈[ε-NH₂.TFA]₈ was obtainedas a colourless oily residue.

LC/MS (Phobic/TFA): ESI (+ve) observed [M+H/4]+m/z=1496;[M+H/5]+m/z=1197; [M+H/6]+m/z=998; [M+H/7]+m/z=855; calculated forC355H417N47055 5982.28; Rf (min)=13.86 mins.

iv. BHALys[Lys]₈[ε-NH₂]₈[α-Lys]₈[α-Fmoc]₈[ε-Boc]₈

Surface Surface Topology Stoichiometry ((((NH₂ Ø)(Fmoc Boc))⁴((NH₂Ø)(Fmoc Boc))⁴)⁸(((NH₂ 8 NH₂ Ø)(Fmoc Boc))⁴((NH₂ Ø)(Fmoc Boc))⁴)⁸)¹⁶ 8Fmoc ((((NH₂ Ø)(Fmoc Boc))⁴((NH₂ Ø)(Fmoc Boc))⁴)⁸(((NH₂ 8 Boc Ø)(FmocBoc))⁴((NH₂ Ø)(Fmoc Boc))⁴)⁸)¹⁶

A suspension of BHALys[Lys]₈[ε-CBz]₈[α-Lys]₈[α-Fmoc]₈[ε-Boc]₈ (19.6 mg,0.0029 mmol), 10% Pd/C (22 mg) and AcOH was stirred vigorously underhydrogen at Rt for 18 h. The black suspension was diluted with AcOH (ca.5 ml) and filtered. Concentration of the clear and colourless filtrateunder reduced pressure gaveBHALys[Lys]₈[ε-NH₂]₈[α-Lys]₈[α-Fmoc]₈[ε-Boc]₈ as a clear oil.

LC/MS (Phobic/TFA): ESI (+ve) observed [M+H/4]+m/z=1429;[M+H/5]+m/z=1143; calculated for C311H433N47O55 5710.14; Rf (min)=14.67mins.

Example 22 BHALys[Lys]₂[GlyLys]₄[ε-NH₂]₄[α-Lys][Boc]₈ i.HO-GlyLys[ε-CBz][α-Lys][Boc]₂

Surface Topology Surface Stoichiometry HO—CO ((CBz Ø)(Boc Boc))⁴ 1 CO₂H1 CBz 2 Boc

To a magnetically stirred solution of MeO-GlyLys[ε-CBz][α-Lys][Boc]₂(1.0 g, 1.47 mmol), methanol (32 ml) and water (16 ml) was added 1M aq.NaOH solution (3 ml) at Rt. The reaction and product isolation werecarried out according to the method described in Example 13.vi to affordHO-GlyLys[ε-CBz][α-Lys][Boc]₂ (942 mg, 96%) as a colourless foam.

LC/MS (Phobic/TFA): ESI (+ve) m/z=666.40 [M+H]+; calculated C33H54N50O9664.83 g/mol. Rf (min)=3.53.

ii. PNPO-GlyLys[ε-CBz][α-Lys][Boc]₂

Surface Topology Surface Stoichiometry PNPO-CO ((CBz Ø)(Boc Boc))⁴ 1CO-OPNP 1 CBz 2 Boc

To a magnetically stirred solution of HO-GlyLys[ε-CBz][α-Lys][Boc]₂ (430mg, 0.65 mmol) and EtOAc (10 ml) was added, in the following order,p-nitrophenol (99 mg, 0.71 mmol) and DCC (147 mg, 0.71 mmol). Afterstirring at Rt for ca. 5 mins, the reaction mixture became a slurry dueto the formation of a gel like precipitate. Stirring was continued at Rtfor a further 22 h. The crude reaction mixture was diluted upon theaddition of EtOAc (15 ml) then filtered. The filtrate was concentratedunder reduced pressure to give an orange/yellow coloured solid. Aftersubjection of the crude material to silica gel flash chromatography(EtOAc), the product PNPO-GlyLys[ε-CBz][α-Lys][Boc]₂ (Rf 0.4) (344 mg,66%) was obtained as an off white solid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=787.31 [M+H]+; calculated C38H54N6O12786.89 g/mol. Rf (min)=5.24.

iii. BHALys[Lys]₂[GlyLys]₄[ε-CBz]₄[α-Lys][Boc]₈

Surface Topology Surface Stoichiometry ((((CBz Ø)(Boc Boc))⁴((CBz Ø)(BocBoc))⁴)⁸ 4 CBz (((CBz Ø)(Boc Boc))⁴((CBz Ø)(Boc Boc))⁴)⁸)¹⁶ 8 Boc

To a magnetically stirred solution of BHALys[Lys]₂[NH₂.TFA]₄ (30 mg,0.029 mmol), TEA (0.06 ml, 0.43 mmol) and DMF (0.5 ml) was added asolution of PNPOGlyLys(α-DBL)(ε-CBz) (172 mg, 0.22 mmol dissolved in 2ml DMF) at Rt. The reaction and product isolation were carried outaccording to the method described in Example 1.i. The product,BHALys[Lys]₂-[GlyLys(Boc)₂(CBz)]₄ (87 mg, 94%), was obtained as an offwhite solid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=1580.31 [M+2H]/2+, 1053.90 [M+3H]/3+;calculated C159H245N27O39 3158.85 g/mol. Data deconvoluted usingtransform calculation to give mw=3158.29. Rf (min)=7.75.

iv. BHALys[Lys]₂[GlyLys]₄[ε-NH₂]₄[α-Lys][Boc]₈

Surface Surface Topology Stoichiometry ((((NH₂ Ø)(Boc Boc))⁴((NH₂ Ø)(BocBoc))⁴)⁸(((NH₂ Ø) 4 NH₂ (Boc Boc))⁴((NH₂ Ø)(Boc Boc))⁴)⁸)¹⁶ 8 Boc

To a magnetically stirred solution of BHALys[Lys]₂[GlyLys(Boc)₂(CBz)]₄(82 mg, 0.026 mmol) and 2,2,2-trifluoroethanol (2 ml) was added 10% Pd/C(55 mg). The black suspension was hydrogenated under standard conditions(rt, atmospheric pressure) for 17 h. After this time, the suspension wasfiltered through a 0.45 micron filter disk. The filtrate wasconcentrated under reduced pressure to give the product BHALys[Lys]₂[GlyLys(Boc)₂(NH₂)]₄ (68 mg, 99%) as a light brown coloured glassysolid.

LC/MS (Philic/TFA): ESI (+ve) m/z=1311.90 [M+2H]/2+, 874.92 [M+3H]/3+,656.46 [M+4H]/4+; calculated C127H221N27031 2622.32 g/mol. Datadeconvoluted using transform calculation to give mw=2621.78. Rf(min)=9.55.

Example 23 BHALys[Lys]₄[ε,α-Boc][ε,ε-NH₂][Boc]₆ i. BHALys[α-Fmoc][ε-Boc]

Surface Topology Surface Stoichiometry (Boc Fmoc) 1 Boc 1 Fmoc

HO-Lys-α-Fmoc-ε-Boc (13.6 g, 29.1 mmol) was dissolved in dry DMF (110mL) and chilled. DCC (6.3 g, 30.6 mmol) was added followed by HOBt (4.1g, 30.6 mmol). Benzhydrylamine (5 mL, 28.9 mol) was dissolved in dry DMF(40 mL) and added drop wise to the reaction under argon. The reactionand product isolation were carried out according to the method describedin Example 19.vii to give BHALys[α-Fmoc][ε-Boc] as a pale yellow solid.Material was dried at 40° C. for 2 hours (17.36 g, 27.3 mmol, 94%).

HPLC (Hydrophobic) rf 12.92 min. ESI MS (+ve) 634.12 (M+H)⁺; Calc. MFC39H43N3O5 M+H. 633.79.

ii. BHALys[α-Fmoc][ε-NH₂.TFA]

Surface Topology Surface Stoichiometry (NH₂ Fmoc) 1 NH₂ 1 Fmoc

BHALys[α-Fmoc][ε-Boc] (17.3 g, 27.3 mmol) was deprotected with in DCM(60 mL) TFA (100 mL, 1.43 mol) and DCM (40 mL) in the method of Example19.ii to give BHALys[α-Fmoc][ε-NH₂.TFA] as a white solid.

HPLC (Hydrophobic) Rt=6.59 min; ESI MS (+ve) 533.9 (M+H)⁺. Calc MF:C₃₄H₃₅N₃O₃; M+H: 533.68

¹H-nmr (300 MHz, D₆DMSO) λ (ppm) 1.15-1.75 (6H); 2.65-2.85 (2H);4.05-4.45 (3H); 6.1 (1H); 7.0-8.0 (18H)

¹³Cnmr (300 MHz, D₆DMSO) λ (ppm) 22.47 (1CH₂); 26.55 (1CH₂); 31.39(1CH₂), 46.65 (1CH₂); 54.38 (1CH); 55.90 (1C); 65.59 (1C); 119.06-143.8716 peaks (24 Ar—C); 155.98 (1C-Carbamate); 171.28 (1C-Amide)

iii. BHALys[α-Fmoc][ε-Lys][Boc]₂

Surface Topology Surface Stoichiometry ((Fmoc Ø)(Boc Boc))⁴ 2 Boc 1 Fmoc

BHALys[α-Fmoc][ε-NH₂.TFA] (14.64 g, 22.6 mmol) was reacted withPNPO-Lys(Boc)₂ (13.4 g, 28.7 mmol) in dry DMF (80 mL) and DIPEA (7.2 mL,37.3 mmol) in DMF (145 mL), in the same manner as in Example 1.i. Thesolid was collected and washed repetitively with Ether to giveBHALys[α-Fmoc][ε-Lys][Boc]₂ as a white solid (13.8 g, 16.0 mmol, 60%)

HPLC (Hydrophobic) rf 13.59 min. ESI MS (+ve) 862.17 (M+H)⁺; 879.27(M+NH₄ ⁺); Calc. MF C₅₀H₆₃N₅O₈ M+H. 862.09.

¹H-nmr (300 MHz, D₆DMSO) λ (ppm) 1.15-1.75 (30H); 2.8-3.2 (4H); 4.3(1H); 4.1-4.3 (3H); 7.2-7.95 (18H)

iv. BHALys[α-NH₂][ε-Lys][Boc]₂

Surface Topology Surface Stoichiometry ((NH₂ Ø)(Boc Boc))⁴ 2 Boc 1 NH₂

The Fmoc protecting group was removed from BHALys[α-Fmoc][ε-Lys][Boc]₂(13.8 g, 16.0 mmol) using piperidine (20 mL, 25.0 mmol) in DMF (80 mL)in similar manner to Example 1.v. Material was purified by flashchromatography (EtOAc:PM 17:2 (PM=Isopropanol:water:concentrated Ammonia20:1:1). to give BHALys[α-NH₂][ε-Lys][Boc]₂ as a white solid (8.04 g,12.5 mmol, 79%) rf product=0.35.

¹H-nmr (300 MHz, MeOD) δ 1.2-1.9 (30H); 3.0-3.3 (4H); 3.4 (1H); 3.95(1H); 6.2 (1H); 7.2-7.4 (10H)

HPLC (Hydrophobic) Rt=7.15 min. ESI MS (+ve) 640.5 (M+H)⁺. Calc MF:C₃₅H₅₃N₅O₆; M+H: 639.84

v. BHALys[Lys]₂[α,ε-Fmoc][Boc]₃

Surface Topology Surface Stoichiometry ((Fmoc Boc)(Boc Boc))⁴ 3 Boc 1Fmoc

HO-Lys-α-Boc-ε-Fmoc (2.94 g, 6.3 mmol) was dissolved in dry DMF (10 mL)and chilled. DCC (1.36 g, 6.60 mmol) in DMF (5 mL) was added followed byHOBt (893 mg, 6.60 mmol) in DMF (5 mL). BHALys[α-NH₂][ε-Lys][Boc]₂ (4.02g, 6.3 mol) was dissolved in dry DMF (12 mL) and added drop wise to thereaction under argon. Reaction stirred at Rt overnight. DCU was filteredand the filtrate concentrated under reduced pressure. The residue wastriturated with Ether, filtered and washed with EtOAc to give BHALys[Lys]₂[α,ε-Fmoc][Boc]₃ as a white solid (5.33 g, 4.88 mmol, 78%.)

HPLC (Hydrophobic) rf 14.58 min. ESI MS (+ve) 1090.31 (M+H)⁺; 1107.39(M+NH₄ ⁺); Calc. MF C₆₁H₈₃N₇O₁₁ M+H. 1090.38

vi. BHALys[Lys]₂[α,ε-Fmoc][NH₂.TFA]₃

Surface Topology Surface Stoichiometry ((Fmoc NH₂)(NH₂ NH₂))⁴ 3 NH₂ 1Fmoc

BHALys[Lys]₂[α,ε-Fmoc][Boc]₃ (92 mg, 84.4 mmol) was deprotected usingTFA and DCM as for the method of Example 19.ii. Reaction concentratedunder reduced pressure and the residue washed with ether to giveBHALys[Lys]₂[α,ε-Fmoc][NH₂.TFA]₃ as a solid (85 mg, 82%)

HPLC (Hydrophobic) rf 15.77 min. ESI MS (+ve) 790.09 (M+H)⁺; 395.71(M+2H⁺)/2; Calc. MF C₄₆H₅₉N₇O₅ M+H. 790.03

¹H-nmr (300 MHz, MeOD) λ (ppm); 1.25 (18H); 2.8-3.0 (4H); 3.8 (1H);4.0-4.5 (5H); 6.2 (1H); 7.2-7.8 (18H)

vii. BHALys[Lys]₂[α,ε-Fmoc][Lys]₃ [Boc]₆

Surface Topology Surface Stoichiometry (((Fmoc Ø)(Boc Boc))⁴((BocBoc)(Boc Boc))⁴)⁸ 6 Boc 1 Fmoc

BHALys[Lys]₂[α,ε-Fmoc][NH₂.TFA]₃ (75 mg, 66.3 umol) was dissolved in dryDMF (1 mL) and added drop wise to a solution of PNPO-Lys(Boc)₂ (120 mg,0.25 mmol) and DIPEA (50 μL, 1.5 eq/NH₂) in dry DMF (1 ml) under argon.Once addition complete, the reaction was stirred at Rt overnight.Reaction was filtered, concentrated under reduced pressure and theresidue triturated with Ether, filtered and then washed with EtOAcrepetitively to give BHALys[Lys]₂[α,ε-Fmoc][Lys]₃ [Boc]₆ as a solid (113mg, 63.6 umol, 96%)

HPLC (Hydrophobic) rf 16.52 min. ESI MS (+ve) 888 (M+2H⁺)/2; Calc. MFC₆₁H₈₃N₇O₁₁ M+H. 1775.26

viii. BHALys[Lys]₂[α,ε-NH₂][Lys]₃ [Boc]₆

Surface Topology Surface Stoichiometry (((Fmoc Ø)(Boc Boc))⁴((BocBoc)(Boc Boc))⁴)⁸ 6 Boc 1 Fmoc

BHALys[Lys]₂[α,ε-Fmoc][Lys]₃ [Boc]₆ (113 mg, 63.6 umol) was dissolved indry DMF (1 mL) using piperidine (0.2 mL) in similar manner to Example1.v. Material was purified by flash chromatography to giveBHALys[Lys]₂[α,ε-NH₂][Lys]₃ [Boc]₆ as an oil (50 mg, 30 umol).

ix. BHALys[Lys]₄[α,ε,α-Boc][α,ε,ε-4-Nitro-CBz][Boc]₆

Surface Surface Topology Stoichiometry (((4-Nitro-CBz Boc)(BocBoc))⁴((Boc Boc)(Boc Boc))⁴)⁸ 7 Boc 1 4-Nitro- CBz

To a magnetically stirred solution of BHALys[Lys]₂[α,ε-NH₂][Lys]₃ [Boc]₆(99.5 mg, 0.064 mmol), DMF (2 ml) and TEA (25 μl, 0.18 mmol) was addedPNPO-Lys-α-Boc-ε-4-Nitro-CBz (45.2 mg, 0.083 mmol) in one portion at Rt.The bright yellow coloured solution was allowed to stir at Rt for 22 h.The reaction and product isolation were carried out according to themethod described in Example 1.i. The product, BHALys[Lys]₄[α,ε,α-Boc][α,ε,ε-4-Nitro-CBz][Boc] (105 mg, 83%) was obtained asan off-white solid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=1961.39 [M+H]+, 981.00 [M+2H]/2+;calculated C98H158N16O25 1960.44 g/mol. Data deconvoluted usingtransform calculation to give mw=1959.99. Rf (min): 7.37.

x. BHALys[Lys]₄[α,ε,α-Boc][α,ε,ε-NH₂][Boc]₆

Surface Topology Surface Stoichiometry (((NH₂ Boc)(Boc Boc))⁴((BocBoc)(Boc Boc))⁴)⁸ 7 Boc 1 NH₂

To a magnetically stirred solution ofBHALys[Lys]₄[ε,α-Boc][ε,ε-4-Nitro-CBz][Boc]₆ (100 mg, 0.051 mmol) andTFE (2 ml) was added 10% Pd/C (27.2 mg). The black suspension washydrogenated at Rt and pressure for 5 h. The suspension was filteredthrough a silica plug and concentration of the filtrate affordedBHALys[Lys]₄[α,ε,α-Boc][α,ε,ε-NH₂][Boc]₆ (68.6 mg, 75%) as a fawncoloured, glass like solid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=1781.34 [M+H]+, 891.63 [M+2H]/2+;calculated C90H153N15O21 1781.31 g/mol. Rf (min): 6.05.

Example 24 BHALys[Lys]₂[α,ε-Lys][NH₂]₂[Lys]₃ [Boc]₆ i.BHALys[Lys]₂[α,ε-Lys][CBz]₂[Lys]₃ [Boc]₆

Surface Topology Surface Stoichiometry (((CBz CBz)(Boc Boc))⁴((BocBoc)(Boc Boc))⁴)⁸ 6 Boc 2 CBz

To a magnetically stirred solution of BHALys[Lys]₂[α,ε-NH₂][Lys]₃ [Boc]₆(50 mg, 0.032 mmol), DMF (1 ml) and TEA (11 μl, 0.08 mmol) was addedPNPO-Lys(CBz)₂ (35 mg, 0.064 mmol) in one portion at room temperature.The reaction and product isolation were carried out according to themethod described in Example 1.i to give BHALys[Lys]₂[α,ε-Lys][CBz]₂[Lys]₃ [Boc]₆ (48.2 mg, 77%) as an off-white solid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=1950.01 [M+H]+, 975.50 [M+2H]/2+;calculated C101H157N15O23 1949.46 g/mol. Data deconvoluted usingtransform calculation to give mw=1948.94. Rf (min): 7.61.

ii. BHALys[Lys]₂[α,ε-Lys][NH₂]₂[Lys]₃ [Boc]₆

Surface Topology Surface Stoichiometry (((NH₂ NH₂)(Boc Boc))⁴((BocBoc)(Boc Boc))⁴)⁸ 6 Boc 2 NH₂

To a magnetically stirred solution of BHALys[Lys]₂[α,ε-Lys][CBz]₂[Lys]₃[Boc]₆ (13.4 mg, 7 μmol) and TFE (2 ml) was added 10% Pd/C (15.9 mg).The black suspension was hydrogenated at room temperature and underpressure (50 PSI) for ca. 10 h. The suspension was filtered andconcentration of the filtrate afforded BHALys[Lys]₂[α,ε-Lys][NH₂]₂[Lys]₃[Boc]₆ (7.6 mg, 66%) as a light brown coloured oil.

LC/MS (Phobic/TFA): ESI (+ve) m/z=1680.93 [M+H]+, 841.14 [M+2H]/2+;calculated C85H145N15O19 1681.19 g/mol. Rf (min): 5.53.

Example 25 BHALys[Lys]₂[Lys]₄[α,ε,α-CBz][α,ε,ε-Alloc][Boc]₆

Surface Surface Topology Stoichiometry (((CBz Alloc)(Boc Boc))⁴((BocBoc)(Boc Boc))⁴)⁸ 6 Boc 1 CBz 1 Alloc

To a magnetically stirred solution of BHALys[Lys]₂[α,ε-NH₂][Lys]₃ [Boc]₆(46.7 mg, 0.03 mmol) and DMF (0.5 ml) was added pyBOP (43 mg, 0.083mmol) in one portion at room temperature. To this mixture was added asolution of HO-Lys-α-CBz-ε-Alloc dicyclohexylamine salt (39 mg, 0.071mmol), DIPEA (45 μl, 0.26 mmol) and DMF (0.5 ml). The flask containingthe capping group was rinsed with DMF (0.5 ml) which was also added tothe reaction mix. The clear and near colourless reaction mixture wasallowed to stir at room temperature for 44 h. The crude reaction mixturewas transferred to a beaker containing acetonitrile (250 ml) and theflocculant precipitate which formed was collected by filtration andallowed to dry overnight under suction. The product,BHALys[Lys]₂[Lys]₄[α,ε,α-CBz][α,ε,ε-Alloc][Boc]₆ (33 mg, 58%) wasobtained as an off-white solid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=1899.80 [M+H]+, 950.83 [M+2H]/2+;calculated C97H155N15O23 1899.40 g/mol. Data deconvoluted usingtransform calculation to give mw=1898.91. Rf (min): 7.39.

Example 26 BHALys[Lys]₂[ε-NH₂]₂[α-Lys]₂[Boc]₄ i.BHALys[Lys]₂[α-Boc]₂[ε-Fmoc]₂

Surface Topology Surface Stoichiometry ((Boc Fmoc)(Boc Fmoc))⁴ 2 Boc 2Fmoc

To a solution of HO-Lys-α-Boc-ε-Fmoc (18.3 g, 39.1 mmol) in DMF (150 mL)on ice, was added DCC (8.47 g, 41.1 mmol) and HOBt (41.1 mmol).BHALys[NH₂.TFA]₂ (10.23 g, 19.6 mmol) was added drop wise as a solutionin DMF (50 mL) with DIPEA (9 mL, 52 mmol). Once addition complete,reaction stirred at Rt overnight. DCU formed was filtered and thefiltrate was added to Ether (2 L) with stirring. The precipitate wascollected and washed with Ether. Filtered solid was then suspended in20% MeOH in EtOAc and sonicated for 20 minutes. A fine white suspensionwas filtered and the process repeated using 20% MeOH in EtOAc (100 mL)to provide BHALys[Lys]₂[α-Boc]₂[ε-Fmoc]₂ as a white solid (18.6 g, 15.3mmol, 78%).

ii. BHALys[Lys]₂[ε-Fmoc]₂[α-NH₂.TFA]₂

Surface Topology Surface Stoichiometry ((NH₂ Fmoc)(NH₂ Fmoc))⁴ 2 NH₂ 2Fmoc

BHALys[Lys]₂[ε-Fmoc]₂[α-Boc]₂ (18.9 g, 15.6 mmol) was suspended in DCM(75 mL) and chilled, TFA (75 mL, 1.08 mol) was added slowly. Thereaction and product isolation were carried out according to the methoddescribed in Example 19.ii to give BHALys [Lys]₂[ε-Fmoc]₂[α-NH₂.TFA]₂ inquantitative yield. (19.6 g, 15.8 mmol)—some excess TFA present.

HPLC (Hydrophobic) Rt=10.4 min; ESI MS (+ve) 1012.15 (M+H)⁺. Calc MF:C₆₁H₆₉N₇O₇; M+H: 1013.27

iii. BHALys[Lys]₂[ε-Fmoc]₂[α-Lys]₂[Boc]₄

Surface Topology Surface Stoichiometry (((Fmoc Ø)(Boc Boc))⁴((FmocØ)(Boc Boc))⁴)⁸ 4 Boc 2 Fmoc

BHALys[Lys]₂[ε-Fmoc]₂[α-NH₂.TFA]₂ (19.6 g, 15.8 mmol) disolved in dryDMF (80 mL) was added drop wise under argon to a solution ofPNPO-Lys(Boc)₂ (18.4 g, 39.4 mmol) and DIPEA (7.88 mL, 45.2 mmol) in dryDMF (200 mL) on ice. The reaction and product isolation were carried outaccording to the method described in Example 1.i. to give the productBHALys[Lys]₂[ε-Fmoc]₂[α-Lys]₂[Boc]₄ in 85% yield (22.3 g, 13.4 mmol).

HPLC (Hydrophobic) RT=6.8 min. ESI MS (+ve) 1269 (M+H)⁺; Calc. MFC₇₃H₉₃N₁₁O₉; M+H. 1269.1

¹H-nmr (300 MHz, D₆DMSO) λ (ppm) 1.4-2.3 (66H); 3.2-3.5 (10H); 4.3 (2H);4.5-4.9 (9H); 6.5 (1H); 7.6-7.9 (28H)

iv. BHALys[Lys]₂[ε-NH₂]₂[α-Lys]₂[Boc]₄

Surface Topology Surface Stoichiometry (((NH₂ Ø)(Boc Boc))⁴((NH₂ Ø)(BocBoc))⁴)⁸ 4 Boc 2 NH₂

BHALys[Lys]₂[ε-Fmoc]₂[α-Lys]₂[Boc]₄ (22.3 g, 13.4 mmol) was suspended indry DMF (120 mL) and piperidine (32 mL, 402 mmol) in DMF (40 mL) wasslowly added to the mixture with stirring. Reaction became homogeneousafter 15 minutes and was stirred for a further 45 minutes at Rt and thencooled overnight. DMF was removed under reduced pressure. Material waspurified by flash chromatography with solvent system 13:1:1Isopropanol:Water:Concentrated Ammonia to give a white solidBHALys[Lys]₂ [ε-NH₂]₂[α-Lys]₂[Boc]₄; 9.28 g, 7.58 mmol, 58%). HPLC(Hydrophobic): Rt=6.84 min. ESI MS (+ve) 1224.57 (M+H)⁺. 612.96((M+2H⁺)/2) Calc MF: C₆₃H₁₀₅N₁₁O₁₃; M+H: 1224.61.

¹H-nmr (300 MHz, D₆DMSO) λ (ppm) 1.2-1.8 (66H); 2.9-3.35 (5H); 3.85-4.0(3H); 4.45 (1H); 6.2 (1H); 7.2-7.4 (10H).

Example 27 BHALys[Lys]₄[GlyLys]₈[ε-NH₂]₈[α-Lys]₈[Boc]₁₆ i.HO-GlyLys[ε-CBz][α-Lys][Boc]₂

Surface Topology Surface Stoichiometry HO—CO ((CBz Ø)(Boc Boc))⁴ 1 CO₂H2 Boc 1 CBz

To a magnetically stirred solution of MeO-GlyLys[ε-CBz][α-Lys][Boc]₂(1.0 g, 1.47 mmol), methanol (32 ml) and water (16 ml) was added 1M aq.NaOH solution (3 ml) at room temperature. The reaction and productisolation were carried out according to the method described in Example13.vi to afford HO-GlyLys[ε-CBz][α-Lys][Boc]₂ (942: mg, 96%) as acolourless foam.

LC/MS (Phobic/TFA): ESI (+ve) m/z 666.40 [M+H]+; calculated C33H54N5O9664.83 g/mol. Rf (min)=3.53.

ii. PNPO-GlyLys[ε-CBz][α-Lys][Boc]₂

Surface Topology Surface Stoichiometry PNPO—CO ((CBz Ø)(Boc Boc))⁴ 1CO₂PNP 2 Boc 1 CBz

To a magnetically stirred solution of HO-GlyLys[ε-CBz][α-Lys][Boc]₂ (430mg, 0.65 mmol) and EtOAc (10 ml) was added, in the following order,p-nitrophenol (99 mg, 0.71 mmol) and DCC (147 mg, 0.71 mmol). Thereaction and product isolation were carried out according to the methoddescribed in Example 19.vi Silica gel flash chromatography (EtOAc)provided PNPO-GlyLys[ε-CBz][α-Lys][Boc]₂ (Rf 0.4) (344 mg, 66%) as anoff white solid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=787.31 [M+H]+; calculated C38H54N6O12786.89 g/mol. Rf (min)=5.24.

iii. BHALys[Lys]₄[GlyLys]₈[ε-CBz]₈[α-Lys]₈[Boc]₁₆

Surface Surface Topology Stoichiometry (((CBz Ø)(Boc Boc))⁴((CBz Ø)(Boc16 Boc Boc))⁴)⁸(((CBz Ø)(Boc Boc))⁴((CBz Ø)(Boc Boc))⁴)⁸)¹⁶ 8 CBz (((CBzØ)(Boc Boc))⁴((CBz Ø)(Boc Boc))⁴)⁸(((CBz Ø)(Boc Boc))⁴((CBz Ø)(BocBoc))⁴)⁸)¹⁶

To a stirred solution of BHALys[Lys]₄[NH₂.TFA]₈ (30 mg, 0.015 mmol), TEA(0.06 ml, 0.43 mmol) and DMF (0.5 ml) was added a solution ofPNPO-GlyLys[ε-CBz][α-Lys][Boc]₂ (172 mg, 0.22 mmol) in DMF (2 ml) at Rt.The reaction and product isolation were carried out according to themethod described in Example 1.i to provide BHALys[Lys]₄[GlyLys]₈[ε-CBz]₈[α-Lys]₈[Boc]₁₆ (80 mg, 85%) as an off white solid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=1566.46 [M+4H]/4+; calculatedC311H489N55O79 6262.63 g/mol. Rf (min)=8.95.

iv. BHALys[Lys]₄[GlyLys]₈[ε-NH₂]₈[α-Lys]₈[Boc]₁₆

Surface Surface Topology Stoichiometry (((NH₂ Ø)(Boc Boc))⁴((NH₂ Ø)(Bo16 Boc Boc))⁴)⁸(((NH₂ Ø)(Boc Boc))⁴((NH₂ Ø)(BocBoc))⁴)⁸)¹⁶ 8 NH₂ (((NH₂Ø)(Boc Boc))⁴((NH₂ Ø)(Boc Boc))⁴)⁸(((NH₂ Ø)(Boc Boc))⁴((NH₂ Ø)(BocBoc))⁴)⁸)¹⁶

To a stirred solution of BHALys[Lys]₄[GlyLys]₈[ε-CBz]₈[α-Lys]₈[Boc]₁₆(73.5 mg, 0.012 mmol) and 2,2,2-trifluoroethanol (3 ml) was added 10%Pd/C (44 mg). The black suspension was hydrogenated under standardconditions (room temperature, atmospheric pressure) for 17 h. LCMSanalysis of an aliquot taken from the crude reaction mixture indicatedthat the reaction was incomplete. A further portion of catalyst wasadded (44 mg) and the crude reaction suspension was re-subjected tohydrogenolysis under high pressure (50 PSI) at room temperature for 48h. After this time, the suspension was filtered through a 0.45 micronfilter disk. The filtrate was concentrated under reduced pressure togive the product BHALys[Lys]₄[GlyLys]₈[ε-NH₂]₈[α-Lys]₈[Boc]₁₆ (52 mg,85%) as a brown coloured glassy solid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=1298.13 [M+4H]/4+, 1038.76 [M+5H]/5+,865.61 [M+6H]/6+; calculated C247H441N55O63 5189.55 g/mol. Datadeconvoluted using transform calculation to give mw=5188.51. Rf(min)=3.99.

Example 28 Chromatographic Behaviour of Topological Isomers

HPLC—Waters 2795 with 2996 Diode Array Detector (DAD)

Solvent A: 1% TFA in water; Solvent B: Acetonitrile; Solvent C: Water.

Column: Waters Xterra MS-C8, 3.5 um, 3 mm×50 mm at 0.4 ml/min

Gradient: Starting eluent A (10%) B (40%) C (50%) isocratic for 1 min;linear gradient to A (10%) B (90%) C (0%) over 6 min; isocratic for 2min; linear gradient to Starting eluent over 2 min; condition column atStarting eluent for 4 min (Total run 15 min).

TABLE 23 HPLC retention times for sets of Topological Isomers Rt* (UV)Set Topology A:B A + B Example: Name (mins) 1 (((AB)(AB))⁴((AB)(AB))⁴)⁸1:1 8 3.ii: BHALys [Lys]4 [α-Boc]4 [ε-NH2]4 0.87 1(((AB)(AB))⁴((AB)(AB))⁴)⁸ 1:1 8 2.ii: BHALys [Lys]4 [α-CBz]4 [ε-Boc]41.55 1 (((AA)(BB))⁴((AA)(BB))⁴)⁸ 1:1 8 13.viii: BHALys [GlyLys]2 [Lys]4[α,α- 1.73 Boc]2 [α,ε-Boc]2 [ε,α-NH2]2 [ε,ε-NH2]2 1(((AA)(AA))⁴((BB)(BB))⁴)⁸ 1:1 8 19.xii: BHALys [a-GlyLys] [Lys]2 [Boc]43.37 [e-GlyLys] [Lys]2 [NH2]4 2 (((AB)(AB))⁴((AB)(AB))⁴)⁸ × 2 1:1 164.ii: BHALys [Lys]8 [α-Boc]8 [ε-NH2]8 1.01 2 (((AB)(AB))⁴((AB)(AB))⁴)⁸ ×2 1:1 16 6.ii: BHALys [Lys]8 [α-NH2]8 [ε-Boc]8 1.02 2(((AA)(BB))⁴((AA)(BB))⁴)⁸ × 2 1:1 16 14.ii BHALys [Lys]₂ [GlyLys]₄[Lys]₈ [α,α- 1.01 Boc]₄ [α,ε-Boc]₄ [ε,α-NH₂]₄ [ε,ε-NH₂]₄ 3(((AB)(BB))⁴((AB)(BB))⁴)⁸ 1:3 8 15.iv: BHALys [GlyLys]₂ [Lys]₄ [Boc]₆[ε,ε- 4.5 NH₂]₂ 3 (((AA)(BB))⁴((BB)(BB))⁴)⁸ 1:3 8 24.ii: BHALys [Lys]₂[α,ε-Lys] [NH₂]₂ [Lys]₃ 5.46 [Boc]₆ 4 (((AB)(BB))⁴((AB)(BB))⁴)⁸ 1:3 815.iii: BHALys [GlyLys]₂ [Lys]₄ [Boc]₆ [ε,ε- 7.14 CBz]₂ 4(((AA)(BB))⁴((BB)(BB))⁴)⁸ 1:3 8 24.i: BHALys [Lys]₂ [α,ε-Lys] [CBz]₂[Lys]₃ 7.56 [Boc]₆ *Rt = Retention time of topological isomer.

This data serves to demonstrate that macromolecules which have differenttopologies of the same surface functional moiety stoichiometry behavedifferently when interacting with a physico-chemical environment.

Antimicrobial Examples Example 29BHALys[Lys]₄[α-COCH₂O-3,6-Naph(SO₃Na)₂]₄[ε-COC₅H₁₂]₄

Surface Topology Surface Stoichiometry (((Hex B)(Hex B))⁴((Hex B)(Hex 4COC₅H₁₂ = Hex B))⁴)⁸ 4 COCH₂O-3,6-Naph[SO3Na]₂ = B

i. BHALys[Lys]₄[α-Boc]₄[ε-COC₅H₁₂]₄ SPL8059

PyBOP (0.20 g, 0.38 mmol) was added to a stirred solution ofBHALys[Lys]₄[α-Boc]₄ [ε-NH₂.TFA]₄ (60 mg, 0.032 mmol) in DMF/DMSO (1:1)(6 mL). A solution of hexanoic acid (42 mg, 0.36 mmol) anddiisopropylethylamine (0.3 mL, 1.72 mmol) in DMF/DMSO (1:1) (3 mL) wasadded gradually. The mixture was stirred at Rt for 16 h. Reactionmixture was poured into ACN (0.3 L) and filtered. The precipitate wasdried in vacuo to give BHALys[Lys]₄[α-Boc]₄[ε-COC₅H₁₂]₄ as a white solid(53 mg, 70%).

LC/MS (phobic) ESI (+ve) m/z=1873.32 (M+); 937.54 ((M+2H)²⁺). Calculated(C₉₉H₁₆₉N₁₅O₁₉) 1873.49 (M+). Rf (min)=7.27.

ii. BHALys[Lys]₄[α-NH₂.TFA]₄[ε-COC₅H₁₂]₄

A solution of TFA/DCM (1:1) (2 mL) was added slowly toBHALys[Lys]₄[α-Boc]₄[ε-COC₅H₁₂]₄ (25 mg, 0.013 mmol) dipersed in DCM (3mL). The mixture was stirred at Rt for 16 h. The solvent was removed invacuo and the residue triturated with Ether. The residue was washed withEther (3×10 mL), dried in vacuo to giveBHALys[Lys]₄[α-NH₂.TFA]₈[ε-COC₅H₁₂]₄ as a white solid (28 mg, 108%).

LC/MS (philic) ESI (+ve) m/z=1473.12 (M+); 737.21 ((M+2H)²⁺); 491.93((M+3H)³⁺). Calculated (C₇₉H₁₃₇N₁₅O₁₁) 1473.03 (NH₂ form). Rf (min)=8.75

iii. BHALys[Lys]₄[α-COCH₂O-3,6-Naph(SO₃Na)₂]₄[ε-COC₅H₁₂]₄

PyBOP (0.07 g, 0.13 mmol) was added to a stirred solution ofBHALys[Lys]₄ [α-NH₂.TFA]₄[ε-COC₅H₁₂]₄ (24 mg, 0.012 mmol) in DMF/DMSO(1:1) (3 mL). A solution of HOCOCH₂O-3,6-Naph(SO₃Na)₂ (0.05 g, 0.12mmol) and diisopropylethylamine (0.1 mL, 0.57 mmol) in DMF/DMSO (1:1) (2mL) was added gradually. The mixture was stirred at Rt for 16 h.Reaction mixture was poured into water (0.3 L) and filtered.Purification was performed by tangential flow filtration on a Centramate(2K membrane, 0.5 L sample reservoir). After an initial wash withMilli-Q water (5 L) the retentate was washed with two aliquots of 1Msodium carbonate (100 mL) separated by a Milli-Q water wash (1 L), thenfiltration was continued until filtrate pH was neutral (approx. 5 L).Retentate was conc. in vacuo, and freeze dried to giveBHALys[Lys]₄[α-COCH₂O-3,6-Naph(SO₃Na)₂]₄[ε-COC₅H₁₂]₄ as a white solid(26 mg, 69%).

1H nmr (300 MHz, D₂O) λ (ppm): 0.5-0.7 (12H); 0.8-1.8 (68H); 1.9-2.1(8H); 2.9-3.3 (14H); 4.0-4.3 (7H); 5.9 (1H); 7.0-7.3, 7.8-8.1, 8.2-8.5(30H). Note the CH₂O protons are obscured by the water peak (4.4-4.9ppm).

LC/MS (Ion Pairing): ESI (−ve) m/z=1424.09 ((M−2H)²⁻); 948.86((M−3H)³⁻); 711.49 ((M−4H)⁴⁻); 569.04 ((M−5H)⁵⁻); 473.98 ((M−6H)⁶⁻).Data deconvoluted using maximum entropy calculation to give MW=2850.00(M−, in H form) Calculated (H form) (C₁₂₇H₁₆₉N₁₅O₄₃S₈) 2850.30 (M−). Rf(min)=9.46 CE (pH 9): 76.0% purity Rf (min)=7.63

Example 30 BHALys[Lys]₄[α-COC₅H₁₂]₄[ε-COCH₂O-3,6-Naph(SO₃Na)₂]₄ SPL8018

Surface Topology Surface Stoichiometry (((Hex B)(Hex B))⁴((Hex B)(Hex 4COC₅H₁₂ = Hex B))⁴)⁸ 4 COCH₂O-3,6-Naph[SO3Na] = B

i. BHALys[Lys]₄[α-COC₅H₁₂]₄[ε-Boc]₄

Prepared from BHALys[Lys]₄[α-NH₂.TFA]₄[ε-Boc]₄ (81 mg, 0.055 mmol) insimilar manner to Example 29.i. The precipitate was dried in vacuo togive BHALys[Lys]₄[α-COC₅H₁₂]₄[ε-Boc]₄ as a white solid (0.07 g, 69%).

LC/MS (phobic) ESI (+ve) m/z=1873.32 (M+); 937.61 ((M+2H)²⁺). Calculated(C₉₉H₁₆₉N₁₅O₁₉) 1873.49 (M+). Rf (min)=7.95

ii. BHALys[Lys]₄[α-COC₅H₁₂]₄[ε-NH₂.TFA]₄

BHALys[Lys]₄[α-COC₅H₁₂]₄[ε-Boc]₄ (35 mg, 0.019 mmol) deprotected as for29.ii to give BHALys[Lys]₄[α-Hexyl]₄[ε-NH₂.TFA]₄ as a white solid (38mg, 105%).

LC/MS (philic) ESI (+ve) m/z=1473.12 (M+); 737.21 ((M+2H)²⁺); 491.87((M+3H)³⁺). Calculated (C₇₉H₁₃₇N₁₅O₁₁) 1473.03 (NH₂ form). Rf (min)=8.23

iii. BHALys[Lys]₄[α-COC₅H₁₂]₄[ε-COCH₂O-3,6-Naph(SO₃Na)₂]₄

Prepared from BHALys[Lys]₄[α-COC₅H₁₂]₄[ε-NH₂.TFA]₄ (36 mg, 0.019 mmol)and HOCOCH₂O-3,6-Naph(SO₃Na)₂ (0.07 g, 0.16 mmol) in similar manner toExample 29.iii to giveBHALys[Lys]₄[α-COC₅H₁₂]₄[ε-COCH₂O-3,6-Naph(SO₃Na)₂]₄ as a white solid(0.04 g, 78%).

LC/MS (Ion Pairing): ESI (−ve) m/z=1423.62 ((M−2H)²⁻); 949.13((M−3H)³⁻); 711.49 ((M−4H)⁴⁻); 568.98 ((M−5H)⁵⁻); 473.98 ((M−6H)⁶⁻).Data deconvoluted using maximum entropy calculation to give MW=2850.00(M−, in H form) Calculated (H form) (C₁₂₇H₁₆₉N₁₅O₄₃S₈) 2850.30 (M−). Rf(min)=9.26

CE (pH 9): 85.9% purity Rf (min)=7.61

Example 31 BHALys[Lys]₄[α-CO-4-PhSO₃Na]₄[ε-COC₅H₁₂]₄

Surface Topology Surface Stoichiometry (((Hex B)(Hex B))⁴((Hex B)(HexB))⁴)⁸ 4 COC₅H₁₂ = Hex 4 CO-4-PhSO₃Na = B

Prepared from BHALys[Lys]₄[α-NH₂.TFA]₄[ε-COC₅H₁₂]₄ (26 mg, 0.013 mmol)and 4-sulfobenzoic acid (0.03 g, 0.15 mmol) in a similar way to Example29.iii to give BHALys [Lys]₄[α-CO-4-PhSO₃Na]₄[ε-COC₅H₁₂]₄ as a whitesolid (25 m g, 80%).

LC/MS (ion Pairing): ESI (−ve) m/z=1103.74 ((M−2H)²⁻); 735.25((M−3H)³⁻); 551.36 ((M−4H)⁴⁻). Data deconvoluted using maximum entropycalculation to give MW=2209.54 (M−, in H form) Calculated (H form)(C₁₀₇H₁₅₃N₁₅O₂₇S₄) 2209.70 (M−). Rf (min)=10.30

CE (pH 9): 85.7% purity Rf (min)=5.24

Example 32 DAH [Lys]₈[α-CO-3,5-Ph(SO₃Na)₂]₈[ε-COC₅H₁₂]₈ SPL7919 i. DAH[Lys]₂[Boc]₄

A suspension of PNPO-Lys(Boc)₂ (44.3 g, 94.9 mmol) in DMF (124 mL) and asolution of 1,6-diaminohexane (4.95 g, 42.6 mmol) and TEA (13.2 mL, 94.7mmol) in DMF (160 mL) were reacted and a product isolated as for Example1.i to give DAH [Lys]₂[Boc]₄ as a colourless solid (19.3 g, 59% yield,95.6% purity by LCMS, [Rt=5.85 mins]). Second and third crops of productwere obtained (3.68 g and 4.47 g respectively) from concentration of thewashing solvents. Total mass of product obtained=27.5 g (84% yield).ESMS m/z 796 (20, M+Na); 674 (100, [M−Boc]+1); 574 (12, [M−Boc]+1.

ii. DAH [Lys]₂[NH₂.TFA]₄

DAH [Lys]₂[Boc]₄ (20.0 g, 25.9 mmol) was deprotected using DCM (110 mL)was added TFA (280 mL, 3.63 mol) according to the method of Example19.ii. The resulting solid was dissolved in the minimum amount of waterthen lyophilized to give DAH [Lys]₂ [NH₂.TFA]₄ as a flocculant,colourless solid. The bulk of this material was used in the nextreaction without further purification.

iii. DAH [Lys]₄[Boc]₈

A suspension of PNPO-Lys(Boc)₂ (55.2 g, 118 mmol) in DMF (190 mL) wasreacted with a solution of DAH [Lys]₂[NH₂.TFA]₄ (24.6 mmol), TEA (TEA)(35.0 mL, 251 mmol) and DMF (180 mL) was reacted and a product isolatedaccording to the method of Example 1.i. The product, DAH [Lys]₄[Boc]₈was obtained as a colourless solid (34.9 g, 84% yield, >99.5% purity byLCMS, [R_(t)=13.6 mins]). ESMS m/z 1587 (8, [M−Boc]+1); 744 (100,½[M−2Boc]+1); 644 (60, ½[M−4Boc]+1); 544 (10, ½[M−6Boc]+1).

iv. DAH [Lys]₄[NH₂.TFA]₈

DAH [Lys]₄[Boc]₈ (1.0 g, 0.60 mmol) was deprotected using DCM (12.8 mL)and TFA (12.8 mL, 166 mmol) according to the method of Example 19.ii.The resulting solid was dissolved in the minimum amount of water thenlyophilized to give DAH [Lys]₄ [NH₂.TFA]₈ as a flocculant, colourlesssolid.

v. DAH [Lys]₈[α-Boc]₈[εCBz]₈

A solution of DAH [Lys]₄[NH₂.TFA]₈ (0.59 mmol), TEA (TEA) (1.65 mL,11.84 mmol) and DMF (12 mL) and solid PNPO-Lys-α-Boc-ε-CBz (2.84 g, 5.66mmol) were reacted, and a product isolated, according to the method ofExample 1.i. The product, DAH [Lys]₈[α-Boc]₈[ε-CBz]₈, was obtained as acolourless solid (1.94 g, 87%).

vi. DAH [Lys]₈[α-Boc]₈[ε-NH₂]₈

DAH [Lys]₈[α-Boc]₈[ε-CBz]₈ (994 mg, 0.26 mmol) was added, as a solid andin one portion, to a chilled (−78° C.) and magnetically stirred solutionof liquid ammonia (ca. 90 mL) and sodium metal (ca. 200 mg) maintainedunder an atmosphere of argon. The cold bath was removed and the bluecoloured reaction mixture was left to reflux at ambient temperatures for40 mins. After this time, the reaction flask was re-chilled to −78° C.and dry methanol (3 mL) was slowly added to the reaction mixture. Thenow white coloured mixture was opened to the atmosphere and left to warmto Rt overnight. The resulting grey coloured solid residue was treatedwith methanol (ca. 200 mL). The suspension was filtered and the filtratewas concentrated under reduced pressure to afford DAH[Lys]₈[α-Boc]₈[ε-NH₂]₈ (0.53 g, 73%) as a colourless foam.

LC/MS (Hydrophilic/TFA) ESI (+ve) m/z=1356 [M+2H]/2+, 905 [M+3H]/3+;calculated C130H248N30O30 2711.58 g/mol. Data deconvoluted usingtransform calculation to give mw=2711.17. Rf (min)=13.1

vii. DAH [Lys]₈[α-Boc]₈[ε-COC₅H₁₂]₈

PyBOP (0.53 g, 1.01 mmol) was added to a stirred solution of DAH[Lys]₈[α-Boc]₈ [ε-NH₂]₈ (152 mg, 0.056 mmol) in DMF/DMSO (1:1) (10 mL).A solution of hexanoic acid (0.10 g, 0.89 mmol) anddiisopropylethylamine (0.7 mL, 4.02 mmol) in DMF/DMSO (1:1) (5 mL) wasadded gradually. The mixture was stirred at Rt for 16 h. Reactionmixture was poured into ACN (0.4 L) and filtered. The precipitate wasdried in vacuo to give DAH [Lys]₈[α-Boc]₈[ε-COC₅H₁₂]₈ as an off-whitesolid (0.16 g, 66%).

LC/MS (phobic) ESI (+ve) m/z=1166.47 ((M+3H)³⁺); 874.96 ((M+4H)⁴⁺). Datadeconvoluted using maximum entropy calculation to give MW=3496.50 (M+)Calculated (C₁₇₈H₃₂₈N₃₀O₃₈) 3496.74 (M+). Rf (min)=18.59.

viii. DAH [Lys]₈[α-NH₂.TFA]₈[ε-COC5H12]₈

DAH [Lys]₈[α-Boc]₈[ε-COC₅H₁₂]₈ (126 mg, 0.036 mmol) dipersed in DCM (3mL) was deprotected with a solution of TFA/DCM (1:1) (3 mL) as forExample 29.ii to give DAH [Lys]₈[α-NH₂.TFA]₈[ε-COC₅H₁₂]₈ as a stickywhite solid (0.15 g, 117%).

LC/MS (philic) ESI (+ve) m/z=899.38 ((M+3H)³⁺); 674.76 ((M+4H)⁴⁺). Datadeconvoluted using maximum entropy calculation to give MW=2695.50 (M+,in the NH₂ form) Calculated (C₁₃₈H₂₆₄N₃₀O₂₂) 2695.80 (NH₂ form). Rf(min)=15.87

ix. DAH [Lys]₈[α-CO-3,5-Ph(SO₃Na)₂]₈[ε-COC5H12]8

AH [Lys]₈[α-NH₂.TFA]₈[ε-COC₅H₁]₈ (76 mg, 0.021 mmol) in DMF/DMSO (1:1)(4 mL) and PyBOP (0.25 g, 0.48 mmol) were reacted with solution of3,5-disulfobenzoic acid (0.16 g, 0.56 mmol) and diisopropylethylamine(0.3 mL, 1.72 mmol) in DMF/DMSO (1:1) (5 mL) according to the method ofExample 29.iii to give DAH [Lys]₈[α-CO-3,5-Ph(SO₃Na)₂]₈[ε-COC₅H₁₂]₈ as awhite solid (0.11 g, 75%).

LC/MS (ion Pairing): ESI (−ve) m/z=686.05 ((M−7H)⁷⁻); 600.21 ((M−8H)⁸⁻);533.51 ((M−9H)⁹⁻); 480.14 ((M−10H)¹⁰⁻); 436.43 ((M−11H)¹¹⁻). Datadeconvoluted using maximum entropy calculation to give MW=4809.50 (M−,in H form) Calculated (H form) (C₁₉₄H₂₉₆N₃₀O₇₈S₁₆) 4809.70 (M−). Rf(min)=9.30

CE (pH 9): 76.4% purity Rf (min)=19.56

Example 33 DAH [Lys]₈[α-COCH₂O-3,6-Naph(SO₃Na)₂]₈[ε-COC₅H₁₂]₈

Example 33 is depicted in FIG. 10.

Surface Topology Surface Stoichiometry ((((Hex B)(Hex B))⁴((Hex B)(Hex 8COC₅H₁₂ = Hex B))⁴)⁸(((Hex B)(Hex B))⁴((Hex B))⁴)⁸)¹⁶ 8COCH₂O-3,6-Naph[SO3Na]₂ = B

DAH [Lys]₈[α-NH₂.TFA]₈[ε-COC₅H₁₂]₈ (76 mg, 0.021 mmol) in DMF/DMSO (1:1)(4 mL) and PyBOP (0.30 g, 0.57 mmol) were reacted with a solution ofHOCOCH₂O-3,6-Naph(SO₃Na)₂ (0.21 g, 0.51 mmol) and diisopropylethylamine(0.3 mL, 1.72 mmol) in DMF/DMSO (1:1) (5 mL) according to the method ofExample 29.iii to give DAH [Lys]₈[α-COCH₂O-3,6-Naph(SO₃Na)₂]₈[ε-COC₅H₁₂]₈ as a white solid (0.16 g,130%).

LC/MS (ion Pairing): ESI (−ve) m/z=907.50 ((M−6H)⁶⁻); 777.73 ((M−7H)⁷⁻);680.68 ((M−8H)⁸⁻); 604.44 ((M−9H)⁹⁻); 543.88 ((M−10H)¹⁰⁻); 494.54((M−11H)¹¹⁻); 453.32 ((M−12H)¹²⁻). Data deconvoluted using transformcalculation to give MW=5450.95 (M−, in H form) Calculated (H form)(C₂₃₄H₃₂₈N₃₀O₈₆S₁₆) 5450.38 (M−). Rf (min)=9.27

CE (pH 9): 79.2% purity Rf (min)=17.03

Example 34 BHALys[Lys]₈[α-CO₂PEG₃]₈[ε-CO-3,5-Ph(SO₃Na)₂]₈

Surface Topology Surface Stoichiometry ((((PEG B)(PEG B))⁴((PEG B)(PEG 8CO₂PEG₃ = PEG B))⁴)⁸(((PEG B)(PEG B))⁴((PEG B)(PEG B))⁴)⁸)¹⁶ 8CO-3,5-Ph[SO₃Na]₂ = B

i. PNPO—CO₂PEG₃

To an ice-cooled stirred mixture of triethyleneglycol monomethyl ether(2.5 g, 15.2 mmol), N-methylmorpholine (2.08 g, 20.6 mmol) and DMAP (93mg, 0.76 mmol) in DCM was added 4-nitrophenylchloroformate (3.38 g,16.75 mmol) in one portion. The mixture was left to warm to Rtovernight, then concentrated. The residue was taken up in EtOAc (120 mL)and washed with dil. HCl (2×100 mL, 1.0 M), saturated NaHCO₃ (100 mL),K₂CO₃ (5%, 4×100 mL) and brine. The organic phase was then dried(MgSO₄), filtered, and concentrated, providing 3.90 g (78%) ofPNPO—CO₂PEG₃ as a pale yellow oil. LCMS (LC: phobic, TFA, RT=3.8 min.;MS (M_(calc). C₁₄H₁₉NO₈=329.31): 352 ([M+Na]⁺, 70%), 330 ([M+H]⁺, 48%).¹H (CDCl₃): δ 8.27 (d, J=9.3 Hz, 2H), 7.38 (d, J=9.3 Hz, 2H), 4.42-4.45(m, 2H), 3.79-3.82 (m, 2H), 3.64-3.74 (m, 6H), 3.55-3.58 (m, 2H), 3.37(s, 3H).

i. HO-Lys-α-CO₂PEG₃-ε-Boc

Surface Topology Surface Stoichiometry HO—CO (CO₂PEG₃ Boc) 1 CO₂H 1CO₂PEG₃ 1 Boc

To a stirred mixture of PNPO—CO₂PEG₃ (3.90 g, 11.84 mmol) in DMF (60 mL)was added HO-Lys-α-NH₂-ε-Boc (2.78 g, 11.28 mmol). The suspension wasstirred at 60° C. overnight, then cooled and poured into NaHCO₃ solution(5%, 150 mL). The aqueous solution was then washed with EtOAc (2×150mL), then acidified (HCl, 1.0 M, 180 mL). The aqueous phase was thenwashed with EtOAc (3×200 mL) again, and the last 3 extracts combined,dried (MgSO₄), filtered and concentrated. The residue was then purifiedby silica gel chromatography (10% MeOH/90% DCM), providingHO-Lys-α-CO₂PEG₃-ε-Boc as a viscous oil (2.50 g, 51%).

LCMS (LC: philic, TFA, RT=11.0 min; MS (M_(calc) C₁₉H₃₆N₂O₉=436.51): 459([M+Na]⁺, 20%), 337 ([M−BOC+H]⁺, 100%).

¹H (CDCl₃): δ 5.64 (br d, 1H), 4.03-4.41 (m, 3H), 3.52-3.71 (m, 9H),3.37 (s, 3H), 3.01-3.20 (m, 4H), 1.81-1.95 (m, 2H), 1.64-1.80 (m, 2H),1.42 (s, 9H).

ii. BHALys[Lys]₈[α-CO₂PEG₃]₈[ε-Boc]₈

A solution of BHALys[Lys]₄[NH₂.TFA]₈ and (0.095 g, 0.048 mmol) and PyBOP(0.30 g, 0.57 mmol) in DMF/DMSO (1:1) (10 mL) was reacted with asolution of HO-Lys-α-CO₂PEG₃-ε-Boc (0.20 g, 0.45 mmol) anddiisopropylethylamine (0.4 mL, 2.30 mmol) in DMF/DMSO (1:1) (5 mL). Themixture was stirred at Rt for 16 h. Solvent was removed in vacuo and theresidue triturated with ACN. The precipitate,BHALys[Lys]₈[α-CO₂PEG₃]₈[ε-Boc]₈ was collected by filtration. (0.15 g,68%).

LC/MS (Hydrophobic): ESI (+ve) m/z=1377.1 ((M−3Boc)+H³⁺); 1008.2((M−4Boc)+H⁴⁻). Calculated MW=4431 (M+) Calculated (C₂₀₇H₃₆₉N₆₃O₇₁) 4428(M+). Rf (min)=14.30

iii. BHALys[Lys]₈[α-CO₂PEG₃]₈[ε-NH₂.TFA]₈

BHALys[Lys]₈[α-CO₂PEG₃]₈[ε-Boc]₈ (0.15 g, 0.034 mmol) suspended in DCM(4 mL). A solution of TFA/DCM (1:1) (4 mL) was added and the mixturestirred at Rt for 16 h. The solvent was removed in vacuo and the residuetriturated with Ether. Solvent was removed from the crude product,BHALys[Lys]₈[α-CO₂PEG₃]₈[ε-NH₂.TFA]₈ by decanting and the triturationrepeated thrice.

LC/MS (Hydrophilic): ESI (+ve) m/z=1210.10 ((M³⁺+1H); 907.82 ((M⁴⁺+1H);726.32 ((M⁵⁺+1H). Data deconvoluted using maximum entropy calculation togive MW=3627 (M+, free base form) Calculated (free base form)(C₁₆₇H₃₀₅N₃₁O₅₅) 3627 (M+). Rf (min)=11.84

iv. BHALys[Lys]₈[α-CO₂PEG₃]₈[ε-CO-3,5-Ph(SO₃Na)₂]₈

A solution of BHALys[Lys]₈[α-CO₂PEG₃]₈[ε-NH₂.TFA]₈ (0.086 g, 0.019 mmol)and PyBOP (0.19 g, 0.37 mmol) in DMF/DMSO (1:1) (4 mL) was reacted witha solution of 3,5-disulfobenzoic acid (0.10 g, 0.34 mmol) anddiisopropylethylamine (0.3 mL, 1.72 mmol) in DMF/DMSO (1:1) (3 mL)according to the method of Example 29.iii to giveBHALys[Lys]₈[α-CO₂PEG₃]₈[ε-CO-3,5-Ph(SO₃Na)₂]₈ as white solid (0.15 g,130%).

1H nmr (300 MHz, D₂O) λ (ppm): 1.0-1.8 (90H); 2.9-3.2, 3.2-3.4, 3.4-3.7,and 3.9-4.3 (165H); 6.0 (1H); 7.1-7.3 (10H); 8.2-8.4 (24H).

LC/MS (Ion Pairing): ESI (−ve) m/z=1912.76 ((M−3H)³⁻); 1434.27((M−4H)⁴⁻); 1147.39 ((M−5H)⁵⁻); 955.63 ((M−6H)⁶⁻). Data deconvolutedusing maximum entropy calculation to give MW=5742 (M−, in the H form)Calculated (H form) (C₂₂₃H₃₃₇N₃₁O₁₁₁S₁₆) 5741 (M−). Rf (min)=6.54

CE (pH 9 method): 87.5% purity Rf (min)=11.09

Example 35 BHALys[Lys]₈[α-CO₂PEG₃]₈[ε-CO-4-PhSO₃Na]₈

Surface Topology Surface Stoichiometry ((((PEG B)(PEG B))⁴((PEG 8CO₂PEG₃ = PEG B)(PEG B))⁴)⁸(((PEG B)(PEG CO-4-Ph[SO₃Na]))⁴((PEG B)(PEGB))⁴)⁸)¹⁶ 8 CO-4-Ph[SO₃Na] = B

A solution of BHALys[Lys]₈[α-CO₂PEG₃]₈[ε-NH₂.TFA]₈ (0.086 g, 0.019 mmol)and PyBOP (0.17 g, 0.33 mmol) in DMF/DMSO (1:1) (4 mL) was reacted witha solution of 4-sulfobenzoic acid (0.07 g, 0.35 mmol) anddiisopropylethylamine (0.3 mL, 1.75 mmol) in DMF/DMSO (1:1) as for themethod of Example 29.iii to giveBHALys[Lys]₈[α-CO₂PEG₃]₈[ε-CO-4-PhSO₃Na]₈ as white solid (0.12 g, 120%).

1H nmr (300 MHz, D₂O) λ (ppm): 1.0-1.8 (90H); 2.9-3.1, 3.2-3.3, 3.4-3.6,and 3.9-4.3 (165H); 6.0 (1H); 7.1-7.3 (10H); 7.7-7.9 (32H).

LC/MS (Ion Pairing): ESI (−ve) m/z=1274.17 ((M−4H)⁴⁻); 1019.09((M−5H)⁵⁻); 849.10 ((M−6H)⁶⁻); 727.71 ((M−7H)⁷⁻); 636.78 ((M−8H)⁸⁻).Data deconvoluted using maximum entropy calculation to give MW=5100 (M−,in the H form) Calculated (H form) (C₂₂₃H₃₃₇N₃₁O₈₇S₈) 5101 (M−). Rf(min)=7.25

CE (pH 9): 93.11% Rf (min)=7.31.

Example 36 BHALys[Lys]₈[α-COCH₂O-3,6-Naph(SO₃Na)₂]₈[ε-CBz]₈ SPL7966

Surface Topology Surface Stoichiometry ((((A CBz)(A CBz))⁴((A CBz)(A 8COCH₂O-3,6-Naph[SO3Na]₂ = CBz))⁴)⁸(((A CBz) A (A CBz))⁴((A CBz)(ACBz))⁴)⁸)¹⁶ 8 CBz

A solution of BHALys[Lys]₈[α-NH₂.TFA]₈[ε-CBz]₈ (35 mg, 0.009 mmol) andPyBOP (79 mg, 0.15 mmol) in DMF/DMSO (1:1) (2 mL) was reacted with asolution of HOCOCH₂O-3,6-Naph(SO₃Na)₂ (59 mg, 0.15 mmol) anddiisopropylethylamine (0.1 mL, 0.57 mmol) in DMF/DMSO (1:1) (2 mL)according to the method of Example 29.iii to give BHALys[Lys]₈[α-COCH₂O-3,6-Naph(SO₃Na)₂]₈[ε-CBz]₈ as a white solid (18 mg,33%).

1H nmr (300 MHz, D₂O) λ (ppm): 0.9-1.8 (90H); 2.7-3.1 (30H); 4.0-4.4(15H); 5.9 (1H); 6.8-7.2 and 7.7-8.3 (90H). Note the CH₂O protons areobscured by the water peak (4.5-4.9 ppm).

LC/MS (ion Pairing): ESI (−ve) m/z=1185.65 ((M−5H)⁵⁻); 987.78((M−6H)⁶⁻); 846.66 ((M−7H)⁷⁻); 740.78 ((M−8H)⁸⁻); 658.32 ((M−9H)⁹⁻).Data deconvoluted using transformation calculation to give MW=5934.40(M−, in the H form) Calculated (H form) (C₂₆₃H₃₀₅N₃₁O₉₅S₁₆) 5933.43(M−). Rf (min)=8.43

CE (pH 9): 72.8% purity Rf (min)=13.67

Example 37 BHALys[Lys]₈[α-CO-3,5-Ph(SO₃Na)₂]₈[ε-CBz]₈ SPL7862

Surface Topology Surface Stoichiometry ((((A CBz)(A CBz))⁴((A CBz)(A 8CO-3,5-Ph[SO3Na]₂ = A CBz))⁴)⁸(((A CBz)(A CBz))⁴((A CBz)(A CBz))⁴)⁸)¹⁶ 8CBz

A solution of (BHALys[Lys]₈[α-NH₂.TFA]₈[ε-CBz]₈) (0.102 g, 0.025 mmol)and PyBOP (0.29 g, 0.55 mmol) in DMF/DMSO (1:1) (7 mL) was reacted witha solution of 3,5-disulfobenzoic acid (0.16 g, 0.55 mmol) anddiisopropylethylamine (0.4 mL, 2.30 mmol) in DMF/DMSO (1:1) (3 mL)according to the method of Example 29.iii to give BHALys[Lys]₈[α-CO-3,5-Ph(SO₃Na)₂]₈[ε-CBz]₈ as white solid (0.17 g, 124%). 1Hmmr (300 MHz, D₂O) λ (ppm): 1.0-1.8 (90H); 2.8-3.3 (30H); 4.0-4.4 (15H);6.0 (1H); 7.0-7.3 and 8.1-8.4 (74H). Note the CH₂O protons are obscuredby the water peak (4.6-5.0 ppm).

LC/MS (Ion Pairing): ESI (−ve) m/z=1762.92 ((M−3H)³⁻); 1321.95((M−4H)⁴⁻); 1057.38 ((M−5H)⁵⁻); Data deconvoluted using maximum entropycalculation to give MW=5295 (M−, in the H form) Calculated (H form)(C₂₇₃H₂₇₃N₃₁O₈₇S₁₆) 5293 (M−). Rf (min)=8.04

CE (pH 9 method): 83.7% purity Rf (min)=19.62

Example 38 BHALys[Lys]₈[α-CO-4-Ph(SO₃Na)]₈[ε-CBz]₈

Surface Topology Surface Stoichiometry ((((A CBz)(A CBz))⁴((A CBz)(A 8CO-4-Ph[SO3Na] = A CBz))⁴)⁸(((A CBz)(A CBz))⁴((A CBz)(A CBz))⁴)⁸)¹⁶ 8CBz

A solution of BHALys[Lys]₈[α-NH₂.TFA]₈[ε-CBz]₈ (0.104 g, 0.025 mmol) andPyBOP (0.30 g, 0.57 mmol) in DMF/DMSO (1:1) (7 mL) was reacted with asolution of 4-sulfobenzoic acid (0.12 g, 0.60 mmol) anddiisopropylethylamine (0.4 mL, 2.30 mmol) in DMF/DMSO (1:1) (3 mL)according to the method of Example 29.iii to give BHALys[Lys]₈[α-CO-4-Ph(SO₃Na)]₈[ε-CBz]₈ as white solid (0.17 g, 108%). 1H nmrindicated 4-sulfobenzoic acid was present. Product was recrystallisedfrom methanol/water (1:1) to give a white solid (15 mg, 9%).

1H nmr (300 MHz, D₂O) λ (ppm): 1.0-1.8 (90H); 2.8-3.2 (30H); 4.0-4.4(15H); 5.9 (1H); 7.0-7.3 and 7.6-7.8 (82H). Note the CH₂O protons areobscured by the water peak (4.5-5.0 ppm).

LC/MS (Ion Pairing): ESI (−ve) m/z=929.31 ((M−5H)⁵⁻); 774.48 ((M−6H)⁶⁻);663.69 ((M−7H)⁷⁻); 580.67 ((M−8H)⁸⁻). Data deconvoluted using maximumentropy calculation to give MW=4654 (M−, in the H form) Calculated (Hform) (C₂₂₃H₂₇₃N₃₁O₆₃S₈) 4652 (M−). Rf (min)=9.65

CE (pH 9 method): 86.7% purity Rf (min)=14.3

Example 39 BHALys[Lys]₁₆ [α-COCH₂O-3,6-Naph(SO₃Na)₂]₁₆ [ε-CBz]₁₆

Surface Topology Surface Stoichiometry ((((A CBz)(A CBz))⁴((A CBz)(ACBz))⁴)⁸ 16 COCH₂O-3,6- (((A CBz) (A CBz))⁴((A CBz)(A CBz))⁴)⁸)¹⁶Naph[SO3Na]₂ = A ((((A CBz)(A CBz))⁴((A CBz)(A CBz))⁴)⁸ 16 CBz (((A CBz)(A CBz))⁴((A CBz)(A CBz))⁴)⁸)¹⁶

A solution of BHALys[Lys]₁₆ [α-NH₂.TFA]₁₆ [ε-CBz]₁₆ (0.102 g, 0.013mmol) and PyBOP (0.29 g, 0.56 mmol) in DMF/DMSO (1:1) (10 mL) wasreacted with a solution of HOCOCH₂O-3,6-Naph(SO₃Na)₂ (0.21 g, 0.51 mmol)and diisopropylethylamine (0.5 mL, 2.87 mmol) in DMF/DMSO (1:1) (5 mL)according to the method of Example 29.iii to give BHALys[Lys]₁₆[α-COCH₂O-3,6-Naph(SO₃Na)₂]₁₆ [ε-CBz]₁₆ as white solid (0.21 g, 136%).

1H nmr (300 MHz, D₂O) λ (ppm): 1.0-1.8 (186H); 2.73.1 (62H); 4.0-4.5(31H); 6.0 (1H); 6.7-7.1 and 7.7-8.5 (170H). Note the CH₂O protons areobscured by the water peak (4.6-5.0 ppm).

LC/MS (Ion Pairing): ESI (−ve) m/z=1180.00 ((M−10H)¹⁰⁻); 1073.00((M−11H)¹¹⁻); 983.46 ((M−12H)¹²⁻); 907.69 ((M−13H)¹³⁻); 842.85((M−14H)¹⁴⁻); 786.53 ((M−15H)¹⁵⁻); 737.25 ((M−16H)¹⁶⁻); 693.72((M−17H)¹⁵⁷⁻); 655.26 ((M−18H)¹⁸⁻). Data deconvoluted using maximumentropy calculation to give MW=11813 (M−, in the H form) Calculated (Hform) (C₄₃₉H₅₄₅N₆₃O₁₇₅S₃₂) 11812 (M−). Rf (min)=7.34

CE (pH 9): 55:3% purity Rf (min)=20.23

Example 40 BHALys[Lys]₁₆ [α-CO-3,5-Ph(SO₃Na)₂]₁₆[ε-CBz]₁₆

Surface Topology Surface Stoichiometry ((((A CBz)(A CBz))⁴((A CBz)(ACBz))⁴)⁸(((A 16 CO-3,5- CBz)(A CBz))⁴((A CBz)(A CBz))⁴)⁸)¹⁶ Ph[SO3Na]₂ =A ((((A CBz)(A CBz))⁴((A CBz)(A CBz))⁴)⁸(((A 16 CBz CBz)(A CBz))⁴((ACBz)(A CBz))⁴)⁸)¹⁶

A solution of BHALys[Lys]₁₆ [α-NH₂.TFA]₁₆ [ε-CBz]₁₆ (0.108 g, 0.013mmol) and PyBOP (0.31 g, 0.59 mmol) in DMF/DMSO (1:1) (7 mL) was reactedwith a solution of 3,5-disulfobenzoic acid (0.17 g, 0.62 mmol) anddiisopropylethylamine (0.4 mL, 2.30 mmol) in DMF/DMSO (1:1) (3 mL)according to the method of Example 29.iii to give BHALys [Lys]₁₆[α-CO-3,5-Ph(SO₃Na)₂]₁₆[ε-CBz]₁₆ as white solid (0.20 g, 134%).

1H nmr (300 MHz, D₂O) λ (ppm): 1.0-1.8 (186H); 2.8-3.3 (62H); 4.0-4.4(31H); 6.0 (1H); 7.0-7.2 and 8.2-8.4 (138H). Note the CH₂O protons areobscured by the water peak (4.6-5.0 ppm).

LC/MS (Ion Pairing): ESI (−ve) m/z=876.84 ((M−12H)¹²⁻); 808.99((M−13H)¹³⁻); 751.20 ((M−14H)¹⁴⁻); 701.27 ((M−15H)¹⁵⁻); 657.37((M−16H)¹⁶⁻); 618.52 ((M−17H)¹⁷⁻); 584.21 ((M−18H)¹⁸⁻). Datadeconvoluted using maximum entropy calculation to give MW=10533 (M−, inthe H form) Calculated (H form) (C₄₃₉H₅₄₅N₆₃O₁₇₅S₃₂) 10531 (M−). Rf(min)-8.06

CE (pH 9 method): 69.5% purity Rf (min)=20.39.

Example 41 BHALys[Lys]₁₆ [α-CO-4-Ph(SO₃Na)]₁₆ [ε-CBz]₁₆

Surface Topology Surface Stoichiometry ((((A CBz)(A CBz))⁴((A CBz)(ACBz))⁴)⁸ 16 CO-4-Ph(SO3Na) = A (((A CBz)(CBz))⁴((A CBz)(A CBz))⁴)⁸)¹⁶((((A CBz)(A CBz))⁴((A CBz)(A CBz))⁴)⁸ 16 CBz (((A CBz)(A CBz))⁴((ACBz)(A CBz))⁴)⁸)¹⁶

A solution of (BHALys[Lys]₁₆ [α-NH₂.TFA]₁₆ [ε-CBz]₁₆) (0.117 g, 0.014mmol) and PyBOP (0.33 g, 0.63 mmol) in DMF/DMSO (1:1) (7 mL) was reactedwith a solution of 4-sulfobenzoic acid (0.14 g, 0.67 mmol) anddiisopropylethylamine (0.4 mL, 2.30 mmol) in DMF/DMSO (1:1) (3 mL)according to the method of Example 29.iii to give BHALys [Lys]₁₆[α-CO-4-Ph(SO₃Na)]₁₆ [ε-CBz]₁₆ as a white solid (0.17 g, 121%).

1H nmr (300 MHz, D₂O) λ (ppm): 1.0-1.9 (186H); 2.7-3.2 (62H); 4.0-4.4(31H); 6.0 (1H); 6.9-7.2 and 7.6-7.8 (154H). Note the CH₂O protons areobscured by the water peak (4.6-5.0 ppm).

LC/MS (Ion Pairing): ESI (−ve) m/z 924.00 ((M−10H)¹⁰⁻); 840.02((M−11H)¹¹⁻); 769.81 ((M−12H)¹²⁻); 710.61 ((M−13H)¹³⁻); 659.78((M−14H)¹⁴⁻); 615.74 ((M−15H)¹⁵⁻); 577.34 ((M−16H)¹⁶⁻). Datadeconvoluted using maximum entropy calculation to give MW=9252 (M−, inthe H form) Calculated (H form) (C₄₃₉H₅₄₅N₆₃O₁₂₇S₁₆) 9250 (M−). Rf(min)=9.08

CE (pH 9 method): 78.0% purity Rf (min)=18.07

Example 42BHALys[GlyLys]₂[Lys]₄[α,α-Boc]₂[ε,α-COCH₂O-3,6-Naph(SO₃Na)₂]₂[ε,ε-COCH₂O-3,6-Naph(SO₃Na)₂]₂

Surface Topology Surface Stoichiometry (((A A)(Boc Boc))⁴((A A)(BocBoc))⁴)⁸ 4 COCH₂O-3, 6-Naph(SO₃Na)₂ = A 4 Boc

A solution of BHALys[GlyLys₂(Boc)₂(NH₂)₂]₂ (34 mg, 0.021 mmol) and PyBOP(0.11 g, 0.21 mmol) in DMF/DMSO (1:1) (2 mL) was reacted with a solutionof HOCOCH₂O-3,6-Naph(SO₃Na)₂ (0.07 g, 0.13 mmol) and DIPEA (0.2 mL, 1.15mmol) in DMF/DMSO (1:1) (1 mL) was added gradually. The mixture wasstirred at room temperature for 16 h. Solvent was removed in vacuo andthe residue triturated with acetonitrile. The precipitate was collectedby filtration and purified on a desalting column (PD-10). Eluent wasfreeze dried to give BHALys[GlyLys₂(Boc)₂(COCH₂O-3,6-Naph(SO₃Na)₂)₂]₂ asa white solid (15 mg, 27%).

LC/MS (Ion Pairing): ESI (−ve) m/z=989.89 ((M−3H)³⁻); 741.94 ((M−4H)⁴⁻);593.56 ((M−5H)⁵⁻). Data deconvoluted using maximum entropy calculationto give MW=2972.50 (M−, in H form) Calculated (H form)(C₁₂₇H₁₆₇N₁₇O₄₉S₈) 2972.29 (M−). Rf (min)=9.57

Example 43BHALys[GlyLys]₂[Lys]₄[α,α-COCH₂O-3,6-Naph(SO₃Na)₂]₂[α,ε-COCH₂O-3,6-Naph(SO₃Na)₂]₂[ε,α-COC₅H₁₂]₂[ε,ε-COC₅H₁₂]₂

Surface Topology Surface Stoichiometry (((Hex Hex)(B B))⁴((Hex Hex)(BB))⁴)⁸ 4 COC₅H₁₂ = Hex 4 COCH₂O-3, 6-Naph(SO₃Na)₂ = B

i. BHALys[GlyLys]₂[Lys]₄[α,α-Boc]₂[α,ε-Boc]₂[ε,α-COC₅H₁₂]₂[ε,ε-COC₅H₁₂]₂

A solution ofBHALys[GlyLys]₂[Lys]₄[α,α-Boc]₂[α,ε-Boc]₂[ε,α-NH₂]₂[ε,ε-NH₂]₂ (42 mg,0.026 mmol) and PyBOP (0.13 g, 0.25 mmol) in DMF/DMSO (1:1) (2 mL) wasreacted with a solution of hexanoic acid (27 mg, 0.23 mmol) and DIPEA(0.2 mL, 1.15 mmol) in DMF/DMSO (1:1) (1 mL) according to the method ofExample 29.i to give BHALys[GlyLys]₂[Lys]₄[α,α-Boc]₂[α,ε-Boc]₂[ε,α-COC₅H₁₂]₂[ε,ε-COC₅H₁₂]₂ as agreyish solid which was used directly for the next step.

ii.BHALys[GlyLys]₂[Lys]₄[α,α-NH₂.TFA]₂[α,ε-NH₂.TFA]₂[ε,α-COC₅H₁₂]₂[ε,ε-COC₅H₁₂]₂

BHALys[GlyLys]₂[Lys]₄[α,α-Boc]₂[α,ε-Boc]₂[ε,α-COC₅H₁₂]₂[ε,ε-COC₅H₁₂]₂dispersed in DCM (1 mL) was deprotected with a solution of TFA/DCM (1:1)(2 mL) according to the method of Example 29.ii to giveBHALys[GlyLys]₂[Lys]₄[α,α-NH₂.TFA]₂[α,ε-NH₂.TFA]₂[ε,α-COC₅H₁₂]₂[ε,ε-COC₅H₁₂]₂as a white solid (28 mg, 47% for two steps). LC/MS (philic) ESI (+ve)m/z=1587.22 (M+); 794.51 ((M+2H)²⁺); 529.93 ((M+3H)³⁺). Calculated(C₈₃H₁₄₃N₁₇O₁₃) 1587.13 (NH₂ form). Rf (min)=8.94

iii.BHALys[GlyLys]₂[Lys]₄[α,α-COCH₂O-3,6-Naph(SO₃Na)₂]₂[α,ε-COCH₂O-3,6-Naph(SO₃Na)₂]₂[ε,α-COC₅H₁₂]₂[ε,ε-COC₅H₁₂]₂

A solution ofBHALys[GlyLys]₂[Lys]₄[α,α-NH₂.TFA]₂[α,ε-NH₂.TFA]₂[ε,α-COC₅H₁₂]₂[ε,ε-COC₅H₁₂]₂ (21 mg, 0.010 mmol) and PyBOP (0.07 g, 0.13 mmol) inDMF/DMSO (1:1) (1 mL) was reacted with a solution ofHOCOCH₂O-3,6-Naph(SO₃Na)₂ (0.03 g, 0.08 mmol) and DIPEA (0.5 mL, 2.87mmol) in DMF/DMSO (1:1) (1 mL) was added gradually. The mixture wasstirred at Rt for 16 h. Solvent was removed in vacuo and the residuedissolved in water and purified by size exclusion chromatography(Sephadex LH-20). Dendrimer containing fractions were, freeze dried togive BHALys [GlyLys₂ (COCH₂O-3,6-Naph(SO₃Na)₂)₂(hexyl)₂]₂ as a whitesolid (11 mg, 34%).

LC/MS (ion Pairing): ESI (−ve) m/z=1480.87 ((M−2H)²⁻); 986.96((M−3H)³⁻); 740.14 ((M−4H)⁴⁻); 592.10 ((M−5H)⁵⁻); 493.54 ((M−6H)⁶⁻);423.39 ((M−7H)⁷⁻). Data deconvoluted using maximum entropy calculationto give MW=2965.00 (M+1, in H form) Calculated (H form),(C₁₃₁H₁₇₅N₁₇O₄₅S₈) 2964.40 (M−). Rf (min)=9.26.

Example 44

Surface Topology Surface Stoichiometry 8 COCH₂O-3,6-Naph(SO₃Na)₂ = B

BHALys[Lys]₂[GlyLys]₄[Lys]₈[α,α-Boc]₄[α,ε-Boc]₄[ε,α-COCH₂O-3,6-Naph(SO₃Na)₂]₄[ε,ε-COCH₂O-3,6-Naph(SO₃Na)₂]₄

A solution of BHALys₂ [GlyLys₂(Boc)₂(NH₂)₂]₄ (33 mg, 0.011 mmol) andPyBOP (0.12 g, 0.24 mmol) in DMF/DMSO (1:1) (2 mL) was reacted with asolution of HOCOCH₂O-3,6-Naph(SO₃Na)₂ (0.07 g, 0.13 mmol) and DIPEA (0.2mL, 1.15 mmol) in DMF/DMSO (1:1) (1 mL). The mixture was stirred at roomtemperature for 16 h. Solvent was removed in vacuo and the residuetriturated with acetonitrile. The precipitate was collected byfiltration purified on a desalting column (PD-10). Eluent was freezedried to giveBHALys[Lys]₂[GlyLys]₄[Lys]₈[α,α-Boc]₄[α,ε-Boc]₄[ε,α-COCH₂O-3,6-Naph(SO₃Na)₂]₄[ε,ε-COCH₂O-3,6-Naph(SO₃Na)₂]₄ as a white solid (25 mg, 38%).

LC/MS (ion Pairing): ESI (−ve) m/z=1471.44 ((M−4H)⁴⁻); 1177.16((M−5H)⁵⁻); 980.55 ((M−6H)⁶⁻); 840.35 ((M−7H)⁷⁻); 735.26 ((M−8H)⁸⁻);653.40 ((M−9H)⁹⁻). Data deconvoluted using maximum entropy calculationto give MW=5890.00 (M−, in H form) Calculated (H form)(C₂₄₇H₃₃₃N₃₅O₉₉S₁₆) 5889.50 (M−). Rf (min)=9.55

Example 45BHALys[Lys]₂[GlyLys]₄[Lys]₈[α,α-COCH₂O-3,6-Naph(SO₃Na)₂]₄[α,εCOCH₂O-3,6-Naph(SO₃Na)₂]₄[ε,α-COC₅H₁₂]₄[ε,ε-COC₅H₁₂]₄

Surface Topology Surface Stoichiometry ((((Hex Hex)(B B))⁴((Hex Hex)(BB))⁴)⁸ 8 COC₅H₁₂ = Hex (((Hex Hex) (B B))⁴((Hex Hex)(B B))⁴)⁸)¹⁶ 8COCH₂O-3,6- Naph(SO₃Na)₂ = B

i.BHALys[Lys]₂[GlyLys]₄[Lys]₈[α,α-Boc]₄[α,ε-Boc]₄[ε,α-COC₅H₁₂]₄[ε,ε-COC₅H₁₂]₄

A solution ofBHALys[Lys]₂[GlyLys]₄[Lys]₈[α,α-Boc]₄[α,ε-Boc]₄[ε,α-NH₂]₄[ε,ε-NH₂]₄ (43mg, 0.014 mmol) and PyBOP (0.13 g, 0.25 mmol) in DMF/DMSO (1:1) (2 mL)was reacted with a solution of hexanoic acid (27 mg, 0.23 mmol) andDIPEA (0.2 mL, 1.15 mmol) in DMF/DMSO (1:1) (1 mL) according to themethod of Example 29.i to giveBHALys[Lys]₂[GlyLys]₄[Lys]₈[α,α-Boc]₄[α,ε-Boc]₄[ε,α-COC₅H₁₂]₄[ε,ε-COC₅H₁₂]₄as a greyish solid which was used directly for the next step.

ii.BHALys[Lys]₂[GlyLys]₄[Lys]₈[α,α-NH₂.TFA]₄[α,ε-NH₂.TFA]₄[ε,α-COC₅H₁₂]₄[ε,ε-COC₅H₁₂]₄

BHALys[Lys]₂[GlyLys]₄[Lys]₈[α,α-Boc]₄[α,ε-Boc]₄[ε,α-COC₅H₁₂]₄[ε,ε-COC₅H₁₂]₄dispersed in DCM (1 mL) was deprotected with a solution of TFA/DCM (1:1)(2 mL) according to the method of Example 29.ii to giveBHALys[Lys]₂[GlyLys]₄[Lys]₈[α,α-NH₂.TFA]₄[α,ε-NH₂.TFA]₄[ε,α-COC₅H₁₂]₄[ε,ε-COC₅H₁₂]₄as a white solid (44 mg, 80% for two steps).

LC/MS (philic) ESI (+ve) m/z=1560.69 ((M+2H)²⁺); 1040.77 ((M+3H)³⁺);780.72 ((M+4H)⁴⁺); 624.85 ((M+5H)⁵⁺). Calculated (C₁₅₉H₂₈₅N₃₅O₂₇)3119.18 (NH₂ form). Rf (min)=9.29

iii.BHALys[Lys]₂[GlyLys]₄[Lys]₈[α,α-COCH₂O-3,6-Naph(SO₃Na)₂]₄[α,ε-COCH₂O-3,6-Naph(SO₃Na)₂]₄[ε,α-COC₅H₁₂]₄[ε,ε-COC₅H₁₂]₄

PyBOP (0.06 g, 0.12 mmol) was added to a stirred solution of BHALys₂[GlyLys₂ (NH₂.TFA)₂(hexyl)₂]₄ (21 mg, 0.005 mmol) in DMF/DMSO (1:1) (1mL). A solution of HOCOCH₂O-3,6-Naph(SO₃Na)₂ (0.04 g, 0.09 mmol) andDIPEA (0.6 mL, 3.44 mmol) in DMF/DMSO (1:1) (1 mL) was added gradually.The mixture was stirred at Rt for 16 h. Solvent was removed in vacuo andthe residue dissolved in water and purified by size exclusionchromatography (Sephadex LH-20). Dendrimer containing fractions werefreeze dried to give BHALys₂ [GlyLys₂(COCH₂O-3,6-Naph(SO₃Na)₂)₂(hexyl)₂]₄ as a white solid (6 mg, 18%).

LC/MS (Ion Pairing): ESI (−ve) m/z=1467.17 ((M−4H)⁴⁻); 1173.62((M−5H)⁵⁻); 978.28 ((M−6H)⁶⁻); 838.08 ((M−7H)⁷⁻); 733.26 ((M−8H)⁸⁻);651.74 ((M−9H)⁹⁻); 586.64 ((M−10H)¹⁰⁻). Data deconvoluted using maximumentropy calculation to give MW=5875.00 (M+1, in H form) Calculated (Hform) (C₂₅₅H₃₄₉N₃₅O₉₁S₁₆) 5873.72 (M−). Rf (min)=10.12

Example 46 BHALys[Lys]₂[α,ε-Lys][CBz]₂[Lys]₃ [COCH₂O-3,6-Naph(SO₃Na)₂]₆

Surface Topology Surface Stoichiometry (((CBzCBz)(B B))⁴((B B)(B B))⁴)⁸2 CBz 6 COCH₂O-3,6-Naph(SO₃Na)₂ = B

i. BHALys[Lys]₂[α,ε-Lys][CBz]₂[Lys]₃ [NH₂.TFA]₆

A solution of TFA (0.5 mL) was added slowly toBHALys[Lys]₂[α,ε-Lys][CBz]₂[Lys]₃ [Boc]₆ (30 mg, 0.015 mmol) dipersed inacetic acid (0.5 mL). The mixture was stirred at room temperature for 16h. The solvent was removed in vacuo to give BHALys[Lys]₂[α,ε-Lys][CBz]₂[Lys]₃ [NH₂.TFA]₆ as a pale yellow oil (31 mg, 99%).

LC/MS (philic) ESI (+ve) m/z=1348.67 ((M+)); 675.09 ((M+2H)²⁺).Calculated (C₇₁H₁₀₉N₁₅O₁₁) 1348.72 (NH₂ form). Rf (min)=7.54

ii. BHALys[Lys]₂[α,ε-Lys][CBz]₂[Lys]₃ [COCH₂O-3,6-Naph(SO₃Na)₂]₆

PyBOP (0.15 g, 0.29 mmol) was added to a stirred solution ofBHALys[Lys]₂[α,ε-Lys][CBz]₂[Lys]₃ [NH₂.TFA]₆ (31 mg, 0.015 mmol) inDMF/DMSO (1:1) (2 mL). A solution of HOCOCH₂O-3,6-Naph(SO₃Na)₂ (0.11 g,0.28 mmol) and DIPEA (0.2 mL, 1.15 mmol) in DMF/DMSO (1:1) (2 mL) wasadded gradually. The mixture was stirred at room temperature for 16 h.Solvent was removed in vacuo and the residue dissolved in water andpurified by size exclusion chromatography (Sephadex LH-20). Dendrimercontaining fractions were freeze dried to giveBHALys[Lys]₂[α,ε-Lys][CBz]₂[Lys]₃ [COCH₂O-3,6-Naph(SO₃Na)₂]₆ as a whitesolid (4 mg, 7%).

LC/MS (ion Pairing): ESI (−ve) m/z=1706.45 ((M−2H)²⁻); 1137.01((M−3H)³⁻); 852.50 ((M−4H)⁴⁻); 681.88 ((M−5H)⁵⁻); 568.40 ((M−6H)⁶⁻).Data deconvoluted using maximum entropy calculation to give MW=3415.00(M−, in H form) Calculated (H form) (C₁₄₃H₁₅₇N₁₅O₅₉S₁₂) 3414.62 (M−). Rf(min)=10.55

Example 47

Surface Topology Surface Stoichiometry (((A A)(Boc Boc))⁴((Boc Boc) 2COCH₂O-3,6-Naph(SO₃Na)₂ = A (Boc Boc))⁴)⁸ 6 Boc

BHALys[Lys]₂[α,ε-Lys][COCH₂O-3,6-Naph(SO₃Na)₂]₂[Lys]₃ [Boc]₆

PyBOP (0.02 g, 0.03 mmol) was added to a stirred solution of BHALys₄[Boc]₆[NH₂]₂ (4 mg, 0.002 mmol) in DMF/DMSO (1:1) (1 mL). A solution ofHOCOCH₂O-3,6-Naph(SO—₃Na)₂ (0.01 g, 0.02 mmol) and diisopropylethylamine(50 μL, 0.29 mmol) in DMF/DMSO (1:1) (1 mL) was added gradually. Themixture was stirred at room temperature for 16 h. Solvent was removed invacuo and the residue triturated with acetonitrile. The crude productwas collected by filtration and triturated with water. The precipitatewas dried in vacuo to give BHALys₄ [Boc]₆[COCH₂O-3,6-Naph(SO₃Na)₂]₂ as agreyish solid (3 mg, 53%).

Example 48 BHALys[GlyLys]₂[Lys]₄[COCH₂O-3,6-Naph(SO₃Na)₂]₆ [ε,ε-CBz]₂

Surface Topology Surface Stoichiometry (((CBz CBz)(B B))⁴((B B)(B 2 CBzB))⁴)⁸ 6 COCH₂O-3,6-Naph(SO₃Na)₂ = B

i. BHALys[GlyLys]₂[Lys]₄[NH₂.TFA]₆[ε,ε-CBz]₂

A solution of TFA (0.5 mL) was added slowly toBHALys[GlyLys]₂[Lys]₄[Boc]₆[ε,ε-CBz]₂ (25 mg, 0.012 mmol) dipersed inacetic acid (0.5 mL). The mixture was stirred at room temperature for 16h. The solvent was removed in vacuo to giveBHALys[GlyLys]₂[Lys]₄[NH₂.TFA]₆[ε,ε-CBz]₂ as a pale yellow oil (24 mg,92%).

LC/MS (philic) ESI (+ve) m/z=1463.88 ((M+1)⁺); 732.29 ((M+2H)²⁺); 488.55((M+3H)³⁺). Calculated (C₇₅H₁₁₅N₁₇O₁₃) 1462.82 (NH₂ form). Rf (min)=7.25

ii. BHALys[GlyLys]₂[Lys]₄[COCH₂O-3,6-Naph(SO₃Na)₂]₆ [ε,ε-CBz]₂

PyBOP (0.11 g, 0.21 mmol) was added to a stirred solution of BHALys[GlyLys₂(NH₂.TFA)₃(CBz)]₂ (24 mg, 0.011 mmol) in DMF/DMSO (1:1) (2 mL).A solution of HOCOCH₂O-3,6-Naph(SO₃Na)₂ (0.08 g, 0.20 mmol) and DIPEA(0.5 mL, 2.87 mmol) in DMF/DMSO (1:1) (2 mL) was added gradually. Themixture was stirred at room temperature for 16 h. Solvent was removed invacuo and the residue triturated with acetonitrile. The precipitate wascollected by filtration purified on a desalting column (PD-10). Eluentwas freeze dried to give BHALys[GlyLys]₂[Lys]₄[COCH₂O-3,6-Naph(SO₃Na)₂]₆[ε,ε-CBz]₂ as a white solid (18 mg, 42%).

LC/MS (ion Pairing): ESI (−ve) m/z=1175.22 ((M−3H)³⁻); 881.14((M−4H)⁴⁻); 704.63 ((M−5H)⁵⁻); 587.24 ((M−6H)⁶⁻); 503.50 ((M−7H)⁷⁻).Data deconvoluted using maximum entropy calculation to give MW=3529.00(M−, in H form) Calculated (H form) (C₁₄₇H₁₆₃N₁₇O₆₁S₁₂) 3528.72 (M−). Rf(min)=10.34.

Example 49 BHALys[GlyLys]₂[Lys]₄[Boc]₆[ε,ε-COCH₂O-3,6-Naph (SO₃Na)₂]₂

Surface Topology Surface Stoichiometry (((A A)(Boc Boc))⁴((Boc Boc) 2COCH₂O-3,6-Naph(SO₃Na)₂ = A (Boc Boc))⁴)⁸ 6 Boc

PyBOP (0.08 g, 0.14 mmol) was added to a stirred solution of BHALys[GlyLys₂(Boc)₃(NH₂)]₂ (19 mg, 0.011 mmol) in DMF/DMSO (1:1) (2 mL). Asolution of HOCOCH₂O-3,6-Naph(SO₃Na)₂ (0.05 g, 0.12 mmol) and DIPEA (0.1mL, 0.57 mmol) in DMF/DMSO (1:1) (1 mL) was added gradually. The mixturewas stirred at room temperature for 16 h. Solvent was removed in vacuoand the residue triturated with acetonitrile. The precipitate wascollected by filtration purified on a desalting column (PD-10). Eluentwas freeze dried to give BHALys[GlyLys₂(Boc)₃(COCH₂O-3,6-Naph(SO₃Na)₂)]₂as a white solid (10 mg, 37%).

LC/MS (ion Pairing): ESI (−ve) m/z=1240.91 ((M−2H)²⁻); 826.99((M−3H)³⁻); 620.01 ((M−4H)⁴⁻). Data deconvoluted using transformcalculation to give MW=2484.00 (M−, in H form) Calculated (H form)(C₁₁₃H₁₆₇N₁₇O₃₇S₄) 2483.89 (M−). Rf (min)=10.55

Example 50 Antiviral Efficacy of Macromolecules with Controlled SurfaceTopology

MT-2 cells are infected with the T cell tropic NL4.3 strain of HIV-1 inthe presence of 6, 5-fold serial concentrations of compound intriplicate wells of a 96 well plate. In the same plate, cells areexposed to the same drug concentrations in the absence of virus todetermine the cytotoxic concentrations of the compound. The prototypemacromolecule, SPL7103, which inhibits HIV replication, is tested ineach assay as a positive control [see Dezzutti C S, James V N, Ramos A,Sullivan S T, Siddig A, Bush T J, Grohskopf L A, Paxton L, Subbarao S,Hart C E. In vitro comparison of topical microbicides for prevention ofhuman immunodeficiency virus type 1 transmission. Antimicrob AgentsChemother. 2004; 48: 3834-44].

After 6 days incubation at 37° C. in a CO₂ incubator, cell viability ofboth virus-infected and uninfected cells is determined by incubatingcells for 3-4 hours with3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium(MTS) according to manufacturer's instructions (CellTiter 96 AQueous OneSolution Cell Proliferation assay (Promega, Madison Wis.)). The 50%cytotoxic concentration (CC₅₀) and 50% inhibitory concentration (IC₅₀)is calculated for each drug from dose response curves using XLfit 4.1software (ID Business Solutions Ltd, Guildford, Surrey, UK). Data fromthis assay is tabulated in Table 5.

TABLE 24 Antiviral activities for macromolecules with controlled surfacestoichiometry EC₅₀* Ex. # Topology A + B A:B A B (ug/ml) Set^(#) 29ABABABAB 8 1:1 COCH₂O-3,6-Naph(SO₋₃Na)₂ COC₅H₁₂ 23.8 1 30 ABABABAB 8 1:1COC₅H₁₂ COCH₂O-3,6- 58.3 1 Naph(SO₃Na)₂ 31 ABABABAB 8 1:1 CO-4-PhSO₃NaCOC₅H₁₂ 344 32 ABABABAB × 2 16 1:1 CO-3,5-Ph(SO₃Na)₂ COC₅H₁₂ 5.8 33ABABABAB × 2 16 1:1 COCH₂O-3,6-Naph(SO₋₃Na)₂ COC₅H₁₂ 0.71 3 34 ABABABAB× 2 16 1:1 CO₂PEG₃ CO-3,5- 84.5 Ph(SO₃Na)₂ 35 ABABABAB × 2 16 1:1CO₂PEG₃ CO-4-PhSO₃Na >500 36 ABABABAB × 2 16 1:1COCH₂O-3,6-Naph(SO₋₃Na)₂ CBz 3.2 37 ABABABAB × 2 16 1:1CO-3,5-Ph(SO₃Na)₂ CBz 2 38 ABABABAB × 2 16 1:1 CO-4-PhSO₃Na CBz 2.2 39ABABABAB × 4 32 1:1 COCH₂O-3,6-Naph(SO₋₃Na)₂ CBz 2.4 40 ABABABAB × 4 321:1 CO-3,5-Ph(SO₃Na)₂ CBz 3.2 41 ABABABAB × 4 32 1:1 CO-4-PhSO₃Na CBz4.2 42 AABB AABB 8 1:1 COCH₂O-3,6-Naph(SO₋₃Na)₂ Boc 10.6 43 AABB AABB 81:1 COCH₂O-3,6-Naph(SO₋₃Na)₂ COC₅H₁₂ 0.24 1 44 AABB AABB × 2 16 1:1COCH₂O-3,6-Naph(SO₋₃Na)₂ Boc 0.33 45 AABB AABB × 2 16 1:1COCH₂O-3,6-Naph(SO₋₃Na)₂ COC₅H₁₂ 0.37 3 46 AABB BBBB 8 1:3 CBzCOCH₂O-3,6- 0.14 Naph(SO₃Na)₂ 47 AABB BBBB 8 1:3COCH₂O-3,6-Naph(SO₋₃Na)₂ Boc >50 2 48 AABB BBBB 8 1:3 CBz COCH₂O-3,6-0.13 Naph(SO₃Na)₂ 49 ABBB ABBB 8 1:3 COCH₂O-3,6-Naph(SO₋₃Na)₂ Boc 2.2 2SPL7013 32 — COCH₂O-3,6-Naph(SO₋₃Na)₂ — 1.5 *All compounds showed CC₅₀values >250 ug/ml ^(#)Sets of compounds in which the surfacestoichiometry of functional moieties is the same, but for which thetopology is different.

This data serves to demonstrate that macromolecules which have differenttopologies of the same surface functional moiety stoichiometry behavedifferently when interacting with a physico-chemical environment. It isimportant also to highlight the potent anti-HIV activity of Examples 46and 48, which can be seen to be considerably more active than SPL7013which is a macromolecule with only a single type of Functional moiety onthe surface.

ADME Examples Example 51 BHALys[Lys]₈[PEG₂₀₀]₁₆

To a stirred solution of BHA[Lys]₈TFA₁₆ (125 mg, 0.03 mmol) in DMF (8mL) was added PyBOP (556 mg, 1.0 mmol), followed by a solution of PEG200 (240 mg, 1.0 mmol), N,N-diisopropylethylamine (709 μL, 4.0 mmol) inDMF (16 mL) and DMSO (2 mL). The solution was stirred at Rt for 16 h.The reaction mixture was poured into water (180 mL) and filtered andwashed with water. The aqueous solution was transferred to a 3K stirredcell and water was passed through the cell, remaining water was removedby freeze drying to give a free flowing white solid (20 mg, 11%)

LC/MS (Philic TFA): Rf (min)=16.72. ESI (+ve) m/z=5598 (M+H⁺).

Example 52 BHALys[Lys]₁₆ [PEG₂₀₀]₃₂

To a stirred solution of BHA[Lys]₁₆TFA₃₂ (30 mg, 0.004 mmol) in DMF (3mL) under argon was added PyBOP (142 mg, 0.271 mmol), followed by asolution of PEG 200 (62 mg, 0.263 mmol), N,N-diisopropylethylamine (182μL, 1.04 mmol) in DMF (3 mL). The solution was stirred at Rt for 16 h.The solvents were removed under reduced pressure and the resulting crudemixture was dissolved in a minimum volume of water. Purification bysephadex column (LH-20) using water as the eluent gave the desiredproduct as a white solid (20 mg, 44%) after removing the water by freezedrying.

LC/MS (Philic TFA): Rf (min)=16.74 ESI (+ve) m/z=11,141 (M+H⁺).

Example 53 BHALys[Lys]₁₆ [PEG₅₇₀]₃₂

To a stirred solution of BHA[Lys]₁₆TFA₃₂ (20 mg, 0.003 mmol) in dry DMF(2 mL) under nitrogen was added TEA (36 μL, 0.261 mmol) and PEG 685.75,NHS ester (119 mg, 0.174 mmol). The reaction mixture was stirred at Rtfor 16 h. The solution was poured into a 5K stirred cell and water (600mL) was passed through the cell, remaining water was removed by freezedrying (×2) to give a glassy solid (50 mg, 88%). LC (Philic TFA): Rf(min) 12.42.

Example 54 BHALys[Lys]₈[PEG_(2KD)]₁₆

To a stirred solution of BHA[Lys]₈TFA₁₆ (30 mg, 0.008 mmol) in dry DMF(2 mL) under nitrogen was added PyBOP (141 mg, 0.271 mmol), followed bya solution of PEG 2000, NHS ester (612 mg, 0.306 mmol),N,N-diisopropylethylamine (180 μL, 1.04 mmol) in DMF (1.4 mL) and DMSO(0.6 mL). The solution was stirred at Rt for 16 h. The reaction mixturewas poured into a 10K stirred cell and water (800 mL) was passed throughthe cell, remaining water was removed by freeze drying to give a freeflowing white solid (149 mg, 54%).

Example 55 BHALys[Lys]₁₆ [PEG_(2KD)]₃₂ SPL 7709

To a stirred solution of BHA[Lys]₁₆TFA₃₂ (30 mg, 0.004 mmol) in dry DMF(2 mL) under argon was added PyBOP (142 mg, 0.272 mmol), followed by asolution of PEG 2000, NHS ester (522 mg, 0.261 mmol),N,N-diisopropylethylamine (182 μL, 1.04 mmol) in DMF (3 mL) and DMSO (1mL). The solution was stirred at Rt for 16 h. The reaction mixture waspoured into water and filtered and washed with water. Purification wasperformed by tangential flow filtration on a Mini-mate (10K membrane, 2L of water). Solvent was removed by freeze drying to give a free flowingwhite solid (210 mg, 76%)

LC/MS (Philic TFA): Rf (min)=16.29 ESI (+ve) m/z=67,696 (M+H⁺).

Example 56 BHALys[Lys]₂[Su(NPN)₂]₄[γ-CO-MTX-α-OtBu]₄[COPEG₁₂]₄

This example is depicted graphically in FIG. 11.

Surface Topology Surface Stoichiometry (((Drug PEG)(Drug PEG))⁴((Drug 16COPEG₁₂ = PEG PEG) (Drug PEG))⁴)⁸ 16 γ-CO-MTX-α-OtBu = Drug

i. EtO-Su(NPN)₂[Boc][NH₂]

To a stirred mixture of EtO-Su(NPN)₂[Boc][CBz] (0.88 g, 1.77 mmol) inDMF/H₂O (9:1, 20 mL) was added ammonium formate (224 mg, 3.55 mmol) andPd/C (10%, 470 mg). The mixture was stirred for 2 h at room temperature,then filtered (0.2 μm PALL filter disc) and concentrated. The residuewas taken up in water and concentrated (2×). This was then repeated withMeOH and DCM, providing 0.54 g (84%) of EtO-Su(NPN)₂[Boc][NH₂] as aclear colourless oil. LCMS (LC: philic, TFA, RT=6.2 min; MS (M_(calc)C₁₇H₃₃N₃O₅=359.47): 360 ([M+H]⁺, 100%). ¹H (CDCl₃): δ 5.30 (br s, 1H),4.80 (br s, 1H), 4.12 (q, J=9.0 Hz, 2H), 3.29-3.46 (m, 4H), 3.14 (m,1H), 3.07 (m, 1H), 2.56-2.80 (m, 6H), 1.60-1.90 (m, 4H), 1.42, 1.43 (2s,9H), 1.25 (t, J=9.0 Hz, 3H).

ii. EtO-Su(NPN)₂[Boc][COPEG₁₂]

To a stirred mixture of EtO-Su(NPN)₂[Boc][NH₂] (157 mg, 0.44 mmol) inDCM (2 mL) was added TEA (121 μl, 0.87 mmol) and NHS—COPEG₁₂ (300 mg,0.44 mmol) as a DCM (2 mL) solution. The mixture was stirred at roomtemperature overnight, concentrated, then purified by flash columnchromatography (2-10% MeOH/DCM, providing 331 mg (82%) ofEtO-Su(NPN)₂[Boc][COPEG₁₂] as a clear colourless oil. LCMS (LC: philic,TFA, RT=8.2 min; MS (M_(calc) C₄₃H₈₃N₃O₁₈=930.15): 948 ([M+NH₄]⁺, 12%),931 ([M+H]⁺, 2%), 416 (½[M−BOC+2H⁺], 100%) ¹H (CDCl₃): δ 7.10 (br s,1H), 7.03 (br s, 1H), 4.16 (q, J=9.0 Hz, 2H), 3.72 (m, 2H), 3.58-3.66(m, 36H), 3.52-3.56 (m, 2H), 3.47 (s, 2H), 2.96-3.42 (m, 7H), 3.37 (s,4H), 2.70 (s, 4H), 2.60 (m, 4H), 2.47 (m, 2H), 1.60-1.90 (m, 4H), 1.41,1.43 (2s, 9H), 1.24 (t, J=9.0 Hz, 3H).

iii. EtO-Su(NPN)₂[NH₂.TFA][COPEG₁₂]

To a stirred mixture of EtO-Su(NPN)₂[Boc][COPEG₁₂] (180 mg, 0.19 mmol)in DCM (2 mL) was added TFA (0.50 mL). The mixture was stirred at roomtemperature for 6 h, concentrated, H₂O added and concentrated (2×). Theresidue was then taken up in H₂O again (20 mL), filtered (0.2 μm PALLfilter disc) then freeze-dried, providing 0.17 g (93%) ofEtO-Su(NPN)₂[NH₂.TFA][COPEG₁₂] as a clear colourless oil. LCMS (LC:philic, TFA, RT=5.9 min; MS (M_(calc) C₃₈H₇₅N₃O₁₆=830.03): 831 ([M+H]⁺,7%), 425 (½[M+Na⁺+H⁺], 30%), 416 (½[M+2H⁺], 100%). ¹H (D₂O): δ 4.17 (q,J=9.0 Hz, 2H), 3.80 (t, J=6.0 Hz, 2H), 3.62-3.75 (m, 43H), 3.38-3.53 (m,4H), 3.40 (s, 3H), 2:90-3.31 (m, 4H), 2.77 (s, 4H), 2.64-2.89 (m, 4H),2.52-2.58 (m, 2H), 1.72-2.11 (m, 4H), 1.13 (t, J=9.0 Hz, 3H).

iv. EtO-Su(NPN)₂[γ-CO-MTX-α-OtBu][COPEG₁₂]

To a stirred mixture of EtO-Su(NPN)₂[NH₂.TFA][COPEG₁₂] (30 mg, 31.7μmol) and MTX-α-OtBu (16.2 mg, 31.7 μmol) {C. L. Francis, Q. Yang, N. K.Hart, F. Widmer, M. K. Manthey and H. Ming He-Williams, Aust. J. Chem.2002, 55, 635} in DMF (0.5 mL) at 0° C. was added PyBOP (18 mg, 34.8μmol) and DIPEA (23 μL, 0.127 mmol). The mixture was stirred at 0° C.for 30 min, then room temperature for 3 h. The DMF was removed, and theresidue purified by preparative TLC (7% MeOH, 93% DCM, Rf=0.3) providing23 mgs (55%) of EtO-Su(NPN)₂[γ-CO-MTX-α-OtBu][COPEG₁₂] as an orange oil.LCMS (LC: philic, TFA, RT=8.0 min; MS (M_(calc) C₆₂H₁₀₃N₁₁O₂₀=1322.57):1323 ([M+H]⁺, 2%), 662 (½[M+2H⁺], 17%), 634 (½[M−tBu+2H⁺], 82%). ¹H(CD₃OD): δ 8.60 (s, 1H), 8.28 (t, J=9.0 Hz, 1H), 7.95-8.05 (m, 1H),7.72-7.80 (m, 1H), 7.75 (d, J=7.8 Hz, 2H), 6.87 (d, J=7.8 Hz, 2H), 4.88(s, 2H), 4.36-4.47 (m, 1H), 4.07 (q, J=7.2 Hz, 2H), 3.61-3.78 (m, 50H),3.18-3.38 (m, 12H), 2.54-2.64 (m, 4H), 2.31-2.48 (m, 4H), 1.75-1.85 (m,2H), 1.59-1.70 (m, 2H), 1.47 (s, 9H), 1.21 (t, J=7.8 Hz, 3H).

v. HO-Su(NPN)₂[γ-CO-MTX-α-OtBu][COPEG₁₂]

To a stirred mixture of EtO-Su(NPN)₂[γ-CO-MTX-α-OtBu][COPEG₁₂] (109 mg,82.4 μmol) in THF/H₂O (2:1, 9 mL) was added NaOH (0.16 mL, 1.0M). Thereaction was left to stir for 16 h at room temperature, and additionalNaOH added if required (reaction judged by tlc). After the reaction wascomplete the pH was adjusted to neutral with HCl (1.0M). The solvent wasthen removed, the residue taken up in MeOH, and filtered to remove salt.The residue was then purified by preparative TLC (18% MeOH, 82% DCM,Rf=0.4) providing 52 mgs (49%) of HO-Su(NPN)₂[γ-CO-MTX-α-OtBu][COPEG₁₂]as an orange oil. LCMS (LC: philic, TFA, RT=6.8 min; MS (M_(calc)C₆₀H₉₉N₁₁O₂₀=1294.52): 1317 ([M+Na]⁺, 3%), 1295 ([M+H]⁺, 2%), 648(½[M+2H⁺], 10%), 620 (½[M−tBu+2H⁺], 74%), 419 (100%).

vi. BHALys[Lys]₂[Su(NPN)₂(MTX-□-OtBu)(PEG₁₂Me)]₄

To a stirred mixture of HO-Su(NPN)₂[γ-CO-MTX-α-OtBu][COPEG₁₂] (10 mg,7.7 μmol) and BHALys[Lys]₂[NH₂.TFA]₄ (1.43 mg, 1.4 μmol) in DMF (1.2 mL)at 0° C. was added PyBOP (4.0 mg, 7.7 μmol) and DIPEA (3.9 μL, 22.4μmol). The mixture was stirred at 0° C. for 30 min, then rt for 3 h. TheDMF was removed, and the residue purified by PREP HPLC (Waters Xterra MSC₁₈, 10 μm, 19×250 mm, 30-60% ACN, 0.1% TFA, 8 mL/min, RT=34 min),providing 2 mg (25%) of the desired dendrimer. LCMS (LC: philic, TFA,RT=8.0 min; MS: 1136 (⅕[M+5H⁺], 18%), 946 (⅙[M+6H⁺], 100%), 812 (1/7[M+7H⁺], 22%) Transforms to 5,673.34. (M_(calc)C₂₇₁H₄₃₇N₅₁O₇₉=5,673.80).

Example 57 BHALys[Lys]₄[Su(NPN)₂]₈[γ-CO-MTX-α-OtBu]₈[COPEG₁₂]₈

Surface Topology Surface Stoichiometry ((((Drug PEG)(Drug PEG))⁴((DrugPEG)(Drug 8 COPEG₁₂ = PEG PEG))⁴)⁸(((Drug PEG)(Drug PEG))⁴ 8 γ-CO-MTX-α-((Drug PEG)(Drug PEG))⁴)⁸)¹⁶ OtBu = Drug

The reaction of HO-Su(NPN)₂[γ-CO-MTX-α-OtBu][COPEG₁₂] with BHALys[Lys]₄[NH₂.TFA]₈ was carried out according to the method of Example 56.vi toprovide BHALys[Lys]₄[Su(NPN)₂]₈[γ-CO-MTX-α-OtBu]₈[COPEG₁₂]₈: 25 mg (63%,1.32 mCi/g) PREP HPLC (5-60% ACN, 90 min, RT 54 min).

LCMS (LC: philic, TFA, RT=9.0 min; MS: 1614 ( 1/7[M+7H⁺], 26%), 1413(⅛[M+8H⁺], 73%), 1256 ( 1/9[M+9H⁺], 100%) Transforms to 11,294.54.(M_(calc) C₅₃₅H₈₇₃N₁₀₃O₁₅₉=11,292.52).

Example 58 BHALys[Lys]₈[Su(NPN)₂]₁₆ [γ-CO-MTX-α-OtBu]₁₆ [COPEG₁₂]₁₆

Surface Topology Surface Stoichiometry ((((Drug PEG)(Drug PEG))⁴((DrugPEG)(Drug 16 COPEG₁₂ = PEG PEG))⁴)⁸(((Drug PEG)(Drug PEG))⁴ 16γ-CO-MTX-α- ((Drug PEG)(Drug PEG))⁴)⁸)¹⁶ OtBu = Drug ((((Drug PEG)(DrugPEG))⁴((Drug PEG)(Drug PEG))⁴)⁸(((Drug PEG)(Drug PEG))⁴ ((Drug PEG)(DrugPEG))⁴)⁸)¹⁶

The reaction of HO-Su(NPN)₂[γ-CO-MTX-α-OtBu][COPEG₁₂] with BHALys[Lys]₈[NH₂.TFA]₁₆ was carried out according to the method of Example 56.vi toprovide BHALys[Lys]₈[Su(NPN)₂]₁₆ [γ-CO-MTX-α-OtBu]₁₆ [COPEG₁₂]₁₆

15 mg (65%, 1.27 mCi/g) PREP HPLC (5-60% ACN, 90 min, Rt 66 min). LCMS(LC: philic, TFA, RT=9.0 min; MS: 2254 ( 1/10[M+10H⁺], 24%), 2049 (1/11[M+11H⁺], 56%), 1879 ( 1/12[M+12H⁺], 100%), 1734 ( 1/13[M+13H⁺],55%) Transforms to 22,531.91 (M_(calc) C₁₀₆₃H₁₇₄₅N₂₀₇O₃₁₉=22,529.73).

Example 59 BHALys[Lys]₁₆ [Su(NPN)₂]₃₂ [γ-CO-MTX-α-OtBu]₃₂ [COPEG₁₂]₃₂

Surface Surface Topology Stoichiometry ((((Drug PEG)(Drug PLG))⁴((DrugPEG)(Drug 32 COPEG₁₂ = PEG))⁴)⁸(((Drug PEG)(Drug PEG))⁴((Drug PEG PEG)(Drug PEG))⁴)⁸)¹⁶ 32 γ-CO-MTX- ((((Drug PEG)(Drug PEG))⁴((Drug PEG)(Drugα- OtBu = PEG))⁴)⁸(((Drug PEG)(Drug PEG))⁴((Drug PEG) Drug (DrugPEG))⁴)⁸)¹⁶ ((((Drug PEG)(Drug PEG))⁴((Drug PEG)(Drug PEG))⁴)⁸(((DrugPEG)(Drug PEG))⁴((Drug PEG) (Drug PEG))⁴)⁸)¹⁶ ((((Drug PEG)(DrugPEG))⁴((Drug PEG)(Drug PEG))⁴)⁸(((Drug PEG)(Drug PEG))⁴((Drug PEG) (DrugPEG))⁴)⁸)¹⁶

The reaction of HO-Su(NPN)₂[γ-CO-MTX-α-OtBu][COPEG₁₂] with BHALys[Lys]₁₆[NH₂.TFA]₃₂ was carried out according to the method of Example 56.vi toprovide BHALys[Lys]₁₆ [Su(NPN)₂]₃₂ [γ-CO-MTX-α-OtBu]₃₂ [COPEG₁₂]₃₂: 21mg (45%, 1.31 mCi/g) PREP HPLC (5-60% ACN, 90 min, RT 71 min). LCMS (LC:philic, TFA, RT=9.2 min; MS: (M_(calc) C₂₁₁₉H₃₄₈₉N₄₁₅O₆₃₉=45,004.27),MALDI, 40,697 (broad hump).

Example 60 BHALys[Lys]₄[Su(NPN)₂]₈[γ-CO-MTX-α-OtBu]₈[COPEG₂₄]₈

Surface Topology Surface Stoichiometry ((((Drug PEG)(Drug PEG))⁴((DrugPEG)(Drug 8 COPEG₂₄ = PEG PEG))⁴)⁸(((Drug PEG)(Drug PEG))⁴((Drug 8γ-CO-MTX-α- PEG)(Drug PEG))⁴)⁸)¹⁶ OtBu = Drug

i. HO-Su(NPN)₂[γ-CO-MTX-α-OtBu][COPEG₂₄]

This material was prepared in stepwise fashion fromEtO-Su(NPN)₂[Boc][NH₂] and NHS—COPEG₂₄ by way of the method for Example56.ii to provide EtO-Su(NPN)₂[Boc][COPEG₂₄]; the Boc group was removedby way of the method for Example 56.iii to provideEtO-Su(NPN)₂[NH₂.TFA][COPEG₂₄]; the MTX-α-OtBu was added by way of themethod for 56.iv to provide EtO-Su(NPN)₂[γ-CO-MTX-α-OtBu][COPEG₂₄] andthe ester was hydrolysed by way of the method for 56.v to provideHO-Su(NPN)₂[γ-CO-MTX-α-OtBu][COPEG₂₄].

LCMS (LC: philic, TFA, RT=7.3 min; MS (M_(calc) C₈₄H₁₄₇N₁₁O₃₂=1823.10):921 (½[M+NH₄+H]⁺, 9%), 912 (½[M+2H⁺], 12%), 608 (⅓[M+3H⁺], 100%), 461(¼[M+NH₄+3H]⁺, 35%.

ii. BHALys[Lys]₄[Su(NPN)₂]₈[γ-CO-MTX-α-OtBu]₈[COPEG₂₄]₈

The reaction of HO-Su(NPN)₂[γ-CO-MTX-α-OtBu][COPEG₂₄] with BHALys[Lys]₄[NH₂.TFA]₈ was carried out according to the method of Example 56.vi toprovide BHALys[Lys]₄[Su(NPN)₂]₈[γ-CO-MTX-α-OtBu]₈[COPEG₂₄]₈ 25 mg (62%,0.96 mCi/g) PREP HPLC (5-60% ACN, 90 min, RT 66 min).

LCMS (LC: philic, TFA, RT=9.2 min; MS: 1726 ( 1/9[M+9H⁺], 25%), 1553 (1/10[M+10H⁺], 63%), 1412 ( 1/11 [M+11H⁺], 77%), 1294 ( 1/12[M+12H⁺],100%), 1195 ( 1/13[M+13H⁺], 83%) Transforms to 15,521.12. (M_(calc)C₇₂₇H₁₂₅₇N₁₀₃O₂₅₅=15,521.15).

Example 61 BHALys[Lys]₈[Su(NPN)₂]₁₆ [γ-CO-MTX-α-OtBu]₁₆ [COPEG₂₄]₁₆

Surface Topology Surface Stoichiometry ((((Drug PEG)(Drug PEG))⁴((DrugPEG) 16 COPEG₂₄ = PEG (Drug PEG))⁴)⁸(((Drug PEG)(Drug PEG))⁴((Drug PEG)16 γ-CO-MTX-α-OtBu = Drug (Drug PEG))⁴)⁸)¹⁶ ((((Drug PEG)(DrugPEG))⁴((Drug PEG) (Drug PEG))⁴)⁸(((Drug PEG)(Drug PEG))⁴((Drug PEG)(Drug PEG))⁴)⁸)¹⁶

The reaction of HO-Su(NPN)₂[γ-CO-MTX-α-OtBu][COPEG₂₄] with BHALys[Lys]₈[NH₂.TFA]₈ was carried out according to the method of Example 56.vi toprovide BHALys[Lys]₈[Su(NPN)₂]₁₆ [γ-CO-MTX-α-OtBu]₁₆ [COPEG₂₄]₁₆: 39 mg(66%, 0.93 mCi/g) PREP HPLC (5-60% ACN, 90 min, RT 70 min). LCMS (LC:philic, TFA, RT=9.4 min; MS: Deconvoluted with Max Ent to 31,033(M_(calc) C₁₄₄₇H₂₅₁₃N₂₀₇O₅₁₁=30,987.22).

Example 62 BHALys[Lys]₁₆ [Su(NPN)₂]₃₂ [γ-CO-MTX-α-OtBu]₃₂ [COPEG₂₄]₃₂

Surface Topology Surface Stoichiometry ((((Drug PEG)(Drug PEG))⁴((DrugPEG)(Drug 32 COPEG24 = PEG PEG))⁴)⁸(((Drug PEG)(Drug PEG))⁴((DrugPEG)(Drug 32 γ-CO-MTX-α-OtBu = Drug PEG))⁴)⁸)¹⁶ ((((Drug PEG)(DrugPEG))⁴((Drug PEG)(Drug PEG))⁴)⁸(((Drug PEG)(Drug PEG))⁴((Drug PEG)(DrugPEG))⁴)⁸)¹⁶ ((((Drug PEG)(Drug PEG))⁴((Drug PEG)(Drug PEG))⁴)⁸(((DrugPEG)(Drug PEG))⁴((Drug PEG)(Drug PEG))⁴)⁸)¹⁶ ((((Drug PEG)(DrugPEG))⁴((Drug PEG)(Drug PEG))⁴)⁸(((Drug PEG)(Drug PEG))⁴((Drug PEG)(DrugPEG))⁴)⁸)¹⁶

The reaction of HO-Su(NPN)₂[γ-CO-MTX-α-OtBu][COPEG₂₄] with BHALys[Lys]₁₆[NH₂.TFA]₈ was carried out according to the method of Example 56.vi toprovide BHALys[Lys]₁₆ [Su(NPN)₂]₃₂ [γ-CO-MTX-α-OtBu]₃₂ [COPEG₂₄]₃₂: 38mg (49%, 0.95 mCi/g) PREP HPLC (5-60% ACN, 90 min, RT 70 min). LCMS (LC:philic, TFA, RT 9.5 min; MS: (M_(calc) C₂₈₈₇H₅₀₂₅N₄₁₅O₁₀₂₃=61, 919.36)

Example 63 BHALys[Lys]₁₆ [Su(NPN)₂]₃₂ [γ-CO-MTX-α-OtBu]₃₂ [COPEG₂₄]₃₂

Surface Topology Surface Stoichiometry ((((Drug PEG)(Drug PEG))⁴((DrugPEG)(Drug 16 COPEG₂₄= PEG PEG))⁴)⁸(((Drug PEG)(Drug PEG))⁴((DrugPEG)(Drug 16 γ-CO-MTX-α-OtBu = Drug PEG))⁴)⁸)¹⁶ ((((Drug PEG)(DrugPEG))⁴((Drug PEG)(Drug PEG))⁴)⁸(((Drug PEG)(Drug PEG))⁴((Drug PEG)(DrugPEG))⁴)⁸)¹⁶

i. HO-Su(NPN)₂[γ-CO-MTX-α-OtBu][COPEG₂₃₀₀]

This material was prepared in stepwise fashion fromEtO-Su(NPN)₂[Boc][NH₂] and NHS—COPEG₂₃₀₀ by way of the method forExample 56.ii to provide EtO-Su(NPN)₂[Boc][COPEG₂₃₀₀]; the Boc group wasremoved by way of the method for Example 56.iii to provideEtO-Su(NPN)₂[NH₂.TFA][COPEG₂₃₀₀]; the MTX-α-OtBu was added by way of themethod for 56.iv to provide EtO-Su(NPN)₂[γ-CO-MTX-α-OtBu][COPEG₂₃₀₀] andthe ester was hydrolysed by way of the method for 56.v to provideHO-Su(NPN)₂[γ-CO-MTX-α-OtBu][COPEG₂₃₀₀].

LCMS (LC: philic, TFA, RT=7.8 min; MS (M_(calc) C₁₃₈H₂₅₀N₁₆O₅₆=3029.6):758 (¼[M+4H⁺], 100%), 607 (⅕[M+5H⁺], 67%), 506 (⅙[M+6H⁺], 22%),Transforms to 3,029.2. (M_(calc) C₁₃₈H₂₅₀N₁₆O₅₆=3029.6). ¹H (CDCl₃): δ8.49 (s, 1H), 7.71 (m, 1H), 7.20-7.52 (m, 2H), 6.64-7.14 (m, 8H), 6.20(m, 1H), 4.75 (s, 1H), 4.42-4.58 (m, 1H), 3.51-3.78 (m, 170H), 3.38-3.46(m, 10H), 3.14-3.28 (m, 6H), 2.65-3.12 (m, 10H), 2.50-2.60 (m, 4H),2.31-2.49 (m, 10H), 2.14-2.28 (m, 4H), 2.02-2.13 (m, 2H), 1.85-1.97 (m,2H), 1.67-1.83 (m, 2H) 1.50-1.63 (m, 2H), 1.46 (s, 9H), 1.36-1.44 (m,2H).

ii. BHALys[Lys]₈[Su(NPN)₂]₁₆ [γ-CO-MTX-α-OtBu]₁₆ [COPEG₂₃₀₀]₁₆

The reaction of HO-Su(NPN)₂[γ-CO-MTX-α-OtBu][COPEG₂₃₀₀] withBHALys[Lys]₈ [NH₂.TFA]₁₆ was carried out according to the method ofExample 56.vi to provide BHALys[Lys]₈[Su(NPN)₂]₁₆ [γ-CO-MTX-α-OtBu]₁₆[COPEG₂₃₀₀]₁₆: 7 mg (23%, 0.57 mCi/g) PREP HPLC (5-60% ACN, 80 min, RT62 min). LCMS (LC: philic, TFA, RT=9.8 min; MS: (M_(calc)C₂₃₁₁H₄₁₆₁N₂₈₇O₈₉₅=50,291.22).

Example 64 Plasma Clearance Studies for Radiolabelled Macromolecules

Tritiated poly-lysine macromolecules were dissolved in phosphatebuffered saline (PBS), pH 7.4) and frozen until required. Rats wereintravenously administered 5 mg/kg of macromolecule via an indwellingcannula (implanted in the jugular vein) over 2 min.

Immediately following dosing, a blood sample (t=0) was collected via anindwelling carotid artery cannula and placed in a heparinised eppendorftube.

Blood samples were then collected at predetermined intervals for thefollowing 30 hr, and the plasma separated. In addition, urine and faeceswere collected at 0-8 hr, 8-24 hr and 24-30 hr. At sacrifice (30 hrafter the intravenous dose) the major organs (liver, kidneys, spleen,pancreas, heart, lung and brain) were collected and weighed. The tritiumcontent of plasma, urine, faeces and the various tissue samples weredetermined using validated scintillation assays.

Data from Example 64 is tabulated in Table 25, and shown in FIGS. 15Aand 15B.

TABLE 25 Pharmacokinetic Parameters for Radiolabelled Macromolecules %of ³H dose MW excreted in Macromolecule Example (kDa) plasma T½ (h)total urine (PEG₂₀₀)₁₆ 51 6 0.25 ± 0.04 82.2 ± 6.4  (PEG₂₀₀)₃₂ 52 11.10.72 ± 0.03 80.4 ± 13.6 (PEG₁₂)₃₂ 53 22.4 9.45 ± 0.42 42.9 ± 2.7 (PEG_(2KD))₁₆ 54 34.1 23.90 ± 2.56  26.0 ± 4.6  (PEG_(2KD))₃₂ 55 6775.35 ± 9.3  3.1 ± 1.9 (PEG₁₂)₄(MTX)₄ 56 — — (PEG₁₂)₈(MTX)₈ 57 11.3  4.0± 1.8^(a) 56.1 ± 8.7  (PEG₁₂)₁₆(MTX)₁₆ 58 22.5  9.0 ± 0.2^(a) 29.0 ±3.4  (PEG₁₂)₃₂(MTX)₃₂ 59 45.0 23.7 ± 5.0  2.4 ± 0.5 (PEG₂₄)₈(MTX)₈ 6015.5  3.9 ± 0.1^(a) 64.2 ± 4.6  (PEG₂₄)₁₆(MTX)₁₆ 61 31.0 21.0 ± 1.7  —(PEG₂₄)₃₂(MTX)₃₂ 62 61.9 51.4 ± 2.7  1.2 ± 0.1 (PEG₂₃₀₀)₁₆(MTX)₁₆ 6350.3 34.1 ± 1.1  8.7 ± 1.6Molecular Modelling

Example 65 Simulation of a 4^(th) Generation BHALys-polylysineMacromolecule

Simulation of 5 types of a BHA substituted (L)-lysine core macromoleculeconsisting of 4 layers of lysine building units was undertaken.

The asymmetric sets contained the following topological isomers:

Macromolecule Topological description Type 1: 16-tet cluster((((AA)(AA))⁴((AA)(AA))⁴)⁸(((AA)(AA))⁴((AA)(AA))⁴)⁸)¹⁶((((BB)(BB))⁴((BB)(BB))⁴)⁸(((BB)(BB))⁴((BB)(BB))⁴)⁸)¹⁶ Type 2: Octetcluster ((((AA)(AA))⁴((AA)(AA))⁴)⁸(((BB)(BB))⁴((BB)(BB))⁴)⁸)¹⁶((((AA)(AA))⁴((AA)(AA))⁴)⁸(((BB)(BB))⁴((BB)(BB))⁴)⁸)¹⁶ Type 3: Quartetcluster ((((AA)(AA))⁴((BB)(BB))⁴)⁸(((AA)(AA))⁴((BB)(BB))⁴)⁸)¹⁶((((AA)(AA))⁴((BB)(BB))⁴)⁸(((AA)(AA))⁴((BB)(BB))⁴)⁸)¹⁶ Type 4: Coupletcluster ((((AA)(BB))⁴((AA)(BB))⁴)⁸(((AA)(BB))⁴((AA)(BB))⁴)⁸)¹⁶((((AA)(BB))⁴((AA)(BB))⁴)⁸(((AA)(BB))⁴((AA)(BB))⁴)⁸)¹⁶ Type 5: Nocluster ((((AB)(AB))⁴((AB)(AB))⁴)⁸(((AB)(AB))⁴((AB)(AB))⁴)⁸)¹⁶((((AB)(AB))⁴((AB)(AB))⁴)⁸(((AB)(AB))⁴((AB)(AB))⁴)⁸)¹⁶

The initial structure was constructed using a computer program whichuses stochastic searching to build an extended structure and minimisethe number of close contacts. This structure was then placed in a waterbox and equilibrated according to the protocol shown in FIG. 20. Thecomposition of the entire system is shown in Table 26.

TABLE 26 Composition of the polylysine macromolecule used in thesimulation. Number Number of atoms per Total number of Component ofmolecules molecule atoms Dendrimer 1 710 710 Water 8254 3 24762 Na⁺ 1261 126 Cl⁻ 158 1 158 Total 25756

The equilibrated macromolecule thus obtained was simulated for a further12 ns. During this simulation, temperature was maintained at 300 K usingLangevin temperature coupling, while pressure was maintained at 1 atmusing Nosé-Hoover pressure coupling.

Simulations were carried out using the OPLS-AA force field (Jorgensen,W. L et al. (1996). J. Am. Chem. Soc 118, 11225-11236) and the moleculardynamics software NAMD. (Kalé, L. et al (1999) J. Comp. Phys. 151,283-312). Where necessary, additional torsional parameters were obtainedby adopting related torsional parameters already present in the forcefield. Water molecules were treated explicitly using the TIP3P watermodel, an implementation of which was present in the OPLS-AA forcefield. (Jorgensen, W. L et al. (1983). J. Chem. Phys. 79, 926-935).

The resulting simulation trajectories were visually inspected using thetrajectory visualisation software, VMD, and the program Sybyl. Inaddition, two types of distances were calculated. The first is thedistance distribution (1), the set of all A-B distances. The seconddistance is the separation between the centres of mass of the two setsof atoms (2); this distance acts as a quantitative measure ofpolarisation, and is computed in a similar manner as electric andmagnetic dipole moments.

$\begin{matrix}{{s = \sqrt{\left( {x_{B} - x_{A}} \right)^{2} + \left( {y_{B} - y_{A}} \right)^{2} + \left( {z_{B} - z_{A}} \right)^{2}}}{{{\overset{\_}{n}}_{B}\left( {k \leq s \leq l} \right)} = \frac{\int_{k}^{l}{{F(s)}\ {\mathbb{d}s}}}{N_{f}}}{{P_{B}\left( {k \leq s \leq l} \right)} = \frac{{\overset{\_}{n}}_{B}\left( {k \leq s \leq l} \right)}{N_{A}}}} & (1) \\{S = \sqrt{\begin{matrix}{\left( {{\frac{1}{N_{B}}{\sum\limits_{j = 1}^{N_{B}}x_{B}}} - {\frac{1}{N_{A}}{\sum\limits_{i = 1}^{N_{A}}x_{A}}}} \right)^{2} + \left( {{\frac{1}{N_{B}}{\sum\limits_{j = 1}^{N_{B}}y_{B}}} - {\frac{1}{N_{A}}{\sum\limits_{i = 1}^{N_{A}}y_{A}}}} \right)^{2} +} \\\left( {{\frac{1}{N_{B}}{\sum\limits_{j = 1}^{N_{B}}z_{B}}} - {\frac{1}{N_{A}}{\sum\limits_{i = 1}^{N_{A}}z_{A}}}} \right)^{2}\end{matrix}}} & (2)\end{matrix}$where (x_(A), y_(A), z_(A)) and (x_(B), y_(B), z_(B)) are the Cartesiancoordinates of any atom in a set of atoms A and in another set of atomsB respectively; N_(A) and N_(B) are the total numbers of atoms in thesets A and B; N_(f) is the total number of frames considered; s is thedistance between an atom in set A and an atom in set B; S is thedistance, in a single frame, between the centre of mass of set A and thecentre of mass of set B; F(s) is the total number of times (across allN_(f) frames) any atom in set B is separated from an atom in set A bythe distance s; n _(B) (k≦S≦l) is the average, over all frames, of thenumber of atoms of set B lying between the distances k and l from anyatom in set A; and P_(B) (k≦s≦l) is the probability of any one atom inset B lying between the distances k and l from an atom in set A. In thepresent work, 1 Å shells were used, i.e., l=k+1.

The final frame of the simulation of the simplified 2-dimensionalstructural drawings in FIG. 16 is shown in FIG. 17, where the functionalmoieties A and B are represented as light and dark balls respectively.

Inflammation Examples Example 66BHALys[Lys]₂[Glu]₄[α-COC2-α-S-GlcNAc]₄[CO₂H]₄ i.BHALys[Lys]₂[Glu]₄[α-Boc]₄[γ-CO₂Me]₄

To a magnetically stirred solution of BHALys[Lys]₂[NH₂.TFA]₄ (400 mg,0.391 mmol), TEA (0.218 ml, 1.56 mmol) and DMF (10 ml) was addedPNPO-Glu-α-Boc-δ-OMe (0.717 g, 1.88 mmol) as a solid and in one portionat room temperature. The reaction suspension immediately turned brightyellow in colour and after stirring for ca. 2 mins, the active ester hadcompletely dissolved. Stirring was continued at room temperature for afurther 66 h. The crude reaction mixture was poured into a large beakerof ice-water and a fine yellow precipitate formed. The suspension wasfiltered and the solids thus retained were washed with water then airdried under suction. The resulting off-white solid cake was resuspendedin ACN and this suspension was stirred at room temperature for 5 minsthen filtered. The solids retained were once again air dried,re-pulverised and re-suspended in ACN before being filtered and airdried. The resulting white solid was dissolved in methanol and themethanolic solution was concentrated in vacuo to giveBHALys[Lys]₂[Glu]₄[α-Boc]₄[γ-CO₂Me]₄ (301 mg, 50%) as a colourlesssolid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=1540.82 [M+H]+, 770.87 [M+2H]/2+;calculated C75H117N11O23 1540.83; Rf (min)=5.96 mins.

ii. BHALys[Lys]₂[Glu]₄[α-NH₂.TFA]₄[γ-CO₂Me]₄

BHALys[Lys]₂[Glu]₄[α-Boc]₄[δ-OMe]₄ (236 mg, 0.153 mmol) was suspended inDCM (2.15 ml) and stirred at room temperature. A solution of 1:1 TFA/DCM(1.4 ml) was added slowly, causing the suspension to clear rapidly.Stirring was continued for 17 h. The reaction was terminated by removalof volatiles in vacuo, giving a syrup which was taken up into water (50ml) and freeze-dried to give BHALys[Lys]₂[Glu]₄[α-NH₂.TFA]₄ [γ-CO₂Me]₄as a colourless lyophilate (261 mg, 107%).

LC/MS (Hydrophilic/TFA): ESI (+ve) m/z=1140.64 [M+H]+, 570.67 [M+2H]/2+;calculated C55H85N11O15 1140.4 g/mol. Data deconvoluted using transformcalculation to give mw=1139.50. Rf (min)=6.27.

iii. (−) 2-Carboxyethyl2-deoxy-2-acetamido-3,4,6-tetra-O-acetyl-1-thio-β-D-glucopyranoside

To a stirred solution of2-deoxy-2-acetamido-3,4,6-O-triacetyl-β-D-glucopyranosyl thiouroniumhydrochloride (35.7 g, 81 mmol) in acetone (200 ml) and water (200 ml)was added potassium carbonate (16.7 g, 122 mmol) and sodiummetabisulfite (15.4 g, 81 mmol) followed by 3-iodopropionic acid (16.1g, 81 mmol). The reaction was allowed to stir for 2 hours and then anadditional portion of sodium metabisulfite (3.0 g, 15.7 mmol) was added.After a further 2 hours, 1N HCl was used to acidify the solution to pH 1and then the mixture was saturated with solid NaCl. The aqueous mixturewas extracted with EtOAc (5×200 ml), the organic extracts were dried(MgSO₄) and concentrated under reduced pressure. The residue wassuspended in hot toluene and then the toluene decanted. After drying,the product was dissolved in boiling ACN (75 ml) and left to crystallizeat −15° C. for 16 hours. The crystalline product was collected and driedunder reduced pressure to give 2-carboxyethyl2-deoxy-2-acetamido-3,4,6-tri-O-acetyl-1-thio-β-D-glucopyranoside as awhite solid (26.8 g). The mother liquor was evaporated and the residualproduct purified by dry flash chromatography then crystallised from ACNto give a further (4.0 g).

[α]_(D) ²² −34.9 (c 1.05, MeOH);

IR (nujol): 3303, 1744, 1701, 1659, 1231, 1035, 721 cm⁻¹;

¹H NMR (300 MHz, d₆DMSO) δ 12.19 (br s, 1H), 7.93 (d, J=9.4 Hz, 1H),5.06 (dd, J=9.7, 9.7 Hz, 1H), 4.83 (dd, J=9.7, 9.7 Hz, 1H), 4.72 (d,J=10.3 Hz, 1H), 4.13 (dd, J=12.2, 5.2 Hz, 1H), 4.03 (dd, J=12.2, 2.1 Hz,1H), 3.89-3.78 (m, 2H), 2.90-2.66 (m, 2H), 2.56 (t, J=7.0 Hz, 2H), 2.01(s, 3H), 1.97 (s, 3H), 1.91 (s, 3H), 1.76 (s, 3H); ¹³C NMR (75 MHz,DMSO) 172.9, 169.9, 169.5, 169.1, 169.0, 83.7, 74.4, 73.5, 68.5, 61.9,51.9, 35.0, 24.9, 22.5, 20.3, 20.3, 20.2;

HRMS calcd for (M+NH₄ ⁺, ESI) C₁₇H₂₉O₁₀N₂S: 453.1537. found: 453.1528.

iv. NHS—COC2-(perAc)-α-S-GlcNAc

To a stirred solution of 2-carboxyethyl2-deoxy-2-acetamido-3,4,6-tri-O-acetyl-1-thio-β-D-glucopyranoside (5.0g, 11.4 mmol) in EtOAc (25 ml) and ACN (25 ml) was addedN-hydroxysuccinimide (1.98 g, 17.2 mmol) then dicyclohexylcarbodiimide(2.83 g, 13.7 mmol). The reaction was allowed to stir for 3 hours andthen the precipitated urea removed by filtration. The urea was washedwell with EtOAc, the filtrate concentrated under reduced pressure andthe residue purified by flash chromatography to giveNHS—COC2-(perAc)-α-S-GlcNAc as a colourless crystalline solid (4.82 g,79%).

¹H NMR (300 MHz, CHCl₃) δ 6.04 (br d, J=9.5 Hz, 1H), 5.15 (dd, J=9.5,9.5 Hz, 1H), 5.07 (dd, J=9.5, 9.5 Hz, 1H), 4.73 (d, J=10.3 Hz, 1H),4.24-4.05 (m, 3H), 3.70 (ddd, J=9.5, 4.8, 2.5 Hz, 1H), 3.20-2.82 (m,4H), 2.87 (s, 4H), 2.07 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H), 1.94 (s,3H);

HRMS calcd for (M+NH₄ ⁺, ESI) C₂₁H₃₂N₃O₁₂S: 550.1701. found: 550.1684;(M+H⁺) C₂₁H₂₉N₂O₁₂S: 533.1454. found: 533.1494;

v. BHALys[Lys]₂[Glu]₄[α-COC2-α-S-GlcNAc]₄[γ-CO₂H]₄

Surface Topology Surface Stoichiometry (((Sacc CO₂H)(Sacc CO₂H))⁴((Sacc4 COC2-α-S-GlcNAc = Sacc CO₂H)(Sacc CO₂H))⁴)⁸ 4 CO₂H

To a stirred solution of BHALys[Lys]₂[Glu]₄[α-NH₂.TFA]₄[γ-CO₂Me]₄ (107mg, 0.067 mmol) disolved in DMF (5 ml) was addedNHS—COC2-(perAc)-α-S-GlcNAc (214 mg, 0.40 mmol) followed by DIPEA (69mg, 0.53 mmol). The reaction mixture was allowed to stir for 2 hours andthen diluted with water (10 ml) and the precipitated solid collectedunder vacuum. The precipitate was washed with water then suspended inhot CHCl₃. After cooling the solid was collected then suspended inmethanol (5 ml) and CH₂Cl₂ (5 ml) and 30% NaOMe (5 drops) added. Themixture was sonicated for 5 minutes and then shaken for 15 minutes. Themixture did not appear to dissolve so the mixture was concentrated undervacuum and diluted with water (5 ml) and potassium carbonate (185 mg)added. The mixture was stirred overnight and then 2N NaOH (100 μl) addedas not all intermediate had dissolved. The mixture was left for afurther 4 hours then acidified to pH 1 with TFA. The volatiles wereremoved under reduced pressure and the product purified by RP-HPLC(Phenomenex Synergi, 95:5 to 50:50 0.1% formic acid:MeOH over 60 minutesat 20 ml/min). The cleanest fractions containing product were combinedand concentrated under reduced pressure and the residue dissolved inwater and lyophilized to giveBHALys[Lys]₂[Glu]₄[α-COC2-α-S-GlcNAc]₄[γ-CO₂H]₄ as a colourless solid(33 mg, 39%); HPLC ret time 14.0 min, purity 90% (Waters Symmetry, 70:30to 30:70 0.1% TFA in water:MeOH over 30 minutes);

¹H NMR (300 MHz, D₂O) δ 7.44-7.23 (m, 10H), 6.09 (s, 1H), 4.40-4.06 (m,7H), 3.99-3.33 (m, 24H), 0.32-3.00 (m, 6H), 3.04-2.87 (m, 8H), 2.70-2.56(m, 8H), 2.14-1.60 (m, 14H), 2.00 (br s, 12H), 1.59-1.20 (m, 12H);

MS calcd for (M−H, Q-TOF) C₉₅H₁₄₄N₁₅O₃₉S₄: 2246.86. Found: 2246.81.

Example 67 BHALys[Lys]₄[Glu]₈[α-COC2-α-S-GlcNAc]₈[δ-CO₂H]₈ i.BHALys[Lys]₄[Glu]₈[α-Boc]₈[γ-CO₂Me]₈

To a magnetically stirred solution of BHALys[Lys]₄[NH₂.TFA]₈ (400 mg,0.201 mmol), TEA (0.560 ml, 4.01 mmol) and DMF (10 ml) was addedPNPO-Glu-α-Boc-δ-OMe (737 mg, 1.93 mmol) as a solid and in one portionat room temperature. The reaction suspension immediately turned brightyellow in colour and after stirring for ca. 3 mins, the active ester hadcompletely dissolved. Stirring was continued at room temperature for afurther 17 h. The crude reaction mixture was poured into a beaker ofice-water and a fine yellow precipitate formed. The suspension wasstirred until the ice melted then filtered and the solids thus retainedwere washed with water (3×30 ml), ACN (2×25 ml) then methanol (3×30 ml).The remaining solids were air dried under suction, givingBHALys[Lys]₄[Glu]₈[α-Boc]₈[γ-CO₂Me]₈ (460 mg, 76%) as a white solid.

LC/MS (Phobic/TFA): ESI (+ve) m/z=1514.43 [M+2H]/2+, 1009.61 [M+3H]/3+;calculated C143H233N23O31 3026.58. Data deconvoluted using transformcalculation to give mw=3025.83. Rf (min)=6.66 mins.

ii. BHALys[Lys]₄[Glu]₈[α-NH₂.TFA]₈[γ-CO₂Me]₈

BHALys[Lys]₄[Glu]₈[α-Boc]₈[γ-CO₂Me]₈ (460 mg, 0.152 mmol) was suspendedin DCM (2.8 ml) and stirred at room temperature. A solution of 1:1TFA/DCM (2.8 ml) was added slowly, causing the suspension to clearrapidly. Stirring was continued for 3 h. The reaction was terminated byremoval of volatiles in vacuo, giving a syrup which was triturated withEther (50 ml). The resulting cloudy white suspension was filtered andthe pellet thus obtained was washed with Ether (2×50 ml) and air-driedto give BHALys [Lys]₄[Glu]₈[α-NH₂.TFA]₈[γ-CO₂Me]₈ as a white solid (423mg, 89%).

LC/MS (Hydrophilic/TFA): ESI (+ve) m/z=1113.59 [M+2H]/2+, 742.77[M+3H]/3+; calculated C103H169N23O31 2225.63 g/mol. Data deconvolutedusing transform calculation to give mw=2224.37. Rf (min)=5.94.

iii. HO—COC2-α-S-GlcNAc

A solution of (−) 2-Carboxyethyl2-deoxy-2-acetamido-3,4,6-tetra-O-acetyl-1-thio-α-D-glucopyranoside(1.30 g, 2.98 mmol) was dissolved in a solution of 7N methanolic ammonia(20 ml) and the resulting solution stirred for 16 hours. The whiteprecipitate formed was collected by vacuum filtration and washed with1:1 methanol/CH₂Cl₂ (20 ml). The precipitate was dissolved in water (50ml) and Amberjet 1200H strongly acidic ion exchange resin (10 g) added.The suspension was stirred for 15 minutes and then the resin wasfiltered and washed well with water. The aqueous washing wereconcentrated under reduced pressure to afford HO—COC2-α-S-GlcNAc as acolourless gum which crystallised upon standing (800 mg, 87%);

[α]_(D) ²² −41.4 (c 1.5, H₂O);

¹H NMR (300 MHz, D₂O) δ 4.61 (d, J=10.4 Hz, 1H), 3.88 (d, J=12.4 Hz,1H), 3.75-3.66 (m, 2H), 3.56-3.40 (m, 3H), 3.01-2.83 (m, 2H), 2.72 (t,J=6.7 Hz, 2H), 1.99 (s, 3H).

HRMS calcd for (M−H⁺, ESI) C₁₁H₁₈NO₇S: 308.0809. found: 308.0809; Analcalcd for C₁₁H₁₉NO₇S: C, 42.71; H, 6.19; N, 4.53. Found: C, 42.40; H,6.31; N, 4.81.

iv. BHALys[Lys]₄[Glu]₈[α-COC2-α-S-GlcNAc]₈[γ-CO₂H]₈

Surface Topology Surface Stoichiometry ((((Sacc CO₂H)(Sacc CO₂H))⁴((SaccCO₂H)(Sacc 8 COC2-α-S-GlcNAc = Sacc CO₂H))⁴)⁸(((Sacc CO₂H)(SaccCO₂H))⁴((Sacc 8 CO₂H CO₂H)(Sacc CO₂H))⁴)⁸)¹⁶

To a stirred solution of BHALys[Lys]₄[Glu]₈[α-NH₂.TFA]₈[γ-CO₂H]₈ (82 mg,0.036 mmol) and HO—COC2-α-S-GlcNAc (137 mg, 0.44 mmol) in DMF (5 ml)were added DIPEA (190 mg, 1.47 mmol) followed by PyBOP (307 mg, 0.59mmol). The reaction mixture was left to stir for 16 hours and thendiluted with ACN and the precipitated solid collected by vacuumfiltration. The precipitate was dissolved in water (10 ml) and basifiedwith 1N NaOH (4 ml) and left to stir for several hours. The mixture wasthen acidified with Amberjet 1200 H resin, the resin removed byfiltration and the product lyophilized. The residue was purified byRP-HPLC to give 2 fractions, one containing pureBHALys[Lys]₄[Glu]₈[α-COC2-α-S-GlcNAc]₈[γ-CO₂H]₈ (19 mg) and one whichwas only 70% pure (29 mg); HPLC ret time 12.0 min, purity>99% (220 nm,Waters Symmetry, 70:30 to 30:70 0.1% TFA in water:MeOH over 30 minutes);

¹H NMR (300 MHz, D₂O) δ 7.43-7.21 (m, 10H), 6.08 (s, 1H), 4.36-4.05 (m,15H), 4.00-3.84 (m, 8H), 3.80-3.31 (m, 40H), 3.27-2.81 (m, 30H), 2.63(br s, 16H), 2.49-2.35 (m, 16H), 2.16-1.15 (m, 58H), 1.99 (br s, 12H),1.98 (br s, 12H);

MS calcd for (M−3H, Q-TOF) C₁₈₃H₂₈₈N₃₁O₇₉S₈: m/z 1479.235. Found:1479.219.

Example 68 BHALys[Lys]₂[Glu]₄[α-COC2CO-2-N-α-OMe-Glc]₄[γ-CO₂H]₄ i.BHALys[Lys]₂[Glu]₄[α-Boc]₄[γ-CO₂Fm]₄

To a magnetically stirred solution of HO-Glu-α-Boc-δ-OFm (831 mg, 1.95mmol), DCC (338 mg, 1.64 mmol), HOBT (222 mg, 1.64 mmol) and DMF (7 ml)was added a solution of BHALys[Lys]₂[NH₂.TFA]₄ (400 mg, 0.391 mmol),DIPEA (0.278 ml, 1.56 mmol) in DMF (3 ml) at 0° C. The reaction wasallowed to warm to room temperature and stirred for 18 hrs. The crudereaction mixture was filtered, with the solid pellet being rinsed withDMF (10 ml). The combined filtrates were concentrated in vacuo to givean off-white syrup which was triturated with Ether (100 ml) to give acloudy white suspension. This suspension was filtered and air-dried,giving BHALys[Lys]₂[Glu]₄[α-Boc]₄[γ-CO₂Fm]₄ (1.02 g, 119%) as a whitesolid. Excess mass is due to residual solvent.

LC/MS (Phobic/TFA): ESI (+ve) m/z=1099.67 [M+2H]/2+; calculatedC127H149N11O23 2197.66. Data deconvoluted using transform calculation togive mw=2197.25. Rf (min)=9:07 mins.

ii. BHALys[Lys]₂[Glu]₄[α-NH₂.TFA]₄[γ-CO₂Fm]₄

BHALys[Lys]₂[Glu]₄[α-Boc]₄[γ-CO₂Fm]₄ (1.02 g, i.e. 858 mg, 0.390 mmol)was suspended in DCM (3.6 ml) and stirred at room temperature. Asolution of 1:1 TFA/DCM (3.6 ml) was added slowly, causing thesuspension to clear rapidly. Stirring was continued for 3 h. Thereaction was terminated by removal of volatiles in vacuo, giving a syrupwhich was triturated with Ether (50 ml), giving a white suspension. Thesolids were collected from the suspension by filtration, and washed withEther (2×50 ml) then air-dried to give and freeze-dried to giveBHALys[Lys]₂[Glu]₄[α-NH₂.TFA]₄[γ-CO₂Fm]₄ as a white solid (829 mg, 94%).

LC/MS (Hydrophilic/TFA): ESI (+ve) m/z=1979.78 [M+H]+, 899.34 [M+2H]/2+;calculated C107H117N11O15 1797.19 g/mol. Data deconvoluted usingtransform calculation to give mw=1796.93. Rf (min)=10.90.

iii. Methyl2-deoxy-2-[3-(methoxycarbonyl)propanamido]-α-D-glucopyranoside

To a stirred solution of glucosamine hydrochloride (20.0 g, 92 mmol)disolved in acetone (40 ml) and water (100 ml) was added sodiumbicarbonate (31 g, 370 mmol) followed by succinic anhydride (13.8 g, 138mmol). The mixture was stirred for 2 hours and then the mixtureacidified to pH 1 with Amberjet 1200 H. The resin was removed byfiltration and the filtrate concentrated under reduced pressure. Theresidue was suspended in hot acetone and collected by filtration, thentaken up in methanol (200 ml) and amberjet 1200 H (30 g) added to themixture which was heated under reflux overnight. The mixture wasfiltered, then concentrated under reduced pressure to give a colourlessgum which was absorbed onto silica gel and purified by dry flashchromatography to give a colourless solid (8.2 g). The product wasisolated clean by crystallization from EtOAc to give methyl2-deoxy-2-[3-(methoxycarbonyl)propanamido]-α-D-glucopyranoside as acolourless solid (3.5 g, 12%);

[α]_(D) ²² +89 (c 1.0, H₂O); R_(f) 0.43 (90:10 CHCl₃:MeOH);

¹H NMR (300 MHz, D₂O) δ 4.72 (d, J=3.6 Hz, 1H), 3.89 (dd, J=10.6, 3.4Hz, 1H), 3.85 (dd, J=12.5, 2.2 Hz, 1H), 3.79-3.60 (m, 3H), 3.67 (s, 3H),3.44 (dd, J=9.3, 9.3 Hz, 1H), 3.36 (s, 3H), 2.69-2.56 (m, 4H);

HRMS calcd for (M+H⁺, ESI) C₁₂H₂₁NO₈: 308.1339. found: 308.1326.

iv. HO—COC2CO-2-N-α-OMe-Glc

To a stirred solution of methyl2-deoxy-2-[3-(methoxycarbonyl)propanamido]-α-D-glucopyranoside (3.54 g,11.5 mmol) disolved in water (10 ml) was added 2N sodium hydroxidesolution (10 ml). The reaction mixture was allowed to stir for 16 hoursand then acidified with Amberjet 1200 H resin. The resin was removed byfiltration through a sintered glass funnel. The solvent was then removedunder reduced pressure leaving HO—COC2CO-2-N-α-OMe-Glc as a whitecrystalline solid (3.37 g, 94%);

[α]_(D) ²² +107.2 (c 1.0, H₂O);

¹H NMR (300 MHz, D₂O) δ4.71 (d, J=3.6 Hz, 1H), 3.89 (dd, J=10.6, 3.6 Hz,1H), 3.85 (dd, J=12.4, 2.3 Hz, 1H), 3.78-3.60 (m, 3H), 3.44 (dd, J=9.5,9.5 Hz, 1H), 3.35 (s, 3H), 2.60-2.48 (m, 4H);

HRMS calcd for (M−H⁺, ESI) C₁₁H₁₉NO₈Na₁: 316.1006. Found: 316.1008;

v. BHALys[Lys]² [Glu]₄[α-COC2CO-2-N-α-OMe-Glc]₄[γ-CO₂H]₄

Surface Topology Surface Stoichiometry (((Sacc CO₂H)(Sacc CO₂H))⁴((SaccCO₂H)(Sacc 4 COC₂CO-2-N-α- CO₂H))⁴)⁸ OMe-Glc = Sacc 4 CO₂H

To a stirred solution of BHALys[Lys]₂[Glu]₄[α-NH₂.TFA]₄[γ-CO₂Fm]₄ (100mg, 0.044 mmol) in DMF (5 ml) was added HO—COC2CO-2-N-α-OMe-Glc (78 mg,0.26 mmol) and DIPEA (68 mg, 0.53 mmol) followed by PyBOP (138 mg, 0.26mmol). The reaction mixture was left to stir for 16 hours and thenpiperidine (0.50 ml) was added and the reaction was left for a further 1hour. The mixture was diluted with chloroform and the precipitated solidcollected. The solid was suspended in water (10 ml) and potassiumcarbonate (200 mg) added. A colloidal suspension formed and so 1N NaOH(4 ml) was added. The reaction was stirred for 2 hours and then storedat 4° C. for 16 hours before being acidified with Amberjet 1200 H. Thereaction mixture was filtered, the volatiles removed under reducedpressure and the residue fractionated by RP-HPLC (Phenomenex Synergi,1200 H, 70:30 to 30:70 0.1% TFA in water:MeOH over 55 minutes) to giveBHALys[Lys]₂[Glu]₄[α-COC2CO-2-N-α-OMe-Glc]₄[γ-CO₂H]₄ as a colourlesssolid (32 mg, 33%); HPLC ret time 15.3 min, purity>99% (220 nm, Waterssymmetry, 70:30 to 30:70 0.1% TFA in water:MeOH over 37 minutes);

¹H NMR (300 MHz, D₂O) 7.43-7.24 (m, 10H), 6.07 (s, 1H), 4.37-4.08 (m,7H), 3.92-3.80 (m, 8H), 3.77-3.60 (m, 12H), 3.48-3.38 (m, 4H), 3.34 (m,12H), 3.18-3.00 (m, 6H), 2.62-2.48 (m, 16H), 2.46-2.34 (m, 8H),2.11-1.59 (m, 14H), 1.57-1.13 (m, 12H);

HRMS calcd for (M−2H, Q-TOF) C₉₅H₁₄₃N₁₅O₄₃: m/z 1090.9737. Found:1090.9701.

Example 69 BHALys[Lys]₄[Glu]₈[α-COC2CO-2-N-α-OMe-Glc]₈[γ-CO₂H]₈

Surface Topology Surface Stoichiometry ((((Sacc CO₂H)(SaccCO₂H))⁴((COC2CO-2-N-α- 8 COC₂CO-2-N-α-OMe-Glc = Sacc OMe-Glc CO₂H)(SaccCO₂H))⁴)⁸(((Sacc CO₂H) 8 CO₂H (Sacc CO₂H))⁴((Sacc CO₂H)(SaccCO₂H))⁴)⁸)¹⁶

To a stirred solution of BHALys[Lys]₄[Glu]₈[α-NH₂.TFA]₈[γ-CO₂Me]₈ (100mg, 0.036 mmol) in DMF (3 ml) was added HO—COC2CO-2-N-α-OMe-Glc (150 mg,0.51 mmol) followed by DIPEA (99 mg, 0.76 mmol) then PyBOP (265 mg, 0.52mmol). The reaction mixture was left to stir overnight then diluted withDCM (15 ml) and the precipitated solid collected under vacuum. Theproduct was taken up in water (10 ml) and potassium carbonate (300 mg)added. The mixture was stirred overnight and then 2N NaOH (4 ml, 4.0mmol) added to drive the reaction to completion. The mixture was dilutedto (40 ml), filtered through a 0.45 mm syringe filter and thenultra-filtered through a tangential flow filtration cartridge (mw cutoff650 da) keeping the volume constant at 40 ml, until the solution was pH9 (200 ml filtrate). The retentate was lyophilized and then purified byRP-HPLC (Phenomenex Synergi, 1200 H, 70:30 to 30:70 0.1% TFA inwater:MeOH over 55 minutes). The fractions containing pure product werecombined and concentrated under reduced pressure then the residue wastaken up in water and lyophilized givingBHALys[Lys]₄[Glu]₈[α-COC2CO-2-N-α-OMe-Glc]₈[γ-CO₂H]₈ as a colourlesssolid (12 mg, 9%);

¹H NMR (300 MHz, D₂O) 7.42-7.23 (m, 10H), 6.07 (s, 1H), 4.39-4.11 (m,15H), 3.96-3.79 (m, 16H), 3.78-3.57 (m, 24H), 3.48-3.38 (m, 8H), 3.34(s, 24H), 3.21-3.00 (m, 14H), 2.56 (br s, 32H), 2.37 (br s, 16H),2.13-1.82 (m, 16H), 1.69 (br s, 14H), 1.54-1.18 (m, 28H);

MS calcd for (M−2H, Q-TOF) C₁₈₃H₂₈₇N₃₁O₈₇: m/z 2155.449. Found 2155.737.

Example 70 BHALys[Lys]₄[Glu]₈[α-COC5-α-S-GlcNAc]₈[γ-CO₂Na]₈ i.BHALys[Lys]₄[Glu]₈[α-Boc]₈[γ-CO₂Bn]₈

To a magnetically stirred solution of BHALys[Lys]₄[NH₂.TFA]₈ (400 mg,0.201 mmol), TEA (0.560 ml, 4.01 mmol) and DMF (10 ml) was addedPNPO-Glu-α-Boc-δ-OBn (936 mg, 1.93 mmol) as a solid and in one portionat room temperature. The reaction and product isolation were carried outaccording to the method of Example 1.i to giveBHALys[Lys]₄[Glu]₈[α-Boc]₈[γ-CO₂Bn]₈ (648 mg, 89%) as a white solid.

ii. BHALys[Lys]₄[Glu]₈[α-NH₂.TFA]₈[γ-CO₂Bn]₈

BHALys[Lys]₄[Glu]₈[α-Boc]₈[γ-CO₂Bn]₈ (648 mg, 0.178 mmol) was suspendedin DCM (3.3 ml) and stirred at room temperature. A solution of 1:1TFA/DCM (3.3 ml) was added slowly, causing the suspension to clearrapidly. Stirring was continued for 4 h. The reaction was terminated byremoval of volatiles in vacuo, giving a syrup which was taken up in 1:1methanol/water, concentrated in vacuo, then taken up in water,freeze-dried, re-suspended in methanol and concentrated to giveBHALys[Lys]₄[Glu]₈[α-NH₂.TFA]₈[γ-CO₂Bn]₈ as a colourless foam (677 mg,101%).

LC/MS: ESI (+ve) m/z=1418.35 [M+2H]/2+, 945.64 [M+3H]/3+, 709.64[M+4H]/4+; calculated C151H201N23O31 2834.42 g/mol. Data deconvolutedusing transform calculation to give mw=2834.00. Rf (min)=8.53.

iii. 5-carboxypentyl2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-1-thio-β-D-glucopyranoside

To a stirred solution ofS-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl)thiouroniumchloride (6.5 g, 16.03 mmol) disolved in acetone (25 ml) and water (25ml) was added potassium carbonate (5.54 g, 40.1 mmol) and sodiummetabisulfite (3.09 ml, 24.05 mmol) followed by 6-bromohexanoic acid(3.75 g, 19.24 mmol). The reaction mixture was left to stir for 2 h thenacetone (25 ml) added and the mixture filtered. The residue wasconcentrated under reduced pressure and then acidified with 1N HCl. Theproduct crystallized from solution and was collected. Additional productwas isolated by extracting the mother liquor with EtOAc (2×25 ml). Thecombined product was further purified by flash chromatography giving acolourless solid (4.67 g, 61%).

[α]_(D) ²² −45.9 (c 1.71, CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃) δ 5.68 (d,J=9.4 Hz, 1H), 5.15 (dd, J=9.5, 9.5 Hz, 1H), 5.08 (dd, J=9.5, 9.5 Hz,1H), 4.58 (d, J=10.3 Hz, 1H), 4.23 (dd, J=12.4, 4.8 Hz, 1H), 4.16-4.03(m, 2H), 3.68 (ddd, J=9.5, 4.9, 2.4 Hz, 1H), 2.78-2.62 (m, 2H), 2.35 (t,J=7.0 Hz, 2H), 2.07 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H), 1.96 (s, 3H),1.71-1.56 (m, 4H), 1.52-1.37 (m, 2H). ¹³C NMR (300 MHz, CDCl₃) δ 177.8,171.1, 170.8, 170.3, 169.3, 84.4, 75.9, 73.9, 68.4, 62.3, 53.2, 33.6,29.5, 28.9, 27.9, 24.1, 23.1, 20.7, 20.6, 19.5. HRMS ESI (+ve)m/z=500.1577 [M+Na]+; calculated C₂₀H₃₁N₁O₁₀Na₁S₁ 1500.1566 g/mol.

iv. PNPO—COC5-α-S-(perAc)-GlcNAc

To a stirred solution of 5-carboxypentyl2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-1-thio-β-D-glucopyranoside (1.20g, 2.44 mmol) disolved in ethyl acetate (10 ml) and dichloromethane (10ml) was added 4-nitrophenol (0.50 g, 3.66 mmol) and then EDC (0.70 g,3.66 mmol). The reaction mixture was stirred for 16 h and thenconcentrated under reduced pressure and purified by flash chromatographyto give PNPO—COC5-α-S-(perAc)-GlcNAc as a colourless solid (0.96 g,64%).

[α]_(D) ²² −35.4 (c 1.67, CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃) δ 8.30-8.25(m, 2H), 7.31-7.26 (m, 2H), 5.49 (d, J=9.2 Hz, 1H), 5.16 (dd, J=9.3, 9.3Hz, 1H), 5.09 (dd, J=9.3, 9.3 Hz, 1H), 4.57 (d, J=10.2 Hz, 1H), 4.24(dd, J=12.4, 5.0 Hz, 1H), 4.18-4.05 (m, 2H), 3.68 (ddd, J=9.3, 4.7, 2.3Hz, 1H), 2.82-2.68 (m, 2H), 2.61 (dd, J=2.35 (t, J=7.2 Hz, 2H), 2.08 (s,3H), 2.04 (s, 3H), 2.03 (s, 3H), 1.95 (s, 3H), 1.84-1.47 (m, 6H). ¹³CNMR (300 MHz, CDCl₃) δ 171.0, 170.5, 169.9, 169.2, 155.4, 145.3, 125.2,122.4, 84.5, 76.0, 73.8, 68.3, 62.3, 53.2, 34.0, 29.5, 29.0, 27.9, 24.1,23.2, 20.7, 20.6, 20.5. HRMS ESI (+ve) m/z=620.1731 [M+Na]+; calculatedC₂₆H₃₄N₂Na₁O₁₂S₁ 621.1730 g/mol.

v. BHALys[Lys]₄[Glu]₈[α-COC5-α-S-GlcNAc]₈[γ-CO₂Na]₈

Surface Topology Surface Stoichiometry ((((Sacc CO₂H)(SaccCO₂H))⁴((COC2CO-2-N-α- 8 COC5-α-S-(perAc)-GlcNAc = Sacc OMe-GlcCO₂H)(Sacc CO₂H))⁴)⁸(((Sacc CO₂H) 8 CO₂H (Sacc CO₂H))⁴((Sacc CO₂H)(SaccCO₂H))⁴)⁸)¹⁶

To a stirred solution of BHALys[Lys]₄[Glu]₈[α-NH₂.TFA]₈[γ-CO₂Bn]₈ (59mg, 15.7 μmol) and PNPO—COC5-α-S-(perAc)-GlcNAc (155 mg, 253 μmol) inDMF (3 ml) was added DIPEA (88 μl, 505 μmol). The reaction mixture wasleft to stir for 16 h and then the intermediate peracetate precipitatedwith ether and collected. The filtrate was concentrated under reducedpressure and the residue washed with methanol. The combined isolatedsolids were suspended in water (10 ml) and 2N NaOH (5 ml) added. Thereaction mixture was allowed to stir for 5 h at which time all materialhad dissolved. The mixture was then filtered through a 0.4 micronsyringe filter to remove particulate matter, diluted to (40 ml) withwater and purified by tangential flow filtration using a 1 KDa cutoffmembrane, dialysing with water (600 ml). The retentate was freeze driedgiving BHALys[Lys]₄[Glu]₈[α-COC5-α-S-GlcNAc]₈[γ-CO₂Na]₈ as a slightlyyellow solid (28 mg, 35%).

¹H NMR (300 MHz, D₂O) δ 7.44-7.20 (m, 10H), 6.09 (s, 1H), 4.57 (d,J=10.5 Hz, 8H), 4.37-4.05 (m, 15H), 3.95-3.80 (m, 8H), 3.80-3.63 (m,16H), 3.59-3.48 (m, 8H), 3.49-3.31 (m, 16H), 3.23-2.99 (m, 14H),2.76-2.55 (m, 16H), 2.34-2.14 (m, 32H), 2.08-1.22 (m, 106H), 2.00 (s,24H). HRMS ESI (+ve) calculated C₂₀₇H₃₃₇N₃₁O₇₉S₈ 4777.10 g/mol. Datadeconvoluted using transform calculation to give mw=4777.12.

Example 71 BHALys[Lys]₈[Glu]₁₆ [α-COC5-α-S-GlcNAc]₁₆ [γ-CO₂Na]₁₆ i.BHALys[Lys]₈[Glu]₁₆ [α-Boc]₁₆ [γ-CO₂Bn]₁₆

To a magnetically stirred solution of BHALys[Lys]₈[NH₂.TFA]₁₆ (400 mg,0.102 mmol), TEA (0.567 ml, 4.07 mmol) and DMF (10 ml) was addedPNPO-Glu-α-Boc-δ-OBn (949 mg, 1.95 mmol) as a solid and in one portionat room temperature. Stirring was continued at room temperature for 64h. The crude reaction mixture was concentrated in vacuo to give a syrup,which was triturated with water (50 ml) to give a beige-coloured gum.The water was decanted off the gum, which was triturated with ACN (100ml) giving a white suspension. The white solid was collected byfilteration under suction, washed with ACN (2×50 ml) and air-dried togive BHALys[Lys]₈[Glu]₁₆ [α-Boc]₁₆ [γ-CO₂Bn]₁₆ (757 mg, 103%) as acolourless solid.

ii. BHALys[Lys]₈[Glu]₁₆ [α-NH₂.TFA]₁₆ [γ-CO₂Bn]₁₆

BHALys[Lys]₈[Glu]₁₆ [α-Boc]₁₆ [γ-CO₂Bn]₁₆ (500 mg, 0.069 mmol) wassuspended in DCM (4 ml) and stirred at room temperature. A solution of1:1 TFA/DCM (2.6 ml) was added slowly, causing the suspension to clearrapidly. Stirring was continued for 17 h. The reaction was terminated byremoval of volatiles in vacuo, giving a syrup which was triturated withEther (50 ml), resulting in a white suspension. The solid was collectedby filtration under suction and washed with Ether (2×50 ml) thenair-dried to give BHALys [Lys]₈[Glu]₁₆ [α-NH₂.TFA]₁₆ [γ-CO₂Bn]₁₆ as anoff-white solid (486 mg, 94%).

LC/MS: ESI (+ve) m/z=1872.14 [M+3H]/3+, 1404.36 [M+4H]/4+, 1123.76[M+5H]/5+, 936.43 [M+6H]/6+, 802.97 [M+7H]/7+; calculated C295H401N47O635613.76 g/mol. Data deconvoluted using transform calculation to givemw=5612.83. Rf (min)=5.43.

iii. BHALys[Lys]₈[Glu]₁₆ [α-COC5-α-S-GlcNAc]₁₆ [γ-CO₂Na]₁₆

Surface Topology Surface Stoichiometry ((((Sacc CO₂H)(SaccCO₂H))⁴((COC2CO-2-N-α-OMe- 16 COC5-α-S-(perAc)-GlcNAc = Glc CO₂H)(SaccCO₂H))⁴)⁸(((Sacc CO₂H)(Sacc Sacc CO₂H))⁴((Sacc CO₂H)(Sacc CO₂H))⁴)⁸)¹⁶16 CO₂H ((((Sacc CO₂H)(Sacc CO₂H))⁴((COC2CO-2-N-α-OMe- Glc CO₂H)(SaccCO₂H))⁴)⁸(((Sacc CO₂H)(Sacc CO₂H))⁴((Sacc CO₂H)(Sacc CO₂H))⁴)⁸)¹⁶

To a stirred solution of BHALys[Lys]₈[Glu]₁₆ [α-NH₂.TFA]₁₆ [γ-CO₂Bn]₁₆(58.2 mg, 7.83 μmol) and PNPO—COC5-α-S-(perAc)-GlcNAc (150 mg, 251 μmol)in DMF (3 ml) was added DIPEA (87 μl, 501 μmol). The reaction was leftto stir for 16 h and then the product precipitated using water (25 ml).The precipitate was collected, suspended in water (10 ml) and methanol(2 ml) and 2N NaOH added (3 ml). The reaction was allowed to stir for 5h at which time all of the starting material had dissolved and thesolution was yellow from residual 4-nitrophenol. The mixture was dilutedwith water to a volume of 50 ml and then concentrated using tangentialflow filtration to 30 ml and then dialysed against water (400 ml), 5%Na₂CO₃ solution (100 ml) then water (600 ml) until the solution wasneutral and colourless. The retentate was freeze dried to give BHALys[Lys]₈[Glu]₁₆ [α-COC5-α-S-GlcNAc]₁₆ [γ-CO₂Na]₁₆ as a colourless solid(67 mg, 87%).

¹H NMR (300 MHz, D₂O) 7.40-7.23 (m, 10H), 6.08 (s, 1H), 4.57 (d, J=10.4Hz, 16H), 4.34-4.10 (m, 31H), 3.87 (br d, J=12.2 Hz, 16H), 3.76-3.65 (m,32H), 3.58-3.50 (m, 16H), 3.48-3.38 (m, 32H), 3.20-3.05 (m, 30H),2.78-2.56 (m, 32H), 2.34-2.14 (m, 64H), 2.08-1.22 (m, 218H), 2.01 (s,48H). MS ESI (+ve) calculated C₄₀₇H₆₇₃N₆₃O₁₅₉S₁₆ 9507.2 g/mol. Datadeconvoluted using transform calculation to give mw=9504.2. MS ESI (+ve)calculated C₄₀₇H₆₇₂N₆₃O₁₅₉S₁₆Na 9529.0 g/mol. Data deconvoluted usingtransform calculation to give mw=9525.1.

Example 72BHALys[Lys]₂[α-GlyLys]₂[CO-3,5-Ph(CO₂Me)₂]₄[ε-GlyLys]₂[α-CO-3,5-Ph(CO₂Me)₂]₂[γ-Glu]₂[α-Boc]₂[γ-CO₂Me]₂ i. BnO-GlyLys[α-Fmoc][ε-Boc]

To a magnetically stirred solution of H-Gly-OBn.HCl (1.63 g, 8.06 mmol)and PFP-Lys-α-Fmoc-ε-Boc (4.65 g, 7.33 mmol) in DMF (60 ml) was slowlyadded a solution of DIPEA (1.27 ml, 7.33 mmol) in DMF (40 ml) at roomtemperature. Stirring was continued at room temperature for 18 h. Asolution of DIPEA (64 μl, 0.367 mmol) in DMF (1 ml) was added andstirring was continued for a further 4 h. The reaction was poured ontoiced water (400 ml), the suspension was filtered and solids washed wellwith water then collected under suction and air-dried then dried in avacuum oven at 40° C. and 20 mm Hg to give BnO-GlyLys[α-Fmoc][ε-Boc](4.04 g, 90%).

LC/MS (Hydrophobic/TFA): ESI (+ve) m/z=1249.61 [2M+NH4]+, 1231.59[2M+H]+, 616.25 [M+H]+; calculated C35H41N3O7 615.73 g/mol. Rf(min)=5.66.

ii. BnO-GlyLys[α-NH2][ε-Boc]

BnO-GlyLys[α-Fmoc][ε-Boc] (1.5 g, 2.44 mmol) was dissolved in DMF (100ml) and stirred at room temperature. A solution of piperidine (3.75 ml)in DMF (46.25 ml) was added slowly, and stirring was continued at roomtemperature for 4 h before the reaction was stored at −18° C. for 66 h.The reaction was terminated by removal of volatiles in vacuo, giving anoff-white residue which was triturated with Ether (50 ml), resulting ina white suspension. The etheric solution was collected by filtration,then concentrated under reduced pressure to give an off-white solidunder suction then air-dried to give BnO-GlyLys[α-NH2][ε-Boc] as anoff-white solid (assume 639 mg, 100%) contaminated with Fmoc-Piperidine.This crude mixture was used without further purification.

LC/MS (Hydrophilic/TFA): ESI (+ve) m/z=787.32 [2M+H]+, 394.19 [M+H]+;calculated C20H31N3O5 393.49 g/mol. Rf (min)=7.00.

iii. BnO-GlyLys[α-CO-3,5-Ph(CO₂Me)₂][ε-Boc]

To a solution of BnO-GlyLys[α-NH2][ε-Boc] (500 mg, 1.27 mmol) and1,3-dimethyl 5-(4-nitrophenyl)benzene-1,3,5-tricarboxylate (456 mg, 1.27mmol in DMF (25 ml), stirring at room temperature, was added TEA (0.186ml, 1.33 mmol). The reaction and product isolation were carried outaccording to the method of Example 13.iii to giveBnO-GlyLys[α-CO-3,5-Ph(CO₂Me)₂][ε-Boc] as a clear, pale yellow glass(495 mg, crude).

LC/MS (Hydrophobic/TFA): ESI (+ve) m/z=1250.35 [2M+Na]+, 636.25 [M+Na]+,614.30 [M+H]+; calculated C31H39N3O10 613.67 g/mol. Rf (min)=4.37.

iv. BnO-GlyLys[α-CO-3,5-Ph(CO₂Me)₂][ε-NH₂.TFA]

BnO-GlyLys[α-CO-3,5-Ph(CO₂Me)₂][ε-Boc] (486 mg, 0.792 mmol) wasdissolved in 1:1 TFA/DCM (6 ml) and stirred at room temperature for 4 h.The reaction was concentrated and the residue was triturated with Ether(30 ml), resulting in a white suspension, which was collected by suctionand washed with acetonitrile. The acetonitrile washings wereconcentrated to dryness, yieldingBnO-GlyLys[α-CO-3,5-Ph(CO₂Me)₂][ε-NH₂.TFA] as an orange foam (191 mg,38%).

LC/MS (Hydrophilic/TFA): ESI (+ve) m/z=1027.28 [2M+H]+, 514.09 [M+H]+;calculated C26H31N3O8 513.55 g/mol. Rf (min)=7.05.

v. BnO-GlyLys[α-CO-3,5-Ph(CO₂Me)₂][ε-Glu][α-Boc][γ-CO₂Me]

To a solution of BnO-GlyLys[α-CO-3,5-Ph(CO₂Me)₂][ε-NH₂.TFA] (191 mg,0.304 mmol) in DMF (5 ml), stirring at room temperature, was added TEA(0.106 ml, 0.761 mmol) followed by PNPO-Glu-α-Boc-δ-Me (140 mg, 0.365mmol). The reaction and product isolation were carried out according tothe method of Example 13.iii to give BnO-GlyLys[α-CO-3,5-Ph(CO₂Me)₂][ε-Glu][α-Boc][γ-CO₂Me] as an orange foam (181 mg,79%).

LC/MS (Hydrophobic/TFA): ESI (+ve) m/z=1536.48 [2M+Na]+, 1514.43[2M+H]+, 779.20 [M+Na]+, 757.16 [M+H]+; calculated C37H48N4O13 756.81g/mol. Rf (min)=4.04.

vi. HO-GlyLys[α-CO-3,5-Ph(CO₂Me)₂][ε-Glu][α-Boc][γ-CO₂Me]

BnO-GlyLys[α-CO-3,5-Ph(CO₂Me)₂][ε-Glu][α-Boc][γ-CO₂Me] (90 mg, 0.119mmol) was dissolved in 2,2,2-trifluoroethanol (4 ml) and stirred at roomtemperature. Non-Degussa Pd/C (10%, 0.030 mmol, 32 mg) was added to thedegassed solution and the system was stirred under hydrogen gas (1 atm)for 24 h. The catalyst was removed by filtration and the filtrate wasconcentrated to dryness to giveHO-GlyLys[α-CO-3,5-Ph(CO₂Me)₂][ε-Glu][α-Boc][γ-CO₂Me] as an orange glass(81 mg, 102%).

LC/MS (Hydrophilic/TFA): ESI (+ve) m/z=1556.52 [2M+Na]+, 1333.43[2M+H]+, 689.16 [M+Na]+, 667.21 [M+H]+; calculated C30H42N4O13 666.69g/mol. Rf (min) 7.45.

vii. BnO-GlyLys[Boc]₂

To a magnetically stirred solution of H-Gly-OBn.HCl (2.50 g, 12.4 mmol)in DMF (80 ml) was added TEA (4.4 ml, 31.0 mmol) followed byPNPO-Lys(Boc)₂ (6.96 g, 14.9 mmol). The reaction and product isolationwere carried out according to the method of Example 72.i to giveBnO-GlyLys[Boc]₂ as a pale yellow foam (6.42 g, 105%).

LC/MS (Hydrophobic/TFA): ESI (+ve) m/z=987.45 [2M+H]+, 494.22 [M+H]+;calculated C25H39N3O7 493.61 g/mol. Rf (min)=4.30.

viii. BnO-GlyLys[NH₂.TFA]₂

BnO-GlyLys[Boc]₂ (6.12 g, 12.4 mmol) was suspended in 90 ml DCM andstirred at room temperature while 1:1 TFA/DCM (60 ml) was slowly added.After stirring for 18 h, the reaction was concentrated and the residuetriturated with Ether (80 ml). The gum was lyophilised from water (100ml) yielding BnO-GlyLys[NH₂.TFA]₂ as a hygroscopic off-white foam (6.51g, 101%).

LC/MS (Hydrophilic/TFA): ESI (+ve) m/z=587.30 [2M+H]+, 294.25 [M+H]+;calculated C15H23N3O3 293.37 g/mol. Rf (min)=3.84.

ix. BnO-GlyLys[CO-3,5-Ph(CO₂Me)₂]₂

To a magnetically stirred solution of BnO-GlyLys[NH₂.TFA]₂ (600 mg, 1.15mmol) in DMF (35 ml) was added TEA (0.802 ml, 5.75 mmol) followed by1,3-dimethyl 5-(4-nitrophenyl)benzene-1,3,5-tricarboxylate (990 mg, 2.76mmol). Stirring was continued at room temperature for 18 h. The reactionmixture was concentrated to dryness and the resulting oil was trituratedwith Ether (100 ml) to give a precipitate which was collected bysuction, washed with diethyl ether and air-dried to yieldBnO-GlyLys[CO-3,5-Ph(CO₂Me)₂]₂ as a white solid (754 mg, 89%).

LC/MS (Hydrophobic/TFA): ESI (+ve) m/z=1490.35 [2M+Na]+, 1468.36[2M+H]+, 756.10 [M+Na]+, 734.16 [M+H]+; calculated C37H39N3O13 733.74g/mol. Rf (min)=3.86.

x. HO-GlyLys[CO-3,5-Ph(CO₂Me)₂]₂

BnO-GlyLys[CO-3,5-Ph(CO₂Me)₂]₂ (750 mg, 1.02 mmol) was dissolved in2,2,2-trifluoroethanol (35 ml) and stirred at room temperature.Non-Degussa Pd/C (10%, 0.255 mmol, 271 mg) was added to the degassedsolution and the system was stirred under hydrogen gas (1 atm) for 66 h.The catalyst was removed by filtration and the filtrate was concentratedto dryness to give HO-GlyLys[CO-3,5-Ph(CO₂Me)₂]₂ as a yellow foam (624mg, 94%).

LC/MS (Hydrophilic/TFA): ESI (+ve) m/z=1288.30 [2M+H]+, 644.09 [M+H]+;calculated C30H33N3O13 643.61 g/mol. Rf (min)=7.19.

xi. BHALys[Lys]₂[ε-Boc]₂[α-GlyLys]₂[CO-3,5-Ph(CO₂Me)₂]₄

A magnetically stirred solution of BHALys[Lys]₂[α-NH₂]₂[ε-Boc]₂ (16.4mg, 0.0213 mmol) and HO-GlyLys[CO-3,5-Ph(CO₂Me)₂]₂ (37.0 mg, 0.0575mmol) in DMF (5 ml) was cooled to 0° C., then PyBOP (30.0 mg, 0.0575mmol) was added, followed by DIPEA (19 μl, 0.107 mmol). Stirring wascontinued at 0° C. for 30 mins, then the reaction was warmed to roomtemperature and stirred for 66 h. The reaction was quenched withmethanol (2 ml) and stirred overnight before being applied to a SephadexLH20 column for purification (eluent:methanol) to giveBHALys[Lys]₂[ε-Boc]₂[α-GlyLys]₂[CO-3,5-Ph(CO₂Me)₂]₄ as a clear glass(33.7 mg, 75%), which was characterised by removal of the Boc groups inthe following step.

xii. BHALys[Lys]₂[ε-NH₂.TFA]₂[α-GlyLys]₂[CO-3,5-Ph(CO₂Me)₂]₄

BHALys[Lys]₂[ε-Boc]₂[α-GlyLys]₂[CO-3,5-Ph(CO₂Me)₂]₄ dissolved in 1:1TFA/DCM (2 ml) and stirred at room temperature for 4 h. The reaction wasconcentrated in vacuo, triturated with Ether and dried to giveBHALys[Lys]₂[ε-NH₂.TFA]₂[α-GlyLys]₂[CO-3,5-Ph(CO₂Me)₂]₄ as a clear glass(32.0 mg, 100%).

LC/MS (Hydrophilic/TFA): ESI (+ve) m/z=1819.82 [M+H]+, 910.16 [M+2H]/2+;calculated C91H111N13O27 1818.97 g/mol. Data deconvoluted usingtransform calculation to give mw=1818.58. Rf (min)=9.14.

xiii.BHALys[Lys]₂[α-GlyLys]₂[CO-3,5-Ph(CO₂Me)₂]₄[ε-GlyLys]₂[α-CO-3,5-Ph(CO₂Me)₂]₂[ε-Glu]₂[α-Boc]₂[γ-CO₂Me]₂

Surface Topology Surface Stoichiometry ((((Dianion Ø)(DianionØ))⁴((Dianion Ø)(Anion 6 CO-3,5-Ph(CO₂Me)₂ = Dianion Boc))⁴)⁸(((DianionØ)(Dianion Ø))⁴((Dianion 2 Glutamate CO₂Me = Anion Ø)(Anion Boc))⁴)⁸)¹⁶2 Boc

A magnetically stirred solution ofBHALys[Lys]₂[ε-NH₂.TFA]₂[α-GlyLys]₂[CO-3,5-Ph(CO₂Me)₂]₄ (32 mg, 0.0156mmol) and HO-GlyLys[α-CO-3,5-Ph(CO₂Me)₂]₂[ε-[Glu]₂ [α-Boc]₂[γ-CO₂Me]₂(28 mg, 0.0422 mmol) in DMF (3 ml) was cooled to 0° C., then PyBOP (22mg, 0.0422 mmol) was added, followed by DIPEA (14 μl, 0.0782 mmol).Stirring was continued at 0° C. for 15 mins, then the reaction waswarmed to room temperature and stirred for 18 h. The reaction wasquenched with methanol (2 ml) and stirred for 66 h before being appliedto a Sephadex LH20 column for purification (eluent:methanol) to giveBHALys[Lys]₂[α-GlyLys]₂[CO-3,5-Ph(CO₂Me)₂]₄[ε-GlyLys]₂[α-CO-3,5-Ph(CO₂Me)₂]₂[ε-[Glu]₂[α-Boc]₂[γ-CO₂Me]₂ as a clear glass (31mg, 63%).

LC/MS (Hydrophobic/TFA): ESI (+ve) m/z=1558.93 [M+2H]/2+, 1039.87[M+3H]/3+, 1006.20 [M−Boc+3H]/3+, 972.66 [M−2Boc+3H]/3+; calculatedC151H191N21O51 3116.32 g/mol. Data deconvoluted using transformcalculation to give mw=3116.22. Rf (min)=5.97.

Example 73 Assays for Anti-Inflammatory Activity

Methods

1. Cell Culture

THP-1 cells were cultured in RPMI 1640 medium (ICN) containing 10% heatinactivated foetal calf serum (FCS), 1.5 g/L sodium bicarbonate (ICN),10 nM HEPES buffer (Sigma), 1 mM sodium pyruvate (JRH), 0.05 mM2-Mercaptoethanol (Sigma), 2 mM L-glutamine and Penicillin/Streptomycin(Life Technologies). They were maintained in medium TC flasks (Cellstar)at a density of <1×10⁻⁶ cells/mL. All experiments were performed incells with passage numbers between 3-8.

2. Experimental Procedure

Cells from one or more TC flasks were collected, counted and transferredto a new TC flask in low-serum medium (0.5% FCS/RPMI). The next day, thecells were counted and seeded into wells of a 24-well plate (Sarstedt)at 5×10⁵ cells/well in 0.5% FCS/RPMI.

Compound treatments, vehicle controls and dexamethasone (Dex) wereimmediately added to the appropriate wells. The plate was then incubatedat 37 degrees, 5% CO2 for 30 minutes. Lipopolysaccharide (LPS—Sigma) wasthen added to appropriate wells and the plate was incubated for afurther 4 hours at 37 degrees, 5% CO2.

After 4 hours, the contents of each well were collected into 1.5 mLtubes (Eppendorf) and centrifuged to pellet the cells. The supernatantwas then collected and stored at −80° C.

3. Enzyme-Linked Immunosorbent Assay (ELISA) Procedure

Supernatants were assayed to determine levels of MIP-1beta and TNF-alphaby standard ELISAs.

3.i TNF Alpha ELISA

Day 1:

ELISA plates coated with monoclonal anti-TNFα capture antibody (R&DSystems) in a volume of 100 uL at 4 ug/mL in PBS. Plates incubatedovernight at 4° C.

Day 2:

Plates washed (×3) with 0.05% Tween 20/PBS

Plates blocked for 2 hrs in 0.1% BSA/PBS

Plates washed (×3) with 0.05% Tween 20/PBS

Supernatants, diluted in 1% BSA/PBS added to plate (100 uL volume/well)along with recombinant human TNF (R&D Systems) as reference standard.Plates incubated overnight at 4° C.

Day 3:

Plates washed (×3) with 0.05% Tween 20/PBS

100 uL of anti-human TNF biotinylated affinity purified polyclonalantibody (R&D Systems) added to each well at 300 ng/mL in 1% BSA/PBS

Plates washed (×3) with 0.05% Tween 20/PBS

100 uL Streptavidin HRP (Chemicon) added to each well (diluted 1/1000 in1% BSA/PBS).

Plate incubated for 2 hrs at room temperature, then washed (×3) with0.05% Tween 20/PBS.

100 uL TMB substrate solution added to each well and plate incubated inthe dark for 10-20 minutes.

100 uL of stop solution (0.5M H₂SO₄) added to each well; plates readimmediately on Victor3 plate reader at a wavelength of 450 nm.

3.ii MIP-1b ELISA

Day 1:

ELISA plates coated with monoclonal anti-MIP-1b capture antibody (R&DSystems) in a volume of 100 uL at 1 ug/mL in phosphate buffered saline(PBS).

Plates incubated overnight at 4° C.

Day 2:

Plates washed (×3) with 0.05% Tween 20/PBS

Plates blocked for 2 hrs in 0.1% BSA/PBS

Plates washed (×3) with 0.05% Tween 20/PBS

Supernatants, diluted in 1% BSA/PBS added to plate in duplicate wells(100 uL volume/well).

Recombinant human MIP-1b (R&D Systems) added as reference standard.Plates incubated overnight at 4° C.

Day 3:

Plates washed (×3) with 0.05% Tween 20/PBS

100 uL of anti-human MIP-1b biotinylated affinity purified polyclonalantibody (R&D Systems) added to each well at 50 ng/mL in 1% BSA/PBS

Plates washed (×3) with 0.05% Tween 20/PBS

100 uL Streptavidin HRP (Chemicon) added to each well (diluted 1/1000 in1% BSA/PBS).

Plate incubated for 2 hrs at room temperature.

Plates washed (×3) with 0.05% Tween 20/PBS

100 uL TMB substrate solution added to each well. Plate incubated in thedark for 10-20 minutes.

100 uL of stop solution (0.5M H2SO4) added to each well.

Plates read immediately on Victor3 plate reader at a wavelength of 450nm.

3.iii Standard Curves for TNF and MIP-1b

Stock recombinant protein at 10 μg/mL

Dilute stock 2 μL/1000 uL 1% BSA/PBS (1)

Dilute (1) 50 μL/1000 uL 1% BSA/PBS (Standard A 1 ng/mL)

Dilute A 220 μL/440 uL 1% BSA/PBS (Standard B 0.5 ng/mL)

Dilute B 220 μL/440 uL 1% BSA/PBS (Standard C 0.25 ng/mL)

Dilute C 220 μL/440 uL 1% BSA/PBS (Standard D 0.125 ng/mL)

Dilute D 220 μL/440 uL 1% BSA/PBS (Standard E 0.0625 ng/mL)

Dilute E 220 μL/440 uL 1% BSA/PBS (Standard F 0.0312 ng/mL)

Dilute F 220 μL/440 uL 1% BSA/PBS (Standard G 0.0156 ng/mL)

Blank (1% BSA/PBS alone)

4. Data Analysis

Data were analysed for statistically significant inhibition of cytokinerelease by 1-way ANOVA with Tukey's post test, and if applicable IC50were derived. GraphPad Prism® 4 software was used.

TABLE 27 Anti-Inflammatory activity of selected Examples. TNF-α IC₅₀MIP-1β IC₅₀ Compound # Name (μg/ml) (μg/ml) 73.1^(a) BHALys[Lys]₁₆[COC2CO-2-N-α-OMe-Glc]₃₂ NA NA 73.2^(a) BHALys[Lys]₁₆[COC2-β-S-GlcNAc]₃₂ Weak NS @ [max] 73.3^(a) BHALys[Lys]₄[COC2-β-S-GlcNAc]₈ NA NA 73.4^(a) BHALys [Lys]₈[COC2CO-2-N-Glc]₁₆NA NA 73.5^(a) BHALys [Lys]₈[COC2CO-2-N-α-OMe-Glc]₁₆ NA NA 73.6^(a)BHALys [Lys]₈[COC2-β-S-GlcNAc]₁₆ NA NA 73.7^(a) MorphLys[Lys]₈[COC2-β-S-GlcNAc]₁₆ NA NA 73.8^(a) BHALys[Lys]₄[COC2CO-2-N-α-OMe-Glc]₈ 64.8 84.8 73.9^(a) MorphLys[Lys]₄[COC2CO-2-N-α-OMe-Glc]₈ NA NA 73.10^(a) MorphLys[Lys]₄[COC2-β-S-GlcNAc]₈ NA NA 73.11^(b) [BHAlys][Lys]16[CONH-Ph-3,5-56.7 74.7 (SO3Na)2]32 73.12^(b) BHALys [Lys]16[A-3,5-BDC]32 132.3 202.2^(a)The preparation of these compounds has been described in Provisionalpatent application: AU2006XXXXXXX ^(b)The preparation of these compoundshas been described in AU2005905858

This data indicates that macromolecules with controlledstoichiometry/topology of Functional Moieties that are either anionic orare N-Acetyl Glucose or analogues thereof, may have anti-inflammatoryproperties.

1. A dendritic motif, comprising at least one subsurface layer of one ormore building units and a surface layer of two or more surface buildingunits wherein the surface layer has at least two different functionalmoieties attached thereto, provided that when there are only two typesof functional moiety A and B, the number of functional moieties A doesnot equal the number of functional moieties B, wherein said functionalmoieties comprise a first and second functional moiety, each selectedfrom the groups consisting of protecting groups, ligands forextracellular receptors, property modifiers, pharmaceutically activeagents or precursors thereof, groups to effect targeting, groups toeffect signalling, antigenic material, genetic material and groups tomediate binding to second entity wherein said building units areselected from the group consisting of: Lysine 1: having the structure:

Glycyl-Lysine 2 having the structure:

Analogue 3, having the structure below, where a is an integer of 1 or 2;b and c are the same or different and are integers of 1 to 4:

Analogue 4, having the structure below, where a is an integer of 0 to 2;b and c are the same or different and are integers of 2 to 6:

Analogue 5, having the structure below, where a is an integer of 0 to 5;b and c are the same or different and are integers of 1 to 5:

Analogue 6, having the structure below, where a is an integer of 0 to 5;b and c are the same or different and are integers of 0 to 5:

Analogue 7, having the structure below, where a is an integer of 0 to 5;b and c are the same or different and are integers of 1 to 5:

and Analogue 9, having the structure below, where a is an integer of 0to 5; b and c are the same or different and are integers of 1 to 5:

and said surface building units are selected from the group consistingof: Lysine 1, Glycyl-Lysine 2, Analogues 3, 4, 5, 6, 7 and 9 above,Analogue 10, having the structure below, where a is an integer of 0 to2; b and c are the same or different and are integers of 1 to 4; A₁ andA₂ are the same or different and selected from NH₂, CO₂H, OH, SH, X,Allyl-X, epoxide, aziridine, N₃ or alkyne, where X is F, Cl, Br or I,

Analogue 11, having the structure below, where a is an integer of 0 to2; b and c are the same or different and are integers of 2 to 6; A₁ andA₂ are the same or different and selected from NH₂, CO₂H, OH, SH, X,Allyl-X, epoxide, aziridine, N₃ or alkyne, where X is F, Cl, Br or I,

Analogue 12, having the structure below, where a is an integer of 0 to5; b and c are the same or different and are integers of 1 to 5; A₁ andA₂ are the same or different and selected from NH₂, CO₂H, OH, SH, X,Allyl-X, epoxide, aziridine, N₃ or alkyne, where X is F, Cl, Br or I,

Analogue 13, having the structure below, where a is an integer of 0 to5; b and c are the same or different and are integers of 0 to 5; A₁ andA₂ are the same or different and selected from NH₂, CO₂H, OH, SH, X,Allyl-X, epoxide, aziridine, N₃ or alkyne, where X is F, Cl, Br or I,

Analogue 14, having the structure below, where a is an integer of 0 to5; b and c are the same or different and are integers of 1 to 5; A₁ andA₂ are the same or different and selected from NH₂, CO₂H, OH, SH, X,Allyl-X, epoxide, aziridine, N₃ or alkyne, where X is F, Cl, Br or I,

and Analogue 16 having the structure below, where a is an integer of 0to 5; b and c are the same or different and are integers of 1 to 5; A₁and A₂ are the same or different and selected from NH₂, CO₂H, OH, SH, X,where X is F, Cl, Br or I, Allyl-X where X is F, Cl, Br or I, epoxide,arizidine, N₃ or alkyne


2. A dendritic motif according to claim 1 wherein said surface layer hasa functional moiety topology selected from the group consisting of:quartets of the type: ((AA)(AB))⁴, ((AB)(AB))⁴, ((AA)(BD))⁴,((AB)(AD))⁴, ((BB)(AD))⁴, ((DD)(AB))⁴, ((BD)(AB))⁴, and ((BD)(AD))⁴;octets of the type: (((AA)(AA))⁴((AA)(AB))⁴)⁸,(((AA)(BB))⁴((AD)(AD))⁴)⁸, (((AA)(AA))⁴((AA)(BB))⁴)⁸,(((AB)(AB))⁴((AA)(DD))⁴)⁸, (((AA)(AA))⁴((AB)(AB))⁴)⁸,(((AB)(AB))⁴((AD)(AD))⁴)⁸, (((AA)(AB))⁴((AA)(AB))⁴)⁸,(((AA)(AB))⁴((BB)(DD))⁴)⁸, (((AA)(AA))⁴((AB)(BB))⁴)⁸,(((AA)(AB))⁴((BD)(BD))⁴)⁸, (((AA)(AB))⁴((AA)(BB))⁴)⁸,(((AA)(BB))⁴((AB)(DD))⁴)⁸, (((AA)(AB))⁴((AB)(AB))⁴)⁸,(((AA)(BB))⁴((AD)(BD))⁴)⁸, (((BB)(BB))⁴((BB)(AB))⁴)⁸,(((AB)(AB))⁴((AB)(DD))⁴)⁸, (((BB)(BB))⁴((BB)(AA))⁴)⁸,(((AB)(AB))⁴((AD)(BD))⁴)⁸, (((BB)(BB))⁴((AB)(AB))⁴)⁸,(((BB)(BB))⁴((BB)(AD))⁴)⁸, (((BB)(BA))⁴((BB)(AB))⁴)⁸,(((BB)(BB))⁴((AB)(BD))⁴)⁸, (((BB)(BB))⁴((AA)(AB))⁴)⁸,(((BB)(AB))⁴((BB)(BD))⁴)⁸, (((BB)(AB))⁴((AA)(BB))⁴)⁸,(((BB)(BB))⁴((BD)(AA))⁴)⁸, (((BB)(AB))⁴((AB)(AB))⁴)⁸,(((BB)(BB))⁴((AB)(AD))⁴)⁸, (((AA)(AA))⁴((AA)(BD))⁴)⁸,(((BB)(AB))⁴((BB)(AD))⁴)⁸, (((AA)(AA))⁴((AB)(AD))⁴)⁸,(((BB)(AB))⁴((AB)(BD))⁴)⁸, (((AA)(AB))⁴((AA)(AD))⁴)⁸,(((AA)(AB))⁴((DD)(DD))⁴)⁸, (((AA)(AA))⁴((AD)(BB))⁴)⁸,(((AA)(AD))⁴((BD)(DD))⁴)⁸, (((AA)(AA))⁴((AB)(BD))⁴)⁸,(((AA)(BD))⁴((AD)(DD))⁴)⁸, (((AA)(AB))⁴((AA)(BD))⁴)⁸,(((AD)(BD))⁴((AD)(DD))⁴)⁸, (((AA)(AB))⁴((AB)(AD))⁴)⁸,(((AA)(DD))⁴((AB)(DD))⁴)⁸, (((AA)(AA))⁴((BB)(BD))⁴)⁸,(((AA)(DD))⁴((AD)(BD))⁴)⁸, (((AA)(AD))⁴((BB)(BA))⁴)⁸,(((AD)(AD))⁴((AB)(DD))⁴)⁸, (((AA)(AB))⁴((AB)(BD))⁴)⁸,(((AD)(AD))⁴((AD)(BD))⁴)⁸, (((AA)(AB))⁴((BB)(AD))⁴)⁸,(((BB)(BB))⁴((AA)(DD))⁴)⁸, (((AA)(BD))⁴((AA)(BB))⁴)⁸,(((BB)(BB))⁴((AD)(AD))⁴)⁸, (((AA)(BD))⁴((AB)(AB))⁴)⁸,(((BB)(AB))⁴((AB)(DD))⁴)⁸, (((AB)(AD))⁴((AA)(BB))⁴)⁸,(((BB)(AB))⁴((AD)(BD))⁴)⁸, (((AB)(AD))⁴((AB)(AB))⁴)⁸,(((AA)(BB))⁴((BB)(DD))⁴)⁸, (((AA)(AA))⁴((BB)(DD))⁴)⁸,(((AA)(BB))⁴((BD)(BD))⁴)⁸, (((AA)(AA))⁴((BD)(BD))⁴)⁸,(((AB)(AB))⁴((BB)(DD))⁴)⁸, (((AA)(AB))⁴((AB)(DD))⁴)⁸,(((AB)(AB))⁴((AD)(AD))⁴)⁸, (((AA)(AB))⁴((AD)(BD))⁴)⁸,(((BB)(AB))⁴((AA)(DD))⁴)⁸, (((AA)(BB))⁴((AA)(DD))⁴)⁸,(((BB)(AB))⁴((AD)(AD))⁴)⁸, (((AA)(DD))⁴((AD)(BB))⁴)⁸,(((AA)(DD))⁴((AB)(BD))⁴)⁸, (((AD)(AD))⁴((AD)(BB))⁴)⁸, and(((AD)(AD))⁴((AB)(BD))⁴)⁸;

16-tets of the type:((((AA)(AA))⁴((AA)(AA))⁴)⁸(((AB)(AB))⁴((AB)(AB))⁴)⁸)¹⁶;((((AA)(AA))⁴((AB)(AB))⁴)⁸(((AB)(AB))⁴((AB)(AB))⁴)⁸)¹⁶; and((((AA)(AA))⁴((AA)(AA))⁴)⁸(((BD)(BD))⁴((BD)(BD))⁴)⁸)¹⁶; and 16-tetscomposed of two octets, wherein the octets are independently selectedfrom the octets listed above, wherein A, B and D are differentfunctional moieties.
 3. A dendritic motif according to claim 1, whereinthe building unit is lysine, glycyl-lysine or Analogue 5, wherein a isan integer of 0 to
 2. 4. A dendritic motif according to claim 1, whereinthe surface building unit is lysine.
 5. A macromolecule comprising acore moiety to which is attached at least a first dendritic motif, saidfirst dendritic motif being a motif according to claim 1; wherein saidcore moiety is selected from the group consisting of: a diamine compoundselected from the benzhydrylamide of lysine or other lysine amide or:

where a is an integer of 1 to 9, preferably 1 to 5;

where a, b and c, which may be the same or different, and are integersof 1-5, and d is an integer from 0-100;

where a and b, may be the same or different, and are integers of 0 to 5;

where a and c, which may be the same or different, are integers of 1 to6 and where b is an integer from 0 to 6;

where a and d, which may be the same or different, are integers of 1 to6 and where b and c, which may be the same or different, are integersfrom 0 to 6; a triamine compound selected from the group consisting of:

where a, b and c, which may be the same or different, are integers of 1to 6;

where a, b and c, which may be the same or different, are integers of 0to 6;

where a, b and c, which may be the same or different, are integers of 0to 6;

where a, b and c, which may be the same or different, are integers of 0to 6; and d, e and f, which may be the same or different, are integersof 1 to 6;

where a, b and c, which may be the same or different, are integers of 1to 6; or a tetramine compound selected from the group consisting of:

where a, b, c and d, which may be the same or different, are integers of0 to 6;

where a, b, c and d, which may be the same or different, are integers of1 to 6; and

where a, b, c and d, which may be the same or different, are integers of0 to 6; and e, f, g and h, which may be the same or different, areintegers of 1 to
 6. 6. A macromolecule according to claim 5 comprising asecond dendritic motif, said second dendritic motif comprising at leastone subsurface layer of one or more building units and a surface layerof two or more surface building units, wherein at least two differentfunctional groups are attached to the surface of the macromolecule andwherein said building units of the second dendritic motif are selectedfrom the group consisting of: Lysine 1: having the structure:

Glycyl-Lysine 2 having the structure:

Analogue 3, having the structure below, where a is an integer of 1 or 2;b and c are the same or different and are integers of 1 to 4:

Analogue 4, having the structure below, where a is an integer of 0 to 2;b and c are the same or different and are integers of 2 to 6:

Analogue 5, having the structure below, where a is an integer of 0 to 5;b and c are the same or different and are integers of 1 to 5:

Analogue 6, having the structure below, where a is an integer of 0 to 5;b and c are the same or different and are integers of 0 to 5:

Analogue 7, having the structure below, where a is an integer of 0 to 5;b and c are the same or different and are integers of 1 to 5:

Analogue 9, having the structure below, where a is an integer of 0 to 5;b and c are the same or different and are integers of 1 to 5:

said surface building units of the second dendritic motif are selectedfrom the group consisting of: Lysine 1, Glycyl-Lysine 2, Analogues 3, 4,5, 6, 7 and 9 above, Analogue 10, having the structure below, where a isan integer of 0 to 2; b and c are the same or different and are integersof 1 to 4; A₁ and A₂ are the same or different and selected from NH₂,CO₂H, OH, SH, X, Allyl-X, epoxide, aziridine, N₃ or alkyne, where X isF, Cl, Br or I,

Analogue 11, having the structure below, where a is an integer of 0 to2; b and c are the same or different and are integers of 2 to 6; A₁ andA₂ are the same or different and selected from NH₂, CO₂H, OH, SH, X,Allyl-X, epoxide, aziridine, N₃ or alkyne, where X is F, Cl, Br or I,

Analogue 12, having the structure below, where a is an integer of 0 to5; b and c are the same or different and are integers of 1 to 5; A₁ andA₂ are the same or different and selected from NH₂, CO₂H, OH, SH, X,Allyl-X, epoxide, aziridine, N₃ or alkyne, where X is F, Cl, Br or I,

Analogue 13, having the structure below, where a is an integer of 0 to5; b and c are the same or different and are integers of 0 to 5; A₁ andA₂ are the same or different and selected from NH₂, CO₂H, OH, SH, X,Allyl-X, epoxide, aziridine, N₃ or alkyne, where X is F, Cl, Br or I,

Analogue 14, having the structure below, where a is an integer of 0 to5; b and c are the same or different and are integers of 1 to 5; A₁ andA₂ are the same or different and selected from NH₂, CO₂H, OH, SH, X,Allyl-X, epoxide, aziridine, N₃ or alkyne, where X is F, Cl, Br or I,

and Analogue 16 having the structure below, where a is an integer of 0to 5; b and c are the same or different and are integers of 1 to 5; A₁and A₂ are the same or different and selected from NH₂, CO₂H, OH, SH, X,Allyl-X, epoxide, aziridine, N₃ or alkyne, where X is F, Cl, Br or I,


7. A macromolecule according to claim 6 wherein the surface layer of afirst dendritic motif has a functional moiety topology selected from thegroup consisting of: quartets of the type: ((AA)(AB))⁴, ((AB)(AB))⁴,((AA)(BD))⁴, ((AB)(AD))⁴, ((BB)(AD))⁴, ((DD)(AB))⁴, ((BD)(AB))⁴ and((BD)(AD))⁴; octets of the type: (((AA)(AA))⁴((AA)(AB))⁴)⁸,(((AB)(AB))⁴((AD)(AD))⁴)⁸, (((AA)(AA))⁴((AA)(BB))⁴)⁸,(((AA)(AB))⁴((BB)(DD))⁴)⁸, (((AA)(AA))⁴((AB)(AB))⁴)⁸,(((AA)(AB))⁴((BD)(BD))⁴)⁸, (((AA)(AB))⁴((AA)(AB))⁴)⁸,(((AA)(BB))⁴((AB)(DD))⁴)⁸, (((AA)(AA))⁴((AB)(BB))⁴)⁸,(((AA)(BB))⁴((AD)(BD))⁴)⁸, (((AA)(AB))⁴((AA)(BB))⁴)⁸,(((AB)(AB))⁴((AB)(DD))⁴)⁸, (((AA)(AB))⁴((AB)(AB))⁴)⁸,(((AB)(AB))⁴((AD)(BD))⁴)⁸, (((BB)(BB))⁴((BB)(AB))⁴)⁸,(((BB)(BB))⁴((BB)(AD))⁴)⁸, (((BB)(BB))⁴((BB)(AA))⁴)⁸,(((BB)(BB))⁴((AB)(BD))⁴)⁸, (((BB)(BB))⁴((AB)(AB))⁴)⁸,(((BB)(AB))⁴((BB)(BD))⁴)⁸, (((BB)(BA))⁴((BB)(AB))⁴)⁸,(((BB)(BB))⁴((BD)(AA))⁴)⁸, (((BB)(BB))⁴((AA)(AB))⁴)⁸,(((BB)(BB))⁴((AB)(AD))⁴)⁸, (((BB)(AB))⁴((AA)(BB))⁴)⁸,(((BB)(AB))⁴((BB)(AD))⁴)⁸, (((BB)(AB))⁴((AB)(AB))⁴)⁸,(((BB)(AB))⁴((AB)(BD))⁴)⁸, (((AA)(AA))⁴((AA)(BD))⁴)⁸,(((AA)(AB))⁴((DD)(DD))⁴)⁸, (((AA)(AA))⁴((AB)(AD))⁴)⁸,(((AA)(AD))⁴((BD)(DD))⁴)⁸, (((AA)(AB))⁴((AA)(AD))⁴)⁸,(((AA)(BD))⁴((AD)(DD))⁴)⁸, (((AA)(AA))⁴((AD)(BB))⁴)⁸,(((AD)(BD))⁴((AD)(DD))⁴)⁸, (((AA)(AA))⁴((AB)(BD))⁴)⁸,(((AA)(DD))⁴((AB)(DD))⁴)⁸, (((AA)(AB))⁴((AA)(BD))⁴)⁸,(((AA)(DD))⁴((AD)(BD))⁴)⁸, (((AA)(AB))⁴((AB)(AD))⁴)⁸,(((AD)(AD))⁴((AB)(DD))⁴)⁸, (((AA)(AA))⁴((BB)(BD))⁴)⁸,(((AD)(AD))⁴((AD)(BD))⁴)⁸, (((AA)(AD))⁴((BB)(BA))⁴)⁸,(((BB)(BB))⁴((AA)(DD))⁴)⁸, (((AA)(AB))⁴((AB)(BD))⁴)⁸,(((BB)(BB))⁴((AD)(AD))⁴)⁸, (((AA)(AB))⁴((BB)(AD))⁴)⁸,(((BB)(AB))⁴((AB)(DD))⁴)⁸, (((AA)(BD))⁴((AA)(BB))⁴)⁸,(((BB)(AB))⁴((AD)(BD))⁴)⁸, (((AA)(BD))⁴((AB)(AB))⁴)⁸,(((AA)(BB))⁴((BB)(DD))⁴)⁸, (((AB)(AD))⁴((AA)(BB))⁴)⁸,(((AA)(BB))⁴((BD)(BD))⁴)⁸, (((AB)(AD))⁴((AB)(AB))⁴)⁸,(((AB)(AB))⁴((BB)(DD))⁴)⁸, (((AA)(AA))⁴((BB)(DD))⁴)⁸,(((AB)(AB))⁴((AD)(AD))⁴)⁸, (((AA)(AA))⁴((BD)(BD))⁴)⁸,(((BB)(AB))⁴((AA)(DD))⁴)⁸, (((AA)(AB))⁴((AB)(DD))⁴)⁸,(((BB)(AB))⁴((AD)(AD))⁴)⁸, (((AA)(AB))⁴((AD)(BD))⁴)⁸,(((AA)(DD))⁴((AD)(BB))⁴)⁸, (((AA)(BB))⁴((AA)(DD))⁴)⁸, and(((AA)(BB))⁴((AD)(AD))⁴)⁸, (((AB)(AB))⁴((AA)(DD))⁴)⁸,

16-tets of the type:((((AA)(AA))⁴((AA)(AA))⁴)⁸(((AB)(AB))⁴((AB)(AB))⁴)⁸)¹⁶;((((AA)(AA))⁴((AB)(AB))⁴)⁸(((AB)(AB))⁴((AB)(AB))⁴)⁸)¹⁶; and((((AA)(AA))⁴((AA)(AA))⁴)⁸(((BD)(BD))⁴((BD)(BD))⁴)⁸)¹⁶; and 16-tetscomposed of two octets, wherein each octet independently selected fromthe group consisting of the octets immediately above, and the surfacelayer of a second dendritic motif has a functional moiety topologyselected from the group consisting of: quartets of the type:((AA)(AB))⁴, ((AA)(BB))⁴, ((AB)(AB))⁴, ((AA)(BD))⁴, ((AB)(AD))⁴,((BB)(AD))⁴, ((DD)(AB))⁴, ((BD)(AB))⁴, ((BD)(AD))⁴, ((AA)(AA))⁴,((BB)(BB))⁴, ((DD)(DD))⁴, and ((AB)(AB))⁴; octets of the type:(((AA)(AA))⁴((AA)(AB))⁴)⁸, (((AB)(AB))⁴((AD)(AD))⁴)⁸,(((AA)(AA))⁴((AA)(BB))⁴)⁸, (((AA)(AB))⁴((BB)(DD))⁴)⁸,(((AA)(AA))⁴((AB)(AB))⁴)⁸, (((AA)(AB))⁴((BD)(BD))⁴)⁸,(((AA)(AB))⁴((AA)(AB))⁴)⁸, (((AA)(BB))⁴((AB)(DD))⁴)⁸,(((AA)(AA))⁴((AB)(BB))⁴)⁸, (((AA)(BB))⁴((AD)(BD))⁴)⁸,(((AA)(AB))⁴((AA)(BB))⁴)⁸, (((AB)(AB))⁴((AB)(DD))⁴)⁸,(((AA)(AB))⁴((AB)(AB))⁴)⁸, (((AB)(AB))⁴((AD)(BD))⁴)⁸,(((AA)(AA))⁴((BB)(BB))⁴)⁸, (((BB)(BB))⁴((BB)(AD))⁴)⁸,(((AA)(AB))⁴((AB)(BB))⁴)⁸, (((BB)(BB))⁴((AB)(BD))⁴)⁸,(((AA)(BB))⁴((AA)(BB))⁴)⁸, (((BB)(AB))⁴((BB)(BD))⁴)⁸,(((AA)(BB))⁴((AB)(AB))⁴)⁸, (((BB)(BB))⁴((BD)(AA))⁴)⁸,(((BB)(BB))⁴((BB)(AB))⁴)⁸, (((BB)(BB))⁴((AB)(AD))⁴)⁸,(((BB)(BB))⁴((BB)(AA))⁴)⁸, (((BB)(AB))⁴((BB)(AD))⁴)⁸,(((BB)(BB))⁴((AB)(AB))⁴)⁸, (((BB)(AB))⁴((AB)(BD))⁴)⁸,(((BB)(BA))⁴((BB)(AB))⁴)⁸, (((AA)(AB))⁴((DD)(DD))⁴)⁸,(((BB)(BB))⁴((AA)(AB))⁴)⁸, (((AA)(AD))⁴((BD)(DD))⁴)⁸,(((BB)(AB))⁴((AA)(BB))⁴)⁸, (((AA)(BD))⁴((AD)(DD))⁴)⁸,(((BB)(AB))⁴((AB)(AB))⁴)⁸, (((AD)(BD))⁴((AD)(DD))⁴)⁸,(((AA)(AA))⁴((AA)(BD))⁴)⁸, (((AA)(DD))⁴((AB)(DD))⁴)⁸,(((AA)(AA))⁴((AB)(AD))⁴)⁸, (((AA)(DD))⁴((AD)(BD))⁴)⁸,(((AA)(AB))⁴((AA)(AD))⁴)⁸, (((AD)(AD))⁴((AB)(DD))⁴)⁸,(((AA)(AA))⁴((AD)(BB))⁴)⁸, (((AD)(AD))⁴((AD)(BD))⁴)⁸,(((AA)(AA))⁴((AB)(BD))⁴)⁸, (((BB)(BB))⁴((AA)(DD))⁴)⁸,(((AA)(AB))⁴((AA)(BD))⁴)⁸, (((BB)(BB))⁴((AD)(AD))⁴)⁸,(((AA)(AB))⁴((AB)(AD))⁴)⁸, (((BB)(AB))⁴((AB)(DD))⁴)⁸,(((AA)(AA))⁴((BB)(BD))⁴)⁸, (((BB)(AB))⁴((AD)(BD))⁴)⁸,(((AA)(AD))⁴((BB)(BA))⁴)⁸, (((AA)(BB))⁴((BB)(DD))⁴)⁸,(((AA)(AB))⁴((AB)(BD))⁴)⁸, (((AA)(BB))⁴((BD)(BD))⁴)⁸,(((AA)(AB))⁴((BB)(AD))⁴)⁸, (((AB)(AB))⁴((BB)(DD))⁴)⁸,(((AA)(BD))⁴((AA)(BB))⁴)⁸, (((AB)(AB))⁴((AD)(AD))⁴)⁸,(((AA)(BD))⁴((AB)(AB))⁴)⁸, (((BB)(AB))⁴((AA)(DD))⁴)⁸,(((AB)(AD))⁴((AA)(BB))⁴)⁸, (((BB)(AB))⁴((AD)(AD))⁴)⁸,(((AB)(AD))⁴((AB)(AB))⁴)⁸, (((AA)(DD))⁴((AD)(BB))⁴)⁸,(((AA)(AA))⁴((BB)(DD))⁴)⁸, (((AA)(DD))⁴((AB)(BD))⁴)⁸,(((AA)(AA))⁴((BD)(BD))⁴)⁸, (((AD)(AD))⁴((AD)(BB))⁴)⁸,(((AA)(AB))⁴((AB)(DD))⁴)⁸, (((AD)(AD))⁴((AB)(BD))⁴)⁸,(((AA)(AB))⁴((AD)(BD))⁴)⁸, (((AA)(AA))⁴((AA)(AA))⁴)⁸,(((AA)(BB))⁴((AA)(DD))⁴)⁸, (((BB)(BB))⁴((BB)(BB))⁴)⁸,(((AA)(BB))⁴((AD)(AD))⁴)⁸, (((DD)(DD))⁴((DD)(DD))⁴)⁸,(((AB)(AB))⁴((AA)(DD))⁴)⁸, and (((AB)(AB))⁴((AB)(AB))⁴)⁸;

16-tets of the type:((((AA)(AA))⁴((AA)(AA))⁴)⁸(((BD)(BD))⁴((BD)(BD))⁴)⁸)¹⁶;((((BB)(DD))⁴((BB)(DD))⁴)⁸(((BB)(DD))⁴((BB)(DD))⁴)⁸)¹⁶;((((BB)(BB))⁴((DD)(DD))⁴)⁸(((BB)(BB))⁴((DD)(DD))⁴)⁸)¹⁶; and((((BD)(BD))⁴((BD)(BD))⁴)⁸(((BD)(BD))⁴((BD)(BD))⁴)⁸)¹⁶; and 16-tetscomposed of two octets, each octet is independently selected from thegroup consisting of the octets listed immediately above, wherein A, Band D are different functional moieties.
 8. A macromolecule according toclaim 6, wherein the core is BHA-Lysine.
 9. A macromolecule according toclaim 6, wherein the building unit of the at least two dendritic motifsis lysine, glycyl-lysine or Analogue 5, wherein a is an integer of 0 to2.
 10. A macromolecule according to claim 6, wherein the surfacebuilding unit of the at least two dendritic motifs is lysine.
 11. Amacromolecule according to claim 5 wherein the core is BHA-Lysine.
 12. Amacromolecule according to claim 5, wherein the building unit is lysine,glycyl-lysine or Analogue 5, wherein a is in an integer of 0 to
 2. 13. Amacromolecule according to claim 5, wherein the surface building unit islysine.
 14. A dendritic motif according claim 1, wherein the protectinggroups are selected from the group consisting of Boc, CBz,4-nitrobenzyloxycarbamate (4-NO₂-Nitro-CBz), Fmoc, Dde, CF₃CO₂,2-halo-CBz, Aloc, Me₃SiEtSO₂, Troc, o-NO-₂PhSO₂ and,2,4-dinitrobenzene-sulfonyl and t-butyldimethylsilyl chloride.